

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14 Attorneys for the Plaintiffs

15 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**
16 **FOR THE COUNTY OF ALAMEDA**

17 CINDY KIEL, J.D., an Executive Associate
18 Vice Chancellor at UC Davis, MCKENNA
19 HENDRICKS, a UC Santa Barbara student,
20 EDGAR DE GRACIA, a UCLA student, and
21 LELAND VANDERPOEL, an employee at the
22 Fresno satellite extension of the UCSF Medical
23 Education Program, and FRANCES OLSEN,
24 Professor of Law at UCLA,

25 Plaintiffs,

26 vs.

27 THE REGENTS OF THE UNIVERSITY OF
28 CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**PLAINTIFFS' NOTICE OF MOTION AND
MOTION FOR PRELIMINARY
INJUNCTION; MEMORANDUM OF
POINTS AND AUTHORITIES IN
SUPPORT THEREOF**

By Fax

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID- 2206283

Action Filed: August 27, 2020

Trial Date: None Set

1 **TO ALL PARTIES AND THEIR COUNSEL OF RECORD:**

2 **PLEASE TAKE NOTICE THAT** on October 14, 2020 at 1:30 PM or as soon thereafter as
3 counsel may be heard in Dept. 511 of the above-captioned Court located at Hayward Hall of Justice,
4 24405 Amador Street, Hayward, CA 94544, Plaintiffs will and hereby do move for a preliminary
5 injunction ordering Defendants Regents of the University of California and Michael V. Drake (in his
6 official capacity as President of the University of California) to cease enforcement of the Executive
7 Order issued by former University of California President Janet Napolitano dated July 31, 2020
8 mandating the flu vaccine for all faculty, staff, other employees, and all students (the “EO”) until
9 such time as there is a final determination of Plaintiffs’ request for a permanent injunction.

10 This motion is made pursuant to the provisions of California Code of Civil Procedure
11 sections 526-27, and Cal. Rule of Court 3.1150.


12 Good cause exists for the requested Preliminary Injunction. As demonstrated in detail in the
13 accompanying Memorandum of Points and Authorities, and the supporting expert declarations of
14 Peter Gotzsche, MD, UCLA Medical School Professor Laszlo Boros, MD, UCI Associate Professor
15 in the Population Health and Disease Prevention Program, Andrew Noymer, PhD, University of
16 Maryland Associate Professor in the Pharmaceutical Health Services Research Department Peter
17 Doshi, and Oxford University Senior Clinical Tutor Tom Jefferson, MD and the Supporting
18 Plaintiffs from Executive Associate Vice Chancellor of Academic Research Cindy Kiel, UCLA law
19 professor Frances Olsen, UCSF Medical Education Program, Leland Vanderpoel, UC Santa Barbara
20 student McKenna Hendricks and UCLA Student Edgar de Gracia, and the papers and pleadings on
21 file and any other such evidence as may be presented at the time of the hearing, the EO is *ultra vires*
22 as it was made without the bylaw-required formal consultative process with the Faculty Senate.
23 Moreover, the EO unconstitutionally interferes with the Plaintiffs’ and all UC students’ and
24 employees’ rights to privacy and bodily integrity under the federal and state constitutions because
25 the purported justification of mandating the flu vaccine to free up hospital beds if there is a large flu
26 outbreak and if there is a large second wave of the pandemic and if there is a shortage of hospital
27 beds, is collateral at best, and against the overwhelming best available evidence that the flu vaccine
28 does not reduce hospitalization, and no court in this country has ever approved such a widespread

1 adult vaccine mandate for a reason not directly related to the cause of the public health crises.
2 Finally, the EO violates the student Plaintiffs' equal protection rights because it interferes with their
3 fundamental religious rights insofar as they are not offered the religious exemption offered to UC
4 employees and their fundamental rights to equal protection of the laws because remote teaching and
5 remote work may be subject to an exception to the EO's mandate, but remote learning by students is
6 not.

7 //

8 //

9 DATED: September 17, 2020

10
11
12 

13 Richard Jaffe, Esq.
14 State Bar No. 289362
15 770 L Street, Suite 950
16 Sacramento, California 95814
17 Tel: 916-492-6038
18 Fax: 713-626-9420
19 Email: rickjaffeesquire@gmail.com

20 Robert F. Kennedy Jr., Esq.
21 (Subject to pro hac vice admission)
22 Children's Health Defense
23 1227 North Peachtree Parkway
24 Peachtree, Georgia 30269
25 Tel: 917-743-3868

26 Attorneys for the Plaintiffs
27
28

TABLE OF CONTENTS

Table of Contents	i
Table of Authorities.....	ii
I. Introduction.....	1
II. Statement of Facts.....	3
A. The Stated Justification for The Executive Order.....	3
B. Changes Released to the EO	3
C. Best Evidence Indicates that the Flu Shot Does Not Reduce Flu Hospitalizations.....	3
D. The Feared Hospital Bed Shortage is Speculative and Contrary to the Best Available Data..	4
E. There is Suggestive Evidence that the Flu Vaccine Could Cause More Harm during this Pandemic.....	5
III. Argument.....	6
A. The Legal Standard.....	6
B. Likelihood of Success on the Merits.....	7
1. The EO is an <i>Ultra Vires</i> act as Alleged in the First Cause of Action.....	7
2. The EO Violates the Fifth and Fourteenth Amendments (Second Cause of Action).....	8
3. The EO violates State Constitutional Privacy Protections (The Third Cause of Action)..	10
4. The EO Violates The Federal Equal Protection Rights of The Students Based on Not Being Provided with A Religious Accommodation in The Mandatory Flu Shot Exemption (The Fourth Cause of Action).....	12
C. The Harm to the Plaintiffs (and others similarly opposed to being forced to take the flu shot) is Much Greater than the Harm in Delaying the Mandate. This is Harm in the Absence of Relief.	13
IV. Conclusion.....	14

TABLE OF AUTHORITIES

United States Constitution

Fifth Amendment.....	8
Fourteenth Amendment.....	8

Federal or Out of State Cases

<i>Cruzan v. Director, Missouri Dept of Health</i> , 497 US 261, 279 (1990)	9
<i>Dunn v. Blumstein</i> , 405 U.S. 330, 341 (1972)	12
<i>Harman v. Forssenius</i> , 380 U.S. 528, 540 (1965)	12
<i>Jacobson v. Massachusetts</i> , 197 U.S. 11 (1905)	2, 9
<i>Northeastern Florida Chapter of Ass'n of General Contractors of America</i> <i>v. City of Jacksonville, Fla.</i> , 896 F.2d 1283, 1285 (11th Cir. 1990)	13
<i>Robinson v. Attorney Gen.</i> No 20-11401-B, April 23, 2020)	2, 9
<i>Robinson v Marshall</i> , Civ: Action No 2:19cv365, April 12, 2020 (District Court).....	2, 9
<i>Skinner v. Oklahoma</i> , 316 U.S. 535, 543 (1942)	12
<i>Univ. of Tex. v. Univ. of Tex.</i> (Court of Appeals of Texas, Third District, Austin Sep 04, 2020, 2020 Tex. App. LEXIS 725)	7
<i>W. Va. State Bd. of Educ. v. Barnette</i> , 319 U.S. 624, 637-38 (1943)	12
<i>Waugh v. Bd. of Trs.</i> , 237 U.S. 589, 594 (1915)	7

California Constitution

Cal. Const. Article I, §1	10, 11
Cal. Const. Article I, §7	10, 11

California Cases

<i>Alfaro v. Terhune</i> , 98 Cal.App.4th 492, 501, 509 (2002)	7, 8, 11
<i>Butt v. State of California</i> , 4 Cal. 4th 668, 678 (1992)	7
<i>Compton Coll. Fed'n of Teachers v. Compton Cmty. Coll. Dist.</i> , 132 Cal. App. 3d 704, 714 (1982)	7
<i>Conservatorship of Wendland</i> (2001) 26 Cal.4th 519, 530-32.....	11
<i>Fullerton Joint Union High Sch. Dist. v. State Bd. of Educ.</i> , 32 Cal. 3d 779, 798-99 (1982).....	12
<i>Integrated Dynamic Sols., Inc. v. VitaVet Labs, Inc.</i> , 6 Cal. App. 5th 1178, 1183 (2016).....	7
<i>Lantz v. Superior Court</i> (1994) 28 Cal. App. 4th 1839, 1848.....	11
<i>Riese v. St. Mary's Hospital & Medical Center</i> (1987) 209 Cal.App.3d 1303, 1317.....	11
<i>Scharf v. Regents of The University of California</i> , 234 Cal.App.3d 1393, 1402-1404 (1991).....	8

1

2 **MEMORANDUM OF POINTS AND AUTHORITIES**

3 **I. INTRODUCTION**

4 This Preliminary Injunction Motion seeks to preserve the status quo by preventing the
5 enforcement of a recent University of California Executive Order requiring all 510,000 students,
6 faculty and staff to obtain the flu vaccine by November 1, 2020 as a condition of continued
7 employment and continued school enrollment for students.¹

8 The EO was issued in violation of the University's bylaws and other governance documents
9 requiring a formal Faculty Senate consultative process, which did not take place, and it is therefore
10 *ultra vires* and subject to a permanent and preliminary injunction.

11 The stated rationale of the Executive Order is that if all members of the UC community
12 receive a flu shot, it might free up some hospital beds, (and on the implied future/conditional
13 possibilities), if there is a bad flu season, and if there is a bad second wave of the COVID-19
14 pandemic, and if California were to experience a shortage of beds, and further based on the tacit but
15 unlikely and unsubstantiated assumption that giving the flu vaccine to the 510,000 members of the
16 UC community will have a meaningful effect on the hospital bed needs for 40 million Californians.

17 Furthermore, the EO's rationale is based on a scientifically disproven notion that mass flu
18 vaccination decreases hospital bed utilization. A recently published analysis of 52 flu *randomized*
19 clinical studies involving 80,000 patients has demonstrated that the flu shot has no significant effect
20 of flu hospitalization.² Further, California Department of Public Health ("CDPH") data about
21 hospital bed usage during high flu seasons, along with data on COVID-19 first wave hospitalizations
22 suggest that the likelihood of California running out of hospital beds is remote, at best. Therefore,
23 the stated rationale of the EO is both disproven and not rationally connected to any realistic
24 prediction of future hospital bed needs.

25

26 ¹ A copy of the Executive Order which is the basis of this lawsuit is attached to the Complaint and
27 the First Amended Complaint as Exhibit "A" and is hereby sometimes referred to as the "EO."

28 ² See section II.C *infra* and the accompanying declaration of Peter Gøtzsche MD.

Core constitutional principles in *Jacobson v. Massachusetts*, 197 U.S. 11 (1905) establish that unless a vaccine mandate (or any government mandate that infringes personal liberty and bodily integrity) has a *real and substantial* connection to the public health crises, it will be struck down. The ‘free up hospital beds’ rationale was recently used by Alabama to justify restricting another fundamental right. However, two levels of federal courts rejected it and preliminarily enjoined a government order restricting a privacy right (the right to access to an abortion) in part based on *Jacobson*, because like here, it was completely speculative and factually unsupported.³ And just three days ago, a Pennsylvania District Court struck down the Governor’s stay at home order, finding the order unprecedented and unconstitutional. (Copy attached to the Memorandum). This decision offers strong support for the Court’s granting a preliminary injunction in this case and shows that courts do and must protect sacred liberty and privacy rights.

Further, only UC employees were offered an “accommodation” from the mandate based on religious beliefs (and disability status). On its face, the EO denies the student Plaintiffs (and all UC students) their First Amendment fundamental right to religious free exercise. It fails strict scrutiny since requiring a flu shot is obviously not the least restrictive means available to further the University’s public health goals since a religious accommodation is available to employees. The equal protection violation and the fundamental unfairness of the EO to students is dramatically increased by the recent change waiving the mandate for remote teaching and working, but not for remote learning. Finally, the EO also places an unfair and disproportionate burden on the students compared to the UC employees, and compared to the 49 million plus other Californians who do not share in this sacrifice of privacy and bodily integrity for the sake of the collateral and speculative ‘free up the hospital beds’ rationale.⁴

Based on the legal analysis and as a matter of fundamental fairness, the Court should enter a preliminary injunction order to preserve the status quo pending a trial of the permanent injunction.

³ *Robinson v Marshall*, Civ: Action No 2:19cv365, April 12, 2020 (District Court); *Robinson v. Attorney Gen.* No 20-11401-B, April 23, 2020) (Eleventh Circuit) discussed in section III.B.2 *infra*. (copies attached to this Memorandum).

⁴ This Preliminary Injunction is based on the First Amended Complaint which is being filed and served on the Defendants with these motion papers.

1 **II. STATEMENT OF FACTS**

2 On July 31, 2020, the last official day of her tenure, now former president Janet Napolitano
3 signed an executive order requiring all 280,000 UC students and all 230,000 faculty and staff to
4 receive a flu vaccine by November 1, 2020 (with certain accommodations discussed *infra.*).⁵

5 The Plaintiffs in this case are employees and students at various UC campuses directly
6 impacted by the EO as they will be required to get a flu shot. As set forth in their accompanying
7 declarations, all of them are opposed to taking a flu shot.

8 **A. The Stated Justification for The Executive Order**

9 The justification for mandating the flu vaccine is stated in the EO “Background and
10 Findings” is that 1. there are a few described studies which suggest that the flu vaccine reduces flu
11 hospitalizations and the level of flu sickness in some groups like seniors and pregnant women, and 2.
12 mandating a flu vaccine on the entire UC community might free up hospital beds if there were to be
13 a hospital bed shortage during a second wave of the coronavirus pandemic.

14 **B. Changes Released to the EO**

15 Since the EO was released on August 7, 2020, the UC administration announced that faculty
16 and staff who can teach and work entirely remotely do not have to take the flu shot. However, all
17 students even those attending class remotely still have to comply with the mandate and get the flu
18 shot. (Declaration of McKenna Hendrick).⁶ Whether a faculty member or staff member is allowed to
19 work remotely may be granted or withdrawn in the discretion of their superior, which discretion is
20 subject to change at any moment.

21 **C. Best Evidence Indicates that the Flu Shot Does Not Reduce Flu Hospitalizations**

22 As set forth in the Declaration of Peter Gøtzsche, a 2018 review of 52 randomized clinical
23 studies involving 80,000 patients demonstrated that the flu vaccine did not reduce hospital bed
24

25 ⁵ For reasons unknown to the Plaintiffs, the EO was not released to the UC community or the public
26 until August 7, 2020.

27 ⁶ The change makes the equal protection violation even more glaring and exacerbates the
28 fundamental unfairness of the EO to UC students.

usage. (Gøtzsche Dec. page 4, para. 9 to page 5 ln 15).⁷ Dr. Gøtzsche states that the “case-control studies” used to justify the EO are notoriously unreliable and are inconsistent with the large number of fully controlled studies which showed no reduction in flu hospitalization from the flu vaccine. He concludes that their use in the EO as a justification for the vaccine mandate amounts to “scientific misconduct” according the definition established by the US Office of Research Integrity (*Id.* at page 4 para. 12).

D. The Feared Hospital Bed Shortage is Speculative and Contrary to the Best Available Data.

According to the most recent CDPH data on hospital beds usage, the flu hospitalization rates during the 2016–2017 and 2017–2018 influenza seasons were 12.2 and 20.4 influenza hospitalizations per 100,000, respectively), which did not overburden hospitals. Assuming worst case COVID-19 numbers (using data to date), California has not exceeded more than 10 Hospitalizations per 100,000/week, since March 7th through August 22nd.⁸

According to Kaiser Permanente, there are about 180 hospital beds per 100,000 California residents.⁹ Therefore, even at a peak flu rate, plus the average COVID-19 hospital rate means that hospital bed utilization is much less than the 180-hospital bed availability per 100,000. Therefore, the EO’s stated rationale of the need to free up hospital beds in case there is a hospital bed shortage is extremely unlikely based on CDPH published hospital bed utilization rates.

⁷ Included in this motion are the Declarations of Thomas Jefferson, MD who was a lead investigator of this study., and the Declaration of Peter Doshi, PhD, also a Cochrane Collaborator, who, like every expert proffered, strongly disagrees with an influenza vaccine mandate and explains how it is not effective and could cause more harm than good during this pandemic.

⁸ CDPH (2020). Influenza Surveillance Program. *Flu Reports*.
<https://www.cdph.ca.gov/Programs/CID/DCDC/pages/immunization/flu-reports.aspx>;
CDC (2020). Laboratory-Confirmed COVID-19-Associated Hospitalizations, Preliminary cumulative rates as of Aug 15, 2020. *Covid-Net*.
https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html

⁹ Kaiser Family Foundation (2020). Hospital Beds per 1,000 Population by Ownership Type. *State Health Facts*. <https://www.kff.org/other/state-indicator/beds-by-ownership/?currentTimeframe=0&selectedRows=%7B%22states%22:%7B%22california%22:%7B%7D%7D%7D&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D>

1 **E. There is Suggestive Evidence that the Flu Vaccine Could Cause More Harm**
2 **during this Pandemic.**

3 A Department of Defense observational study published in early January 2020, is the only
4 actual scientific evidence currently available about the relationship between the flu vaccine and
5 coronavirus susceptibility. Here are the first words of the abstract: “Purpose: Receiving the
6 influenza vaccine may increase the risk of other respiratory viruses, a phenomenon known as virus
7 interference.”¹⁰

8 The study compared respiratory virus status among DOD personnel based on their influenza
9 vaccination status. Here is the author’s conclusion: “Receipt of influenza vaccination was not
10 associated with virus interference among our population. Examining virus interference by specific
11 respiratory viruses showed mixed results. **Vaccine derived virus interference was significantly**
12 **associated with coronavirus and human metapneumovirus;** however, significant protection with
13 vaccination as associated not only with most influenza viruses, but also parainfluenza, RSV, and
14 non-influenza virus coinfections.” [emphasis added] *Id.*¹¹

15 The accompanying Declarations of (a) Peter Gøtzsche MD, (b) UCLA Professor of Pediatrics
16 Laszlo Boros, (c) University of Maryland Associate Professor (and Associate editor of the BMJ)
17 Peter Doshi PhD, and (d) UC Irvine epidemiologist Andrew Noymer all agree that forcing the UC
18 community to take the flu shot is a bad idea, poor public policy, and could cause increased harm due
19 to viral interference. All agree that the influenza vaccine can negatively interfere with the immune
20 system (*see e.g.*, Gøtzsche Dec. page 5 para 13), has serious potential for harm (*Id.* at page 5 para. 13
21 to page 8, ln. 4), the flu vaccine has little practical benefit for individuals (and has to be administered
22 to 71 adults to prevent 1 case of the flu, *Id.* page 4 para 9), and that the package insert of the flu

23 _____
24 ¹⁰ Wolff, G. (2020). Influenza vaccination and respiratory virus interference among Department of
25 Defense personnel during the 2017-2018 influenza season. *Vaccine*;38(2):350-354. doi:
[10.1016/j.vaccine.2019.10.005](https://doi.org/10.1016/j.vaccine.2019.10.005)

26 ¹¹ This study was published in early January 2020, Recently, the author wrote that the positive virus
27 interference results (36% increased risk/association between the flu vaccine and coronavirus) might
28 not apply to the “novel” pandemic coronavirus.” Wolff, G (2020). Letter to the Editor.
Vaccine;38(30):4651. doi.org/10.1016/j.vaccine.2020.04.016.

1 vaccine shows that although adverse events might be relatively rare, they are and can cause serious
2 adverse events (*Id.* at page 6 para 14). Dr. Gøtzsche also opines that the EO is “deeply unethical,
3 violates basic human rights, and is based on no reliable evidence whatsoever. In fact, the best
4 evidence we have tells us that her [the former UC President’s] forced vaccination scheme is highly
5 likely to be harmful.” *Id.* at page 7 para. 18).

6 Dr. Doshi makes the important point that the CDC is knowingly overselling the effectiveness
7 and benefits of the influenza vaccine (Doshi Dec at paras. 8-9). Dr. Noymer points that that the
8 influenza vaccine is not particularly effective in general, but will likely be less so due to the
9 pandemic (Noymer Dec. page paras 5-6).

10 Dr. Boros explains viral interference in more biological perspective as the flu vaccine
11 causing as a loss of balance resulting in acute inflammation (sympathetic-parasympathetic,
12 anabolic/catabolic, wear and tear), that is the protective mechanism for maintenance of health. Dr.
13 Boros gives the cellular mechanism of action about how viral interference will likely cause an
14 increase in pandemic coronavirus cases, and the increased risk of autoimmune disease from the
15 vaccine (Boros Dec., especially paras. 5, 22-23).

16 In short, all five experts, including two UC medical and health professors, and three of the
17 world’s leading experts on the medical literature on vaccines conclude this mandate is bad health
18 policy and in a time of a pandemic may cause more or much more harm than good, and that the
19 stated justification of ‘free up hospital beds’ is inconsistent with the best available evidence, which
20 consist of 52 randomized clinical trials.

21 **III. ARGUMENT**

22 **A. The Legal Standard**

23 Injunctions against public officials for their official actions are available (1) where the
24 statute is unconstitutional and there is a showing of irreparable injury, (2) where the statute is valid
25 but is enforced in an unconstitutional manner, (3) where the statute is valid but, as construed, does
26 not apply to the plaintiff; and (4) where the public official's action exceeds his or her authority.”
27 *Alfaro v. Terhune*, 98 Cal.App.4th 492, 501 (2002). This Preliminary Injunction is based upon the
28 first and fourth exceptions.

1 Plaintiffs are entitled to a preliminary injunction if they show that (1) they are “likely to
2 prevail on the merits at trial” and (2) the interim harm they will suffer “if an injunction is denied is
3 greater than the interim harm the opposing party is likely to suffer if the injunction is issued.”
4 *Integrated Dynamic Sols., Inc. v. VitaVet Labs, Inc.*, 6 Cal. App. 5th 1178, 1183 (2016) (citation and
5 alterations omitted). Courts apply a sliding scale approach to these factors: “the greater the plaintiff’s
6 showing on one, the less must be shown on the other.” *Butt v. State of California*, 4 Cal. 4th 668, 678
7 (1992).

8 **B. Likelihood of Success on the Merits**

9 **1. The EO is an *Ultra Vires* act as Alleged in the First Cause of Action.**

10 State schools are required to act within their bylaws and charters, or else their activities are
11 voidable as *ultra vires*. See e.g., *Compton Coll. Fed'n of Teachers v. Compton Cmty. Coll. Dist.*, 132
12 Cal. App. 3d 704, 714 (1982); *Waugh v. Bd. of Trs.*, 237 U.S. 589, 594 (1915); and the just released
13 *Univ. of Tex. v. Univ. of Tex.* (Court of Appeals of Texas, Third District, Austin Sep 04, 2020, 2020
14 Tex. App. LEXIS 725) (upholding student’s *ultra vires* challenge to public university’s attempt to
15 discipline the student outside the proper procedures outlined by its authority).

16 The stated authority for issuing the EO is set out as “the authority vested in me by Bylaw,
17 30, Bylaw 22.1, Regents Policy 1500 and Standing Order 100.4(ee)” (EO at page 2, Exhibit
18 “A” attached to the Complaint and First Amended Complaint). However, none of these documents
19 justify the unilateral action taken by the former president.

20 To the contrary, the bylaws specifically provide that *inter alia*, the president is “expected to
21 consult with the Academic Senate, consistent with the principles of shared governance, on **issues of**
22 **significance to the general welfare and conduct of the faculty.**” (Bylaw 30, emphasis added).

23 There is nothing in the text of the EO which states or implies that the former president
24 consulted with or received any formal input from the University’s faculty Senate, and the
25 Declaration of Cindy Kiel establishes that there was no such formal consultative process (See Kiel
26 Declaration at page 5, para. 17).

1 The other cited governance documents either refer back to bylaw 30¹² or do not expressly
2 grant the President to make such a momentous unprecedented decision on her own.¹³

3 Based on the expert declarations (Gøtzsche, Doshi, Jefferson, Noymer, and Boros) the risks
4 and dangers of the flu vaccine during a non-flu pandemic, the Court must conclude that mandating
5 the flu vaccine for the entire 510,000 members of the UC community is an issue of “significance to
6 the general welfare and conduct of the faculty”, especially since the flu shot is not directly related to
7 the pandemic, (2) has resulted in the payment of almost \$1 billion in federal compensation,¹⁴ (3) and
8 has been shown in the Declarations to increase the risk of harm from some coronaviruses, (4) has
9 been demonstrated to be ineffective in over half of its recipients, and (5) can actually spread the flu.

10 If the flu mandate is an issue of “significance to the general welfare and conduct of the
11 faculty” then the EO was issued in violation of the bylaws and it is *ipso facto ultra vires*¹⁵ and
12 should be declared null and void by this Court under established California law. *Alfaro v. Terhune*,
13 *supra*, 98 Cal.App.4th at 501.¹⁶

14 **2. The EO Violates the Fifth and Fourteenth Amendments (Second Cause of** 15 **Action).**

16 Every person has an undeniable right of privacy, which includes the right to control his or her
17 own body and be free of forced medical interventions. *See e.g., Cruzan v. Director, Missouri Dept*

18 ¹² *e.g.* bylaw 22.1, and Regents Policy Statement 1500 “The President is expected to direct the
19 management and administration of the University of California System consistent with the Bylaws...”

20 ¹³ Standing Order 100.4 (ee) sets out several dozen specific things the President is permitted to do,
21 like to award degrees, hire and fire staff and set compensation, modify budget estimates and many
22 very specific tasks. This Standing Order does not appear to permit a president to mandate a flu
vaccine during a coronavirus pandemic.

23 ¹⁴ United States Health & Human Services (2020). Vaccine Injury Compensation Data. *HRSA*.
<https://www.hrsa.gov/vaccine-compensation/data/index.html>

24 ¹⁵ The former President’s failure to comply with the Bylaws, to consult the faculty before issuing the
25 EO, and to so note such consultation in the EO is also a breach of the shared governance norms
deeply embedded in the UC community.

26 ¹⁶ Even if the EO is not *ultra vires*, it should still be overturned under *Scharf v. Regents of The*
27 *University of California*, 234 Cal.App.3d 1393, 1402-1404 (1991) because it is a matter of statewide
28 concern which requires a statewide resolution.

1 of *Health*, 497 US 261, 279 (1990). But like all rights, privacy is not absolute and must be balanced
2 against other important rights.

3 In the area of mandatory vaccination, the balancing test of these competing rights was first
4 set out in *Jacobson v. Massachusetts*, 197 U.S. 11 (1905), which set out a clear red line on when a
5 vaccine mandate *must* be struck down, warning the government that "if a statute purporting to have
6 been enacted to protect the public health, the public morals, or the public safety, has no real or
7 substantial relation to those objects, or is, beyond all question, a plain, palpable invasion of rights
8 secured by the fundamental law, it is the duty of courts to so adjudge, and thereby give effect to the
9 Constitution."

10 On its face, the proffered justification of the mandate of freeing up hospital beds has no
11 "real... relation" to the pandemic because it is based on at least three speculations about what will
12 happen in the future. The mandate has no *substantial* relation to the pandemic since there is no basis
13 in fact to conclude or even predict that there will be a hospital bed shortage, and more importantly,
14 *the best available scientific evidence has disproven that alleged rationale, that the flu shot will*
15 *reduce hospital bed usage.*

16 As indicated, the UC's 'free up the hospital beds' justification was recently rejected by two
17 levels of Alabama federal courts when it was used by the state to justify the denial of another
18 fundamental right (abortion). The district court rejected the hospital bed rationale because there was
19 no proof, and preliminarily enjoined the state from enforcing the restrictive order. *Robinson v*
20 *Marshall*, Civ: Action No 2:19cv365, April 12, 2020 order). The State moved for a stay, but in a
21 lengthy opinion, the Eleventh Circuit denied the request citing (as did the District Court) *Jacobson's*
22 requirement of a real and substantial relation. *Robinson v. Attorney Gen.* No 20-11401-B, April 23,
23 2020). (Copies of both cases are attached to this Memorandum). These opinions are four-square on
24 point.

25 Beyond the real and substantial relation test, *Jacobson* may also stand for the proposition that
26 public health regulations require five elements to be constitutional: (1) public health necessity, (2)
27
28

1 reasonable means, (3) proportionality, (4) harm avoidance, and (5) non-discrimination. The
2 executive order issued by the former President meets none of these required elements.¹⁷

3 On September 14, 2020, a Pennsylvania District court just struck down the Governor's stay
4 at home order, discussing the *Jacobson* rationale (Copy attached to this Memorandum). While the
5 analysis is different, that decision offers strong support for voiding this UC action which so
6 obviously tramples on the rights of Plaintiffs and all UC community members and is so potentially
7 dangerous given lack of evidence showing the safety of the influenza vaccine during a novel
8 coronavirus pandemic. The Court should conclude that Plaintiffs have met their burden of proving a
9 likelihood of success on the Second Cause of Action.

10 **3. The EO violates State Constitutional Privacy Protections (The Third Cause**
11 **of Action).**

12 Plaintiffs are likely to succeed on the third cause of action which parallel's the federal
13 constitutional second cause of action. The California test is:

14 "The evaluation of privacy claims under our state Constitution requires (1) the
15 identification of a specific, legally protected privacy interest, (2) a determination whether
16 there is a reasonable expectation of privacy in the circumstances, (3) an assessment of the
17 extent and gravity of the alleged invasion of privacy, and (4) a balancing of the invasion
18 against legitimate and competing interests. (*Hill v. National Collegiate Athletic Assn.*
19 (*1994*) 7 Cal.4th 1, 35-39, 26 Cal.Rptr .2d 834, 865 P.2d 633.) **The key element in this**
20 **process is the weighing and balancing of the justification for the conduct in question**
21 **against the intrusion on privacy resulting from the conduct whenever a genuine,**
22 **nontrivial invasion of privacy is shown.** (*Loder v. City of Glendale* (*1997*) 14 Cal.4th
23 846, 893, 59 Cal.Rptr.2d 696, 927 P.2d 1200.)

24 *Alfaro v. Terhune, supra*, 98 Cal.App.4th at 509 (2002) (emphasis added)

25 ¹⁷ There is no public health necessity for a flu vaccine during this COVID-19 pandemic as
26 previously demonstrated. The means are not reasonable. There is no proportionality in singling out
27 and denying the privacy and bodily integrity rights of 510,000 UC affiliated people from the 39
28 million other Californians who do not have to take the shot. There is not harm avoidance, and in fact
there is suggestive evidence that the flu shot will increase novel coronavirus infections. Finally, the
EO discriminates against the UC students by not offering a religious accommodation and
discriminates against the 510,000-member community because the overwhelming majority of the
rest of the State's residents do not have to take the shot.

1 In 1974, an amendment to the California Constitution elevated the right of privacy to an
2 "inalienable right." Cal. Const. Article I, §1, *Lantz v. Superior Court* (1994) 28 Cal. App. 4th 1839,
3 1848. *See also*, California Constitution, Article I, §7, especially "A person may not be deprived of
4 life, liberty, or property without due process of law or denied equal protection of the laws" and
5 "maximizing the educational opportunities and protecting the health and safety of all public-school
6 pupils".

7 The California courts recognize the "relatively certain principle that a competent adult has
8 the right to refuse medical treatment, even treatment necessary to sustain life." *Conservatorship of*
9 *Wendland* (2001) 26 Cal.4th 519, 530 and the California Constitution, Article I, §1 "guarantee[ing]
10 to the individual the freedom to choose to reject, or refuse to consent to, intrusions of his bodily
11 integrity." *Id.* at pp. 531-532; *see also Riese v. St. Mary's Hospital & Medical Center* (1987) 209
12 Cal.App.3d 1303, 1317. This right is grounded in both state constitutional and common law,
13 together with the right of privacy guaranteed.

14 In balancing privacy rights against competing public health rights, the Court must come
15 down in favor of privacy because 1. There is no proven direct benefit the flu shot has on COVID-19
16 2. There is evidence it may increase the risk of contracting the pandemic coronavirus and cause harm
17 to many in the UC community 3. The best available evidence demonstrates that the flu shot does not
18 reduce hospital bed usage, which is the stated justification for the mandate, and 4. the best available
19 public health data indicates that it is extremely unlikely there will be a hospital bed shortage this flu
20 season during a second wave, if it occurs. Thus, the non-existent purported benefit of forcing
21 510,000 to get a flu shot is collateral, based on multiple layers of speculation, and the factual basis is
22 contradicted by the best available information from the CDPH and the randomized clinical trials
23 evaluating the influenza vaccine.

24 In this country, adults have a reasonable expectancy of privacy that they will not have to
25 submit to forcible vaccination as a condition of employment or to attend university, and certainly not
26 for a vaccine that is unrelated to the pandemic. Therefore, based on a state constitutional analysis, it
27 is likely that Court will ultimately rule that the EO violates Plaintiffs' privacy rights and rights of
28 bodily integrity conferred by the California Constitution.

1 **4. The EO Violates The Federal Equal Protection Rights of The Students Based**
2 **on Not Being Provided with A Religious Accommodation in The Mandatory**
3 **Flu Shot Exemption (The Fourth Cause of Action).**

4 The University of California is a state-created, state-financed and state-run public trust
5 education system, and as such, it is subject to the Fifth Amendment right to equal protection of the
6 law through the Fourteenth Amendment. The EO provides that university employees may seek a
7 “religious accommodation” to the flu vaccine to be “adjudicated through the interactive process
8 consistent with existing location policies and procedures (EO at page 2 paragraph 1c to page 3).

9 There is no similar religious accommodation for the university students, which violates
10 Plaintiff students’ rights to the equal protection of the law and First Amendment protected religious
11 rights, which must be governed by strict scrutiny because they are fundamental rights. *See e.g.,*
12 *Fullerton Joint Union High Sch. Dist. v. State Bd. of Educ.*, 32 Cal. 3d 779, 798-99 (1982) (reversing
13 a judgement in favor of a school district, the California Supreme Court stated, “ . . . in cases
14 involving ‘suspect classifications’ or touching on ‘fundamental interest,’ . . . the court has adopted
15 an attitude of active and critical analysis, subjecting the classification to strict scrutiny.”); *W. Va.*
16 *State Bd. of Educ. v. Barnette*, 319 U.S. 624, 637-38 (1943); *Dunn v. Blumstein*, 405 U.S. 330, 341
17 (1972); *Harman v. Forssenius*, 380 U.S. 528, 540 (1965); *Skinner v. Oklahoma*, 316 U.S. 535, 543
18 (1942) (utilizing the equation protection clause to reverse an Oklahoma Supreme Court order that
19 attempted to perform the medical procedure of sterilization upon a convicted felon).

20 There are less restrictive means of achieving whatever goal the UC wants to achieve in terms
21 of hospital bed usage (even on the counterfactual assumption that the flu vaccine reduced flu related
22 hospital beds) by granting the two students the same religious accommodation as it granted to
23 employees. Further, there is no compelling state interest in reducing hospital bed usage because there
24 is no evidence that there will be a shortage of hospital beds and the data indicated that there will be
25 no such need even if the seasonal flu is as bad as it ever has been. And as indicated the best evidence
26 is that the flu shot does not decrease flu hospitalizations. For these reasons, it is likely that the Court
27 will rule in Plaintiffs’ favor at the trial of this action.
28

1 **C. The Harm to the Plaintiffs (and others similarly opposed to being forced to take**
2 **the flu shot is Much greater than the harm in delaying the mandate. This is**
3 **Harm in the Absence of Relief.**

4 A violation of a federal constitutional right inflicts *per se* irreparable injury. See e.g.,
5 *Northeastern Florida Chapter of Ass'n of General Contractors of America v. City of Jacksonville,*
6 *Fla.*, 896 F.2d 1283, 1285 (11th Cir. 1990); citing *Cate v. Oldham*, 707 F.2d 1176, 1189 (11th

7 Cir.1983); *Deerfield Medical Center v. City of Deerfield Beach*, 661 F.2d 328, 338 (5th Cir.1981).
8 However, as set forth in detail in Section II *supra* and accompanying expert declarations, the
9 injury which will be inflicted by the EO is obvious and potentially grave, based on the risk of
10 Adverse Events in the Flu Vaccine's package inserts, vaccine or viral interference potential from the
11 flu vaccine to coronaviruses, and the proven harm to UC's community's elderly and pregnant
12 women.

13 The risk from a delay in the implementation of the EO is minimal to nonexistent. The best
14 clinical trials evidence demonstrates that the flu vaccine does not reduce hospitalizations. The
15 California hospitalization bed utilization numbers strongly suggests that there will not be a hospital
16 bed shortage even if there is a high seasonal flu combined with a large second wave. There is no
17 convincing evidence that the flu vaccine will prevent COVID-19 infections, but there is some
18 specific evidence that viral interference might well increase COVID-19 infections.

19 Regardless of how the science ends up, the notion that 510,000 Californians can be
20 compelled to take a vaccine which has not been proven to be safe for administration during a
21 coronavirus pandemic, turns all these people into human guinea pigs and is repugnant to established
22 scientific and ethical norms, and of course, it is completely unconstitutional under the bright red line
23 set up by the Supreme Court in *Jacobson*, and recently reaffirmed on the exact same proffered
24 rationale.

25 //

26 //

27 //

28 //

1 **IV. CONCLUSION**

2 For the foregoing reasons, the Plaintiffs, speaking for hundreds of thousands of members of
3 the UC community, respectfully request that the Court enter a preliminary injunction order barring
4 the EO pending the trial of this action.

5
6 DATED: September 17, 2020



Richard Jaffe, Esq.
State Bar No. 289362
770 L Street, Suite 950
Sacramento, California 95814
Tel: 916-492-6038
Fax: 713-626-9420
Email: rickjaffeesquire@gmail.com

Robert F. Kennedy Jr., Esq.
(Subject to pro hac vice admission)
Children's Health Defense
1227 North Peachtree Parkway
Peachtree, Georgia 30269
Tel: 917-743-3868

Attorneys for the Plaintiffs

Richard Jaffe, Esq.
State Bar No. 289362
770 L Street, Suite 950
Sacramento, California 95814
Tel: 916-492-6038
Fax: 713-626-9420
Email: rickjaffeesquire@gmail.com

Robert F. Kennedy Jr., Esq.
(Subject to *pro hac vice* admission)
Children's Health Defense
1227 North Peachtree Parkway
Peachtree, Georgia 30269
Tel: 917-743-3868

Attorneys for the Plaintiffs

**SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF ALAMEDA**

CINDY KIEL, J.D., an Executive Associate Vice
Chancellor at UC Davis, MCKENNA
HENDRICKS, a UC Santa Barbara student,
EDGAR DE GRACIA, a UCLA student, and
LELAND VANDERPOEL, an employee at the
Fresno satellite extension of the UCSF Medical
Education Program, and FRANCES OLSEN,
Professor of Law at UCLA,

Plaintiffs,

vs.

THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG20072843

**PETER GÖTZSCHE MD'S
DECLARATION IN SUPPORT OF
PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION**

BY FAX

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID- 2206283

Action Filed: August 27, 2020

Trial Date: None Set

I Peter Gøtzsche, MD declare as follows:

**PETER GÖTZSCHE MD'S DECLARATION IN SUPPORT OF PLAINTIFFS' MOTION
FOR A PRELIMINARY INJUNCTION**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1. I submit this declaration in support of Plaintiffs’ Motion for a preliminary injunction.
2. I am a medical doctor and I have been involved in medical research and the evaluation of medical research for 45 years (even before I became a doctor). I have personal knowledge of the information set forth herein, and if called to testify, I could competently testify as follows:
3. In 1993, I co-founded the Cochrane Collaboration which is a collaborative effort by patients, scientists and researchers around the world to evaluate medical research to assist patients, health professionals and policy makers to make better decisions. During the twenty-five years I worked with the Cochrane Collaboration, the group has published about 10,000 systematic reviews or protocols for upcoming reviews on the benefits and harms of interventions used in healthcare.
4. In 2018, I founded the Institute for Scientific Freedom where I continue with the same kind of work, I performed at the Cochrane Collaboration. (A copy of my CV with a list of books, book chapters and publications are attached as Exhibit “A.”)
5. I am the author of seven books since 2007, the first of which is Rational Diagnosis and Treatment: Evidence-based Clinical Decision-making (4th ed.).
6. One of my most recent books, published earlier this year, and the one which is most relevant to the issues in this case is titled “Vaccines: Truths, Lies and Controversy.” The book was published by People’s Press in Denmark; will be published by Skyhorse in New York later this year; and will appear in many languages. The book has a chapter on the flu vaccines, and specifically reviews the evidence of its benefits and harms. In this declaration, I will present some of the conclusions I reached in the chapter drawing in

particular on the results from the three reviews the Cochrane Collaboration published on the flu vaccine to healthy adults in 2010, 2014 and 2018.

The Efficacy and Public Benefit of the Flu Vaccine is so questionable that it Should not be Given Routinely to Healthy Adults

7. My general conclusion is that the recommendation in some countries that healthy adults should take the seasonal flu vaccine is not supported by the medical literature, despite American government agencies', e.g. CDC's, enthusiastic support for giving this vaccine to healthy people. The 2010 Cochrane review, "Vaccines for preventing influenza in healthy adults," was based on randomized clinical trials and comparative studies assessing serious and rare harms.¹ It concluded: "The results of this review seem to discourage the utilization of vaccination against influenza in healthy adults as a routine public health measure." The researchers furthermore noted that, "We found no evidence that vaccines prevent viral transmission or complications" and that: "Inactivated vaccines caused local harms and an estimated 1.6 additional cases of Guillain-Barré Syndrome per million vaccinations. The harms evidence base is limited."
8. Four years later, the Cochrane review was updated with 41 new trials.² This massive addition of new data had no material influence on the results of the review and the researchers' conclusion was similar to that in their 2010 review: "The results of this review provide no evidence for the utilization of vaccination against influenza in healthy adults as a routine public health measure."

¹ Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub4.

² Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub5.

- 1 9. In 2018, the Cochrane review was updated again and the review now included 52
2 randomized clinical trials and over 80,000 people:³ “Inactivated influenza vaccines
3 probably reduce influenza in healthy adults from 2.3% without vaccination to 0.9% (risk
4 ratio (RR) 0.41, 95% confidence interval (CI) 0.36 to 0.47; 71,221 participants;
5 moderate-certainty evidence).” This could be considered a worthwhile effect at the
6 population level but hardly at the individual level, as “71 healthy adults need to be
7 vaccinated to prevent one of them experiencing influenza.”
8
- 9 10. It can be debated, however, whether flu shots for healthy adults are worthwhile
10 interventions at the population level. It was quite disappointing that vaccination did not
11 decrease admissions to hospital (risk ratio 0.96; 95% CI 0.85 to 1.08) or days off work
12 (difference -0.04 days; 95% CI -0.14 to 0.06).
13
- 14 11. The Executive Order mandating the flu vaccine is based on a belief that it will reduce
15 hospital bed usage. That belief is simply wrong, which the Cochrane review showed.
16
- 17 12. The Executive Order from Janet A. Napolitano is a three-page document where she
18 quotes the literature selectively to such an extent that I consider it scientific misconduct.
19 According to the US Office of Research Integrity, research misconduct includes
20 “changing or omitting data or results such that the research is not accurately represented
21 in the research record.”⁴ This is exactly what Napolitano did in her document. Cochrane
22 reviews are widely respected for their high standards but instead of quoting the relevant
23 Cochrane review of the randomized trials, she quoted a number of deeply flawed case-

24
25 ³ Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy
26 adults. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD001269. DOI:
10.1002/14651858.CD001269.pub6.

⁴ <https://ori.hhs.gov/definition-misconduct>.

control studies, even though case-control studies are known to be notoriously unreliable for assessing the benefits of interventions in healthcare. I have criticized some of the worst of these studies in my vaccine book, including two of the studies mentioned by Napolitano, and shown why the benefit they claim for flu shots are simply impossible, given other evidence. For one of the two studies,⁵ I wrote in my book that the CDC claimed that, “In recent years, flu vaccines have reduced the risk of flu-associated hospitalizations among adults on average by about 40%. How is this possible when the randomized trials didn’t find anything? Oh well, it was a systematic review of case-control studies. Forget it.” For the other study that Napolitano quotes,⁶ I wrote: “A 2018 study showed that from 2012 to 2015, flu vaccination among adults reduced the risk of being admitted to an intensive care unit (ICU) with flu by 82 percent. Interesting game. We are approaching 100% vaccine efficacy but are witnessing a scientific playroom, totally detached from reality.”

There is Convincing Evidence that Flu Shots Can Cause Harm

13. Systematic reviews have noted serious deficiencies in the reporting of harms in published influenza vaccine trials. But it is a fact that flu shots can cause serious harm. I mention in my vaccine book that it has been firmly established that the influenza vaccine Pandemrix can cause narcolepsy, a life-long, seriously debilitating condition with poor treatment

⁵ Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design case-control studies. *J Infect* 2017;75:381-94.

⁶ Thompson MG, Pierse N, Sue Huang Q, et al. Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012-2015. *Vaccine* 2018;36:5916-25.

options where people suddenly fall asleep, with an onset from about two months after vaccination and up to at least two years later. The likely mechanism is an autoimmune cross-reaction in people with a particular tissue type between the active component of the vaccine and receptors on brain cells controlling the day rhythm. More than 1300 people developed narcolepsy. I also mention that, in 2009, Australia suspended its universal vaccination influenza program for children younger than five years because of a surge in febrile convulsions following vaccination (1 in 110 children). Official inquiries confirmed the vaccine's role, also in this case. These harms came to light because their incidence was ten times the background rate. Influenza vaccines are biologics, and biologic manufacturing is messy, with risks of contamination far in excess of that seen in ordinary drug production.

14. I agree with the statement in the Complaint that the package insert of a popular flu vaccine relates many local and systemic adverse events including serious adverse events.

15. I also agree with the concerns in the complaint about possible harmful virus interferences between the flu vaccine and various viruses, including not only the novel pandemic coronavirus but even the influenza virus itself. Studies by Canadian researchers indicated that people who received a seasonal influenza vaccine in 2008 had an increased risk of getting infected with another influenza strain in 2009.⁷ They replicated their findings in five different studies and I find their methods and results convincing.

16. The most reliable studies and reviews we have suggest that administering the flu vaccine to the 510,000 members of the University of California community might cause serious

⁷ Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during spring–summer 2009: four observational studies from Canada. PLoS Med 2010;7:e1000258.

1 harm and will likely cause more harm than good. This is particularly because mandatory
2 flu shots are highly likely to increase vaccine hesitancy in general, including refusing
3 life-saving vaccines to people's children like the MMR vaccine. I therefore consider it
4 likely that mandatory vaccination of 510,000 members of the University of California
5 community will increase deaths from infections because public distrust in the authorities
6 will be nourished by this ill-thought through and totally inappropriate use of force.
7

8 17. No one has any idea about what the results would be of increased vaccine coverage for
9 influenza on the risk of getting infected with coronavirus and dying from it, but I am not
10 optimistic that the results would be beneficial. For example, it has been thoroughly
11 documented in many carefully conducted studies that vaccination with non-live viruses
12 increases mortality from other infections (see my book; particularly Peter Aaby has made
13 groundbreaking research in this area).
14

15 18. My overall conclusion about Napolitano's forced vaccination scheme is that it is deeply
16 unethical, violates basic human rights, and is based on no reliable evidence whatsoever.
17 In fact, the best evidence we have tells us that her forced vaccination scheme is highly
18 likely to be harmful.

19 19. I have a balanced view on vaccines, based on reliable science. This is the reason why my
20 new vaccine book, first published in February 2020, has already appeared in Danish,
21 Swedish and Dutch, three very small language areas, and will also appear in major
22 languages like Spanish, French and German. My evidence-based approach to vaccines is
23 apparent on the first page in my vaccine book: "Some vaccinations are so beneficial that
24 we should all get them while others should not be used except for special circumstances.
25 Some are so controversial that many healthcare professionals do not use them for
26

1 themselves even though they are officially recommended, e.g. the influenza vaccines. We
2 must evaluate carefully each vaccine, one by one, assessing the balance between its
3 benefits and harms, just as we do for other drugs, and then form an opinion about whether
4 we think the vaccine is worth getting or recommending to other people.”

5 20. I declare under penalty of perjury under the laws of the State of California that the
6 foregoing is true and correct and that this declaration was executed on September 9, 2020
7 in Denmark.
8

9
10 

11 _____
Peter Gøtzsche
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

EXHIBIT “A”

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Curriculum vitae

for

Peter C. Gøtzsche

last update November 2019
(apart from books and a few other things)

Contents

Personal data	3
Education.....	3
Appointments	3
Pregraduate.....	3
Postgraduate, previous	3
Postgraduate, recent	4
Funding support.....	4
Awards and other academic honours	5
Some recent appearances in documentary films and satires	6
Publications	6
DrMedSci thesis	6
Academic books	6
Travel book	7
Articles in international journals with peer review	7
Articles without peer review	18
Book chapters.....	22
Correspondence, book reviews and similar.....	23
Secondary publications in Danish	34
Teaching	35
Pregraduate courses.....	35
Postgraduate courses	35
Lectures	38
Research mentorships.....	50
Scientific assignments	52
General	52
Editorial work.....	53
Chairman at congresses and meetings.....	54
Advisory Board member at international congresses.....	55
Expert witness in court cases	55
Management experience.....	55

Personal data

Peter Christian Gøtzsche, Kløvervang 39, 2970 Hørsholm, Denmark
MD, DrMedSci, MSc (biology and chemistry), fil. mag.
Director, Institute for Scientific Freedom, Copenhagen
Visiting Professor, Institute of Health & Society, University of Newcastle, England

Email: pcg@scientificfreedom.dk
Mobile: +45 53 64 20 66
Websites: scientificfreedom.dk and deadlymedicines.dk.
Twitter: [@PGtzsche1](https://twitter.com/PGtzsche1)

Date of birth: 26 November 1949
Family relation: Married, 2 children
Citizenship: Danish

Education

1968 Student exam, Næstved Gymnasium. Marks: 9.0.
1970 First part of biology, University of Copenhagen. Marks: ug-.
1970-73 Studies at the universities of Uppsala and Lund.
1973 MSc in biology and chemistry, University of Lund.
1974 MSc in biology and chemistry, University of Copenhagen.
Special subject in entomology. Marks: 10.
1984 MD, University of Copenhagen. Marks: 10.0.
1987 Diploma Course in Tropical Medicine, Copenhagen (2 months; passed).
1990 Thesis, University of Copenhagen.
1995 Specialist in internal medicine.

Appointments

Pregraduate

01.04.75 - 31.03.77 Drug representative and product manager, Astra Group A/S.
01.04.77 - 31.08.83 Chief of medical department, Astra-Syntex A/S.

Postgraduate, previous

		months
01.06.84 - 30.09.84	Registrar, Bispebjerg Hospital, Med Dept C	4
01.10.84 - 31.12.85	Registrar, Herlev Hospital, Surgical Dept	12
01.06.85 - 31.08.85	Registrar, Herlev Hospital, Med Dept F	3
01.01.86 - 31.08.86	Registrar, Rigshospitalet, Dept of Infect Dis	8
01.09.86 - 30.09.87	Registrar, Hvidovre Hospital, Dept of Hepatology	13
01.09.87 - 31.05.95	Chief, Nordic coordination office for AIDS trials, Rigshospitalet	93
01.09.88 - 31.01.90	Junior Lecturer, Theory of Medicine, University of Copenhagen	17
01.02.89 - 28.02.90	Registrar, Herlev Hospital, Med Dept C	11
01.03.90 - 28.02.91	Registrar, Rigshospitalet, Med Dept A	12
01.03.91 - 31.08.91	Registrar, Rigshospitalet, Med Dept L	6
01.09.91 - 29.02.92	Registrar, Rigshospitalet, Dept of Infect Dis	6
01.03.92 - 30.06.93	Senior registrar, Hvidovre Hospital, Dept of Rheumatology	16
01.09.92 - 30.06.93	Lecturer, internal medicine, Hvidovre Hospital	10
01.07.93 - 31.08.95	Senior registrar, Rigshospitalet, Dept of Infect Dis	12
01.10.93 - 31.05.97	Senior House Medical Officer, Rigshospitalet	45
01.03.92 - 31.12.98	Editor, Bibliotek for Læger	82
01.02.90 - 31.03.10	Lecturer, Theory of Medicine, University of Copenhagen	242

Postgraduate, recent

01.10.93 - 30.04.19	Director, The Nordic Cochrane Centre
01.06.97 - 30.04.19	Chief physician, Rigshospitalet
01.04.10 - 30.04.19	Professor, Clinical Research Design and Analysis, University of Copenhagen

Funding support

1987	Danish Medical Research Council
1988	Danish Medical Research Council
1989	Danish Medical Research Council
1990	Danish Medical Research Council
1990	Danish Arthritis Foundation
1992	Medical Society in Copenhagen
1992	Fund for progress in Medical Science
1992	Danish Arthritis Foundation
1992	Fonden til Lægevidenskabens Fremme
1992	Todelegatet
1993	Rigshospitalet
1993	Research Foundation for Greater Copenhagen, Faroe Islands and Greenland.
1993	Ministry of Health
1994	Rigshospitalet
1994	European Union, BIOMED I
1995	European Union, BIOMED II
1995	Nordic Council of Ministers
1995	Rigshospitalet
1995	Copenhagen Hospital Foundation
1996	Danish Medical Research Council
1996	Nordic Council of Ministers
1996	Apothecary Foundation
1997	Fonden "En god start i livet"
1997	Nordic Council of Ministers
1997	Sygekassernes Helsefond
1997	Research Fund, Leo Pharmaceuticals
1998	State Institute for Medical Health Technology Assessment
1998	European Union, BIOMED 2
1998	Nordic Council of Ministers
1998	Danish Medical Research Council
1999	Nordic Council of Ministers
1999	Danish Ministry of Health
2000	Nordic Council of Ministers
2000	Ministry of Health
2000	Mindelegat (Mrs. Kay Lynæs)
2001	Nordic Council of Ministers
2001	Mindelegat (Mrs. Kay Lynæs)
2002	Mindelegat (Mrs. Kay Lynæs)
2002	Nordic Council of Ministers
2003	Danish Medical Research Council
2003	Danish Ministry of Health
2003	Rigshospitalet
2003	Nordic Council of Ministers
2004	Nordic Council of Ministers
2005	Nordic Council of Ministers
2006	Nordic Council of Ministers
2006	IMK Charitable Fund
2007	Danish Medical Research Council
2007	The Cancer Foundation

2008	Nordic Council of Ministers
2008	Sygekassernes Helsefond
2008	Rigshospitalet
2008	Danish Medical Research Council
2009	Rigshospitalet
2009	Capital Region of Denmark
2009	Agnes and Poul Friis' Foundation
2010	Augustinus Foundation
2010	Oticon Foundation
2010	Rigshospitalet
2010	Lundbeck Foundation
2010	Kontorchef Gerhard Brønsted's Travel Grant
2010	Tryg Foundation
2010	University of Copenhagen
2010	Sygekassernes Helsefond
2010	Julie von Müllen's Foundation
2010	The Free Research Councils
2011	The Cochrane Collaboration
2011	Rigshospitalet
2012	Rigshospitalet
2012	Tryg Foundation
2012	Sygekassernes Helsefond
2012	The Cochrane Collaboration
2014	Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2014	Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2015	University of Copenhagen, PhD stipend

Awards and other academic honours

1992	Farmer from Stenløse, Peder Laurids Pedersen's donation.
1993	Co-founder of the Cochrane Collaboration
1997	Award of the year from the foundation "A good start in life".
1999	Henrik R. Wulff's prize from Danish Society for Theory in Medicine
2001	Skrabanek Foundation Prize, Trinity College, Dublin.
2001	Niels A. Lassen's prize.
2003	Queen Ingrid's Lecture, Åbenrå Hospital.
2004	Harry Boström Lecture, Swedish Society for Internal Medicine, Annual Meeting.
2006	Top-ten peer reviewer for British Medical Journal for the year 2006.
2007	Winner of the 2007 Society of Medical Writers' Academic Writing Award (for: Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. <i>BMJ</i> 2006;332:538-41).
2009	Michael Berger Award, Düsseldorf.
2012	Winner of the annual Prescrire Prize for medical and pharmaceutical books (for: Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012:1-388).
2014	Winner of the Annual LAP Award (psychiatry award), Denmark.
2014	Co-founder and member of the Board of the Council for Evidence-based Psychiatry, London.
2014	Winner of the British Medical Association's Annual Book Award in the category Basis of Medicine for <i>Deadly Medicines and Organised Crime: How big pharma has corrupted health care</i> .
2014	Award from the International Society of Ethical Psychology and Psychiatry for "intellectual honesty and bravery in tackling the biomedical-industrial complex."
2015	Honourable Award, Consul General Ernst Carlsen's Foundation.
2015	Book of the Year, US Tributaries Radio, for <i>Deadly Psychiatry and Organised Denial</i> .
2015	Top ten finalist for the award "Dane of the year," nominated by psychiatric patients.
2016	HealthWatch Award, London
2016	Protector for Stemmehørernetværket (Hearing Voices Network)
2016	Co-founder and member of the Board, International Institute for Psychiatric Drug Withdrawal.
2017	Elected member of the Cochrane Governing Board, with the most votes of the 11 candidates.
2017	Honored Guests Award in Ethical Human Sciences and Services. Breggin: <i>Psychiatric Drug Facts</i> .
2018	Member of the Advisory Council of International Center for the Study of Patient-Oriented Psychiatry.

- 2018 Member of the Advisory Council of the Center for the Study of Empathic Therapy, Education & Living.
- 2020 Award from the Danish Patient Association for being the bravest doctor in the last decade.

Some recent appearances in documentary films and satires

1. The Daily Show, New York. 2014; Sept 16.
2. Frank Wittig Frank.Wittig@swr.de Südwestrundfunk
3. Lægemiddelindustrien, NRK1, 2014.
4. Danmark på piller. Tre dokumentarer i DR TV 2014.
5. TV fra en anden planet, kanal 1, juni 2015. <http://kanal-1.dk/tv-fra-en-anden-planet/>.
6. Crazywise, 2016.
7. "Lykkepillen". [Dokumentarfilm om Silje Marie Strandberg](#). 2017.
8. [Cause of death: unknown](#). Documentary film about filmmaker's sister, Renate Hoel. 2017.
9. [Diagnosing psychiatry](#). Documentary film about Peter Gøtzsche. 2018.
10. Speed Demons: Dying For Attention. 2018.
11. sera@westernmassrlc.org
12. The drug industry. sejucer@gmail.com. Russia 1
13. Michael Siewierski, New Roots Films. info@foodchoicesmovie.com 2018 launch.
14. [Medicating normal](#). Periscope Moving Pictures. 2019.

Publications

My scientific works have been cited about 50,000 times. My H-index is 67 according to Web of Science, September 2018, which means that 67 papers have been cited at least 67 times.

DrMedSci thesis

Bias in double-blind trials. Dan Med Bull 1990;37:329-36. Defended 10 May 1990 at the University of Copenhagen, Faculty for Health Sciences. Examiners: Professor, DrMedSci Ib Lorenzen and chief physician, DrMedSci Henrik R. Wulff.

Academic books

- Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 4. udgave. København: Munksgaard; 1997.
- Wulff HR, Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 3rd edition. Oxford: Blackwell Scientific; 2000. Translated into Swedish, Spanish and Polish.
- Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 5. udgave. København: Munksgaard Danmark; 2006.
- Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 4th edition. Chichester: Wiley; 2007.
- Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
- Gøtzsche PC. Deadly medicines and organised crime: How big pharma has corrupted health care. London: Radcliffe Publishing; 2013. Translated into 15 languages.
- Gøtzsche PC. Dødelig medicin og organiseret kriminalitet: Hvordan medicinalindustrien har korrumpet sundhedsvæsenet. København: People's Press; 2013.
- Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People's Press; 2015. Translated into many languages.
- Gøtzsche PC. Dødelig psykiatri og organiseret fornægtelse. København: People's Press; 2015.
- Gøtzsche PC. Overlevelse i en overmedicineret verden: Find selv evidensen. København: People's Press; 2018.
- Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself. Copenhagen: People's Press; 2019.
- Gøtzsche PC. Death of a whistleblower and Cochrane's moral collapse. Copenhagen: People's Press; 2019.
- Gøtzsche PC. Vaccines: truth, lies and controversy. Copenhagen: People's Press; 2020.

Gøtzsche PC. Mental health survival kit and withdrawal from psychiatric drugs. Copenhagen: Institute for Scientific Freedom; 2020.

Gøtzsche PC. Mentalt overlevelsesskit og udtrækning af psykofarmaka. København: Institute for Scientific Freedom; 2020.

Travel book

Gøtzsche PC. På safari i Kenya. København: Samlerens forlag; 1985.

Articles in international journals with peer review

Total number of citations: about 50,000; H-index: 67 (Web of Science, September 2018).

1. Andersen LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in sportsmen. *Pharmatherapeutica* 1984;3:535-41.
2. Sindet-Pedersen S, Petersen JK, Gøtzsche PC. Incidence of pain conditions in dental practice in a Danish county. *Community Dent Oral Epidemiol* 1985;13:244-6.
3. Geisler C, Gøtzsche PC, Hansen SS, Juul K, Plesner AM, Nissen NI. Naproxen has greater antipyretic effect on fever related to Hodgkin's disease than to other tumours or to infection. *Scand J Haematol* 1985;35:325-8.
4. Sindet-Pedersen S, Petersen JK, Gøtzsche PC, Christensen H. A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. *Int J Oral Maxillofac Surg* 1986;15:389-94.
5. Gøtzsche PC, Hvidberg EF, Juul P. Rational choice of dose: insufficient background knowledge? *Ration Drug Ther* 1986;20:1-7.
6. Gøtzsche PC. Reference bias in reports of drug trials. *BMJ* 1987;295:654-6.
7. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, Rønn A, Gøtzsche PC. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine/pyrimethamine. *BMJ* 1988;296:820-2.
8. Gøtzsche PC, Hørding M. Condoms to prevent HIV transmission do not imply truly safe sex. *Scand J Infect Dis* 1988;20:233-4.
9. Gøtzsche PC, Andreasen F, Egsmose C, Lund B. Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. *Scand J Rheumatol* 1988;17:11-6.
10. Gøtzsche PC, Bygbjerg IC, Olesen B, Møller LH, Salim YS, Faber V. Yield of diagnostic tests of opportunistic infections in AIDS: a survey of 33 patients. *Scand J Infect Dis* 1988;20:395-402.
11. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gøtzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. *Cephalalgia* 1989;9:29-32.
12. Gøtzsche PC. Patients' preference in indomethacin trials: an overview. *Lancet* 1989;i:88-91.
13. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. *Controlled Clin Trials* 1989;10:31-56 (amendment:356).
14. Gøtzsche PC. Multiple publication in reports of drug trials. *Eur J Clin Pharmacol* 1989;36:429-32.
15. Gøtzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. *Dan Med Bull* 1989;36:395-9.
16. Gøtzsche PC. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. *Dan Med Bull* 1989;36:493-5.
17. Hørding M, Gøtzsche PC, Bygbjerg I, Pedersen M, Faber V, Berg K. Lack of immunomodulating effect of disulfiram in HIV positive patients. *Internat J Immunopharmacol* 1990;12:145-7.
18. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K. Opportunistic infections and malignancies in 231 Danish AIDS patients. *AIDS* 1990;4:233-8.
19. Jørgensen A, Shao J, Maselle S, Yangi E, Thomsen A, Matunda S, Bygbjerg I, Gøtzsche P, Svendsen J, Skinhøj P, Faber V. Evaluation of simple tests for detection of HIV antibodies: analysis of interobserver variation in Tanzania. *Scand J Infect Dis* 1990;22:283-5.
20. Jørgensen AF, Mwakyusa D, Cegielski P, Gøtzsche P, Hørding M, Lallinger G, Mbaga I, Pallangyo K, Richter C, Shao J, Bygbjerg I, Skinhøj P, Faber V. The effect of fusidic acid on Tanzanian patients with AIDS. *AIDS* 1990;4:1037-8.
21. Jørgensen AF, Jensen VG, Shao JF, Maselle S, Mbaga IM, Mwakyusa DH, Gøtzsche PC, Richter C, Pallangyo K, Cegielsky P, Lallinger G, Bygbjerg I, Skinhøj P, Faber V. Beta-2-microglobulin as a prognostic marker for patients with AIDS in Dar es Salaam, Tanzania. *AIDS* 1990;4:1168-9.

22. Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. *J Clin Epidemiol* 1990;43:1313-8.
23. Hørting M, Gøtzsche PC, Christensen LD, Bygbjerg IC, Faber V. Double-blind trial of bestatin in HIV-positive patients. *Biomed Pharmacother* 1990;44:475-8.
24. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K, Nielsen JO. Trends in survival of Danish AIDS patients from 1981 to 1989. *AIDS* 1990;4:1111-6.
25. Gøtzsche PC, Kelbæk H, Vissing SF, Nielsen SL, Munck O, Christensen NJ, Lyngsøe J, Mathiesen ER. Acute cardiovascular effects of insulin in hyperglycaemic type I diabetics. *Scand J Clin Lab Invest* 1991;51:93-7.
26. Gøtzsche PC. Patients' views on the least acceptable increase in survival with zidovudine treatment. *Scand J Infect Dis* 1991;23:509-10.
27. Gjørup IE, Gøtzsche PC, Baden H, Andersen B. Surgical treatment of morbid obesity: a survey of overall outcome 1968-89. *Dan Med Bull* 1991;38:405-7.
28. Nielsen C, Nielsen CM, Petersen JL, Gøtzsche PC, Pedersen C, Arendrup M, Vestergaard BF. Isolation of HIV from cultures of purified CD4+ lymphocytes. *J Virol Methods* 1991;35:15-25.
29. Gøtzsche PC, Lange B. Comparison of search strategies for recalling double-blind trials from MEDLINE. *Dan Med Bull* 1991;38:476-8.
30. Nordic Medical Research Councils' HIV Therapy Group. Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. *BMJ* 1992;304:13-7 (manuscript and scientific coordinator: PC Gøtzsche).
31. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. *J Clin Epidemiol* 1992;45:587-94.
32. Nielsen C, Gøtzsche PC, Nielsen CM, Gerstoft J, Vestergaard BF. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. *Antiviral Res* 1992;18:303-16.
33. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Trend towards decreased survival in patients infected with HIV resistant to zidovudine. *Scand J Infect Dis* 1992;24:563-5.
34. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Critique of meta-analysis of second-line antirheumatic drugs. *J Clin Epidemiol* 1993;46:319-21.
35. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. *BMJ* 1993;306:1093-6.
36. Gøtzsche PC. Zidovudine in HIV infection. *Ann Med* 1993;25:213-4.
37. Rasmussen MH, Andersen T, Breum L, Hilsted J, Gøtzsche PC. Observer variation in measurements of waist-hip ratio and the abdominal sagittal diameter. *Int J Obes* 1993;17:323-7.
38. Gøtzsche PC. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. *Scand J Rheumatol* 1993;22:255-60.
39. Gøtzsche PC. Is there logic in the placebo? *Lancet* 1994;344:925-6.
40. Gøtzsche PC. Steroids and peptic ulcer: an end to the controversy? *J Intern Med* 1994;236:599-601.
41. The Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. *JAMA* 1994;272:1926-31 (member of writing committee).
42. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. *BMJ* 1995;310:1495-8.
43. Ullum H, Gøtzsche PC, Victor J, Dickmeiss E, Skinhøj P, Pedersen BK. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. *J Exp Med* 1995;182:789-99.
44. Mulward S, Gøtzsche PC. Sample size of randomized double-blind trials 1976-1991. *Dan Med Bull* 1996;43:96-8.
45. Gøtzsche PC, Liberati A, Luca P, Torri V. Beware of surrogate outcome measures. *Int J Technol Ass Health Care* 1996;12:238-46.
46. Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. *Scand J Rheumatol* 1996;25:194-9.
47. Ullum H, Diamant M, Victor J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Increased circulating levels of interleukin-6 in HIV seropositive subjects. *J AIDS* 1996;13:93-9.
48. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. *Controlled Clin Trials* 1996;17:285-90.
49. Gøtzsche PC, Johansen HK. Antifungal prophylactic or empiric therapy vs placebo or no treatment in cancer patients with neutropenia (Cochrane Review). In: *The Cochrane Library*, Issue 2. Oxford: Update Software; 1997. Updated quarterly.
50. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: *The Cochrane Library*, Issue 3. Oxford: Update Software; 1997. Updated quarterly.

51. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1997. Updated quarterly.
52. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. *Eur J Clin Pharmacol* 1997;51:389-93.
53. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. *BMJ* 1997;314:1238-44.
54. Gerstoft J, Melander H, Bruun JN, Pedersen C, Gøtzsche PC, Berglund O, et al. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection: the ALTER study. *Scand J Infect Dis* 1997;29:121-8.
55. Ullum H, Victor J, Katzenstein TL, Gerstoft J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Decreased short-term production of tumor necrosis factor- α and interleukin-1 α in human immunodeficiency virus-seropositive subjects. *J Infect Dis* 1997;175:1507-10.
56. Ullum H, Cozzi-Lepri A, Bendtzen K, Victor J, Gøtzsche PC, Phillips AN, Skinhøj P, Klarlund Pedersen B. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. *AIDS Res Hum Retroviruses* 1997;13:1039-46.
57. Hammarquist C, Burr ML, Gøtzsche PC. House dust mites and control measures in the management of asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1998. Updated quarterly.
58. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 1998. Updated quarterly.
59. Gøtzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal, anti-inflammatory drugs in rheumatoid arthritis. *BMJ* 1998;316:811-8.
60. Rønn AM, Rønne-Rasmussen J, Gøtzsche PC, Bygbjerg IC. Neuropsychiatric manifestations after mefloquine therapy for *Plasmodium falciparum* malaria: comparing a retrospective and a prospective study. *Trop Med Int Health* 1998; 3:83-8.
61. Gøtzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. *BMJ* 1998;317:1105-10.
62. Hróbjartsson A, Gøtzsche PC, Gluud C. The controlled trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. *BMJ* 1998;317:1243-5.
63. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. *Pharmacogenetics* 1998;8:473-9.
64. Astrup A, Gøtzsche PC, van de Werken K, Ranneries C, Toubro S, Raben A, Buemann B. Meta-analysis of resting metabolic rate in formerly obese subjects. *Am J Clin Nutr* 1999;69:1117-22.
65. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. *JAMA* 1999;282:1752-9.
66. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 1999;2:430-6.
67. Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? *Lancet* 2000;355:129-34.
68. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. *BMJ* 2000;320:1058-61.
69. Gøtzsche PC. Do patients with osteoarthritis get the clinical research they need? *Ann Rheum Dis* 2000;59:407-8.
70. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2000;3:521-8 (updated).
71. Gøtzsche PC. Why we need a broad perspective on meta-analysis: It may be crucially important for patients. *BMJ* 2000;321:585-6.
72. Johansen HK, Gøtzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
73. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
74. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
75. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2000. (updated).

76. Olesen V, Engell L, Jensen KL, Gøtzsche PC. Randomised clinical trials in the Scandinavian Journal of Rheumatology. *Scand J Rheumatol* 2000;29:349-51.
77. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
78. Gøtzsche PC. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. *Ann Rheum Dis* 2001;60:349-52.
79. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. *Ann Intern Med* 2001;134:663-94.
80. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *N Engl J Med* 2001;344:1594-602.
81. Gøtzsche PC, Johansen HK, Burr ML, Hammarquist C. House dust mite control measures for asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
82. Olsen O, Middleton P, Ezzo J, Gøtzsche PC, Hadhazy V, Herxheimer A, et al. Quality of Cochrane reviews: assessment of sample from 1998. *BMJ* 2001;323:829-32.
83. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;5:800-7 (updated).
84. Hróbjartsson A, Gøtzsche PC. Core belief in powerful effects of placebo interventions is in conflict with no evidence of important effects in a large systematic review. *Adv Mind-Body Med* 2001;17:312-8.
85. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. *Lancet* 2001;358:1340-2.
86. Olsen O, Gøtzsche PC. Systematic review of screening for breast cancer with mammography. *Lancet* 2001 (<http://image.thelancet.com/extras/fullreport.pdf>).
87. Olsen O, Gøtzsche PC. Screening for breast cancer with mammography (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
88. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;6:894-901 (updated).
89. Gøtzsche PC. Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software (updated).
90. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
91. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
92. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
93. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;7:1063-70.
94. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagan A, Yank V, MacLennan G, Gøtzsche PC, Bero LA. Prevalence of honorary and ghost authorship in Cochrane reviews. *JAMA* 2002;287:2769-71.
95. Gøtzsche PC. Medicalisation of risk factors. *BMJ* 2002;324:890-1.
96. McDonald S, Lefebvre C, Antes G, Galandi D, Gøtzsche P, Hammarquist C, Haugh M, Jensen KL, Kleijnen J, Loep M, Pistotti V, Rütther A. The contribution of handsearching European general health care journals to the Cochrane Controlled Trials Register. *Evaluation & The Health Profession* 2002;25:65-76.
97. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;8:1203-11 (updated).
98. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2003;9:1292-300.
99. Hróbjartsson A, Gøtzsche PC. Placebo treatment versus no treatment (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
100. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
101. Gøtzsche PC. The debate on breast cancer screening with mammography is important. *J Am Coll Radiol* 2004;1:8-14.

102. Wienecke T, Gøtzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester: John Wiley & Sons, Ltd.
103. Jørgensen KJ, Gøtzsche PC. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. *BMJ* 2004;328:148-51.
104. Gøtzsche PC. On the benefits and harms of screening for breast cancer. *Int J Epidemiol* 2004;33:56-64.
105. Johansen HK, Nørregaard L, Gøtzsche PC, Pressler T, Koch C, Høiby N. Antibody response to *Pseudomonas aeruginosa* in cystic fibrosis patients: A marker of therapeutic success?-A 30-year Cohort study of survival in Danish CF patients after onset of chronic *P. aeruginosa* lung infection. *Pediatr Pulmonol* 2004;37:427-32.
106. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004;291:2457-65.
107. Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. *Clin Infect Dis* 2004;39:38-46.
108. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;11:1551-9 (updated).
109. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd (updated).
110. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. *J Intern Med* 2004;256:91-100.
111. Gøtzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD001187.
112. Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, for the CONSORT Group. Better reporting of harms in randomized trials: An extension of the CONSORT statement. *Ann Intern Med* 2004;141:781-8.
113. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;12:1702-10 (updated).
114. Schmidt LM, Gøtzsche PC. Of mites and men: reference bias in narrative review articles: a systematic review. *J Fam Pract* 2005;54:334-8.
115. Pildal J, Chan A-W, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. *BMJ* 2005;330:1049-52.
116. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;13:1525-32 (updated).
117. Karmisholt K, Gyntelberg F, Gøtzsche PC. Physical activity for primary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:86-9.
118. Karmisholt K, Gøtzsche PC. Physical activity for secondary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:90-4.
119. Gøtzsche PC. Research integrity and pharmaceutical industry sponsorship: trial registration, transparency and less reliance on industry trials are essential. *Med J Aust* 2005;182:549-50.
120. Gluud LL, Sørensen TIA, Gøtzsche PC, Gluud C. The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepato-biliary randomized clinical trials. *Am J Gastroenterol* 2005;100:2431-5.
121. Haug C, Gøtzsche PC, Schroeder TV. Registries and registration of clinical trials. *N Engl J Med* 2005;353:2811-2.
122. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;14:1498-1505 (updated).
123. Jørgensen KJ, Johansen HK, Gøtzsche PC. Voriconazole versus amphotericin B in cancer patients with neutropenia. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004707.
124. Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. *Trials* 2006;7:3.
125. Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. *BMJ* 2006;332:538-41.
126. Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. *JAMA* 2006;295:1171-3.
127. Hróbjartsson A, Gøtzsche PC. Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. *J Clin Epidemiol* 2006;59:336-8.
128. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. *JAMA* 2006;295:1645-6.

129. Johansen HK, Gøtzsche PC, Keogan MT. Vaccines for preventing infection with *Pseudomonas aeruginosa* in people with cystic fibrosis. The Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD001399 (updated).
130. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross-sectional study. *BMJ* 2006;333:231-4.
131. Due AK, Johansen HK, Gøtzsche PC. Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. *BMC Medical Research Methodology* 2006;6:40.
132. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. *BMJ* 2006;333:782-5.
133. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD001877.
134. Haedersdal M, Gøtzsche PC. Laser and photoepilation for unwanted hair growth. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004684.
135. Zahl P-H, Gøtzsche PC, Andersen JM, Mæhlen J. Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. *Dan Med Bull* 2006;53:438-40.
136. Gøtzsche PC, Mæhlen J, Zahl P-H. What is publication? *Lancet* 2006;368:1854-5.
137. Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. *PLoS Med* 2007; 4(1):e19.
138. Gøtzsche PC, Hrobjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. *JAMA* 2007; 298(4):430-7.
139. Hrobjartsson A, Gøtzsche PC. Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. *J Clin Psychol* 2007; 63(4):373-7.
140. Jørgensen KJ, Klahn A, Gøtzsche PC. Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. *BMC Med* 2007; 5:12.
141. Pildal J, Hrobjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. *Int J Epidemiol* 2007; 36(4):847-57.
142. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007; 18(6):805-35.
143. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007; 4(10):e297.
144. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Ann Intern Med* 2007; 147(8):W163-94.
145. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; 370(9596):1453-7.
146. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Epidemiology* 2007; 18(6):800-4.
147. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ* 2007; 85(11):867-72.
148. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Prev Med* 2007; 45(4):247-51.
149. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; 335(7624):806-8.
150. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007; 4(10):e296.
151. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147(8):573-7.

152. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gøtzsche PC, Harris R, Kramer BS, Ransohoff DF. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. *Arch Intern Med* 2007; 167(21):2289-95.
153. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. *Allergy* 2008 Jun;63(6):646-59.
154. Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. *BMC Med Res Methodol* 2008 Apr 21;8:22.
155. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. *Cochrane Database Syst Rev* 2008; (2):CD001187.
156. Gøtzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. *Cochrane Database Syst Rev* 2008; (3):CD000193.
157. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2008; (4):CD001399.
158. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008 Apr;61(4):344-9.
159. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; Iniciativa STROBE. [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. *Gac Sanit* 2008 Mar-Apr;22(2):144-50.
160. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. *Rev Esp Salud Publica* 2008; 82(3):251-9.
161. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. *Internist (Berl)* 2008; 49(6):688-93.
162. Zahl PH, Jørgensen KJ, Machlen J, Gøtzsche PC. Biases in estimates of overdetection due to mammography screening. *Lancet Oncol* 2008 Mar;9(3):199-201.
163. Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. *BMC Med Res Methodol* 2008; 8:60.
164. Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Reporting of sample size calculations and data analysis methods in randomized trials: comparison of publications with protocols. *BMJ* 2008;337:1404-7.
165. Madsen MV, Gøtzsche PC, Hrobjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. *BMJ* 2008;338:330-3.
166. Gøtzsche PC. Readers as research detectives. *Trials* 2009;10:2.
167. Gøtzsche P, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: the facts - or maybe not. *BMJ* 2009;338:446-8.
168. Krogsbøll LT, Hróbjartsson A, Gøtzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. *BMC Medical Research Methodology* 2009, 9:1.
169. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C. What should be done to tackle ghostwriting in the medical literature? *PLoS Med* 2009;6(2):e23.
170. Jørgensen KJ, Brodersen J, Hartling OJ, Nielsen M, Gøtzsche PC. Informed choice requires information about both benefits and harms. *J Med Ethics* 2009;35(4):268-9.
171. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; Iniciativa STROBE. [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. *Gac Sanit.* 2009 Mar-Apr;23(2):158.
172. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ* 2009;339:b2587.
173. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009 Aug 18;151(4):W65-94.
174. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009 Jul 21;6(7):e1000100.

175. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62(10):e1-34.
176. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009 Jul 21;339:b2700.
177. Tendal B, Higgins JP, Jüni P, Hróbjartsson A, Trelle S, Nüesch E, Wandel S, Jørgensen AW, Gesser K, Ilsøe-Kristensen S, Gøtzsche PC. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. *BMJ* 2009 Aug 13;339:b3128.
178. Hróbjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. *J Clin Epidemiol*. 2009 Sep;62(9):967-73.
179. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD001877.
180. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason. *J Negat Results Biomed* 2009 Jun 10;8:7.
181. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. *BMC Women's Health* 2009;9:36.
182. Jørgensen KJ, Gøtzsche PC. Who evaluates public health programmes? A review of the NHS Breast Screening Programme. *J R Soc Med* 2010;103:14-20.
183. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003974.
184. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. *BMJ* 2010;340:c1241.
185. Brodersen J, Jørgensen KJ, Gøtzsche PC. The benefits and harms of screening for cancer with a focus on breast screening. *Pol Arch Med Wewn* 2010;120:89-94.
186. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Obstet Gynecol* 2010 May;115(5):1063-70.
 - a. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010 Mar 24;7(3):e1000251.
187. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):834-40.
188. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* 2010 Jun 1;152(11):726-32.
189. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Med* 2010 Mar 24;8:18.
190. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Trials* 2010 Mar 24;11:32.
191. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c332.
192. Gøtzsche PC, Berg S. Sleep apnoea: from person to patient, and back again. *BMJ* 2010 Mar 30;340:c360.
193. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c869.
194. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):e1-37.
195. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. [CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (Chinese version)]. *Zhong Xi Yi Jie He Xue Bao* 2010;8(8):701-41.
196. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8(5):336-41.
197. Jørgensen AW, Jørgensen KJ, Gøtzsche PC. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. *Eur J Clin Pharmacol* 2010 Apr;66(4):341-7.
198. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Syst Rev* 2010;(7):CD007851.

199. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. *Dan Med Bull* 2010;57(9):A4175.
200. Lundh A, Barbateskovic M, Hrobjartsson A, Gøtzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. *PLoS Med* 2010;7(10):e1000354.
201. Gøtzsche PC, Delamothe T, Godlee F, Lundh A. Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study. *BMJ* 2010 Aug 10;341:c3926.
202. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. *BMJ* 2010;341:c3920.
203. la Cour JL, Brok J, Gøtzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. *BMJ* 2010;341:c3653.
204. Lundh A, Gøtzsche PC. Sponsorship of medical textbooks by drug or device companies. *CMEJ* 2011;1:e10-7.
205. Gøtzsche PC. Time to stop mammography screening? *CMAJ* 2011;183:1957-8.
206. Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency. *BMJ* 2011;342:d2686.
207. Gøtzsche PC, Jørgensen KJ. The Breast Screening Programme and misinforming the public. *J R Soc Med* 2011;104(9):361-9.
208. Gøtzsche PC. Niels Finsen's treatment for lupus vulgaris. *J R Soc Med* 2011;104(1):41-2.
209. Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. *Dan Med Bull* 2011;58(3):A4246.
210. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
211. Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? *Radiology* 2011;260(3):621-7.
212. Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored trials. *Lancet* 2011;378(9808):1995-6.
213. Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. *Int J Risk Saf Med* 2011;23(2):125-32.
214. Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. *BMC Med Res Methodol* 2011;11:22.
215. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
216. Tendal B, Nuesch E, Higgins JP, Juni P, Gøtzsche PC. Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. *BMJ* 2011;343:d4829.
217. Zahl PH, Gøtzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. *Lancet Oncol* 2011;12(12):1118-24.
218. Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. *Trials* 2011;12(1):249.
219. Gøtzsche PC, Jørgensen KJ, Zahl PH, Maehlen J. Why mammography screening has not lived up to expectations from the randomised trials. *Cancer Causes Control* 2012;23:15-21.
220. Gøtzsche PC. Strengthening and opening up health research by sharing our raw data. *Circ Cardiovasc Qual Outcomes* 2012;5:236-7.
221. Grønhøj Larsen C, Jørgensen KJ, Gøtzsche PC. Regular health checks: cross-sectional survey. *PLoS One* 2012;7:e33694.
222. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2012;10:28-55.
223. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. *Addict* 2012;107:900-8.
224. Lundh A, Krogsbøll LT, Gøtzsche PC. Sponsor's participation in conduct and reporting of industry trials: a descriptive study. *Trials* 2012;13:146.
225. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. *PLoS One* 2012;7:e41174.
226. Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical trials. *BMJ* 2012;345:e8522.
227. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *Cochrane Database Sys Rev* 2012;(10):CD009009.

228. Gøtzsche PC, Ioannidis JPA. Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? *BMJ (Online)* 2012;345:e7031.
229. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. *BMJ (Online)* 2012;345:e7191.
230. Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped. *BMJ* 2012;345:e8462.
231. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern Med* 2013;158:200-7.
232. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I et al. PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. *PLoS Med* 2013;10:e1001419.
233. Bindslev JBB, Schroll J, Gøtzsche PC, Lundh A. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. *BMC Med Ethics* 2013;14:19.
234. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ (Online)* 2013;346:e7586.
235. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. *Cochrane Database Syst Rev* 2013;(6):CD001877.
236. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *JAMA* 2013;309:2489-90.
237. Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? *Int J Risk Saf Med* 2013;25:155-68.
238. Rasmussen K, Jørgensen KJ, Gøtzsche PC. Citations of scientific results and conflicts of interest: the case of mammography screening. *Evidence - Based Medicine (English Edition)*. 2013;18:83-9.
239. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. *BMJ (Online)* 2013;346:f2231.
240. Wolfe N, Gøtzsche PC, Bero LA. Strategies for obtaining unpublished drug trial data: a qualitative interview study. *Syst Rev* 2013;2:31.
241. Zahl P-H, Juhl Jørgensen K, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *Br J Cancer* 2013;109:2014-9.
242. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, Krumholz HM, Gherzi D, van der Worp HB. Increasing value and reducing waste: addressing inaccessible research. *Lancet* 2014;383:257-66.
243. Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the drug industry? *BMJ* 2014 ;348:g171.
244. Maund E, Tendal B, Hróbjartsson A, Lundh A, Gøtzsche PC. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. *BMJ* 2014;348:g3555.
245. Maund E, Tendal B, Hróbjartsson A, Jørgensen KJ, Lundh A, Schroll J, Gøtzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. *BMJ* 2014;348:g3510.
246. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. *J R Soc Med* 2014;107:256-7.
247. Gøtzsche PC. Why I think antidepressants cause more harm than good. *Lancet Psychiatry* 2014;1:104-6.
248. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. *Cochrane Database Syst Rev* 2014;(9):CD002033.
249. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. *Cochrane Database Syst Rev* 2014;(9):CD000026.
250. Gøtzsche PC. "Human guinea pig" asks for animal studies. *BMJ (Online)* 2014;349:g6714.
251. Gøtzsche PC. Our prescription drugs kill us in large numbers. *Polskie Archiwum Medycyny Wewnętrznej* 2014;124:628-34.
252. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. *Cochrane Database Syst Rev* 2014;(9):CD000239.
253. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. *Cochrane Database Syst Rev* 2014;(9):CD000969.
254. Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. *Cochrane Database Syst Rev* 2014;(2):CD004707.

255. Jørgensen AW, Lundstrøm LH, Wetterslev J, Astrup A, Gøtzsche PC. Comparison of results from different imputation techniques for missing data from an anti-obesity drug trial. *PLoS One* 2014;9:e111964.
256. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014;12:1500-24.
257. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg* 2014;12:1495-99.
258. Zahl P-H, Jørgensen KJ, Gøtzsche PC. Lead-time models should not be used to estimate overdiagnosis in cancer screening. *J Gen Intern Med* 2014;29:1283-6.
259. Gøtzsche PC. Does long term use of psychiatric drugs cause more harm than good? *BMJ* 2015;350:h2435.
260. Gøtzsche PC. Mammography screening is harmful and should be abandoned. *J R Soc Med* 2015;108:341-5.
261. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777-84.
262. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2015;(8):CD001399.
263. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Screening with urinary dipsticks for reducing morbidity and mortality. *Cochrane Database Syst Rev* 2015;(1):CD010007.
264. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
265. Rasmussen KM, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of interest among trialists: a cross-sectional study. *J R Soc Med* 2015;108:101-7.
266. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Sys Rev* 2016;(9):CD007851.
267. Johansson M, Brodersen J, Gøtzsche PC, Juhl Jørgensen K. Screening for reducing morbidity and mortality in malignant melanoma (Protocol). *Cochrane Database Sys Rev* 2016;(9):CD012352.
268. Bielefeldt AØ, Danborg PB, Gøtzsche PC. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. *J R Soc Med* 2016;109:381-92.
269. Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M. "Adaptive pathways" to drug authorisation: adapting to industry? *BMJ* 2016;354:i4437.
270. Jørgensen KJ, Gøtzsche PC. Breast cancer: Updated screening guidelines - much ado about small improvements. *Nat Rev Clin Oncol* 2016;13:139-40.
271. Schroll JB, Penninga EI, Gøtzsche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. *PLoS Med* 2016;13:e1002101.
272. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *BMJ* 2016;352:i65.
273. Simonsen AL, Danborg PB, Gøtzsche PC. Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies. *Int J Risk Saf Med* 2016;28:1-12.
274. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. *CMAJ* 2017;189:E194-203.
275. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. *Ann Intern Med* 2017;166:313-23.
276. Danborg PB, Simonsen AL, Gøtzsche PC. Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies. *Int J Risk Saf Med* 2017;29(1-2):107-24.
277. Sharma T, Gøtzsche PC, Kuss O. The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. *J Clin Epidemiol* 2017;91:129-36.
278. Boesen K, Saiz LC, Erviti J, Storebø OJ, Gluud C, Gøtzsche PC, Jørgensen KJ. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. *Evid Based Med* 2017;22:143-7.
279. Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review. *J R Soc Med* 2017;110:404-10.
280. Rasmussen K, Bero L, Redberg R, Gøtzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. *BMJ* 2018;363:k3654.
281. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. *BMJ Evid Based Med* 2018;23:165-8.

282. Marquardsen M, Ogden M, Gøtzsche PC. Redactions in protocols for drug trials: what industry sponsors concealed. *J R Soc Med* 2018;111:136-41.
283. Jørgensen L, Gøtzsche PC, Jefferson T. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. *Syst Rev* 2018;7:8.
284. Gøtzsche PC. Patients not patents: Drug research and development as a public enterprise. *Eur J Clin Invest* 2018;48(2):e12875.
285. Gøtzsche PC. A totally new system is needed for drug research and development. *Eur J Clin Invest* 2018;48(2):e12883.
286. Jørgensen L, Doshi P, Gøtzsche PC, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. *BMJ* 2018;362:k3694.
287. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *Cochrane Database Syst Rev* 2019;1:CD009009.
288. Börjesson J, Gøtzsche PC. Effect of lithium on suicide and mortality in mood disorders: A systematic review. *Int J Risk Saf Med* 2019;30(3):155-166.
289. Danborg PB, Gøtzsche PC. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. *Int J Risk Saf Med* 2019 Sep 14. doi: 10.3233/JRS-195063. [Epub ahead of print].
290. Danborg PB, Valdersdorf M, Gøtzsche PC. Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review. *Int J Risk Saf Med* 2019;30(2):59-71.
291. Gøtzsche PC. What is the moral collapse in the Cochrane Collaboration about? *Ind J Med Ethics* 2019 Oct-Dec;4(4) NS:303-9.
292. Gøtzsche PC. Cochrane authors on drug industry payroll should not be allowed. *BMJ Evid Based Med* 2019 Apr 11.
293. Gøtzsche PC. Institute for Scientific Freedom. *BMJ Evid Based Med* 2019 Aug;24(4):123-4.
294. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. Screening for reducing morbidity and mortality in malignant melanoma. *Cochrane Database Syst Rev* 2019 Jun 3;6:CD012352.
295. Jørgensen L, Gøtzsche PC, Jefferson T. Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination. *BMJ Sex Reprod Health* 2019 Sep 18. pii: bmjsrh-2018-200245. doi: 10.1136/bmjsrh-2018-200245. [Epub ahead of print].
296. Paludan-Müller AS, Ogden MC, Marquardsen M, Vive J, Jørgensen KJ, Gøtzsche PC. Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols. *BMJ Open* 2019;9:e026661.
297. Gøtzsche PC, Vinther S, Sørensen A. Forced medication in psychiatry: Patients' rights and the law not respected by Appeals Board in Denmark. *Clin Neuropsychiatry* 2019;16:229-33.
298. Sharma T, Guski LS, Freund N, Meng DM, Gøtzsche PC. Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. *Int J Risk Saf Med* 2019;30:217-32.

Articles without peer review

1. Gøtzsche PC. Vandtæggers respirationsforhold (Heteroptera, Hydrocorisae). Special subject, University of Copenhagen, Faculty for Natural Sciences, 1974, 83 pp.
2. Gøtzsche PC, Marinelli K, Gylding-Sabroe JP, Larsen N-E, Sørensen K. Bioavailability of naproxen tablets and suppositories in steady state. *Scand J Rheumatol* 1983;suppl 50:1-9.
3. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. *Ugeskr Læger* 1983;145:3902-4.
4. Gøtzsche PC, Karlsen FØ, Andersen B. Dosis-respons bias. *Nord Med* 1986;101:24-5.
5. Jørgensen FR, Gøtzsche PC, Hein P, Jensen CM, Nielsen BM, Nielsen FM, Rønholt EB, Tranberg FH. Naproxen (Naprosyn) og mobilisering ved behandling af akut ankeldistorsion. *Ugeskr Læger* 1986;148:1266-8.
6. Gøtzsche PC. Vurdering af kliniske lægemiddelundersøgelser. *Ugeskr Læger* 1986;148:2417-20.
7. Ørnskov F, Gøtzsche PC. Lodtrækningsprincippet. Et forsøg på en medicinsk-etisk analyse. *Ugeskr Læger* 1988;150:897-900.
8. Gøtzsche PC. Oversigtsartikler og meta-analyser (leder). *Ugeskr Læger* 1988;150:1765-6.
9. Olesen B, Gøtzsche PC, Bygbjerg IC, Møller LH, Faber V. Hospitalsomkostninger ved diagnostik og behandling af AIDS-patienter. De første 33 patienter på Rigshospitalet. *Ugeskr Læger* 1988;150:2250-2.
10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Artikeltype og forsøgsdesign. *Ugeskr Læger* 1989;151:218-20.

11. Gøtzsche PC, Forrest M, Hermann GG, Jørgensen PE, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Analyse og tolkning af forsøgsresultater. Ugeskr Læger 1989;151:220-2.
12. Gøtzsche PC. Medicinske studenter holdning til lodtrækning og selvvalg ved brystkræftkirurgi og forslag om et nyt design. Ugeskr Læger 1989;151:2719-21.
13. Mandrup-Poulsen T, Gøtzsche PC, Ott P, Pedersen BK, Sørensen JB. Dansk intern medicin i en brydningstid på tærsklen til det 21. århundrede. Bibliotek for Læger 1991;183:69-82.
14. Gøtzsche PC. Biasproblemer i kort- og langtidsdobbelblindforsøg og forslag til forbedringer. Månedsskr Prakt Lægegern 1992;70:159-64.
15. Gøtzsche PC. Metaanalyser: metodologiske og forskningsetiske overvejelser. Bibliotek for Læger 1993;185:17-29.
16. Gøtzsche PC. Det Nordiske Cochrane Center: samarbejde om systematiske oversigter over behandlingers effekter. Nord Med 1994;109:244-5.
17. Gøtzsche PC. Meta-analyser og kvalitetssikring. Journal 1994;2:16-7.
18. Gøtzsche PC. Er placebobegrebet logisk? Bibl Læger 1995;187:71-8.
19. Rigshospitalets Forskningspolitik, 1994, 16 pp.
20. Gøtzsche PC. Supplement til Rigshospitalets Forskningspolitik, 1994, 40 pp.
21. Gøtzsche PC. Kontrollerede kliniske forsøgs troværdighed - randomiseringsproblemet. Ugeskr Læger 1995;157:597-8.
22. Gøtzsche PC, Krog JW, Moustgaard R. Bibliometrisk analyse af dansk sundhedsvidenskabelig forskning 1988-1992. Ugeskr Læger 1995;157:5075-81.
23. Gøtzsche PC. Patientbehandling og sikkerhed - Cochrane-databasernes betydning. Ugeskr Læger 1995;157:6247.
24. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. København: Det Ethiske Råd; 1996:1-32.
25. Gøtzsche PC. Det Nordiske Cochrane Center og Netværk: Nordisk samarbejde om systematiske oversigter over behandlingers effekter. Social- och Hälsovårdsnytt i Norden 1996;13:10-11.
26. Gøtzsche PC. Anvendte procedurer skal være videnskabeligt dokumenterede. Lægen 1996;14:10-2.
27. Hallas J, Gøtzsche PC. Det Nordiske Cochrane Center og Netværk - et samarbejde om systematiske oversigter over behandlingseffekter. Farmakoepti-Nyt 1996;nov:4-5.
28. Olsen O, Gøtzsche PC. Nødvendigheden af elektronisk opdaterede metaanalyser: Doppler-ultralyd i obstetrikken som eksempel. Ugeskr Læger 1997;159:27-8.
29. Gøtzsche PC. Fibigers forsøg om serumbehandling af difteri. Bibl Læger 1997;189:143-6.
30. Gøtzsche PC, Jensen KL, Hammarquist C. Randomiserede kliniske forsøg i Ugeskrift for Læger 1948-1995. Ugeskr Læger 1997;159:4762-5.
31. Gøtzsche PC. Cochrane-samarbejdets betydning for evidensbaseret medicin. Ugeskr Læger 1997;159:6721-4.
32. Gøtzsche PC. Hjælp til et evidensbaseret sundhedsvæsen. Social- & Hälsovårdsnytt i Norden 1998;2:12-13 og www.shn.dk/2-98/cochrane.htm.
33. Gøtzsche PC. Randomisering og blinding i sundhedsvidenskabelig forskning. Bibl Læger 1998;190:369-80.
34. Gøtzsche PC. Lus i skindpelsen. Ugeskr Læger 1998;160:7610-1.
35. Gøtzsche PC. Det Nordiske Cochrane Center: Status efter 5 år og fremtidsperspektiver. Ugeskr Læger 1999;161:932-4.
36. Olsen O, Gøtzsche PC. Der er noget galt i mammografistudierne! Ingen støtte til konklusionen at brystkræftscreening har gavnlig effekt. Läkartidningen 2000;97:286-7.
37. Gøtzsche PC. Cochranesamarbetets betydelse för evidensbaserad medicin. Läkartidningen 2000;97:3180-2.
38. Wille-Jørgensen PA, Gøtzsche PC. Evidensbaseret kirurgi. Ugeskr Læger 2001;163:737-40.
39. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
40. Pedersen T, Gluud CN, Gøtzsche PC, Matzen P, Wille-Jørgensen P. Hvad er evidensbaseret medicin? Ugeskr Læger 2001;163:3769-72.
41. Gøtzsche PC, Olsen O. Screening for mammacancer - to år efter. Ugeskr Læger 2002;164:204-6.
42. Gøtzsche PC, Jørgensen KJ. Screening for brystkræft - et tveægget sværd. Ugeskr Læger 2005;167:1312-4.
43. Gøtzsche PC. Uafhængig klinisk interventionsforskning er meget påkrævet. Ugeskr Læger 2005;167:1491-4.
44. Gøtzsche PC. COX-2-hæmmere og andre nonsteroidale antiinflammatoriske stoffer - hvad er fremtiden? Ugeskr Læger 2006;168:1972-3.

45. Gøtzsche PC. Paracetamol har samme effekt som nonsteroidale antiinflammatoriske stoffer ved akutte skader i bevægeapparatet. Ugeskr Læger 2006;168:1981-2.
46. Gøtzsche PC. [Freedom of expression and editorial independence: Four firings and a Kafkaian process]. Ugeskr Læger 2008 Apr 28;170(18):1537-8.
47. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. Månedsskr Prakt Lægegern 2008;86 (maj):551-7.
48. Gøtzsche PC. Kasuistiske meddelelser: fortsat en hovedkilde til forvirring, men nu på patientgruppeniveau. Bibl Læger 2009;201:87-91.
49. Gøtzsche PC, Johansen HK, Haahr MT, Altman DG, Chan A-W. Videnskabelig uredelighed. Ugeskr Læger 2009;171:1206-9.
50. Gøtzsche PC. Atter fri adgang til Cochrane-biblioteket for alle danskere. Ugeskr Læger 2009;171:932-3.
51. Gøtzsche PC, Hartling O, Nielsen M, Jørgensen KJ, Brodersen J. Invitation til brystkræftscreening: propaganda eller information? Ugeskr Læger 2009;171:1963.
52. Gøtzsche PC, Lundh A. Industrisponsoreret efteruddannelse hører ikke hjemme i et evidensbaseret sundhedsvæsen. Ugeskr Læger 2009;171:2228-9.
53. Gøtzsche PC, Jørgensen KJ. [Honest information about mammography screening, please!]. Lakartidningen. 2009;106(44):2860-1.
54. Gøtzsche PC. Evidensbaseret medicin: Ankestyrelsen mod Sundhedsstyrelsen om husstøvmider. Ugeskr Læger 2009;171:3727.
55. Jørgensen AW, Gøtzsche PC. [Insufficient access to research data not acceptable]. Ugeskr Læger 2010 May 24;172(21):1585.
56. Gøtzsche PC. Lovforslaget om kliniske forsøg viger uden om de allerstørste problemer. Ugeskr Læger 2011;173(11):840.
57. Gøtzsche PC. Hvorfor fejlinformerer Sundhedsstyrelsen om mammografiscreening? Videnskab.dk 2011; <http://videnskab.dk/krop-sundhed/hvorfor-fejlinformerer-sundhedsstyrelsen-om-mammografiscreening>.
58. Gøtzsche PC. Medicinalindustriens forskningsfusk og de købte læger. 2011; <http://videnskab.dk/kultur-samfund/medicinalindustriens-forskningsfusk-og-de-kobte-laeger>.
59. Gøtzsche PC. Åbent brev til Lundbeck om antidepressiva og selvmord. Videnskab dk 2011; <http://videnskab.dk/krop-sundhed/abent-brev-til-lundbeck-om-antidepressiva-og-selvmod>.
60. Gøtzsche PC, Tendal B, Clarke M. Review production in The Cochrane Collaboration - where is it happening and why? Cochrane Database Syst Rev 2011;Suppl 1:16-9.
61. Gøtzsche PC. We need access to all data from all clinical trials. Cochrane Database Syst Rev 2011;12:ED000035.
62. Gøtzsche PC. Hvorfor så snævre grænser for omfang i Ugeskriftet? Ugeskr Læger 2012;174:297.
63. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for breast cancer with mammography. The Nordic Cochrane Centre 2012. Available from: <http://nordic.cochrane.org/>
64. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for brystkræft med mammografi. The Nordic Cochrane Centre 2012. Available from: <http://nordic.cochrane.org/>
65. Jørgensen KJ, Gøtzsche PC. [Mortality in breast cancer is decreasing - but not because of screening. Time to abolish the mammography screening]. Lakartidningen 2012;109:690-2.
66. Jørgensen KJ, Gøtzsche PC. Rintasyöpäkuolleisuus vähenee, muttei seulonnan ansiosta. Suomen Lääkärilehti 2012;11:856-8.
67. Gøtzsche PC. Mammografiscreening gør raske kvinder syge. Fokus på Kræft og sygepleje 2012;2:18-20.
68. Gøtzsche PC. Lægers råd om medicin er ikke sunde. Politikens kronik 2012 Nov 29.
69. Gøtzsche PC. Vores lykkepille-epidemi er dybt skadelig. Berlingskes kronik 2012 Dec 16.
70. Gøtzsche PC. Overdiagnostik og overmedicinering i børnepsykiatrien. Pædagogisk Psykologisk Tidsskrift 2013;50:95-100.
71. Gøtzsche PC. Bør bekendtgørelsen om videnskabelig uredelighed revideres endnu en gang? Ugeskr Læger 2013;175:2512-3.
72. Gøtzsche PC. Alvorlige skadevirkninger af HPV-vaccinen. HPV-magasinet 2016;1:18-9.
73. Gøtzsche PC. De mange usynlige medicindødsfald: Et chokerende højt antal mennesker dør på grund af den medicin, de tager. Men ofte er de dødsfald usynlige før lægen. Løsningen er at bruge mindre medicin. Ugeskr Læger 2016;10:990-1.
74. Gøtzsche PC, Lund K. Tvangsmedisinering må forbys. Kritisk Juss 2016;2:118-57.
75. Gøtzsche PC. What do we know about the safety of the HPV vaccines? Tidsskr Nor Laegeforen 2017;137:11-2.
76. Gøtzsche PC. Hvad er der kommet ud af kræftindsatserne? Dagens Medicin 2017;2:8-9.

77. Gøtzsche PC. Chemical or Psychological Psychotherapy? 2017; Jan 29. www.madinamerica.com/.
78. Gøtzsche PC. Editorial Misconduct: Finnish Medical Journal Rejects Paper on Suicide Risk. 2017; Feb 22. www.madinamerica.com/.
79. Gøtzsche PC. Vi kan og bør undvære antidepressiv medicin: kritik af Sundhedsstyrelsen. www.deadlymedicines.dk.
80. Gøtzsche PC. DSAM-formand på afveje om antidepressiva. Dagens Medicin 2017; 3. marts.
81. Gøtzsche PC. Svar til: DepressionsForeningen: Medicin bliver ofte det eneste mulige valg. <http://videnskab.dk/> 2017; 8. marts.
82. Gøtzsche PC. Medikamentfri behandling. Dagens Medicin 2017; 10. marts.
83. Gøtzsche PC. Antidepressiva bör inte användas till barn och ungdomar. Läkartidningen 2017; 12. marts.
84. Gøtzsche PC. Antidepressiva skader mere end de gavner. Dagens Medicin 2017; 15. marts.
85. Gøtzsche PC. Norske Renate Hoel døde pludseligt og uventet i juli 2005, 34 år gammel. Ugeskr Læger 2017; 23. marts.
86. Toft B, Gøtzsche PC. Psykofarmakaepidemien kan bekæmpes. Information 2017; 3. april.
87. Jørgensen KJ, Gøtzsche PC, Jørgensen T. Tilstrækkelig evidens til at undlade tjek. Dagens Medicin 2017; 7:23.
88. Gøtzsche PC. Private virksomheder skal også kunne undersøges for videnskabelig uredelighed. Ugeskr Læger 2017; 179:633.
89. Gøtzsche PC. Røgfrit Danmark. 2017; 28. april. www.deadlymedicines.dk.
90. Gøtzsche PC. Kræftens Bekæmpelse vildleder. Dagens Medicin 2017; 17. marts.
91. Gøtzsche PC. Ingen pålitlig evidens visar att läkemedel kan förebygga självmord. Läkartidningen 2017; 1. maj.
92. Gøtzsche PC. Medicin mod Alzheimer virker ikke. Ugeskr Læger 2017; 8. maj.
93. Gøtzsche PC. Måske kan du blive medicinfri. Kronik. Jyllands-Posten 2017; 13. maj.
94. Gøtzsche PC. Skal angst behandles med piller? Angstavisen 2017; nr. 57, juni:4-6.
95. Gøtzsche PC. Depressionspiller gør større skade end gavn. Politiken 2017; 25. juni.
96. Gøtzsche PC. Hun fik den sidste kemo på vej til kapellet. Kronik. Politiken 2017; 2. juli.
97. Gøtzsche PC. Antidepressants increase the risk of suicide, violence and homicide at all ages. BMJ 2017; Sept 3. <http://www.bmj.com/content/358/bmj.j3697/rr-4>.
98. Gøtzsche PC. Psychiatry Ignores an Elephant in the Room. 2017; Sept 21. www.madinamerica.com/.
99. Gøtzsche PC. Din overvægt er en selvskabt plage - derfor skal du selv betale. Berlingske 2017; 12. aug.
100. Gøtzsche PC. What is it like being on the Governing Board? 2017; Sept 27. <http://community.cochrane.org/news/what-it-being-governing-board>.
101. Gøtzsche P. Medicinfri psykiatri. <http://tidsskriftet.no/comment-view/11179>. 2017 (ingen dato).
102. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Hvordan skal man trappe ud af psykofarmaka? Kronik. Jyllands-Posten 2017; 10. okt.
103. Danborg PB, Simonsen AL, Hróbjartsson A, Gøtzsche PC. Long-term changes in observed behaviour after exposure to psychiatric drugs: a systematic review of animal studies. Nordic Cochrane Centre 2017; Nov 14. <http://nordic.cochrane.org/>.
104. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Learning About Psychiatric Drug Withdrawal. 2017; Nov 16. <https://www.madinamerica.com/>.
105. Gøtzsche PC. Psychiatrists Roadblock Psychiatric Drug Withdrawal Initiatives: Part 1. 2017; Dec 4. <https://breggin.com/>.
106. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Udtrapning af psykofarmaka: En opfordring til de praktiserende læger. Practicus 2017; 17. dec:48-50.
107. Jørgensen KJ, Gøtzsche PC. Lægemiddelstyrelsen og lægemiddelindustrien ligner et lukket kredsløb. Ugeskr Læger 2017; 179:2336-7.
108. Gøtzsche PC. What do we know about the safety of the HPV vaccines? Tidsskr Nor Lægeforen 2017; 137:11-2.
109. Jørgensen KJ, Gøtzsche PC. Lægemiddelstyrelsen og lægemiddelindustrien ligner et lukket kredsløb. Ugeskr Læger 2017; 179:2336-7.
110. Jørgensen KJ, Gøtzsche PC. Lægemiddelstyrelsens nonchalante holdning til kræftmedicin og interessekonflikter. Ugeskr Læger 2018; 180:170-1.
111. Jørgensen KJ, Gøtzsche PC. Uhæderlighed og interessekonflikter er to forskellige ting, Henrik Ullum. Ugeskr Læger 2018; 180:172.
112. Jørgensen KJ, Gøtzsche PC. Arbejder Lægemiddelstyrelsen for patienterne? Politikens Kronik 2018; 5 febr.
113. Jørgensen KJ, Gøtzsche PC. Interessekonflikter er allerede diskvalificerende. Helligvis. Ugeskr Læger 2018; 180:268.

114. Boesen K, Simonsen AL, Danborg PB, Jørgensen KJ, Gøtzsche PC. Lægemiddelannoncer i Ugeskrift for Læger bør ikke forekomme. Ugeskr Læger 2018;180:1596-7.
115. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias: Response to the Cochrane editors. BMJ Evidence-Based Medicine. 2018; 17 September.
116. Gøtzsche PC. Moralsk ledelseskriser i Cochrane-samarbejdet. Politikens Kronik 2018; 27. sept.
117. Gøtzsche PC. Cochrane—no longer a Collaboration. <https://blogs.bmj.com/bmj/2018/11/08/peter-c-gotzsche-cochrane-no-longer-a-collaboration/>. 2018; 8 Nov.
118. Gøtzsche PC. It's Unlikely That 'Antidepressants' Have a True Effect on Depression. <https://www.madinamerica.com/2018/01/antidepressants-effect-depression/>. 2018; 8 Jan.
119. Gøtzsche PC. Psychiatrists Roadblock Psychiatric Drug Withdrawal Initiatives: Part 2.
120. Gøtzsche PC. <https://breggin.com/psychiatrists-roadblock-psychiatric-drug-withdrawal-initiatives-part-2/>. 2018 (not dated).
121. Gøtzsche PC. Endnu et tragisk selvmord på depressionspiller. Jyllands-Postens Kronik 2018; 3. feb.
122. Gøtzsche PC. Rewarding the Companies That Cheated the Most in Antidepressant Trials. March 7, 2018 <https://www.madinamerica.com/2018/03/rewarding-companies-cheated-most-antidepressant-trials/>. 2018; 7 March.
123. Gøtzsche PC. Forbruget af depressionspiller er næsten halveret hos børn og unge i Danmark. <http://www.deadlymedicines.dk/forbruget-af-depressionspiller-er-naesten-halveret-hos-born-og-unge-i-danmark/>. 2018; 1 maj.
124. Gøtzsche PC. Usage of depression pills almost halved among children in Denmark. <https://www.madinamerica.com/2018/05/usage-depression-pills-almost-halved-among-children-denmark/>. 2018; 4 May.
125. Davies J, Read J, Hengartner MP, Cosci F, Fava G, Chouinard G, van Os J, Nardi A, Gøtzsche P, Groot P, Offidani E, Timimi S, Moncrieff J, Spada M, Guy A. Clinical guidelines on antidepressant withdrawal urgently need updating. BMJ 2019 May 20;365:l2238.
126. Gøtzsche PC. The harmful myth about the chemical imbalance causing psychiatric disorders. CrossFit 2019 June 28.
127. Gøtzsche PC. "Trust me, I'm a doctor". CrossFit 2019 June 16.
128. Gøtzsche PC. Expert Report. Effect of DTP Vaccines on Mortality in Children in Low-Income Countries. 2019 June 19.
129. Gøtzsche PC. Forced drugging with antipsychotics is against the law: decision in Norway. Mad in America 2019 May 4. <https://www.madinamerica.com/2019/05/forced-drugging-antipsychotics-against-law/>
130. Gøtzsche PC. Institutional corruption in the Cochrane Collaboration. Mad in America 2019 Feb 14.
131. Gøtzsche PC. Norsk ombudsmand har afgjort, at tvangsmedicinering ikke kan begrundes. Psykiatriavisen 2019 Jan 27.
132. Gøtzsche PC. The depression pill epidemic. CrossFit 2019 June 4.
133. Gøtzsche PC. Why we're establishing an Institute for Scientific Freedom. Mad in America 2018 Dec 30.
134. Gøtzsche PC, Runcimann O, Bækgaard J, Sørensen A, Toft BS. Fem læger, psykologer og farmaceuter: Skru ned for psykofarmaka. Piller er ikke løsningen. Politikens kronik 2019 Sept 8.
135. Gøtzsche PC, Runcimann O, Bækgaard J, Sørensen A, Toft BS. The epidemic of psychiatric drug usage – taper off the pills. Deadly Medicines 2019 Oct 22.
136. Gøtzsche PC. Surviving psychiatry: a typical case of serious psychiatric drug harms. Mad in America 2020 Jan 7.

Book chapters

1. Gøtzsche PC. Problemer og muligheder ved lægemiddelundersøgelser ved reumatoid artrit. I: Jarner D, Friis J, eds. Dansk Reumatologisk Selskab: postgraduat kursus om arthritis rheumatoides. København: Astra, 1992:18-30.
2. The Cochrane Collaboration Handbook. Sackett D, Chalmers I, Silagy C, Gøtzsche PC, Dickersin K, Oxman A, eds. 1994.
3. Gøtzsche PC. Clinical practice should reflect clinical science. In: Gordon C, Christensen JP, eds. Health Telematics for Clinical Guidelines and Protocols. Amsterdam: IOS Press, 1995:17-25.
4. Gøtzsche PC. Meta-analyses: assets and limitations. In: Rose C, Larsen S, Hansen O, Bergh J, Andersen J, eds. Recent advances in breast cancer. Colloquium, Scandinavian Breast Group, Hindsgavl, Oct 11-14. Bristol-Myers Squibb, 1996:139-45.

5. Kleijnen J, Gøtzsche PC, Kunz RH, Oxman A, Chalmers I. So what's so special about randomisation? In: Maynard A, Chalmers I, eds. *Non-random reflections on health services research: on the 25 anniversary of Archie Cochrane's Effectiveness and Efficiency*. London: BMJ Books, 1997:231-49.
6. Gøtzsche PC. Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? I: *Evidensbaseret sundhedsvæsen. Rapport fra II symposium om evidensbaseret sundhedsvæsen*. København: Institut for Sundhedsvæsen, DSI rapport 98.04, 1998:119-25.
7. Gøtzsche PC. Metaanalyse - begreber og metoder. I: Andersen D, Almind G, Bock E, Havsteen B, Hørder M, Riis P. *Sundhedsvidenskabelig forskning*, 5. udg. København: FADL's Forlag, 1999:303-14.
8. Gøtzsche PC. Eettisiä näkökulmia systemaattisiin kirjallisuuskatsauksiin. Helsinki: Stakes, FinOHTAn raportti 11, 1999:19-24.
9. Gøtzsche PC, red. *Introduktion til forskning*. http://www.dadlnet.dk/dok/?2videnskab/bibliotekforlaeger/frz_forskning.htm, april 2000.
10. Gøtzsche PC. Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. I: MTV, sundhedstjenesteforskning og klinisk praksis. Rapport fra et symposium om evidensbaseret sundhedsvæsen. København: Statens Institut for Medicinsk Teknologivurdering, 2000. p. 38-44.
11. Johansen HK, Gøtzsche PC. Lægemiddelindustrien og ytringsfriheden. I: Høiby (red): *Råb op og sig stop*. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
12. Gøtzsche PC. Screeningsindustrien og ytringsfriheden. I: Høiby (red): *Råb op og sig stop*. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
13. Gøtzsche PC. Assessment bias. In: Kotz S, Balakrishnan N, Read CB, Vidakovic B, eds. *Encyclopedia of statistical sciences*, 2nd ed. Hoboken, New Jersey: John Wiley & Sons, 2006;vol 1:237-40.
14. Also published in: *Wiley Encyclopedia of Clinical Trials*, 2007. DOI: 10.1002/9780471462422.eoct062.
15. Gøtzsche PC. Commercial interests versus common goods. In: Lötjönen S, von Troil H, eds. *Bioethics, Politics and Business*. Copenhagen: Nordic Council of Ministers, TemaNord 2008:125-32. ISBN 978-92-893-1728-3.
16. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. *Medicinsk Kompendium*, 17. udg. København: Nyt Nordisk Forlag, 2009, kap. 75. ISBN 978-87-17-03933-9.
17. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Informerat samtykke ved mammografiscreening. I: Brodersen J, Hovelius B, Hvas L, eds. *Skapar vården ohälsa? Allmänmedicinske reflektioner*. Lund: Studentlitteratur AB, 2009:167-75.
18. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. I: Brodersen J, Hovelius B, Hvas L, eds. *Kan sundhedsvæsenet skabe usundhed? Refleksioner fra almen praksis*. København: Månedsskrift for Praktisk Lægegerning, 2009:153-162.
19. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. *Medicinsk Kompendium*. 18. udg. København: Nyt Nordisk Forlag; 2013, kap. 73.
20. Gøtzsche PC. Overdiagnostik og overbehandling i psykiatrien. I: Brinkmann S and Petersen, eds. *Diagnoser*. Aarhus: Klim; 2015:kapitel 7.
21. Gøtzsche PC. Psychopharmacology is not evidence-based medicine. In: Davies J, ed. *The sedated Society*. London: Palgrave Macmillan; 2017:23-50.
22. Gøtzsche PC, Lund K. Intet kunnskapsgrunnlag for tvangsmedisinering. In: Kolstad A, Kogstad R, eds. *Medikalisering av psykososiale problemer*. Oslo: Abstrakt Forlag; 2019: 175-210.

Correspondence, book reviews and similar

1. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. *Ugeskr Læger* 1984;146:207.
2. Gøtzsche PC. Turnusordningen - eller hvordan tre måneder bliver til ingenting. *Ugeskr Læger* 1984;146:2765.
3. Gøtzsche PC, Karlsen FØ. Buprenorfin og morfin. *Ugeskr Læger* 1985;147:1786.
4. Gøtzsche PC, Bygbjerg IC. Leverbiopsi ved AIDS? *Ugeskr Læger* 1988;150:173-4.
5. Gøtzsche PC. Enalapril, atenolol, and hydrochlorothiazide in hypertension. *Lancet* 1986;iii:38-9.
6. Gøtzsche PC, Karlsen FØ. Lodtrækningsprincippet. *Ugeskr Læger* 1988;150:1899-1990.
7. Gøtzsche PC, Hørting M. Kondomers sikkerhed. *Ugeskr Læger* 1988;150:1000.
8. Gøtzsche PC, Hørting M. Kondomers sikkerhed. *Ugeskr Læger* 1988;150:1697.
9. Gøtzsche PC. Ditiocarb in HIV infection. *Lancet* 1988;Oct 29:1024.

10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. (U)videnskabeligt bogholderi. Ugeskr Læger 1989;151:901.
11. Gøtzsche PC. Forskningsmetodologisk lærestykke 2. Ugeskr Læger 1989;151:319.
12. Gøtzsche PC. Forskningsmetodologiske lærestykker 4. Vurdering af korrelationer. Ugeskr Læger 1989;151:456-7.
13. Gøtzsche PC (book review). Duodenal ulcer. Analyses of 293 randomized trials. Stat Med 1990;9:1225-6.
14. Rosenberg R, Gøtzsche PC. Urigtig påstand om naturmedicin. Ugeskr Læger 1991;153:3027.
15. Gøtzsche PC (boganmeldelse). Schou I, ed. Good clinical practice. Kvalitetskrav til klinisk undersøgelse. Ugeskr Læger 1991;153:3636.
16. Gøtzsche PC. P-piller giver ikke brystkræft. Ugeskr Læger 1992;154:1437.
17. Gøtzsche PC. Kommentar (til artikel om placebo). Ugeskr Læger 1992;154:2452.
18. Gøtzsche PC. Placeboeffekt? Ugeskr Læger 1992;154:3006.
19. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine and weight loss. BMJ 1993;307:446-7.
20. Gøtzsche PC. Trials of homeopathy. Lancet 1993;June 12:1533.
21. Gøtzsche PC. Zidovudine dosage. BMJ 1993;307:682-3.
22. Gøtzsche PC. Randomiseret undersøgelse af oxytocin? Ugeskr Læger 1994;156:201.
23. Gøtzsche PC (boganmeldelse). Skrabanek P, McCormick J. Follies and fallacies in medicine, anden udgave. Ugeskr Læger 1994;156:7386.
24. Gøtzsche PC. Metaanalyse af magnesiumbehandling af myokardieinfarkt. Ugeskr Læger 1995;157:2727-8.
25. Gøtzsche PC (book review). Xenotransplantation. J Med Ethics 1995:190-1.
26. Gøtzsche PC (boganmeldelse). Chalmers I, Altman DG, eds. Systematic reviews. Ugeskr Læger 1995;157:4364-5.
27. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering? Ugeskr Læger 1996;158:6291-2.
28. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. Ugeskr Læger 1997;159:68-9.
29. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering II. Ugeskr Læger 1997;159:70-1.
30. Gøtzsche PC, Johansen HK. Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. BMJ 1997;315:489.
31. Johansen HK, Gøtzsche PC. Meta-analysis of prophylactic or empirical antifungal therapy in cancer with neutropenia. Topics Supp Care Oncol 1997;26:9-10.
32. Johansen HK, Gøtzsche PC. Use of odds ratio in calculation of number needed to treat was inappropriate. BMJ 1997;315:879.
33. Gøtzsche PC. Screening for colorectal cancer. Lancet 1997;349:356.
34. Gøtzsche PC. Greenhalgh T: How to read a paper: the basics of evidence based medicine (boganmeldelse). Ugeskr Læger 1998;160:305-6.
35. Gøtzsche PC. Løgn, forbandet løgn og ... metaanalyse (svar). Ugeskr Læger 1998;160:896-7.
36. Gøtzsche PC. Somatostatin for acute oesophageal variceal bleeding. Lancet 1998;351:911.
37. Gøtzsche PC, Johansen HK. Intermittent low dose prednisolone is safe in rheumatoid arthritis. BMJ 1998;316:1606-7.
38. Gøtzsche PC. Statusartikel om antibiotikas effekt ved halsbetændelse. Ugeskr Læger 1998;160:5376.
39. Gøtzsche PC. Hvad er relationen mellem randomiserede forsøg og evidensbaseret medicin? Ugeskr Læger 1999;161:624.
40. Gøtzsche PC. Probability without equations (book review). Stat Med 1999;18:622-3.
41. Gøtzsche PC, Hammarquist C, Burr M. Control of house dust mite in managing asthma. BMJ 1999;318:871.
42. Gøtzsche PC. Var zoneterapiforsøget randomiseret? Ugeskr Læger 1999;161:2224.
43. Gøtzsche PC. Cochranologiens voksevækst. Ugeskr Læger 1999;161:2690-1.
44. Gøtzsche PC. Om Cochrane og brugen af albumin. Ugeskr Læger 1999;161:5552-4.
45. Gøtzsche PC. Skal radikal prostatektomi indføres? Ugeskr Læger 1999;161:3472-3.
46. Gøtzsche PC. Radikal prostatektomi er udokumenteret. Ugeskr Læger 1999;161:5691-2.

47. Gøtzsche PC, Olsen O. Screening mammography re-evaluated. *Lancet* 2000;355:752.
48. Johansen HK, Gøtzsche PC. Improving the conduct and reporting of clinical trials. *JAMA* 2000;283:2789.
49. Gøtzsche PC. "Skarp kritik af mammografiscreening"(svar). *Ugeskr Læger* 2000;162:817.
50. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed. *Läkartidningen* 2000;97:3105-6.
51. Gøtzsche PC, Olsen O. God begrundelse for mammografiscreening. *Ugeskr Læger* 2000;162:4166-7.
52. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. *BMJ* 2000;321:568-9.
53. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed (author's reply). *Läkartidningen* 2000;97:3105.
54. Gøtzsche PC, Olsen O. More on mammography. *Lancet* 2000;356:1276.
55. Gøtzsche PC. Albumin: et vigtigt princip i behandlingen af dekompenaseret leversygdom (svar). *Ugeskr Læger* 2001;163:63-4.
56. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? *Ugeskr Læger* 2001;163:1576.
57. Gøtzsche PC. Er evidensbaseret medicin evidensbaseret? (svar). *Ugeskr Læger* 2001;163:182.
58. Gøtzsche PC, Olsen O. Postoperativ strålebehandling øger mortaliteten hos kvinder, der får diagnosticeret brystkræft ved screening. *Läkartidningen* 2001;98:347.
59. Wille-Jørgensen PA, Gøtzsche PC. Angående evidensbaseret kirurgi (svar). *Ugeskr Læger* 2001;163:1450.
60. Pedersen T, Møller AM, Gøtzsche PC. Albumin, evidens og metaanalyse: kan dommen appelleres (svar)? *Ugeskr Læger* 2001;163:1719-20.
61. Gøtzsche PC. Mortalitet efter humant albumin. *Ugeskr Læger* 2001;163:2260-1.
62. Gøtzsche PC. Debate on screening for breast cancer is not over. *BMJ* 2001;323:693.
63. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? *N Engl J Med* 2001;345:1278-9.
64. Gøtzsche PC. Office of NHS cancer screening programme misrepresents Nordic work in breast screening row. *BMJ* 2001;323:1131.
65. Gøtzsche PC. Cochrane-rapport om mammografiscreening. *Ugeskr Læger* 2001;163:6768.
66. Pildal, Gøtzsche PC. Kritikken er berettiget. *Läkartidningen* 2001;98:5625.
67. Gøtzsche PC. Screening for breast cancer with mammography. *Lancet* 2001;358:2167-8.
68. Gøtzsche PC. Kritik af Cochrane-oversigt om screening med mammografi er uberettiget. *Ugeskr Læger* 2002;164:653-4.
69. Gøtzsche PC. Trends in breast-conserving surgery in the Southeast Netherlands: Comment on article by Ernst and colleagues *Eur J Cancer* 2001, 37, 2435-2440. *Eur J Cancer* 2002;38:1288.
70. Gøtzsche PC. Update on effects of screening mammography. *Lancet* 2002;360:338-9.
71. Gøtzsche PC. Terlipressin for acute esophageal variceal hemorrhage. Comment on Cochrane Review. In: *The Cochrane Library*, Issue 3. Oxford: Update Software; 2002.
72. Gøtzsche PC. Beyond randomized controlled trials. *Cancer* 2002;94:578.
73. Gøtzsche PC. Mammographic screening: no reliable supporting evidence? *Lancet* 2002;359:706.
74. Gøtzsche PC. Alarmerande att screeningsförsöken inte ger minskad cancerdödlighet. *Läkartidningen* 2002;99:945.
75. Hróbjartsson A, Gøtzsche PC. Placebo og bevisbyrde. *Ugeskr Læger* 2002;164:1525-6.
76. Gøtzsche PC. Misvisende fremstilling af vort arbejde om screening med mammografi. *Läkartidningen* 2002;99:75-6.
77. Gøtzsche PC. Albumin ved dekompenaseret levercirrose. *Ugeskr Læger* 2002;164:1203-4.
78. Gøtzsche PC. Screening mammography: setting the record straight. *Lancet* 2002;359:440-1.
79. Gøtzsche PC. Misleading paper on mastectomy rates in a screening programme. <http://bmj.com/cgi/eletters/325/7361/418#24972>, 26 Aug 2002.
80. Gøtzsche PC. How to swallow one's words with a standard deviation. <http://bmj.com/cgi/eletters/325/7366/682#26186>, 11 Oct 2002.
81. Gøtzsche PC. Grønt lys for udokumenteret behandling. *Ugeskr Læger* 2002;164:3568-9.
82. Gøtzsche PC. WHO og The Lancet: ja til mammografiscreening (svar). *Ugeskr Læger* 2002;164:3082-3.

83. Gøtzsche PC. Invited reponse to "The mammographic screening trials: commentary on the recent work by Olsen and Gøtzsche". J Surg Oncol 2002;81:162-3.
84. Gøtzsche PC. Placebokirurgi: artroskopisk lavage og débridement ved slidgigt. Ugeskr Læger 2002;164:5151.
85. Gøtzsche PC. Kræftens Bekæmpelse, screening og troværdigheden. Ugeskr Læger 2003;165:611-2.
86. Gøtzsche PC. Screening mammography and mortality. Med J Aust 2003;178:189-90.
87. Gøtzsche PC, Hartling O. Er oplysninger om brystkræftscreening troværdige? Ugeskr Læger 2003;165:1068-70.
88. Gøtzsche PC. Uærlighed i lægemiddelfoprøvnninger koster samfundet dyrt. Ugeskr Læger 2003;165:1691-2.
89. Gøtzsche PC. Breast cancer screening. International Agency for Research on Cancer (IARC) Handbooks of Cancer Prevention (book review). Int J Epidemiol 2003;32:472.
90. Gøtzsche PC. Screening for breast cancer. Ann Intern Med 2003;138:769-70.
91. Gøtzsche PC, Hartling O. Svar på debatindlæg "Mister kvinder unødigt brystet, hvor der screenes for brystkræft?". Ugeskr Læger 2003;165:2586-7.
92. Gøtzsche PC. Uærlighed i lægemiddelfoprøvnninger koster samfundet dyrt (svar). Ugeskr Læger 2003;165:2673-4.
93. Gøtzsche PC, Hartling O. Svar på "Ingen evidens for at mammografiscreening fører til overbehandling". Ugeskr Læger 2003;165:3026-7.
94. Gøtzsche PC. Uærlighed i lægemiddelforskning og Cochrane Centeret (svar). Ugeskr Læger 2003;165:3098-9.
95. Gøtzsche PC. Skadelig screening for kræft. Politiken 2003; 1. juni, 3. sektion, s. 9.
96. Gøtzsche PC. Mammographic screening for breast cancer. N Engl J Med 2003;349:611.
97. Gøtzsche PC. Mortality reduction by breast-cancer screening. Lancet 2003;362:246.
98. Gøtzsche PC. Mammographic service screening and mortality. Lancet 2003;362:329-30.
99. Gøtzsche PC. Hvornår er noget skadeligt? Politiken 2003; 31. august, 3. sektion, s. 9.
100. Hróbjartsson A, Gøtzsche PC. Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms. Pain 2003;104:714-5.
101. Gøtzsche PC. "Behandlingen er veldokumenteret". Politiken 2003; 5. oktober, 3. sektion, s. 9.
102. Gøtzsche PC. Medicinalindustrien har alt for let spil. Politiken 2003; 23. november, 3. sektion, s. 9.
103. Gøtzsche PC. Ikke-evidensbaseret kommentar om nytten af madrasbetræk ved astma med husstøvmideallergi. Ugeskr Læger 2003;165:4234-5.
104. Gøtzsche PC, Johansen HK, Burr M. Are encasings effective in asthma caused by house dust mite allergens (letter)? J Allergy Clin Immunol 2003;112:220.
105. Gøtzsche PC. Martin Bland and Janet Peacock, Statistical questions in evidence-based medicine (book review). Stat Med 2003;22:2817-20.
106. Gøtzsche PC. Hendes Majestæt Dronning Ingrid XI Festforelæsning, 2003. SØLK 2003;27(9):16-20.
107. Gøtzsche PC. Ondt i ryggen og muskelrelaksantia (reply). Ugeskr Læger 2004;166:1034.
108. Jørgensen KJ, Gøtzsche PC. Websites on screening for breast cancer (authors' reply). BMJ 2004;328:769-70.
109. Gøtzsche PC. Vær forsigtig med videnskabelig uredelighed. Politiken 2004; 25. januar, 3. sektion, s. 9.
110. Gøtzsche PC, Vestergård B. Åbent bibliotek om virkninger og bivirkninger. Politiken 2004; 9. maj, 3. sektion, s. 9.
111. Gøtzsche PC. What to conclude when treatments are harmful. CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8:2-4.
112. Hróbjartsson A, Gøtzsche PC. Tesen om the powerless placebo. Ugeskr Læger 2004;166:2693-4.
113. Jørgensen KJ, Gøtzsche PC. Overfortolkning af inkonklusivt populationsstudie om brystkræft. Ugeskr Læger 2004;166:2822.
114. Gøtzsche PC. Kreativ markedsføring af margarine og medicin. Politiken 2004; 15. aug., 3. sektion, s. 9.
115. Gøtzsche P. Niels Finsen's treatment for lupus vulgaris. James Lind Library (www.jameslindlibrary.org). © Peter Gøtzsche, 2004.
116. Gøtzsche PC. Re: Trends in the treatment of ductal carcinoma *in situ* of the breast. J Natl Cancer Inst 2004;96:1257.

117. Gøtzsche PC, Jørgensen KJ. Mammografiscreening uden overdiagnostik (reply). Ugeskr Læger 2004;166:3737-8.
118. Gøtzsche PC, Møller A, Pedersen T. Albumin eller fysiologisk saltvand til volumendepleterede intensivpatienter? Ugeskr Læger 2004;166:3835.
119. Gøtzsche PC, Hróbjartsson A. Undocumented editorial on placebos. <http://bmj.bmjournals.com/cgi/eletters/329/7472/927>, 2004.
120. Gøtzsche PC. Reply: What to conclude when treatments are harmful (reply). CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8(2):4.
121. Gøtzsche PC. Misleading quotations and other errors persist in rejoinder on breast cancer screening. Int J Epidemiol 2004;33:1404.
122. Gøtzsche PC. Does exercise training lower mortality in patients with chronic heart failure? <http://bmj.bmjournals.com/cgi/eletters/328/7433/189>, 2005.
123. Gøtzsche PC, Jørgensen KJ, Thornton H. Benefits and harms of breast cancer screening. <http://bmj.bmjournals.com/cgi/eletters/330/7485/220>, 2005.
124. Gøtzsche PC, Jørgensen KJ, Hartling O. Mammografiscreening - igen. Ugeskr Læger 2005;167:783-4.
125. Gøtzsche PC, Wille-Jørgensen P. Ghost authorship in evidence-based medicine. <http://bmj.bmjournals.com/cgi/eletters/330/7484/163>, 2005.
126. Gøtzsche PC, Jørgensen KJ. Outcomes of screening mammography: information to support informed choices. <http://bmj.bmjournals.com/cgi/eletters/bmj.38398.469479.8Fv1>, 2005.
127. Gøtzsche PC. Reporting bias: any consequences for Methods and Results sections in Cochrane Reviews? Cochrane News 2005;33:1+8. Also published in: The Cochrane Collaboration Methods Groups Newsletter 2005;9:5.
128. Gøtzsche PC. Screening for brystkræft. Ugeskr Læger 2005;167:1871.
129. Gøtzsche PC, Jørgensen KJ, Thornton H. Presentation of benefits and harms needs to be balanced. BMJ 2005;330:1024.
130. Pedersen T, Møller AM, Gøtzsche PC. Human albumin in critically ill patients. Crit Care Med 2005;33:1183.
131. Gøtzsche PC. Klinisk interventionsforskning: to ledere og et indlæg. Ugeskr Læger 2005;167:2308-9.
132. Gøtzsche PC, Jørgensen KJ. Information needs to support informed choices. BMJ 2005;331:350-1.
133. Gøtzsche PC. Uafhængig klinisk interventionsforskning - eller evidence biased medicine? Ugeskr Læger 2005;167:2916-7.
134. Gøtzsche PC. ALLHAT - epokegørende? Ugeskr Læger 2005;167:3422-3.
135. Gøtzsche PC. The mammography controversy (book review). Lancet 2005;366:1519-20.
136. Gøtzsche PC, Johansen HK. Misleading statements in industry-sponsored meta-analysis of itraconazole. J Clin Oncol 2005;23:9428-9.
137. Gøtzsche PC. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 2005; 15 Oct: DOI 10.1002/ijc.21632 (and 2006;118:2648).
138. Gøtzsche PC. Screening and breast cancer. N Engl J Med 2006;354:768.
139. Gøtzsche PC. Ramifications of screening for breast cancer: overdiagnosis in the Malmö trial was considerably underestimated. BMJ 2006;332:727.
140. Haug C, Gøtzsche PC, Schroeder TV. Clinical trials report card (reply). N Engl J Med 2006;354:1429.
141. Gøtzsche PC, Jørgensen KJ. Estimate of harm/benefit ratio of mammography screening was five times too optimistic. <http://bmj.bmjournals.com/cgi/eletters/332/7543/691>, 2006.
142. Hróbjartsson A, Gøtzsche PC. Follow-up commentary. J Clin Epidemiol 2006;59:340-1.
143. Gøtzsche PC. Disclosures should not be delayed. WHO International Clinical Trials Registry Platform (ICTRP) 2006, March 31 (http://www.who.int/ictrp/006-Peter_Gøtzsche_31March06.pdf)
144. Gøtzsche PC. No double standards in research, please. <http://bmj.bmjournals.com/cgi/eletters/333/7564/374>, 2006.
145. Gøtzsche PC, Jørgensen KJ. Mammografiscreening - ideologi kontra videnskab (svar). Ugeskr Læger 2006;168:2263-5.
146. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur. Ugeskr Læger 2006;168:3635.
147. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur 2. Ugeskr Læger 2006;168:4331-2.

148. Hróbjartsson A, Gøtzsche PC. Were patients with unfavorable outcomes deleted in a covert duplicate publication reporting effect of placebo on hypertension? *Am J Hypertens* 2006;19:655.
149. Gøtzsche PC, Hróbjartsson, Marić K, Tendal B. Comment on Cochrane review CD004878. *Cochrane Database of Systematic Reviews* 2007.
150. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews and other meta-analyses, authors' reply. <http://bmj.bmjournals.com/cgi/eletters/333/7572/782>, 2006.
151. Gøtzsche PC. Mammography screening leads to an increase in mastectomies, not a decrease. <http://www.annals.org/cgi/eletters/146/7/511>, 2007.
152. Gøtzsche PC. Comment on: A Martí-Carvajal, G Salanti, AF Cardona. Human recombinant activated protein C for severe sepsis. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD004388.
153. Gøtzsche P, Hróbjartsson A, Johansen HK, Altman DG, Chan AW. Criticism is unwarranted: Please read our paper again. September 12, 2007. <http://medicine.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pmed.0040019#r1759>, 2007.
154. Gøtzsche PC. Asthma guidelines on house dust mites are not evidence-based. *Lancet* 2008; 370(9605):2100-1.
155. Gøtzsche PC. Mammographic screening from age 40 years. *Lancet* 2007; 369(9563):737-8.
156. Gøtzsche PC, Bjarnason NH. COX-2 inhibitor. *Rheumatology (Oxford)* 2007; 46(10):1623-4.
157. Gøtzsche PC, Maehlen J, Zahl PH. Undeclared motives in withdrawing a publication. *Lancet* 2007; 369(9574):1690.
158. Gøtzsche PC. Covert duplicate publication and misleading sample size calculation: commentary on Lee et al. (2008). *Int J Nurs Stud* 2008; 45(9):1398.
159. Gøtzsche PC. [Non-useful cancer survival statistics following the Danish Cancer Control Plan]. *Ugeskr Laeger* 2008; 170(43):3442.
160. Gøtzsche PC. Osteoarthritis of the knee: Topical NSAIDs have unknown effectiveness. *BMJ* 2008; 336(7640):344.
161. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Comment on review of intercessory prayer for the alleviation of ill health (Roberts L, Ahmed I, Hall S. Intercessory prayer for the alleviation of ill health). *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No.: CD000368.
162. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Estimate of breast screening benefit was 6 times too large. http://www.bmj.com/cgi/eletters/338/jan27_2/b86. 2009.
163. Gøtzsche PC, Jørgensen KJ. Stephen Duffy's claims on the benefits and harms of breast screening are seriously wrong. http://www.bmj.com/cgi/eletters/338/jan27_2/b86#212985. 2009.
164. Gøtzsche P. Are new drugs for schizophrenia better than old ones? *Lancet* 2009;373:1248.
165. Gøtzsche PC, Jørgensen KJ, Maehlen J, Zahl PH. Estimation of lead time and overdiagnosis in breast cancer screening. *Br J Cancer* 2009;100(1):219.
166. Berry DA, Baines CJ, Baum M, Dickersin K, Fletcher SW, Gøtzsche PC, Jørgensen KJ, Junod B, Maehlen J, Schwartz LM, Welch HG, Woloshin S, Thornton H, Zahl PH. Flawed inferences about screening mammography's benefit based on observational data. *J Clin Oncol* 2009;27(4):639-40.
167. Gøtzsche PC. Quackery, chiropractic and alternative medicine. *BMJ* 2009: http://www.bmj.com/cgi/eletters/339/jul08_4/b2766.
168. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Svar til Lif. *Ugeskr Læger* 2009;171:1308.
169. Hróbjartsson A, Gøtzsche PC. Acupuncture for pain: our result is robust to trial selection, and our threshold for minimal clinically effect is low. *BMJ rapid responses* (17 March); 2009.
170. Hróbjartsson A, Gøtzsche PC. Authors' reply: The quality of the acupuncture interventions was considered in our systematic review. *BMJ rapid responses* (5 October); 2009.
171. Hróbjartsson A, Gøtzsche PC. Effect of acupuncture and placebo acupuncture. *BMJ rapid responses* (3 March); 2009.
172. Hróbjartsson A, Gøtzsche PC. Reply to Linde. *FACT* 2009;14:105.
173. Gøtzsche PC, Johansen HK. Authors' reply on 'House dust mite control measures for asthma'. *Allergy* 2009;64:190.
174. Jørgensen KJ, Brodersen J, Nielsen M, Hartling OJ, Gøtzsche PC. Fall in breast cancer deaths. A cause for celebration, and caution. *BMJ*. 2009 May 27;338:b2126.

175. Jørgensen KJ, Gøtzsche PC. Fundamental mistakes in estimate of lives saved by breast screening. *BMJ* 2009; http://www.bmj.com/cgi/eletters/339/jul21_2/b2922.
176. Jørgensen KJ, Gøtzsche PC. Fundamental errors in estimate of lives saved by screening. *BMJ* 2009 Aug 25;339:b3359.
177. Jørgensen KJ, Gøtzsche PC. It is time for a new paradigm for overdiagnosis with screening mammography. http://www.bmj.com/cgi/eletters/339/jul09_1/b2587.
178. Jørgensen KJ, Gøtzsche PC. Wald et al.'s estimate of the effect of breast screening is about 10 times higher than the most reliable evidence shows. http://www.bmj.com/cgi/eletters/339/aug25_1/b3359#220390.
179. Jørgensen KJ, Gøtzsche PC. Overdiagnosis with breast screening was seriously underestimated. http://www.annals.org/content/151/10/727.full/reply#annintmed_el_120127. 2009, 20 Nov.
180. Gøtzsche PC, Johansen HK. Alpha1-antitrypsin deficiency. *N Engl J Med*. 2009;361(21):2101-2.
181. Gøtzsche PC, Jørgensen KJ. [Overdiagnosis with mammography screening is a serious problem]. *Lakartidningen*. 2009;106(47):3180.
182. Jørgensen KJ, Gøtzsche PC. No visible effect of mammography screening in Denmark. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
183. Jørgensen KJ, Gøtzsche PC. Mammography screening hasn't lived up to expectations. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
184. Gøtzsche PC. Overdiagnosis with mammography screening is around 25-50%, not 10%. http://www.bmj.com/cgi/eletters/340/jun24_1/c3106.
185. Gøtzsche P. Depression severity and effect of antidepressant medications. *JAMA* 2010 Apr 28;303(16):1597.
186. Gøtzsche PC. [When one doesn't WANT to see the evidence?]. *Ugeskr Laeger* 2010 Mar 1;172(9):733.
187. Jørgensen KJ, Gøtzsche PC. The background review for the USPSTF recommendation on screening for breast cancer. *Ann Intern Med* 2010 Apr 20;152(8):538-9.
188. Jørgensen KJ, Gøtzsche PC. Where is the effect of mammography screening? *BMJ* 2010. http://www.bmj.com/cgi/eletters/341/aug11_1/c3620.
189. Baum M, Thornton H, Gøtzsche PC, Bewley S, Jørgensen KJ, Barratt A, et al. Breast cancer awareness month. Still awaiting screening facts. *BMJ* 2010;341:c6152.
190. Gøtzsche PC, Lundh A. [The rheumatologists' conflict of interest and biological medicines]. *Ugeskr Laeger* 2010;172(45):3126.
191. Gøtzsche PC, Jørgensen KJ, Zahl PH. Breast screening: why estimates differ by a factor of 20-25. *J Med Screen* 2010;17(3):158-9.
192. Gøtzsche PC. Lessons from the mammography wars. *N Engl J Med* 2010;363(26):2569.
193. Gøtzsche PC, Jørgensen KJ. Kopans, Smith and Duffy Misrepresent Facts about Mammographic Screening. *Radiology* 2011; http://pubs.rsna.org/doi/suppl/10.1148/radiol.11110716/suppl_file/110716supp.pdf.
194. Gøtzsche PC, Lundh A. Vigtig deklarering af interessekonflikter. *Dagens Medicin* 2011;13:27.
195. Gøtzsche PC. [Control should be counteracted]. *Ugeskr Laeger* 2011;173(33):1991.
196. Gøtzsche PC. Mammography screening ten years on: reflections on a decade since the 2001 review. *The Cochrane Collaboration* 2011; <http://www.cochrane.org/news/blog/mammography-screening-ten-years-reflections-decade-2001-review>.
197. Gøtzsche PC. Stop medicinudgifternes himmelflugt. *Politiken* 5 marts 2011. <http://politiken.dk/debat/kroniker/ECE1214179/stop-medicinudgifternes-himmelflugt/>
198. Gøtzsche PC. UK drug regulator destroys all evidence after 15 years. *BMJ* 2011;343:d4203.
199. Gøtzsche PC. Unreliable studies are quoted instead of reliable ones. *CMAJ* 2011;183:1957-8.
200. Jørgensen KJ, Gøtzsche PC. Elementary flaws in the FH01 study. *Lancet Oncol* 2011;12(3):215-6.
201. Jørgensen KJ, Gøtzsche PC. The proposed review will not be independent without NICE. *BMJ* 2011;343:d7533.
202. Jørgensen KJ, Hrobjartsson A, Gøtzsche PC. Leibovici's non-study must be excluded from the Cochrane review. <http://www.cochranefeedback.com/cf/cda/citation.do?id=10133#10133> 2011;
203. Jørgensen KJ, Zahl PH, Gøtzsche PC. More on screening mammography. *N Engl J Med* 2011;364(3):284-6.

204. Krogsgaard LT, Jørgensen KJ, Gøtzsche PC. [Should the population be offered general health screenings?]. *Ugeskr Laeger* 2011;173(23):1671.
205. Lunde IM, Gøtzsche PC. [Transparency, reliability and conflict of interest]. *Ugeskr Laeger* 2011;173(33):1989.
206. Gøtzsche PC. Psykiaterne har ukritisk accepteret ssri-præparaterne. *Dagens Medicin* 2011;<http://www.dagensmedicin.dk/opinion/debat/psykiaterne-har-ukritisk-accepteret-ssri-præparaterne/>.
207. Gøtzsche PC. RE: Peter Gøtzsche burde anerkende det vigtige forskningssamarbejde, der foregår mellem læger og medicinalindustrien. *Ugeskr Laeger* 2011;173(8):599-600.
208. Gøtzsche PC. Selektiv rapportering er et stort problem. *Ugeskr Laeger* 2011;173(15):1154.
209. Gøtzsche PC. Vigtig debat om gavnlige og skadelige virkninger. *Dagens Medicin* 2011;14:29.
210. Gøtzsche PC, Jørgensen KJ. RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
211. Gøtzsche PC, Jørgensen KJ. RE: RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
212. Gøtzsche PC. Cancer specific mortality is biased in breast screening trials. *BMJ* 2011;343:d6395.
213. Gøtzsche PC. Total mortality should be the primary outcome in cancer screening trials. *BMJ* 2011;343:d6397.
214. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. RE: Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
215. Gøtzsche PC. Kopans' arguments are untruthful. 2011 Aug 18. Available at: www.auntminnie.com/index.aspx?sec=log&URL=http%3a%2f%2fwww.auntminnie.com%2findex.aspx%3fsec%3dsup%26sub%3dwom%26pag%3ddis%26ItemID%3d96204 (accessed 1 Sept).
216. Gøtzsche PC. Etisk analyse på automatpilot. *Dagens Medicin* 2012;<http://www.dagensmedicin.dk/blog/kristians-blog/blog-etisk-analyse-pa-automatpilot/>.
217. Jørgensen KJ, Gøtzsche PG. Breast Cancer Screening. An independent review is under way. *BMJ* 2012; 24 April. <http://www.bmj.com/content/343/bmj.d6843?tab=responses>
<http://www.bmj.com/content/343/bmj.d6843/rapid-responses>.
218. Jørgensen KJ, Keen JD, Zahl PH, Gøtzsche PC. The Two-County breast screening trial cannot provide a reliable estimate of the effect of breast cancer screening. *Radiology* 2012;262:729-30.
219. Gøtzsche PC. Why does the BMJ support donations of pulse oximeters when they have no effect? *BMJ* 2012;344:e409.
220. Gøtzsche PC, Jørgensen KJ. Effect of population-based screening on breast cancer mortality. *Lancet* 2012;379:1297.
221. Jørgensen KJ, Gøtzsche PC. Mammografiscreening redder ikke liv. *Dagens Medicin* 2012;28 Sept.
222. Gøtzsche PC. Screening for tvangstanker, depression og ADHD?. *Ugeskr Læger* 2013;175:77.
223. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. *BMJ* 2013;346:f398.
224. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. *N Engl J Med* 2013;368:677-8.
225. Gøtzsche PC. The EMA should continue its new openness policy despite current lawsuits. <http://www.bmj.com/content/346/bmj.f2961?tab=responses> 2013;21 June.
226. Gøtzsche PC, Maund E. Re: Restoring invisible and abandoned trials: a call for people to publish the findings. <http://www.bmj.com/content/346/bmj.f2865/rr/650915> 2013;21 June.
227. Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. *BMJ* (Online) 2013;347:f7569.
228. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. *BMJ* 2013;346:f398.
229. Gøtzsche PC. Roche continues to drag its feet on access to Tamiflu data. *BMJ* (Online) 2013;346:f3001.
230. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. *N Engl J Med* 2013;368:677-8.
231. Jørgensen KJ, Brodersen J, Gøtzsche PC. Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway. *Int J Cancer* 2013;132:1725-6.

232. Krogsbøll L, Juhl Jørgensen K, Gøtzsche PC. Social ulighed i sundhed. Ugeskr Læger 2013;175:74-5.
233. Zahl P-H, Suhrke P, Jørgensen KJ. Overdiagnosis of breast cancer in Norway: what have the authors adjusted for? Int J Cancer 2013;133:2754-5.
234. Gøtzsche PC. Nye cancermidler er ikke bedre end gamle. Ugeskr Læger 2013;175:2138.
235. Gøtzsche PC. Screening for tvangstanker, depression og ADHD? Ugeskr Læger 2013;175:77.
236. Gøtzsche PC. Tvivlsomt om lokalt appliceret NSAID har nogen effekt. Ugeskr Læger 2013;175:377-8.
237. Gøtzsche PC. Vildledning fra Kræftens Bekæmpelse om mammografiscreening. Ugeskr Læger 2013;175:1056.
238. Gøtzsche PC. Vores forskning om lægemiddelindustrien er veldokumenteret. Ugeskr Læger 2013;175:3048.
239. Gøtzsche PC. Der er ikke effekt af drotrecogin alfa ved svær sepsis. Ugeskr Læger 2013;175:903-4.
240. Gøtzsche PC, Jørgensen KJ. The benefits and harms of breast cancer screening. Lancet 2013;381:799.
241. Krogsbøll LT, Jørgensen KJ. Helbredstjek - igen. Ugeskr Læger 2013;175:532.
242. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Universal health checks should be abandoned. BMJ (Online) 2013;347:f5227.
243. Gøtzsche PC. Mammography screening increases non-breast cancer mortality. Trials 2013;14:368.
244. Gøtzsche PC. The drug industry is similarly harmful as the tobacco industry. BMJ 2013;347:f5193.
245. Gøtzsche PC. Treatment of urinary incontinence with antimuscarinic drugs is pointless. BMJ 2013;347:f5170.
246. Gøtzsche PC. "I don't want the truth, I want something I can tell Parliament!" BMJ 2013;347:f5222.
247. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Health check check. The Times 2013;Aug 20:25.
248. Gøtzsche PC. Incorrect statements by Novo Nordisk. BMJ 2013;347:f4386.
249. Gøtzsche PC. SSRI kan føre til selvmord. Dagens Medicin 2013;3Maj .
250. Gøtzsche PC. Whistleblowere skal beskyttes. Berlingske 2013;5Aug:21.
251. Gøtzsche PC. GlaxoSmithKline and Roche won't disclose their results. BMJ 2013;346:f819.
252. Gøtzsche PC. Comment on risk of bias tool. www.thecochranelibrary.com/details/editorial/5655441.2014;10 Jan.
253. Gøtzsche PC. Medicinalindustriens mange løgne. Jyllands-Postens kronik 2014;4 Jan..
254. Gøtzsche PC. Psykiatri på afveje. Politiken, kronik, 2014;6 Jan.
255. Gøtzsche PC. Lykkepille-epidemien: skyd ikke budbringeren, men se budskabet. www.epracticus.dk/flx/debat/?FID=2&MID=30 ?. 2014;13 Jan.
256. Gøtzsche PC. Toneangivende psykiatere er fortsat på afveje. Politiken, kronik, 2014;21 Jan .
257. Gøtzsche PC. Brug psykofarmaka mindre og bedre. Weekendavisen 2014;31 Jan.
258. Gøtzsche PC. Vi skal bruge mindre psykofarmaka. Ugeskriftet.dk 2014;6 Feb .
259. Gøtzsche PC. Om statistik og bias. Ugeskr Læger 2014;176:273.
260. Gøtzsche PC. Unwarranted criticism of "Psychiatry Gone Astray". davidhealy.org/get-real-peter-gotzsche-responds/ 2014;17 Feb .
261. Gøtzsche PC. Vildledende forskning og markedsføring. Ugeskr Læger 2014;176:373.
262. Gøtzsche PC. Fejlciteringer om psykiatri. Berlingske 2014;23 Feb.
263. Gøtzsche PC. Fup eller fakta om dødelig medicin. Dagens Medicin 2014;28 Feb .
264. Gøtzsche PC. Screening virker ikke. Jyllands-Posten 2014;8 Mar.
265. Gøtzsche PC. Screening af gravide for depression. Månedsskr Almen Praksis 2014;326-8.
266. Auken M, Gøtzsche PC. Kun via EU sikrer vi åbenhed i medicinalindustrien. Information 2014;5 April.
267. Auken M, Gøtzsche PC. Hyklerisk medicinalindustri. Information 2014;9 April.
268. Gøtzsche PC. Misvisende oplysninger om Cochrane. Altinget 2014;8 April.
269. Gøtzsche PC. Lægger ikke luft til mig. Politiken 2014;9 April.
270. Gøtzsche PC. Cochrane-fjeren, der blev til fem høns. Dagens Medicin 2014;11 April.
271. Gøtzsche PC. Antidepressiv medicin bør undgås til børn og unge. OCD-nyt 2014;1-14:7.
272. Gøtzsche PC. Nyhed om Cochrane var misvisende. <http://ugeskriftet.dk/nyhed/cochrane-laegger-afstand-til-goetzsche#comment-354>. 2014;8 Apr.

273. Gøtzsche PC. Adverse effects of statins are very common. 2014;21 May .
www.bmj.com/content/348/bmj.g3306/rr/698864.
274. Gøtzsche PC. Sundhedstjek: Den politiserende Sundhedsstyrelse. Dagens Medicin 2014;10 Okt.
275. Bewley S, Rose L, Gøtzsche P, Blennerhassett M, Colquhoun D, Pryke M, et al. Time to halt an out of control trial with ineffective oversight. B M J (Online) 2014;349:g5601.
276. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin. B M J (Online) 2014;349:g4790.
277. Gøtzsche PC. Muscular adverse effects are common with statins. BMJ (Online) 2014;348:g3724.
278. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. General health checks don't work. BMJ (Online) 2014;348:g3680.
279. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. J R Soc Med 2014;107:256-7.
280. Gøtzsche PC. Study of study of changes in antidepressant use after FDA warnings is not reliable. BMJ (Online) 2014;349:g5623.
281. Gøtzsche PC, Jørgensen KJ, Zahl P-H. Lead-Time Models Produce Far Too Low Estimates of Overdiagnosis With Mammographic Screening. JACR 2014;11:1098.
282. Gøtzsche PC. Przepisywane leki przyczyną zgonu rzeszy pacjentów. Pol Arch Med Wewn 2014;124:750-6.
283. Gøtzsche PC. Antidepressiva bør ikke bruges til børn og unge. Ugeskr Læger 2015;18 Maj.
284. Gøtzsche PC. Atomoxetin til ADHD er værre end sit rygte. Ugeskr Læger 2015;177:1301-2.
285. Gøtzsche PC. Author's reply to Tovey and colleagues. BMJ 2015;350:h2955.
286. Gøtzsche PC. Comment on "Our prescription drugs kill us in large numbers". Author's reply. Pol Arch Med Wewn 2015;125:106-7.
287. Gøtzsche PC. Correction to "Author's reply to Tovey and colleagues". BMJ 2015;350:h3138.
288. Gøtzsche PC. Days tomme postulat om psykiatrien. Berlingske Tidende 2015;12 Sep;16.
289. Gøtzsche PC. Gøtzsche melder psykiater til Lægeetisk Nævn. Dagens Medicin 2015;9 Okt;16:1.
290. Gøtzsche PC. Hvor stor en rolle spiller antipsykotika i overdødeligheden ved skizofreni? Ugeskr Læger 2015;177:895-6.
291. Gøtzsche PC. Psychiatric drugs should not be used in demented people. BMJ 2015;350:h369.
292. Gøtzsche PC. Psykiateren prøver at skyde budbringeren. Dagens Medicin 2015;9 Okt;16:1.
293. Gøtzsche PC. RE: Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015;351:h6019.
294. Gøtzsche PC. Re: Suicide risk assessment and intervention in people with mental illness. BMJ 2015;351:h4978.
295. Gøtzsche PC. Re: Does long term use of psychiatric drugs cause more harm than good?: Maudsley debate and guild interests. BMJ 2015;351:h2435.
296. Gøtzsche PC. Screening doesn't reduce the occurrence of advanced cancers. BMJ 2015;350:h867.
297. Gøtzsche PC. Svar: Børn behandlet med stimulanser udvikler ofte hjerneatrofi. Ugeskr Læger 2015;4 Nov .
298. Gøtzsche PC. Svar: Dokumentation for, at antidepressiva forårsager selvmord. Ugeskr Læger 2015;177:1649.
299. Gøtzsche PC. Svar: Selvmord forårsaget af antidepressiva skal frem i lyset. Ugeskr Læger 2015;177:1303.
300. Gøtzsche PC. Svar: Tavshedspligt, akademisk dannelse, lægelig pli. Ugeskr Læger 2015;18 Jun.
301. Gøtzsche PC. Tre psykiatriprofessorer på afveje. Politiken 2015;4 Sep.
302. Gøtzsche PC. Tvang i psykiatrien bør forbydes. Politiken 2015;5 Aug.
303. Gøtzsche PC. Usandheder i psykiaterformands boganmeldelse. Ugeskr Læger 2015;7 Okt 7.
304. Jørgensen KL, Gøtzsche PC. Helbredstjek til lavtuddannede er skadeligt. Ugeskr Læger 2015;11 Feb.
305. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Influence of mammography screening on use of mastectomies in Denmark. Acta Oncol 2015;133:54.
306. Gøtzsche PC. SVAR: Begrebet interessekonflikter bør ikke udvandes (svar på Kronik: Interessekonflikter – mere end ussel mammon). Ugeskr Læger 2016;19:1840.

307. Boesen K, Gøtzsche PC, Juhl Jørgensen K. Re: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Sys Rev* 2016;(1):CD005041.
308. Boesen K, Gøtzsche PC. Quality of life of adult patients with attention-deficit/hyperactivity disorder taking methylphenidate. *Arch Gen Psychiatry* 2016;73:533-4.
309. Gøtzsche PC. Abolishing forced treatment in psychiatry is an ethical imperative [Online] 2016 [Citeret 2016 jun. 17] <https://www.madinamerica.com/2016/06/abolishing-forced-treatment-in-psychiatry-is-an-ethical-imperative/>
310. Gøtzsche PC. Antidepressants are addictive and increase the risk of relapse. *BMJ* 2016;352:i574.
311. Gøtzsche PC. Antidepressants increase the risk of suicide and violence at all ages [Online] 2016 [Citeret 2016 nov. 16] <https://www.madinamerica.com/2016/11/antidepressants-increase-risk-suicide-violence-ages/>
312. Gøtzsche PC. Author's reply to Dubicka and colleagues and Stone. *BMJ* 2016;352:i915.
313. Gøtzsche PC. Bliv hjemme, næste gang du får en invitation til brystkræftscreening. *Politiken* 2016;31 Maj:1.
314. Gøtzsche PC. Bred afvisning af mere tvang på bosteder. *Ugeskr Læger* 2016;13 Sep:9.
315. Gøtzsche PC. Fakta om sundhedstjek er mørkelagt (kronik). *Politiken* 2016;14 Jan.
316. Gøtzsche PC. Forced admission and treatment in psychiatry are violations of basic human rights and must be abolished. Lecture in Anchorage 2 June 2016. <http://psychrights.org/education/GoetzscheJune2016/160602PeterGoetzscheAnchorageTalkTranscript.htm>.
317. Gøtzsche PC. Forårsager benzodiazepiner demens? *Ugeskr Læger* 2016;178:693.
318. Gøtzsche PC. Hvad er der kommet ud af vore indsatser mod kræft?: Hvad har fremskridtet på kræftområdet så været i virkeligheden? Med enkelte undtagelser ikke ret meget. *Dagens Medicin* 2016;6 Dec .
319. Gøtzsche PC. Medicin og screening mod demens virker ikke: Sundhedsministeren ønsker tidlig opsporing af demens. Men det kan gøre mere skade end gavn. *Ugeskr Læger* 2016;178:1291.
320. Gøtzsche PC. Polyfarmaci med antipsykotika øger dødeligheden: Studier, der viser, at antipsykotika med polyfarmaci ikke medfører øget dødelighed, er fejlbehæftede, mener Peter Gøtzsche. *Ugeskr Læger* 2016;178:397.
321. Gøtzsche PC. Praktiserende læger er guld værd (kronik). *Jyllands-Posten* 2016;9 Nov .
322. Gøtzsche PC Prescription drugs are the third leading cause of death [Online] 2016 [Citeret 2016 jun. 16] <http://blogs.bmj.com/bmj/2016/06/16/peter-c-gotzsche-prescription-drugs-are-the-third-leading-cause-of-death/>
323. Gøtzsche PC. Psykofarmaka øger risikoen for vold: Noget bør laves om i retspsykiatrien. *Ugeskr Læger* 2016;178:2039.
324. Gøtzsche PC. Seks ting der er værd at vide om masseskyderier. *Videnskab.dk* 2016;1 Jun.
325. Gøtzsche PC. Tvangslovene i psykiatrien skal afskaffes. *Psykologernes Fagmagasin* 2016;17 Mar.
326. Gøtzsche PC Tvangsbehandling med elektrochok bør forbydes [Online] 2016 [Citeret 2016 mar. 12] Tilgængelig fra: URL:<http://www.deadlymedicines.dk/tvangsbehandling-med-elektrochok-bor-forbydes/>
327. Gøtzsche PC. Unblinding in SSRI trials due to side effects is an important source of bias. *Br J Psychiatry* 2016;208.
328. Jørgensen KJ, Gøtzsche PC. Breast Cancer Screening: Benefit or Harm? *JAMA* 2016;315:1402.
329. Gøtzsche PC. Antidepressiva øger risikoen for selvmord og vold i alle aldre. *Medicinsk Tidsskrift* 2016; 20 Nov:506.
330. Gøtzsche PC. Patients should have free and immediate access to all information related to clinical trials. *BMJ* 2017;356:j1221.
331. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl P-H. Breast Cancer Screening in Denmark. *Ann Inter Med* 2017;167:524.
332. Gøtzsche PC. Hyllning till en enastående psykiatriker. Forord til: Breggin PR. Att sluta med psykofarmaka. Stockholm: Karneval Förlag, 2018.
333. Gøtzsche PC. What is it like being on the Governing Board? <http://community.cochrane.org/news/what-it-being-governing-board>. 2017; 27 Sept.
334. Gøtzsche PC. Akupunktur virker ikke. Det er ikke dokumenteret, at akupunktur har nogen klinisk relevant effekt på noget som helst. *Dagens Medicin* 2018; 7 feb.
335. Gøtzsche PC. Nej, jeg står ikke bag 'uhyrlige påstande'. *Politiken* 2018; 30. april.
336. Gøtzsche PC. Psychiatry is a disaster area in healthcare that we need to focus on. <http://www.bmj.com/content/360/bmj.k9/rr-15>. 2018; 10 Jan.

337. Gøtzsche PC. Skærpet tilsyn med psykiatere kan være nødvendigt. Dagens Medicin 2018; 9. feb.
338. Gøtzsche PC. Selvmordene forårsaget af depressionspiller vil fortsætte – man bør simpelthen undgå dem. Jyllands-Posten 2018; 11. feb.
339. Gøtzsche PC. Om depression, videnskabelig debat og Cochrane. Jyllands-Posten 2018; 20. feb.
340. Gøtzsche PC. Cipriani review does not add anything. Council for Evidence-based Psychiatry. 2018; 22 Feb.
341. Gøtzsche PC. Learning to live with hearing voices – an authoritative statement lacks documentation. BMJ 2018;361:k2018.
342. Gøtzsche PC. Comment on: “My OCD story: evidence-based medicine to the rescue!” Evidently Cochrane 2019 May 29.
343. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Esketamine for depression? No thanks, please. BMJ 2019 Oct 3.
344. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Re: Esketamine for treatment resistant depression. BMJ 2019 Oct 11.
345. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Re: Esketamine for treatment resistant depression. BMJ 2019 Oct 22.
346. Jørgensen KJ, Gøtzsche PC, Krogsbøll LT. Ønskedrømme til en høj pris. Dagens Medicin 2019 June 25.
347. Urato AC, Abi-Jaoude E, Abramson J, et al. National Partnership for Maternal Safety: consensus bundle on venous thromboembolism. Obstet Gynecol 2019;134:1115-7.
- 348.

Secondary publications in Danish

1. Gøtzsche PC. Reference-bias. Ugeskr Læger 1988;150:228-9.
2. Nordic Medical Research Councils' HIV Therapy Group. Dobbeltblind dosis-responsundersøgelse af zidovudin ved AIDS og fremskreden HIV-infektion. Ugeskr Læger 1993;155:104-7.
3. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Patientoverlevelse ved zidovudinresistent HIV. Ugeskr Læger 1994;156:185-6.
4. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Randomiseret undersøgelse og metaanalyse af somatostatin overfor placebo ved blødende øsofagusvaricer. Ugeskr Læger 1996;158:2393-6.
5. Gøtzsche PC. Vigtigheden af et bredt perspektiv på metaanalyse: kan have afgørende betydning for patienterne. Ugeskr Læger 2000;162:5601.
6. Gøtzsche PC. Bredt perspektiv på metaanalyse af afgørende betydning for patienten. Läkartidningen 2000;97:5882-3.
7. Gøtzsche PC. Bredt perspektiv på metaanalyse - kan have afgørende betydning for patienterne. Tidsskr Nor Lægeforen 2000;120:2810-1.
8. Hróbjartsson A, Gøtzsche PC. Hvad er effekten af placebobehandling? Ugeskr Læger 2002;164:329-33.
9. Jørgensen KJ, Gøtzsche PC. Information om brystkræftscreening på internetsider er ensidig og mangelfuld - sekundærpublikation. Ugeskr Læger 2005;167:174-8.
10. Gøtzsche PC. Forbedret rapportering af skadevirkninger i randomiserede forsøg: udvidelse af CONSORT-vejledningen. Ugeskr Læger 2005;167:1520-2.
11. Hróbjartsson A, Chan A-W, Haahr MT, Gøtzsche PC, Altman DG. Selektiv rapportering af effektmål i randomiserede forsøg. Sekundærpublikation. Ugeskr Læger 2005;167:3189-91.
12. Haug C, Gøtzsche PC, Schroeder T. Registre og registrering af kliniske forsøg. Sekundærpublikation. Ugeskr Læger 2006;168:457-8.
13. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Begrænsninger i publikationsrettighederne i industriinitierede kliniske forsøg - sekundærpublikation. Ugeskr Læger 2006;168:2467-9.
14. Jørgensen KJ, Gøtzsche PC. Er invitationer til mammografiscreening et rimeligt udgangspunkt for det informerede samtykke? Sekundærpublikation. Ugeskr Læger 2006;168:1658-60.
15. Gøtzsche PC. Er relative risici og oddsratioer i resumeer troværdige? Sekundærpublikation. Ugeskr Læger 2006;168:2678-80.

Teaching

Pregraduate courses

1988-89	Junior lecturer, Theory of Science, University of Copenhagen.
1990-2012	Lecturer, Theory of Science, University of Copenhagen.
1992-93	Lecturer, internal medicine, Hvidovre Hospital.
1993, 13 May	Course in research methodology, human biology, University of Copenhagen.
1994, 2-3 Feb	Course in research methodology, human biology, University of Copenhagen.
2003, 2 Sept	When is one drug better than another? Denmark's Pharmaceutical University.
2003, 20 Oct	Meta-analyses and their role in systematic reviews. Students in Public Health, Copenhagen.
2015, 15 April	Lectures on Theory of Science for pharmacy students.
2016, 8 Dec	Vore lægemidler er den 3. hyppigste dødsårsag. Farmaceutstuderende, København.
2017, 7 Dec	Kliniske forsøg. Farmaceutstuderende, København.
2018, 30 Apr	Psykiatriske diagnoser og depressionsmedicin. Psykogistuderende, København.
2018, 11 Oct	Kliniske forsøg. Farmaceutstuderende, København.

See also Lectures below, which include many for students.

Postgraduate courses

C: course manager.

1. Controlled clinical trials of drugs, Rigshospitalet, 3-5 Nov 1986.
2. C Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 28 Oct 1987.
3. A-course in research methodology. National Board of Health, 15 Nov 1988.
4. A-course in clinical decision theory. National Board of Health, 17 Apr 1989.
5. C Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 2 Nov 1989.
6. C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1989.
7. C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1990.
8. Course on meta-analyses. Medicom, Copenhagen, 21 May 1990.
9. C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 10 Nov 1990.
10. PhD course in medical ethics. University of Southern Denmark, 17 May 1991.
11. Course on rheumatoid arthritis. Danish Rheumatological Society, 27 Okt 1991.
12. Course in clinical trials. Apothecary Society, Hillerød, 5 Nov 1991.
13. C Literature evaluation for pharmacists, Hillerød, 2-4 Dec 1991.
14. Bias. Course in pharmacodynamics. Danish Society for Clinical Pharmacology, 6 Dec 1991.
15. C Rigshospitalet's course in clinical trials. Hillerød, 2-6 Mar 1992.
16. A-course in clinical pharmacology. National Board of Health, 3 Mar 1992.
17. Research methodology for back diseases. Back research group, Copenhagen, 2 Apr 1992.
18. A-course in clinical pharmacology. National Board of Health, 5 May 1992.
19. PhD course in medical ethics. University of Southern Denmark, 8 May 1992.
20. A-course in clinical pharmacology. National Board of Health, 6 Oct 1992.
21. C Rigshospitalet's course in clinical trials. Hillerød, 19-23 Oct 1992.

22. A-course in rheumatology. National Board of Health, 24 Nov 1992.
23. A-course in clinical pharmacology. National Board of Health, 8 Dec 1992.
24. A-course in rheumatology. National Board of Health, 9 Feb 1993.
25. A-course in clinical pharmacology. National Board of Health, 2 Mar 1993.
26. PhD course in medical ethics. University of Southern Denmark, 26 Mar 1993.
27. C Rigshospitalet's course in clinical trials. Hillerød, 31 Mar-2 Apr 1993.
28. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 19-20 Oct 1993.
29. A-course in clinical pharmacology. National Board of Health, 1 Mar 1994.
30. C PhD course in systematic reviews. Panum Institute, 11-12 Apr 1994.
31. C PhD course in systematic reviews. Panum Institute, 13-14 Apr 1994.
32. C Rigshospitalet's course in clinical trials. Hillerød, 18-22 Apr 1994.
33. Rigshospitalet's research policy. Rigshospitalet, 18 Aug 1994.
34. Course in biological psychiatric research. Bispebjerg Hospital, 17 Jan 1995.
35. Scientific dishonesty. University hospitals' Centre for Nursing Research. Rigshospitalet, 23 Feb 1995.
36. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Copenhagen, 27-29 Mar 1995.
37. Post Conference Course in Evidence-based Health Care: critical appraisal of evidence. International Society for Technology Assessment in Health Care, Dalarna, Sweden, 7-10 June 1995.
38. Use of research results. Rigshospitalet's course in quality development, 15 June 1995.
39. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 29-31 Oct 1995.
40. Course in quality development. Rigshospitalet, 13 Dec 1995.
41. C Course on systematic reviews. Panum Institute, 14-15 Dec 1995.
42. Meta-analyses and evaluation of the quality of research. Danish Society for Internal Medicine. Sundby Hospital, 27 Mar 1996.
43. C Workshop on Handsearching. Nordic Cochrane Centre, 16 Apr 1996.
44. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 17 Apr 1996.
45. C Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 18 Apr 1996.
46. Workshop on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 12-14 May 1996.
47. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 12 Sept 1996.
48. C Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 13 Sept 1996.
49. Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 4-6 Dec 1996.
50. C Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Göteborg, 17 Dec 1996.
51. The controlled clinical trial and meta-analysis. Danish Society for Internal Medicine. Sundby Hospital, 10 Mar 1997.
52. Meta-analyses and the international Cochrane Collaboration. PhD course in clinical intervention research. MEDIF/MEFA, 13 Mar 1997.
53. Second Nordic Course in Evidence-based Medicine. Oslo, 1-5 June 1997.
54. Minicourse in evidence-based medicine and the Cochrane Library. Rigshospitalet, 5 Nov 1997.
55. C Workshop on Handsearching. Nordic Cochrane Centre, 12 Nov 1997.
56. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 13 Nov 1997.
57. Course in evidence-based medicine. Rigshospitalet, 30 Apr-2 May 1998.

58. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 May 1998.
59. C Workshop on Handsearching. Nordic Cochrane Centre, 9 July 1998.
60. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Helsinki, 21 Sept 1998.
61. Course in evidence-based medicine. Rigshospitalet, 9-12 Nov 1998.
62. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 1 Mar 1999.
63. C Workshop on Handsearching. Nordic Cochrane Centre, 3 Mar 1999.
64. Course in evidence-based medicine. Panum, 14-17 June 1999.
65. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 21 Mar 2000.
66. Workshop on Handsearching. Nordic Cochrane Centre, 22 Mar 2000.
67. C Evidence-based medicine. Ringe Back Centre, 14 Apr 2000.
68. C Evidence-based cardiology. Society for Younger Cardiologists, 15 Apr 2000.
69. Workshop on controversial issues related to clinical trials and systematic reviews. Barcelona, 30 June 2000.
70. Workshop on Handsearching. Nordic Cochrane Centre, 11 Sept 2000.
71. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, 31 Jan 2001.
72. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 Mar 2001.
73. Meta-analyses - use and misuse. Danish Drug Industry Association, 30 May 2001.
74. C Workshop on Cochrane editing. Hotel Marina, 6-8 Sept 2001.
75. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Karrebæksminde, 6 Feb 2002.
76. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 23 Apr 2002.
77. Course in evidence-based medicine. Rigshospitalet, 3-4 og 17-18 June 2002.
78. C Workshop on Cochrane editing. Hotel Marina, 12-14 Sept 2002.
79. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 7 Oct 2002.
80. Meta-analysis and potential and limitations of evidence-based medicine. 6. Lübecker course, Lübeck, 9-10 Oct 2002.
81. PhD course, Panum Institute, 12 Dec 2002.
82. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Tune Landbrugsskole, 29 Jan 2003.
83. Prioritisation and evidence-based medicine. Nordjyllands Amtsråd, Ålborg, 13 Feb 2003.
84. C Workshop on Cochrane editing. Nordic Cochrane Centre, 18-19 Sept 2003.
85. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 6 Oct 2003.
86. C Quality of allocation concealment. 11th Cochrane Colloquium, Barcelona, 28 Oct 2003.
87. PhD course, Panum Institute, 24 Nov 2003.
88. Workshop on research in alternative medicine, Rigshospitalet, 30-31 Mar 2004.
89. Course in evidence-based medicine. Panum Institute, 1-2 og 14-15 June 2004.
90. C PhD course in systematic reviews and meta-analyses. Rolighed, 8-11 Nov 2004.
91. PhD course, Panum Institute, 1 Dec 2004.
92. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, KVL, 24 Aug 2005.
93. Course in infection pathogenesis. Rigshospitalet, 5 Sept 2005.
94. Doctors' Annual Gathering (Lægedage). Copenhagen, 18 Nov 2005.

95. PhD course in planning clinical research. Panum Institute, 21 Feb 2006.
96. PhD course in epidemiology. Køge, 30 Mar 2006.
97. Reporting of harms. GCP units in Denmark, Nyborg, 31 Mar 2006.
98. PhD course. Pharmaceutical University, 13 June 2006.
99. Doctors' Annual Gathering (Lægedage). Copenhagen, 11 Nov 2006.
100. Systematic reviews. Advanced seminar, Madrid, 16-17 Nov 2006.
101. Seminar on peer review and scientific misconduct. Karolinska Institute, Stockholm, 30 Nov 2006.
102. PhD course, Research ethics. Copenhagen Business School, 19 Mar 2007.
103. Course in clinical decision theory. National Board of Health, Copenhagen, 8 May 2007.
104. PhD course, Ethics in science. Faculty of life sciences, Copenhagen, 13 Aug 2007.
105. Evidence-based medicine. WHO, delegation from Uzbekistan, Hillerød, 21 Sept 2007.
106. Course for clinical microbiologists. National Board of Health, Copenhagen, 24 Sept 2007.
107. PhD course, Research ethics. Copenhagen Business School, 31 Oct 2007.
108. PhD course, Research ethics. Copenhagen Business School, 31 Mar 2008.
109. Course in Clinical Pharmacology, National Board of Health, 17 April 2008.
110. PhD course in planning clinical research. University of Copenhagen, 31 May 2008.
111. Workshop: Clinical trials registration & results reporting: The CONSORT guidelines and beyond. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
112. Course in clinical decision theory. National Board of Health, Copenhagen, 7 and 20 May 2007.
113. PhD course in clinical epidemiology. Køge, 9 Oct 2008.
114. Course in clinical decision theory. National Board of Health, Copenhagen, 19 Nov 2008.
115. Course in clinical decision theory. National Board of Health, Copenhagen, 24 Nov 2009.
116. PhD course in planning clinical research. University of Copenhagen, 21 Jan 2010.
117. Course in clinical decision theory. National Board of Health, Copenhagen, 18 May 2010.
118. Course in clinical pharmacology. National Board of Health, Copenhagen, 1 Apr 2011.
119. Forskeruddannelsesnetværket. Korsør, 17 May 2011.
120. PhD course. Herlev, 16 June 2011.
121. Highlights i reumatologien. Korsør, 1 Sept 2011.
122. PhD course, systematic reviews. University of Copenhagen, 26-29 Sept 2011.
123. Lægemedelinformation – fup eller fakta? DULM-kursus, 20 April 2012.
124. PhD course, Good scientific practice and reporting, University of Copenhagen, 26-28 Sept 2012.
125. Screening. Speciallægeuddannelsen, Sundhedsstyrelsen, Rigshospitalet, 12 May 2016.
126. Screening. Speciallægeuddannelsen, Sundhedsstyrelsen, Bispebjerg, 10 Nov 2016.
- 127.C Myter, misforståelser og skader i psykiatrien. Heldagsseminar, Sydhavnen, 15 Dec 2016.
- 128.C Myter, misforståelser og skader i psykiatrien. Heldagsseminar, Fredericia, 25 April 2017.
- 129.C Udtrapning af psykofarmaka. Heldagskursus, København, 12 June 2017.
130. Withdrawal of psychiatric drugs, Göteborg, 18-20 Oct 2017.
131. Varför SSRI & liknande antidepressiva bör utgå. Swedish Psychiatrists, Göteborg, 25 Jan 2018.
- 132.C Seminar om udtrapning af psykofarmaka. Nyborg, 16 March.
- 133.C Seminar om udtrapning af psykofarmaka. Nyborg, 16 March. (seminar held twice the same day).
- 134.C Research seminar about depression pills. Copenhagen, 14 June.
135. Power versus rationality: fighting conflicts of interest. Oxford, 19 June 2019.

Lectures

IS: invited speaker; more recent titles have been translated into English, for convenience.

1. IS Steady state pharmacokinetics of naproxen in rheumatoid arthritis. XV congrès international de rhumatologie, Paris, 21-27 June 1981.

2. Dosis-respons forhold ved rheumatoid arthritis. Ribe amts lægekredsforening, 5 nov 1982.
3. Klinisk farmakologi af naproxen (Naprosyn). Aftenmøder den 7, 11, 12, 19, 25 og 26 april 1983 på hhv. Store Kro, Fredensborg, Hotel H. C. Andersen, Odense, Hotel Impala, Silkeborg, Mogenstrup kro, Hotel Sheraton, København og Rold Storkro.
4. Månedens forskningsproblem: bedre end sig selv. Staff-meeting, amtssygehuset i Herlev, 24 okt 1985.
5. IS Reference bias. En undersøgelse af litteraturreferencemønstret i offentliggjorte lægemiddelundersøgelser. Dansk Selskab for Klinisk Farmakologi, 27 jan 1987.
6. IS Værdien af mikrobiologiske undersøgelser hos HIV-inficerede patienter. Dansk Selskab for Klinisk Mikrobiologi, 7 dec 1987.
7. Yield of diagnostic investigations of opportunistic infections in 33 AIDS patients. European Conference on Clinical Aspects of HIV Infection, Bruxelles, 10-11 Dec 1987.
8. IS Bias i dobbeltblinde undersøgelser af NSAID's med perspektiver for meta-analyser. Dansk Selskab for Medicinsk Reumatologi, 17 feb 1989.
9. IS Meta-analyse af antirheumatica behandling. Møde om den kontrollerede kliniske undersøgelses metodologi: status og perspektiver. Rigshospitalet, 28 apr 1989.
10. IS Meta-analyse af non-steroide antiinflammatoriske stoffer. Dansk Selskab for Intern Medicin, amtssygehuset i Herlev, 13 okt 1989.
11. IS Hvordan stiller man forsøg op, og hvordan analyserer man resultaterne? Årsmøde i Den Danske Klub for Centralsterilisering og Sygehushygiejne, Hotel Frederik II, Slagelse, 10 nov 1989.
12. IS Valg af NSAID ud fra kliniske studier. Specialistmøde for reumatologer, Novo Nordisk, København, 3 maj 1990.
13. IS Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. 23rd Nordic Congress of Rheumatology, Tampere, 15 June 1990.
14. IS Bias. Fællesundervisning for den medicinske blok, Hvidovre Hospital, 19 sept 1990.
15. IS Bias in NSAID trials. Italian Meeting on Meta-analysis within Hepatology. Erice, Sicilien, 3-5 Dec 1990.
16. IS Meta-analysis of multiple clinical trials: biases revealed by analysis of trials on first- and secondline antirheumatic drugs. 75th Anniversary of the Danish Association for Internal Medicine, København, 24 Jan 1991.
17. IS Muligheder og farer ved meta-analyser. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 13 feb 1991.
18. IS Hvilket NSAID er bedst? Møde arrangeret af medicinsk afdeling C med de praktiserende læger, amtssygehuset i Herlev, 9 apr 1991.
19. IS Præliminære resultater fra AIDSDOSE studiet. Dansk Selskab for Infektionsmedicin, Rigshospitalet, 30 apr 1991.
20. IS Detection of bias problems through the use of meta-analysis with examples from drug trials in rheumatology. Society for Clinical Drug Trials and Society for Medical Statistics, Stockholm, 22 May 1991.
21. IS Meta-analysis of DMARD's: are they effective? DAK's Rheuma Meeting in Tivoli, 23 Aug 1991.
22. IS Dobbelt-blind dosis responsundersøgelse af zidovudin ved AIDS og fremskreden HIV infektion, Statens Sundhedsvidenskabelige Forskningsråd, 12 nov 1991.
23. IS Internationella och nordiska erfarenheter av zidovudinbehandling. XLVIII Läkaresällskapets Riksstämman, Stockholm, 27 nov 1991.
24. Clinimetric problems in arthritis. Seminar on Bias and Controversies in Clinical Research, Rigshospitalet, 28 Feb 1992.
25. IS Problems and opportunities in drug trials with DMARDs. 24th Scandinavian Congress of Rheumatology, Malmö, 1 June 1992.
26. Meta-analysis is more than a combination of odds ratios. 13th International Meeting of International Society for Clinical Biostatistics, København, 18 Aug 1992.
27. IS Faldgruber i den klinisk kontrollerede undersøgelse. Medicinsk Selskab for Fyns Stift, Odense, 2 nov 1992.
28. IS Statistiske og filosofiske aspekter ved score systemer. Reumatologisk symposium, Nyborg, 12 mar 1993.

29. IS Good Clinical Practice. Ph.d.-studerende på Hvidovre Hospital, 30 sept 1993.
30. The Scandinavian Cochrane Centre. Dansk Selskab for Medicinsk Filosofi, Etik og Metode og Dansk Selskab for Medicinsk Prioritering, København, 13 okt 1993.
31. Det etiske grundlag for det danske sundhedsvæsen. Folkeuniversitetet, 9 november 1993.
32. IS NSAID og gastrointestinal tractus. Metodologiske problemer: er der forskelle mellem midlerne af klinisk relevans? Dansk Gastroenterologisk Selskabs E-kursus, København, 11 jan 1994.
33. IS Clinical practice should reflect clinical science. EU meeting, AIMCOM, Bruxelles, 24 Apr 1994.
34. IS Systematic reviews of clinical trials in policy making and health planning. Nordisk konference om kritiske valg i sundhedssektoren, Dansk Sygehus Institut, 26 Apr 1994.
35. IS Bias in statistical reporting: should the data analyst be blinded? Society for Clinical Trials, 15th annual meeting, Houston, Texas, 9 May 1994.
36. IS Meta-analyses in rheumatology. 25th Scandinavian Congress of Rheumatology, Lillehammer, 2 June 1994.
37. IS Cochrane Center på Rigshospitalet - meta-analyser i klinikken. Dansk Medicinsk Selskabs 75-års jubilæumsmøde, København, 26 aug 1994.
38. IS Orientering om Det Nordiske Cochrane Center. GCP-selskabet, Gentofte, 2 feb 1995.
39. IS Forskningen som prioriteringsgrundlag. Dansk Selskab for Medicinsk Prioritering, Svendborg, 28 apr 1995.
40. IS Meta-analysis of continuous data - NSAIDs as an example. Dansk Epidemiologisk Selskab, København, 2 June 1995.
41. IS Philosophy of sciences - in meta-analysis. 4th Nordic Conference for Medical Libraries, København, 24 Aug 1995.
42. IS Det internationale Cochrane-samarbejde. Nordisk medicinaldirektørmøde, Hornbæk, 1 sept 1995.
43. IS Cochrane Collaboration: implementering i *evidence based medicine*. Prioritering i sundhedsvæsenet, Ringkøbing amtskommune, 27 sept 1995.
44. Cochrane centres. 3rd Annual Cochrane Colloquium, Oslo, 6 Oct 1995.
45. IS Meta-analyses: assets and limitations. Recent Advances in Breast Cancer, Scandinavian Breast Cancer Group, Hindsgavl, 13 Oct 1995.
46. IS A randomized trial of withdrawal of slow acting antirheumatic drugs. Dansk Reumatologisk Selskab, København, 20 okt 1995.
47. IS Forskning som grundlag for indførelse af nye behandlingsmetoder. Temadag om prioritering i sundhedsvæsenet. Nordjyllands amt, Rebild, 1 nov 1995.
48. IS What is sound evidence for decision making? Medicine 96, Finnish Medical Association (Duodecim), Helsinki, 10 Jan 1996.
49. IS Cochrane Collaboration and the health care technology assessment. Medicine 96, Finnish Office for Health Care Technology Assessment, Helsinki, 11 Jan 1996.
50. IS Metaanalyse og kvalitetssikring. Dansk Selskab for Medicinsk Onkologi, Helsingør, 19 jan 1996.
51. Cochrane Centret, Rigshospitalet. Staff-meeting, Sundby Hospital, 23 jan 1996.
52. IS Nordic Cochrane Centre. H:S Forskningsråd, København, 12 mar 1996.
53. Cochrane-samarbejdet. Staff-meeting, Sankt Elisabeths Hospital, 9 apr 1996.
54. IS Bibliometrisk analyse af publikationer udgået fra danske intern medicinske afdelinger 1988-92. Dansk Selskab for Intern Medicins konference om forskningens vilkår i intern medicin, Hillerød, 12 apr 1996.
55. IS Hvad ved vi, og hvad gør vi? Temadag om tværfaglige specialeråd, Rigshospitalet, 2 maj 1996.
56. IS The Cochrane Collaboration. Cochrane Hepato-Biliary Group Meeting, Genève, 25 Aug 1996.
57. IS Medicinsk teknologivurdering og lægemidler. MEDIF's direktørseminarium, Hornbæk, 4 sept 1996.
58. Cochrane-samarbejdet. Staff-meeting, Hvidovre Hospital, 17 sept 1996.
59. IS Meta-analyser. Det Medicinske Selskab i København, Domus Medica, 24 sept 1996.
60. IS Debate: Within ten years, all health decisions will be evidence-based. 4th Annual Cochrane Colloquium, Adelaide, 24 Oct 1996.
61. IS Hvad skal diagnosen bruges til? Dansk Selskab for Klinisk Mikrobiologi, Kolding, 8 nov 1996.
62. Omsorg som effektiv behandling? Næstekærlighed, placebo og alternativ medicin. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, Domus Medica, 14 nov 1996.

63. IS MTV - en nødvendighed i sundhedsvæsenet. Dansk Selskab for Sygehusledelse, Kolding, 28 nov 1996.
64. IS Is the Norwegian Minister of Health correct in saying that the Cochrane Collaboration has made a fetish of the randomised controlled trial? Annual Meeting for The Nordic Cochrane Centre and Network, Oslo, 17 Jan 1997.
65. IS Det Nordiske Cochrane Center. H:S Bestyrelse, København, 29 jan 1997.
66. IS Cochrane centeret. Sundhedsministeriet, København, 30 jan 1997.
67. IS Evidensbaseret medicin. Foreningen af Læger i Erhvervslivet, København, 19 mar 1997.
68. IS The Cochrane Collaboration. Svensk Internmedicinsk förenings vårmöte, Umeå, 20 mar 1997.
69. IS Hvilken sundhedsforskning har vi brug for? (paneloplæg). Forskningsudvalgets og Sundhedsudvalgets høring om sundhedsforskning, Folketinget, 2 apr 1997.
70. IS Nordiska Cochrane-centrat i Köpenhamn. Karolinska Institutet och Stockholm läns landsting, 3 apr 1997.
71. IS Beware of surrogate outcome measures. Dansk hypertensionsselskabs årsmøde, Svendborg, 11 Apr 1997.
72. IS The Cochrane Collaboration. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
73. IS Systematic review: somatostatin and octreotide in bleeding oesophageal varices. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
74. IS Quality and relevance of clinical trials. European Headache Federation 5th Summer School. Rungsted, 25 Apr 1997.
75. IS Sammenfattende vurderinger af behandlingsmetoders værdi - metaanalyser. Møde mellem medlemmerne af de regionale videnskabsetiske komiteer og Den Centrale Videnskabsetiske Komité. Kolding, 21 aug 1997.
76. IS "Evidence Based Medicine". Overlægeforeningens Årsmøde. Nyborg Strand, 29 Aug 1997.
77. The Cochrane Collaboration. WHO's European Office, Programme Manager's Meeting. København, 3 Sept 1997.
78. Cochrane-samarbejdet. Lægemiddelstyrelsen. København, 16 sept 1997.
79. IS Rigshospitalets forskningsproduktion i 1994-96. Temadag om budgettering af forsknings- og udviklingsmidler, Rigshospitalet, 23 sept 1997.
80. IS Scopes and topic lists of Review Groups. 5th Annual Cochrane Colloquium, Amsterdam, 9 Oct 1997.
81. IS Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? Institut for Sundhedsvæsen, Symposium, Køge, 24 okt 1997.
82. IS Evidence based medicine - oplæg og diskussion. H:S Sundhedsfaglige råd, Rigshospitalet, 28 okt 1997.
83. IS Vad är - och hur arbetar - Cochrane Collaboration? Regiondag om Evidence Based Medicine, Södra sjukvårdsregionen, Malmö, 21 nov 1997.
84. Cochrane-samarbetet. Läkemedelsverket, Uppsala, 5 dec 1997.
85. IS Evidence-based medicine: the present and the future. Duodecim, 10th Anniversary Seminar of the Physician's Desk Reference and Database, Helsinki, 28 Jan 1998.
86. IS Ethical aspects in the use of systematic reviews in health care. Workshop on systematic reviews, Stakes & FinOHTA, Helsinki, 30 Jan 1998.
87. IS Præsentation af Cochrane-projektet. Nordisk Ministerråd, Hellerup, 25 mar 1998.
88. IS Getting the message across. 7th European Stroke Conference, Edinburgh, 29 May 1998.
89. IS RCT, status og visioner. Dansk Selskab for Medicinsk Filosofi, Etik og Metode. Festmøde, København, 17 sept 1998.
90. IS Evidensbaseret medicin. Farmaciens Dag, Danmarks Farmaceutiske Selskab, København, 2 okt 1998.
91. IS Demonstrating evidence in action: a case study. 6th Annual Cochrane Colloquium, Baltimore, 25 Oct 1998.
92. IS Bias i randomiserade försök och meta-analyser. Svenska Läkarsällskapets Riksstämman, Göteborg, 24 nov 1998.
93. IS Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. Statens Sundhedsvidenskabelige Forskningsråd og Statens Institut for Medicinsk Teknologivurdering, Middelfart, 11 feb 1999.

94. IS Evidens fra systematiske reviews. Dansk Endokrinologisk Selskab, Domus Medica, 22 feb 1999.
95. IS Overall status of the Cochrane Collaboration. Cochrane Colorectal Cancer Group meeting, København, 19 Mar 1999.
96. Det Nordiske Cochrane Center og evidensbaseret medicin. Folketingets Sundhedsudvalg, 24 mar 1999.
97. IS Evidensbaseret klinisk praksis. Områdeledelsens Stab og Sekretariat, Odense Universitetshospital, 8 apr 1999.
98. IS Hvad kan Cochrane-databasen bruges til? Dansk Kirurgisk Selskabs Forårsmøde, Herlev, 15 apr 1999.
99. Presentation of The Cochrane Collaboration. Exploratory meeting to consider establishing a Russian Branch of The Nordic Cochrane Centre. Hotel Akademicheskaya, Moskva, 7-8 June 1999.
100. IS Mega-trials or meta-analysis? European Society for Paediatric Research, Panum Institutet, 28 June 1999.
101. IS Hvad er rationel farmakoterapi? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 22 okt 1999.
102. IS The Cochrane Collaboration i Norden. SBU, Evidensbaseret sjukvård. Stockholm, 27 jan 2000.
103. IS Hvad vil det sige, at behandlingen er evidensbaseret? Jydsk Medicinsk Selskab, Århus, 5 apr 2000.
104. IS Meta-analyser, systematiske reviews. Kursus i evidensbaseret klinik. Frederiksberg hospital, 9 juni 2000.
105. IS Systematic review of breast cancer screening. Meeting with local minister of health and specialist societies. Barcelona, 29 June 2000.
106. IS History of The Cochrane Collaboration. 8th Cochrane Colloquium, Cape Town, 25 Oct 2000.
107. IS Er det alvorlige mangler ved det vitenskapelige grunnlaget for mammografi-screeningen? Årsmøde i Norsk Patologforening, Oslo, 10 nov 2000.
108. IS Är mammografiscreening värdefull? Svensk förening för radiologisk bröstdiagnostik, Rigshospitalet, 16 nov 2000.
109. IS Systematic review of mass screening for breast cancer with mammography. Dansk Selskab for Medicinsk Onkologi, Panum, 20 Nov 2000.
110. IS Hvornår er ændret klinisk praksis nødvendig? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 23 nov 2000.
111. IS Evidensbaseret medicin. KAS Herlev, 28 nov 2000.
112. IS Fallstudie Mammographie Screening. Bern's Universität, 6 Dec 2000.
113. IS Cochrane Collaboration. SBU, Stockholm, 7 feb 2001.
114. IS Utility of mammographic screening for detection of breast cancer and the measurement of the placebo effect. São Paulo, 23 Feb 2001.
115. IS Screening for breast cancer with mammography: a systematic review. Breast and Cervical Cancer Screening Conference, Bielefeld, 6 Apr 2001.
116. IS Concept and methods in Cochrane reviews. Dansk Selskab for Psykiatrisk Epidemiologi, 20 apr 2001.
117. IS Putting the evidence into breast cancer care - challenges and controversies for the future. National Breast Cancer Coalition's Annual Meeting, Washington, 6 May 2001.
118. IS Ankelligament-metaanalyse. Dansk Fod- og Ankelkirurgisk Selskab, Gjern, 18 aug 2001.
119. Misleading publications of major mammography screening trials in major medical journals. Fourth International Congress on Peer Review in Biomedical Publication, Barcelona, 14 Sept 2001.
120. IS Cochrane reviews - the clinical application of evidence. Skandinavisk Forening af Oral og Maxillofacial Kirurger, 21 Sept 2001.
121. IS Hvilke problemer ved screeningsmetoder er politikere ikke blevet informeret om? Dansk Selskab for Medicinsk Prioritering og Dansk Selskab for Almen Medicin, København, 30 okt 2001.
122. IS Mammografiscreening - undersøgt i en metaanalyse. Dansk Selskab for Almen Medicins Risikogruppe, Silkeborg, 23 nov 2001.
123. IS Metaanalyse. Foredrag efter modtagelse af Niels A Lassen prisen, Bispebjerg Hospital, 7 dec 2001.
124. IS Metaanalyse, styrke og svaghed, metodologiske betragtninger. Gruppen af Yngre Gastroenterologer På Vej, København, 12 dec 2001.
125. IS Metaanalyser - hvad kan og skal de bruges til? Selskabet for Teoretisk og Anvendt Terapi, København, 7 feb 2002.

126. IS The old vs the new review. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
127. IS The importance of the published, peer reviewed protocol. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
128. IS Problemer ved vurderingen af lægemiddelundersøgelser. Dansk Reumatologisk Selskab, Horsens, 19 apr 2002.
129. IS Conflict of interest. Cochrane Colorectal Cancer Group's Status Meeting, København, 19 Apr 2002.
130. IS Lægers videnskabelige ytringsfrihed, interkollegiale problemer. Dansk Selskab til Sikring af Lægers Ytringsfrihed, København, 3 juni 2002.
131. IS Things to be cautious about when making policy recommendations based on systematic reviews, randomised trials, cohort studies, and expert opinion. Delegates from The Ministry of Health, China, Rigshospitalet, 20 Aug 2002.
132. IS Forskning er ikke fuldstændig objektiv - den kan drejes og vendes, så den passer politisk. Kursus for journalister, København, okt 2002.
133. IS Mammascreeing: a critical analysis. Wenckebach Symposium, Groningen, 5 Nov 2002.
134. IS Dissemination experiences in the Cochrane Collaboration. Nordic Campbell Center inauguration seminar, Helsingør, 13 Nov 2002.
135. IS Hva kan epidemiologer bidra med i deatten om mammografiscreening? Den tiende norske epidemiologikonferansen, Trondheim, 14 nov 2002.
136. IS Unambiguous and comparable results as quality measures in health related research. Is randomisation a necessity to obtain reliable knowledge? How are self-selection and self-conscious efforts handled? Conference arrangeret af Videns- og Forskningscenter for Alternativ Behandling, Århus, 27 Nov 2002.
137. IS Ten years of the Cochrane Collaboration. Seminar for Finnish doctors, Biomedicum, Helsinki, 23 Jan 2003.
138. IS Dronning Ingrid's Festforelæsning. Hvad er vore behandlinger værd? Åbenrå Sygehus, 8 maj 2003.
139. IS Temaeftermiddag. Evidensbaseret forebyggelse og behandling. Ålborg Sygehus, 9 sept 2003.
140. IS Plenary lecture. Pitfalls in evidence based medicine. 4th Congress, European Federation of Internal Medicine, Berlin, 11 Sept 2003.
141. IS Debate. Population based breast cancer screening. ECCO 12, Federation of European Cancer Societies, København, 25 Sept 2003.
141. Evidensbaseret forbrugeroplysning. Konference arrangeret af Forbrugerrådet og Det Nordiske Cochrane Center, Christiansborg, København, 22 okt 2003.
142. IS Plenary lecture. Conflicts of interest. XIth Cochrane Colloquium, Barcelona, 27 Oct 2003.
143. IS Evidensbaseret medicin: eksempler og betydning. Møde om medicinforsøg, arrangeret af Institut for Rationel Farmakoterapi, København, 19 nov 2003.
144. Discrepancies between protocols and publications: Evidence of outcome reporting bias in randomised trials. De Videnskabsetiske komitéer for Københavns og Frederiksbergs kommuner, 11 dec 2003.
145. IS Experiences within the Cochrane Collaboration. WHO workshop on grading of evidence, København, 16 Dec 2003.
146. IS Evidensbaseret medicin. Sosial- og helsedirektoratet, Oslo, 15 jan 2004.
147. IS Why is the practice of evidence-based medicine more difficult than it seems? Læknadager 2004, Reykjavik, 23 Jan 2004.
148. IS Doctor, should I have a mammography? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
149. IS The management of hypertension, should we rely on the good old drugs? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
150. IS Evidence-based microbiology. Dansk Selskab for Klinisk Mikrobiologi, uddeling af Wyeth-prisen for 2003, København, 27 jan 2004.
151. IS Mammografi-screening, contra. Foreningen af Yngre Gynækologer og Obstetrikere Forårsmøde, Odense, 18 marts 2004.
152. IS Evidensgrundlag. Institut for Rationel Farmakoterapi, møde om kriterier for rationelt valg af lægemidler, Kolding, 30 april 2004.
153. IS Hvad er vore behandlinger værd? Gentofte-Vangede Rotary Klub, 26 aug 2004.

154. IS Empirical evidence for selective reporting of outcomes in randomised trials. Den Centrale Videnskabsetiske Komité, København, 27 aug 2004.
155. IS Risikovurdering og formidling omkring screening, og industrisponsoreret forskning. Det Ethiske Råd, København, 16 sept 2004.
156. IS Fortsat udbredelse af mammografiscreening. Nordjyllands amtsråd, Ålborg, 19 nov 2004.
157. IS Harry Boström föreläsningen: Cochrane-samarbetet och evidensbaserad medicin. Riksstämman, Svensk Internmedicinsk Förening, Göteborg 25 nov 2004.
158. IS Nutidens og fremtidens krav om evidens for det lægelige arbejde. Nordjyllands Lægekredsforenings 150 års jubilæum, Ålborg, 26 nov 2004.
159. IS Blinding. Expert Discussion Workshop. Institute of Public Health, Cambridge, 17 maj 2005.
160. Sponsorship, bias and methodology: Cochrane Reviews compared with industry-sponsored meta-analyses of the same drugs. 5th International congress on peer review and biomedical publication, Chicago, 17 Sept 2005.
161. Are relative risks and odds ratios in abstracts believable? 5th International congress on peer review and biomedical publication, Chicago, 18 Sept 2005.
162. IS Medical statistics in practice: Dr Jekyll and Mr Hyde. 10 year celebration, Centre for Statistics in Medicine, Oxford, 20 Sept 2005.
163. IS Introduction to key concepts and principles of evidence-based medicine. Moscow Medical Academy, 13 Oct 2005.
164. Constraints on academic freedom in industry-initiated clinical trials. XIII Cochrane Colloquium, Melbourne, 22-26 Oct 2005.
165. IS Should we believe in epidemiology? Scientific seminar, Royal Veterinary and Agricultural University, Copenhagen, 14 Nov 2005.
166. IS Evidence in health care. Health Administration, Copenhagen County, 28 April 2006.
167. IS Commercial interests versus common goods. Nordic Committee on Bioethics, Malmö, 16 Oct 2006.
168. Far too many excluded studies listed in Cochrane Reviews. XIV Cochrane Colloquium, Dublin, 23-26 Oct 2006.
169. IS Cochrane Library. Ministry of Health, Warszawa, 18 Dec 2006.
170. IS Editorial misconduct. Finnish Medical Association, Helsinki, 25 Jan 2007.
171. IS Evidence-based health care. Institute for Competence Development, Copenhagen, 27 Feb 2007.
172. IS Commercial interests. Institute of Technology, Copenhagen, 14 Mar 2007.
173. IS Screening. Danish Society for Pathology, Copenhagen, 23 Mar 2007.
174. IS Selective reporting. Dutch Cochrane Centre's 12.5-year anniversary, Amsterdam, 18 April 2007.
175. IS Evidence-based health care. Aalborg University Hospital, 26 Sept 2007.
176. IS Bias in drug trials. Eur Assoc Clin Pharmacol, Amsterdam, 29 Aug 2007.
177. IS Commercial influence on clinical research. University of Southern Denmark, 15 Nov 2007.
178. IS Evidence-based medicine. Clinical microbiologists, Copenhagen, 21 Nov 2007.
179. IS Evidence for prevention. National Board of Health, Nyborg, 26 Nov 2007.
180. IS Can we trust clinical research results? Medical Society of Copenhagen, 27 Nov 2007.
181. IS Tainted evidence: drug companies and the power of marketing. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
182. IS Research collaboration. Danish Society for Theory in Medicine, Panum, 21 Apr 2008.
183. IS Mammography screening. Dept of Obstetrics, Rigshospitalet, 15 May 2008.
184. IS The corruption of drug research. Swiss Soc Intern Med, Lausanne, 21 May 2008.
185. IS Credibility of clinical research. Central Ethics Committee, Copenhagen, 13 June 2008.
186. IS The burdens of screening. Euroscience Open Forum, Barcelona, 21 July 2008.
187. IS Unhealthy health care. Distinguished scholar lecture, University of Minneapolis, 9 Sept 2008.
188. IS Unhealthy health care. Visiting scientist, University of Dartmouth, 11 Sept 2008.
189. IS Off-label use of drugs. Danish Pharmaceutical Society, Copenhagen, 29 Oct 2008.
190. IS Bias in drug trials. Danish Society for Psychiatric Epidemiology, Copenhagen, 6 Nov 2008.
191. IS Screening for lung cancer. Symposium, Focus on Lung Cancer, Copenhagen, 17 Nov 2008.

192. IS Screening for lung cancer. Danish Society for Pulmonary Medicine, Kolding, 28 Nov 2008.
193. IS Commercial interests. Institute of Technology, Copenhagen, 17 Dec 2008.
194. IS Screening and ethics. Clinical Ethics Committee, Frederiksberg Hospital, 2 Apr 2009.
195. IS Reflexions on screening. Region Middle Jutland, 15 Apr 2009.
196. IS Is the university trustworthy? LIFE, The Bioscientific Faculty, 6 May 2009.
196. IS Mammography screening. Nordic Congress in General Medicine, Copenhagen, 15 May 2009.
197. IS Opening lecture, Evidence-Based Medicine. 8th Congress of European Federation of Internal Medicine, Istanbul, 27 May 2009.
198. IS Cancer screening. Heinrich-Heine University, Düsseldorf, 17 June 2009.
199. IS Overdiagnosis of breast cancer. Cancer Intervention and Surveillance Modelling Network (CISNET), Rotterdam, 24 June 2009.
200. IS Good quality of drug trials. GCP meeting, Gentofte Hospital, 21 Sept 2009.
201. IS Forskningspolitisk debat, cancer screening. Forskningsens dag, Herlev Hospital, 28 Okt 2009.
202. IS Breast screening. Norwegian-Danish Seminar, Oslobåden, 2 Nov 2009.
203. IS Breast screening - the facts. Royal College of Obstetricians, London, 9 Nov 2009.
204. IS Er det dyreste det bedste? Region Sjælland, Sørup Heregård, 1 Dec 2009.
205. IS Randomisering i praksis. Trygfondens Forebyggelsescenter, 14 Jan 2010.
206. IS Mammographie-Screening. Berlin, German Cancer Society, 25 Feb 2010.
207. IS Klinisk relevans, hvad er det? Danish Society for Clinical Pharmacology, 2 Mar 2010.
208. IS Evidence: conflict of interest. Auckland, 22 Mar 2010.
209. IS Lægers interaktioner med medicinalindustrien. Region Nordjylland, 4 May 2010.
210. IS Fungal infections. Rigshospitalet, 12 May 2010.
211. IS Arguments for RCTs. Nordic Gastroenterology Congress, Copenhagen, 11 June 2010.
212. IS Ghostwriting is scientific misconduct. Polish Academy of Sciences, 8 Oct 2010.
213. IS Conflicts of interest. Danish University Antidepressant Group, Nyborg, 5 Nov 2010.
214. IS Bioethics: access to data and mammography screening. EU Parliament, Strassbourg, 24 Nov 2010.
215. IS Hvem har mest gavn af lægens medicinudskrivning? Patientforeningen Danmark, 18 Jan 2011.
216. IS Ethical aspects of public vs private research. Nordic Committee on Bioethics, Helsinki, 1 Nov 2011.
217. IS Strengthening and opening up EU's health research. EU Parliament, Brussels, 30 Nov 2011.
218. IS Medicinalindustrien. EU Parliament, Brussels, Social democrats, 1 Feb 2012.
219. IS Access to data from regulatory authorities. Paris, 19 April 2012.
220. IS European Drug Regulators' meeting. Why we need easy access to all data from all clinical trials and how to accomplish it. Copenhagen, 26 April 2012.
221. IS Why we need to open up health research by sharing our raw data. EU Parliament, Brussels, 6 June 2012.
222. IS Access to medical research data in the EU. HAI Europe, Amsterdam, 12 Oct 2012.
223. IS Rethinking clinical practice. Danish University Antidepressant Group, Nyborg, 9 Nov 2012.
224. IS Open access to all data is a moral obligation towards the patients. EU Parliament, Brussels, 13 Nov 2012.
225. IS Introductory statement. European Medicines Agency, London, 22 Nov 2012.
226. IS Time to stop mammography screening. Selling sickness, Washington DC, 21 Feb 2013.
227. IS Transparency saves lives. EU Parliament, Brussels, 10 Apr 2013.
228. IS Medical data transparency. Ombudsman meeting, EU Parliament, Brussels, 23 Apr 2013.
229. IS Overblik over børn med psykisk sygdom/diagnoser. Sundhedsudvalget, Folketinget, 27 May 2013.
230. IS Gavnfulde og skadelige virkninger ved medicinering af børn med psykisk sygdom. Sundhedsudvalget, Folketinget, 27 May 2013.
231. IS Mammografiscreening er skadelig og bør stoppes. Dagens Medicin, Folketinget, 31 May 2013.
232. IS What will we do about overdiagnosis? Dartmouth Institute for Health Policy & Clinical Practice, 12 Sept 2013.

233. IS Deadly medicines and organised crime. Johns Hopkins School of Public Health, Baltimore, 13 Sept 2013.
234. IS Deadly medicines and organised crime. Georgetown University, Washington DC, 16 Sept 2013.
235. IS Why drugs are the third leading cause of death. University College, London, 2 Oct 2013.
236. IS Early diagnosis. University College, London, 2 Oct 2013.
237. IS Psykiatri: medicinalindustriens paradis. Dispuk, Helsingør, 3 Oct 2013.
238. IS Working with evidence. Dansk Selskab for Obstetrik og Gynækologi, Roskilde, 7 Oct 2013.
239. IS 12 usandheder om depression til skade for patienterne. Psykovision, København, 7 Nov 2013.
240. IS Deadly medicines and organised crime. Harvard University, Safra Center for Ethics, 5 Dec 2013.
241. IS Deadly medicines and organised crime. McGill University, Montreal, 6 Dec 2013.
242. IS Deadly medicines and organised crime. Quebec University, Quebec, 9 Dec 2013.
241. IS Deadly medicines and organised crime. Ottawa Hospital, 10 Dec 2013.
243. IS Deadly medicines and organised crime. Women's College Hospital, Toronto, 11 Dec 2013.
244. IS Deadly medicines and organised crime. Toronto University, 12 Dec 2013.
- 245 IS Dødelig medicin og organiseret kriminalitet. Patientforeningen Danmark, Rigshospitalet, 14 Jan 2014.
- 246 IS Myter og facts om antidepressiva. Plastikkirurgisk afd., 16 Jan 2014.
- 247 IS Lægers samarbejde med industrien, Overlægeforeningen, Hvidovre Hospital, 23 Jan 2014.
- 248 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 25 Feb 2014.
- 249 IS Dødelig medicin og organiseret kriminalitet. Ølstykke Bibliotek, 27 Feb 2014.
- 250 IS Dødelig medicin og organiseret kriminalitet. JP Læserarrangement, 4 Mar 2014.
- 251 IS Psykofarmaka. Psykologisk Studenterforum, Århus Universitet, 4 Mar 2014.
- 252 IS Dødelig medicin og organiseret kriminalitet. Enhedslisten, Region Hovedstaden, 6 Mar 2014.
- 253 IS Psykofarmaka og andre lægemidler. Plan & Handling, Socialt-Lægeligt Seminar, Valby, 10 Mar 2014.
- 254 IS General health checks in adults. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
- 255 IS Why mammography screening should be stopped. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
- 256 IS Dødelig medicin og organiseret kriminalitet. Gentofte Bibliotek, 18 Mar 2014.
- 257 IS Why are prescription drugs the third leading cause of death? Panama City, 2 Apr 2014.
- 258 Health checks, what were the reactions? Nordic Cochrane Centre, 8 Apr 2014.
- 259 IS Set all data free. Young Investigators Network, Faculty Club, Panum, 10 Apr 2014.
- 260 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 22 Apr 2014.
- 261 IS Why the use of psychiatric drugs may be doing more harm than good. House of Lords, UK, 30 Apr 2014.
- 262 IS This is not a symptom. South London Gallery, 30 Apr 2014.
- 263 IS Hvorfor er lægemidler den 3. hyppigste dødsårsag? Studenterforeningen, København, 2 May 2014.
- 264 IS Good scientific practice. Institute for Public Health, Copenhagen, 7 May 2014.
- 265 IS Dødelig medicin og organiseret kriminalitet. Praktiserende læger, Hotel Hesselet, 9 May 2014.
- 266 IS Psykiatri. Sundhedspolitisk Netværk, Ingeniørforeningen, 12 May 2014.
- 267 IS Psykiatri på afveje. Psykovision, Bethesda, København, 14 May 2014.
- 268 IS Interessekonflikter i lægeverdenen. Panum Instituttet, 19 May 2014.
- 269 IS Lægers relation til medicinalindustrien. Roskilde Sygehus, 21 May 2014.
- 270 IS Psychiatric drugs: does the way we use them cause more harm than good? Distinguished seminars in neuroscience and pharmacology. Panum Institute, 28 May 2014.
- 271 IS Håndtering af kommercielle interesser. Københavns Universitet, 10 June 2014.
- 272 IS Psychiatric drugs: does the way we use them cause more harm than good? Amsterdam, 13 June 2014.
- 273 IS Psykiatri på afveje. Stemmehørernetværket, Christiansborg, 17 June 2014.
- 274 IS Academia and industry. Annual Nobel Laureate meeting, Lindau, 3 July 2014.
- 275 IS Overdiagnosis and overtreatment in psychiatry. Finnish Psychological Association, Helsinki, 1 Sept 2014.
- 276 IS Deadly medicines and organised crime. Helsinki University, 2 Sept 2014.

- 277 IS Medicamentos que matan y crimen organizado. Barcelona, Institut d'Estudis Catalans, 8 Sept 2014.
- 278 IS Medicamentos que matan y crimen organizado. Madrid, Organización de Consumidores y Usuarios (OCU), 9 Sept 2014.
- 279 IS Psykofarmaka-debat. Århus Universitet, 11 Sept 2014.
- 280 IS What are the true benefits and harms of our drugs? Jagiellonian University, Krakow, 7 Oct 2014.
- 281 IS Cochrane reviews and their importance for evidence-based medicine. Jagiellonian University, Krakow, 7 Oct 2014.
- 282 IS Deadly medicines and organised crime. Maynooth University, Dublin, 8 Oct 2014.
- 283 IS Deadly medicines and organised crime. Stillorgan Park Hotel, Dublin, 8 Oct 2014.
- 284 IS Danmark på lykkepiller. Herstedøster Forsamlingshus, 21 Oct 2014.
- 285 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Carlsberg, 23 Oct 2014.
- 286 IS Danskernes mentale sundhed. Folkeuniversitetet, Panum, 3 Nov 2014.
- 287 IS Kliniske forsøg. Pharmaschool, Copenhagen, 5 Nov 2014.
- 288 IS Dødelig medicin og organiseret kriminalitet. Lægeforeningen Syddanmark, Kolding, 5 Nov 2014.
- 289 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Århus, 5 Nov 2014.
- 290 IS Mammography screening: why it hasn't lived up to expectations. Santa Rosa, California, 8 Nov 2014.
- 291 IS Why very few patients benefit from the drugs they take and why many are killed by them. Santa Rosa, California, 9 Nov 2014.
- 292 IS Why very few patients benefit from the drugs they take and why many are killed by them. Stanford Medical School, 11 Nov 2014.
- 293 IS Why very few patients benefit from the drugs they take and why many are killed by them. University of British Columbia, Vancouver, 11 Nov 2014.
- 294 IS Mammography screening: why it hasn't lived up to expectations. University of British Columbia, Vancouver, 12 Nov 2014.
- 295 IS How to reduce big pharma's influence on guidelines. Kaiser Permanente, Los Angeles, 13 Nov 2014.
- 296 IS Transforming mad science, reimagining mental health care. International Society of Ethical Psychology and Psychiatry, Los Angeles, 15 Nov 2014.
- 297 IS Medisinering av psyken – mer skade enn gagn? Cinemateket, Oslo, 25 Nov 2014.
- 298 IS Global Health. Univ. of Copenhagen, 6 Jan 2015.
- 299 IS Depression. Young Psychiatrists, Rigshospitalet, 19 Jan 2015.
- 300 IS Psychiatry. Nurses, Silkeborg 20 Jan 2015.
- 301 IS Selective publication. Joanna Briggs Institute, Adelaide, 9 Feb 2015.
- 302 IS Drugs. Grand round. Royal Adelaide Hospital, Adelaide, 10 Feb 2015.
- 303 IS Psychiatry. Univ. of Adelaide, Adelaide, 10 Feb 2015.
- 304 IS Drug crimes. Alfred Hospital, Melbourne, 11 Feb 2015.
- 305 IS Psychiatry. State Library of Victoria, Melbourne, 11 Feb 2015.
- 306 IS Mammography screening. Alfred Hospital, Melbourne, 12 Feb 2015.
- 307 IS Drug crimes. Grand round. Royal Melbourne Hospital, Melbourne, 12 Feb 2015.
- 308 IS Antidepressants. Garvan Institute, Sydney, 12 Feb 2015.
- 309 IS Drug crimes. Concord Hospital Clinical School, Sydney, 13 Feb 2015.
- 310 IS Mammography screening. Dougherty Community Centre, Sydney, 13 Feb 2015.
- 311 IS Psychiatric drugs. University of Sydney Law School, Sydney, 14 Feb 2015.
- 312 IS Drug crimes. Grand round. Princess Alexandra Hospital, Brisbane, 16 Feb 2015.
- 313 IS Drug crimes. RACGP College House, Brisbane, 16 Feb 2015.
- 314 IS Drug crimes. Univ. of Queensland Medical School, Brisbane, 17 Feb 2015.
- 315 IS Psychiatry. Lady Cilento Children's Hospital, Brisbane, 18 Feb 2015.
- 316 IS Psychiatry. Adina Apartment Hotel, Brisbane, 18 Feb 2015.
- 317 IS Drug crimes. Grand round. Gold Coast University Hospital, 19 Feb 2015.
- 318 IS Lægemedler. Medicinsk Studenterforskning, Nyborg, 12 Mar 2015.

- 319 IS Depression. Rigshospitalet, 16 Apr 2015.
- 320 IS Psychiatric drugs. Lansing, Michigan, 17 Apr 2015.
- 321 IS Antidepressiva. Ålborg Sygehus, 21 Apr 2015.
- 322 IS Drugs. Danish National Board of Health, 27 Apr 2015.
- 323 IS The Maudsley Debate. London, 13 May 2015.
- 324 IS Drugs. Robert-Bosch-Stiftung, Berlin 22 May 2015.
- 325 IS Psychiatry. General Practitioners Annual Meeting, Bergen 27 May 2015.
- 326 IS Lægemedler. Læger fra Lolland, 29 May 2015.
- 327 IS Regulatory data. Int Soc Drug Bull, Pamplona, 29 June 2015.
- 328 IS Overdiagnosis and overtreatment. Int Soc Drug Bull, Pamplona, 30 June 2015.
- 329 IS Psykofarmaka. Dansk Psykologforening, København, 12 Sep 2015.
- 330 IS Antidepressants. Int Meeting, Copenhagen, 16 Sep 2015.
- 331 IS Forced treatment. Int Meeting, Copenhagen, 16 Sep 2015.
- 332 IS Antidepressants. Univ. of Roehampton, London, 18 Sept 2015.
- 333 IS Drugs. Katowice, 19 Sept 2015.
- 334 IS Mammography screening. Cochrane Colloquium, Wien, 3 Oct 2015.
- 335 IS Drugs. Oslo 20 years Anniversary Seminar, 19 Oct 2015.
- 336 IS Tvangsmedicinering. Litteraturhuset, Oslo, 19 Oct 2015.
- 337 IS Lægemedler. Guldborgsund Bibliotekerne, Nykøbing F, 21 Oct 2015.
- 338 IS Psykofarmaka. Benzorådgivningen, Middelfart, 23 Oct 2015.
- 339 IS Psykofarmaka. Enhedslisten, København, 23 Oct 2015.
- 340 IS Lægemedler. Norsk Studenterforening, Tromsø, 30 Oct 2015.
- 341 IS Psykofarmaka. Dansk Psykologforening, København, 7 Nov 2015.
- 342 IS Drugs. Medical Centre in Leiden, 11 Nov 2015.
- 342 IS Drugs. Arminius, Rotterdam, 12 Nov 2015.
- 343 IS Lægemedler. FOF Hvalsø, 23 Nov 2015.
- 344 IS Cancer screening. Gemeinschaftskrankenhaus Havehöhe, Berlin, 25 Nov 2015.
- 345 IS Psykofarmaka. Dansk Socialrådgiverforening, Fredericia, 30 Nov 2015.
- 346 IS Deadly medicines. Roma, Italy, 1 Dec 2015.
- 347 IS Deadly medicines. Univ. of Verona, 2 Dec 2015.
- 348 IS Deadly medicines. Gruppo Abele, Torino, 3 Dec 2015.
- 349 IS Deadly medicines. Alba, 3 Dec 2015.
- 350 IS Psykofarmaka. LAP, København, 18 Dec 2015.
- 351 IS Global Health. Univ. of Copenhagen, 6 Jan 2016.
- 352 IS Psykofarmaka. Hvidovre og Glostrup Psykiatri, 7 Jan 2016.
- 353 IS Psykofarmaka. Bedre Psykiatri, Odense, 14 Jan 2016.
- 354 IS Läkemedel. Stockholm läns landstings läkemedelskomité, 20 Jan 2016.
- 355 IS Psykofarmaka. Socialmedicinsk Enhed, Frederiksberg Hospital, 22 Jan 2016.
- 356 IS Vore overmedicinerede ældre. Assens Ældreråd, 26 Jan 2016.
- 357 IS Vore overmedicinerede ældre. School of Culture and Society, Karup, 11 Feb 2016.
- 358 IS Dødelig medicin og organiseret kriminalitet, LOF Slagelse, 29 Feb 2016.
- 359 IS Receptpligtig medicin – den tredjehyppigste dødsårsag, Tåstrup Bibliotek, 29 Feb 2016.
- 360 IS Antidepressants Do More Harm Than Good, Tampa, Florida, Adlerian Society, 4 March 2016.
- 361 IS Mammography screening, European Breast Cancer Meeting, Amsterdam, 9 March 2016.
- 362 IS Hvorfor gør psykofarmaka større skade end gavn? FOF Gladsaxe, 15 March 2016.
- 363 IS Drugs: the Dutch Medicines vision. Dutch Parliament, 29 March 2016.
- 364 IS Medicinsk behandling af psykiske sygdomme. Danske Regioner, Aarhus, 6 April 2016.
- 365 IS Psykofarmaka gør langt større skade end gavn. Aarhus Universitet, Aarhus, 6 April 2016.

- 366 IS Fup og fakta om antidepressiv medicin. Folkeuniversitetet i Aalborg, 7 April 2016.
- 367 IS Dødelig psykiatri. Sind på Frederiksberg, 10 May 2016.
- 368 IS Hvorfor gør psykofarmaka større skade end gavn? FOF Gladsaxe, 17 May 2016.
- 369 IS Without data sharing, there is no science, only marketing. Krakow University, 20 May 2016.
- 370 IS Den psykiatriske epidemi. National Neurokonference, Middelfart, 26 May 2016.
- 371 IS Dødelig biologisk psykiatri. Dansk Retspsykologisk Selskab, 30 May 2016.
- 372 IS Forced Psychiatric Treatment Must Be Abolished. Anchorage, 2 June 2016.
- 373 IS Prescription drugs are the third leading cause of death. Evidence Live, Oxford, 21 June 2016.
- 374 IS Mortality and drugs (top-3). 50th Anniversary of the Geneesmiddelenbulletin, Leiden, 30 June 2016.
- 375 IS What is wrong with research and treatment in psychiatry? 50th Anniversary, Leiden, 30 June 2016.
- 376 IS Hvorfor så få har gavn af psykofarmaka? Social- og Sundhedsskolen. Middelfart, 30 Aug 2016.
- 377 IS Varning för psykofarmaka! Stockholm, ABF-huset, 5 Sept 2016.
- 378 IS Deadly psychiatry. Spanish Association for Mental Health, Madrid, 19 Sept 2016.
- 379 IS Deadly psychiatry. Alibri Llibreria, Barcelona, 20 Sept 2016.
- 380 IS Varning för psykofarmaka! Bokmässan, Göteborg, 23 Sept 2016.
- 381 IS Why is it controversial to tell the truth about health care? HealthWatch Award, London, 20 Oct 2016.
- 382 IS Mammography screening. Cochrane Colloquium, Seoul, 25 Oct 2016.
- 383 IS Why so few patients benefit from the drugs they take. 21th WONCA, Rio de Janeiro, 3 Nov 2016.
- 384 IS Varning för psykofarmaka! Stockholm, ABF-huset, 22 Nov 2016.
- 385 IS Hvorfor er udtrapning af psykofarmaka så vigtigt? Høring i Folketinget, 13 Dec 2016.
- 386 IS Deadly psychiatry. De Balie, Amsterdam, 19 Dec 2016.
- 387 IS Myter, misforståelser og skader i psykiatrien. Pædagogisk Psykiatrisk Vejledning, Greve, 4 Jan 2017.
- 388 IS Psychiatric drugs. Sherbrooke, education for doctors, 20 Jan 2017.
- 389 IS Myten om den biologiske psykiatri. Christiansborg, 3 March 2017.
- 390 IS Prescription drugs are the third leading cause of death. University of Helsinki, 9 March 2017.
- 391 IS Forskning; med eller uden industri. Medicinsk Studenterforskning, Nyborg, 17 March 2017.
- 392 IS Psykofarmaka. Diplomuuddannelsen for socialarbejdere, Faxe Ladeplads, 23 March 2017.
- 392 IS Dödlig psykiatri och organiserad förnekelse. ISPS, Stockholm, 31 March 2017.
- 393 IS Vi kan leve uden antipsykotika. Stemmehørneretværket, Odense Rådhus, 27 April 2017.
- 394 IS Psykofarmaka slår mange ihjel og forkrøbler langt flere. Slagelse Kommune, 3 May 2017.
- 395 IS Psykofarmaka, psykoterapi og udtrapning. Psykoterapeuter, København, 22 Aug 2017.
- 396 IS Psykofarmaka, psykoterapi og udtrapning. Psykoterapeuter, Vejle, 28 Aug 2017.
- 397 IS Overdiagnostik og overbehandling i psykiatrien. Bedre Psykiatri, Odense, 31 Aug 2017.
- 398 IS Myter om psykofarmaka? København, 26 Sept 2017.
- 399 IS Myter, misforståelser og skader i psykiatrien. Socialpædagoger, Kolding, 2 Oct 2017.
- 400 IS Den biologiske psykiatri bygger på en række misforståelser og myter. SIND, Aalborg, 10 Oct 2017.
- 401 IS International Institute for Psychiatric Drug Withdrawal. World Congress in Psychiatry, Berlin, 11 Oct.
- 402 IS Psychiatric drugs are the third leading cause of death. World Congress in Psychiatry, Berlin, 11 Oct.
- 403 IS Psykofarmaka. Neurologisk afd., Herlev Sygehus, 1 Oct.
- 404 IS How to survive in an over-medicated world. Columbus, Ohio, 11 Nov.
- 405 IS Harmful drugs you should know about. Columbus, Ohio, 12 Nov.
- 406 IS Afhængighed af og udtrapning af psykofarmaka. BBH, Klinisk Farmakologisk afd., 1 Dec.
- 407 IS Mental health in crisis. Sydney, 24 Feb 2018.
- 408 IS Mental health in crisis. Christchurch, 26 Feb 2018.
- 409 IS Mental health in crisis. Wellington, 27 Feb 2018.
- 410 IS Mental health in crisis. Hamilton, 28 Feb 2018.
- 411 IS Mental health in crisis. Auckland, 2 March 2018.
- 412 IS Psykofarmaka bør undgås, især til børn og unge. FADD, Slangerup, 7 March.

- 413 IS How to survive in an overtreated world. Public health course, Madrid, 10 March.
- 414 IS Why you should usually avoid cancer screening. Cambridge University, 5 April.
- 415 IS Depressionspiller gör mer skada än nytta. Stockholm, 13 April.
- 416 IS Complaint to the European Ombudsman and maladministration at EMA. Dublin 21 April via Skype.
- 417 IS Benefits and harms of depression pills. Copenhagen, 14 June.
- 418 IS Heroes of Science: Survival of a Whistleblower. Berlin, Max Planck Institute, 27 June.
- 419 IS Why the current usage of psychiatric drugs does far more harm than good. Berlin, Charité, 28 June.
- 420 IS Why systematic reviews of published drug trials lead to too much medicine. Helsinki, 17 Aug.
- 421 IS Overlevelse i en overmedicineret verden. Hillerød, 27 Sept.
- 422 IS Hvordan overlever man i en overmedicineret verden? Odense, Seniorhøjskolen, 3 Oct.
- 423 IS Why did we get a Cochrane Collaboration and what is it like today? Rigshospitalet, 12 Oct.
- 424 IS Chemical and physical interventions for house dust mites: why not? Rigshospitalet, 12 Oct.
- 425 IS Survival in an overtreated world: Look up the evidence yourself. Univ. of Groningen, 22 Oct.
- 426 IS Survival in an overtreated world: Look up the evidence yourself. Patiëntenfederatie, Utrecht, 23 Oct.
- 427 IS Survival in an overtreated world: Look up the evidence yourself. De Balie, Amsterdam, 23 Oct.
- 428 IS Survival in an overtreated world: Look up the evidence yourself. Ministry of Health, den Haag, 24 Oct.
- 429 IS Psykofarmaka gør større skade end gavn. Thisted, 31 Oct.
- 430 IS We need a revolution in psychiatry, the only medical specialty that does more harm than good. Berlin, Charité Hospital, 27 Nov.
- 431 IS Open science for better health-care for all. Bruxelles, EU Parliament, 29 Nov.
- 432 Death of a whistleblower: scientific censorship in action. Copenhagen, 9 Mar 2019.
- 433 IS Evidensbasert medisin. Trondheim, 20 Mar.
- 434 IS Myter, misforståelser og skader i psykiatrien. København, 13 May.
- 435 IS Death of a whistleblower and Cochrane's moral collapse. Santa Cruz, California, 9 June.
- 436 IS Mammography screening should be stopped. Barcelona, 15 June.
- 437 IS Death of a whistleblower and Cochrane's moral collapse. Madison, Wisconsin, 30 July.
- 438 IS Critical thinking about psychiatric drugs. Tromsø, 5 Sept.
- 439 IS Myter, misforståelser og skader i psykiatrien. Århus, 3 Oct.
- 440 IS The Cochrane affair and conflicts of interest. Paris, 11 Oct.
- 441 IS Hvordan overlever man i en overmedicineret verden? Esbjerg, 30 Oct.
- 442 IS Breast cancer screening: state of the art. Porto, 4 Nov.
- 443 IS General health checks: state of the art. Porto, 5 Nov.

Research mentorships

PhD and other degrees

- 1992 - 1994 Pia Therkildsen. Clinical research behaviour in Denmark. Main tutor. PhD not finished.
- 1993 - 1994 Flemming Ørnskov. Drug treatment. Main tutor. PhD not finished (emigration).
- 1996 - 2001 Asbjørn Hróbjartsson. The placebo concept. Main tutor. PhD defended 8 June 2001 at the University of Copenhagen.
- 2001 - 2004 Jan Peter Kösters (German doctor). Breast cancer screening. Main tutor. Doktors der Medizin defended 17 Sept 2004 at the University of Hamburg.
- 2000 - 2004 Lise Lotte Kjærgaard. The randomised clinical trial. PhD, changed to DrMedSci, defended 19 Aug 2005 at the University of Copenhagen.
- 2001 - 2005 Bodil Als-Nielsen. Hepatic encephalopathy. PhD defended 13 May 2005 at the University of Copenhagen.
- 2001 - 2005 Julie Pildal. Bias in systematic reviews. Main tutor. PhD defended 6 Sept 2005 at the University of Copenhagen.
- 2004 - 2013 Karsten Juhl Jørgensen. Screening for breast cancer. Main tutor. PhD changed to DrMedSci, defended 11 Jan 2013 at the University of Copenhagen.

2008 - 2009	Marija Barbateskovic. Impact factors and sponsorship. Main tutor. Candidate in science. Marks 12 (top on new scale)
2007 - 2010	Britta Tendal. Standardised mean difference in meta-analysis. Main tutor. PhD defended 26 Aug 2010 at the University of Copenhagen.
2007 - 2011	Anders W. Jørgensen. Robustness of results and conclusions in systematic reviews, trials and abstracts. Main tutor. PhD defended 16 Nov 2011 at the University of Copenhagen.
2007 - 2013	Margrethe Nielsen. Selective serotonin reuptake inhibitors. Main tutor. PhD defended 19 April 2013 at the University of Copenhagen.
2008 - 2013	Andreas Lundh. Conflicts of interest in biomedical publishing. Main tutor. PhD defended 25 April 2013 at the University of Copenhagen.
2010 - 2015	Lasse Teis Krogsbøll. Health checks. Main tutor. PhD defended.
2011 - 2015	Jeppe Schroll. Coding of harms in randomised trials. Main tutor. PhD defended.
2011 - 2016	Emma Maund. Harms of Selective serotonin reuptake inhibitors. Main tutor. PhD defended.
2012 - 2016	Michelle Ogden. Are randomised trials ethical? Main tutor. Stopped 2016.
2012 - 2018	Tarang Sharma. Suicidality and violence on SSRIs. Main tutor. PhD defended.
2016 - 2018	Kristine Rasmussen. Conflicts of interest. Main tutor. PhD defended.
2014 - 2018	Pia Danborg. Psychiatric animal studies. Main tutor.
2016 - 2018	Camilla Hansen. Conflicts of interest. Tutor.
2016 - 2019	Lars Jørgensen. HPV vaccines. Main tutor. PhD defended.
2016 -	Anders Sørensen. Psychiatry. Main tutor.
2016 -	Marie Bohlbro. Psychiatry. Main tutor.
2017 -	Kim Boesen. ADHD drugs. Main tutor.

Training students in research

2003	Troels Wienecke. OSVAL II, marks 9, ref. 153 in reference list above.
2003	Karsten Juhl Jørgensen. OSVAL II, marks 10, ref. 154 in reference list above.
2003	Mette Haahr, scholar student, ref. 157 in reference list above.
2003	Lasse Schmidt. OSVAL II, marks 10, ref. 169 in reference list above.
2003	Katrine Karmisholt, scholar student, ref. 172 og 173 in reference list above.
2004	Anne Due, OSVAL II, marks 10, ref. 189 in reference list above.
2004	Anders Jørgensen, OSVAL II, marks 10, ref. 190 in reference list above.
2005	Anders Klahn, OSVAL II, marks 10, ref. 198 in reference list above.
2006	Britta Tendal, scholar student, ref. 196 in reference list above.
2006	Katja Maric, scholar student, ref. 196 in reference list above.
2007	Matias Vested Madsen, OSVAL II, marks 9, ref. 215 in reference list above.
2007	Lasse Krogsbøll, OSVAL II, marks 10, ref. 221 in reference list above.
2007	Jørgen Jacob Eschen, OSVAL II, marks 11. No journal manuscript.
2009	Marija Barbateskovic, manuscript under preparation.
2009	Jeppe Lerche Hansen, manuscript under revision.
2009	Jeppe Schroll, manuscript under revision.
2010	Ann-Sofia Skou Thomsen, OSVAL II, marks 12
2010	Frida Samuelsson, OSVAL II, marks 12
2010	Christian Grønhøj Larsen, OSVAL II, marks 12
2010	Nino Ortner, OSVAL II, marks 12 (Hróbjartsson tutor)
2011	Kristine Rasmussen, special subject, marks 12
2011	Anine Skibsted, special subject, marks 12
2011	Jon Egelund Jensen, special subject, marks 10
2012	Julie Bindslev, special subject, marks 12
2012	Marie Damkjær Hansen, special subject, marks 10 (Hróbjartsson tutor)
2014	Mikkel Marquardsen, special subject, marks 12
2014	Andreas Bielefeldt, special subject, marks 12
2014	Jakob Jensen, special subject, marks 7
2014	Louise Jensen
2014	Nana Freund, no special subject
2014	Asmus Mortensen, special subject, marks 10
2015	Asger Paludan-Müller, bachelor subject, marks 12
2015	Kim Boesen, special subject, marks 12
2015	Anders Simonsen, special subject, marks 12

Expert, Medical Research Council's Statistical Aid Service

- 1991 Nick Rasmussen. Randomised trial, steroids in periarthrosis.
- 1991 Holger Sørensen. Randomised trial, haloperidol vs. oxazepam.
- 1991 Arne Gam. Meta-analysis, soft laser treatment.
- 1992 Søren Eiskjær. Meta-analysis, osteosynthesis methods in collum fracture.
- 1993 Arne Gam. Meta-analysis, ultrasound in musculoskeletal disorders.
- 1993 Hanne Olesen. Meta-analysis, oxygen deficit by anaerobic training.
- 1993 Kim Brøsen. Meta-analysis, genetic polymorphism and disease risk.
- 1993 Anita Rønn. Randomised trial, Maloprim vs. placebo in malaria.
- 1993 Mette Bitsch-Christensen. Immune therapy of children with allergy.
- 1993 Anne-Lise Christensen. Comparison of methods to diagnose pneumonia.
- 1993 Anne-Cathrine Halvorsen. Diagnostic methods in bleeding disorders.
- 1993 Michael Hansen. Biochemical markers for bone formation and resorption.
- 1994 Robin Bohen. Treatment of fibromyalgia based on psychomotoric theory.
- 1994 Helle Rask. Randomised trial, volume expansion in surgery.
- 1995 Allan Ibsen Sørensen. Meta-analysis of endoscopic carpal tunnel dissection.
- 1996 Hanne Sørensen. Randomised trial, physiotherapy in back pain.
- 1997 Judith Kongsted. Healing in breast cancer.
- 1998 Poul Sindberg Eriksen. Risks after laser conisation of cervix uteri.
- 1998 Niels Petri. Orthodontic treatment of sleep apnoea.
- 2000 Hanne Sørensen. Training for back pain.
- 2002 Lars Højgaard-Rasmussen. Asthma and osteopathy.
- 2002 Mette Pedersen. Vocal cord nodules: non-surgery vs. surgery.
- 2004 Thorkil Christensen. Randomised trial, herbal cream for pain.

Scientific assignments

General

Previously

- 1988 - 1990 Secretary, Danish Society for Theory in Medicine.
- 1990 Examiner, prize report in medicine, University of Copenhagen.
- 1990 Member of WHO's expert group in Bukarest, evaluation of AIDS trial in children.
- 1991 Member of drug committee's quality group, Rigshospitalet.
- 1992 Member of Ministry of Education's group in Latvia, research evaluation.
- 1991 - 1998 Expert, Medical Research Council's Statistical Aid Service.
- 1992 - 1996 Chairman, Danish Society for Theory in Medicine.
- 1993 - 2005 Examiner, PhD applications, Rigshospitalet.
- 1993 - 2005 Member of Research Council, Rigshospitalet.
- 1993 - 2010 Member of Drug Committee, Rigshospitalet.
- 1995 Member of HS's working group on clinical databases.
- 1998 Examiner, PhD thesis (Rasmus Licht).
- 1998 Chairman and examiner, PhD thesis (Palle Valentiner-Brandt).
- 1998 Member of ad hoc committee, Office for Scientific Integrity.
- 1998 - 2005 Expert, Medical Research Council's Statistical Aid Service for East Denmark.
- 1999 Member of ad hoc committee, Office for Scientific Integrity.
- 2001 Member of ad hoc committee, Office for Scientific Integrity.
- 2008 Examiner of case of suspected scientific misconduct in Iran for The Oxford Health Alliance.
- 2008 Examiner of case of suspected scientific misconduct in Norway.
- 2011 Examiner, PhD thesis (Bendt Johansen), University of Southern Denmark
- 2013 Chairman, assessment of candidates for a professorship, University of Copenhagen
- 2014 Chairman and examiner, PhD thesis (Robert Eriksson), University of Copenhagen
- 2015 Chairman and examiner, PhD thesis (Bruno Heleno), University of Copenhagen

Currently

- 1993 - Member CONSORT (Consolidated Standards of Reporting Trials), see www.consort-statement.org.
- 2004 - Member of STROBE (Developing Standards of Reporting for Observational Studies in Epidemiology), see www.strobe-statement.org.
- 2005 - Member of PRISMA (Quality of reporting of meta-analyses), see <http://www.prisma-statement.org/>.
- 2005 - Member of SPIRIT (Standard Protocol Items for Randomised Trials), see www.spirit-statement.org/.

Editorial work

- 1992 - 1998 Editor, Bibliotek for Læger.
- 1995 - 2002 Member of Editorial Board, British Medical Journal.
- 1995 - Member of Editorial Advisory Board, Scandinavian Journal of Rheumatology.
- 1995 - Member of Editorial Advisory Board, The Cochrane Collaboration.
- 1997 - 2014 Editor, Cochrane Methodology Review Group
- 1997 - Member of Advisory Board, Clinical Evidence, BMJ Publishing.
- 2000 - Editorial advisor, BioMedCentral (supports PubMedCentral, USA).
- 2000 - 2010 Member of Scientific Board, Ugeskrift for Læger
- 2004 - Member of Editorial Board, BioMedCentral Medical Research Methodology
- 2004 - Member of BMJ Knowledge Advisory Board
- 2007 - Academic editor, PLoS Medicine

Performed peer reviews for:

Acta Neuropsychiatrica
 Annals of Internal Medicine
 BioMed Central Medical Research Methodology
 BioMed Central Family Practice
 BioMed Central Infectious Diseases
 Bibliotek for Læger
 BMJ
 BMJ Open
 Breast Cancer Research and Treatment
 Canadian Medical Association Journal
 Cancers
 Clinical Evidence
 Clinical Trials
 Clinical Trials and Meta-analysis
 Cochrane Airways Group
 Cochrane Anaesthesia Group
 Cochrane Gynaecological Cancer Group
 Cochrane Hepato-Biliary Group
 Cochrane Infectious Diseases Group
 Cochrane Musculoskeletal Group
 Cochrane Musculoskeletal Injuries Group
 Cochrane Oral Health Group
 Controlled Clinical Trials
 Danish Medical Bulletin
 European Journal of Neurology
 Hong Kong Government Research Council
 International Journal of Cancer
 International Journal of Epidemiology
 International Journal of Technology Assessment in Health Care
 JAMA
 Journal of Clinical Epidemiology
 Journal of Medical Ethics
 Lancet
 La revue Prescrire
 Medical Journal of Australia

Medical Research Council, UK
 Medicine, Philosophy and Health Care
 Nature Reviews Nephrology
 New England Journal of Medicine
 PLoS Medicine
 Politik
 Pharmacogenetics
 Pharmacoeconomics
 Radiotherapy and Oncology
 Scandinavian Journal of Gastroenterology
 Scandinavian Journal of Medicine and Science in Sports
 Scandinavian Journal of Rheumatology
 Scandinavian Journal of Social Medicine
 Science
 Statens beredning för medicinsk utvärdering
 Statistics in Medicine
 Tobacco Control
 Ugeskrift for Læger
 Vetenskapsrådet, Sverige
 Women's Health

Chairman at congresses and meetings

1. Seminar on Bias and Controversies in Clinical Research. Rigshospitalet, 28 Feb 1992.
2. Pharmacotherapy I - methodological aspects. 25th Scand Congr Rheumatol, Lillehammer, 2 June 1994.
3. Reviews of data on continuous scales. Workshop, 2nd Cochrane Colloq, Hamilton, Canada, 1 Oct 1994.
4. Reviews and Syntheses. 11th Meeting, International Society of Technology Assessment in Health Care, Stockholm, 6 June 1995.
5. Cochrane Hepato-biliary Review Group Meeting. European Association for the Study of the Liver, København, 19 Aug 1995.
6. Cochrane Tuberculosis Review Group Meeting. International Union against Tuberculosis and Lung Disease, Paris, 9 Sept 1995.
7. Scientific presentations. 3rd Annual Cochrane Colloquium, Oslo, 4-8 Oct 1995.
8. Cochrane Depression/Neurosis Review Group Meeting. 3rd Annual Cochrane Colloq, Oslo, 8 Oct 1995.
9. Cochrane Placebo Methods Working Group Meeting. 4th Annual Cochrane Colloq, Adelaide, 21 Oct 1996.
10. Cochrane Colorectal Cancer Group Pre-exploratory Meeting. Cochrane Cancer Network Meeting, Bruxelles, 1 Feb 1997.
11. Cochrane Colorectal Cancer Group Exploratory Meeting. København, 12-13 Sept 1997.
12. 50 years of clinical trials: past, present and future. BMA/BMJ, London, 29-30 Oct 1998. Conference chair and chair of session: Quality and relevance of randomised controlled trials.
13. Evidence based medicine: How do we implement research results effectively? Annual meeting for the Nordic Cochrane Centre and Network, Rigshospitalet, 28 Jan 1999.
14. Exploratory meeting for the Cochrane Anaesthesia Group. 7th Annual Meeting of the European Society of Anaesthesiologists, Amsterdam, 29-30 May 1999.
15. Medical Editors. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 8-10 Apr 2002.
16. Scientific presentations. 15th Annual Cochrane Colloquium, São Paulo, 23-27 Oct 2007.
17. Influenza symposium. Rigshospitalet, 23 Sept 2008.
18. Scientific presentations. 16th Annual Cochrane Colloquium, Freiburg, 3-7 Oct 2008.
19. International Cochrane Symposium: EBM and Cochrane reviews. Rigshospitalet, 22 April 2009.
20. Investigating bias. 19th Cochrane Colloquium, Madrid, 21 Oct 2011.
21. Nordic Cochrane Centre's 25th Anniversary Research Symposium. Rigshospitalet, 12 Oct 2018.
22. Institute for Scientific Freedom, inaugural symposium. Copenhagen, 9 March 2019.

Advisory Board member at international congresses

2nd Cochrane Colloquium, Hamilton, Ontario, 1-4 Oct 1994.
 3rd Cochrane Colloquium, Oslo, 4-8 Oct 1995.
 4th Cochrane Colloquium, Adelaide, Australia, 20-24 Oct 1996.
 7th Cochrane Colloquium, Rome, Italien, 5-9 Oct 1999.
 8th Cochrane Colloquium, Cape Town, Sydafrika, 25-29 Oct 2000.
 9th Cochrane Colloquium, Lyon, 9-13 Oct 2001.
 11th Cochrane Colloquium, Barcelona, 26-31 Oct 2003.
 12th Cochrane Colloquium, Ottawa, 2-6 Oct 2004.
 5th Congress on Peer Review and Biomedical Publication, Chicago, 15-17 Sept 2005.
 15th Cochrane Colloquium, São Paulo, 23-27 Oct, 2007, Scientific Program Committee.
 6th Congress on Peer Review and Biomedical Publication, Vancouver, 10-12 Sept 2009.
 7th Congress on Peer Review and Biomedical Publication, Chicago, 8-10 Sept 2013.
 Psychiatric drugs do more harm than good. Copenhagen, 16 Sept 2015.
 8th Congress on Peer Review and Biomedical Publication, Chicago, 10-12 Sept 2017.

Expert witness in court cases

2014 Danish High Court, double homicide attempt on methylphenidate.
 2014 Norwegian High Court, forced treatment with olanzapine.
 2015 Norwegian High Court, Patient Harms Council, oseltamivir for influenza.
 2016 Dutch High Court, double homicide case on paroxetine.
 2016 Alaska High Court, forced retention and medication of a psychiatric patient.
 2019 New York, effects of the DTP vaccine on mortality.
 2019 Montreal, harms caused by psychiatric drugst.
 2019 Los Angeles, harms of the HPV vaccine.

Management experience

1977 - 1983 Founder and head, medical department, Astra-Syntex.
 1987 - 1995 Founder and head, Nordic coordination office for AIDS trials, Rigshospitalet.
 1993 Co-founder of the Cochrane Collaboration
 1993 - 2019 Founder and head, The Nordic Cochrane Centre (39 people employed in 2014, incl. those in Copenhagen Trial Unit).
 1993 - 1996 Member of the Steering Group, the Cochrane Collaboration.
 1996 - 2001 Founder and head, Cochrane Placebo Methods Group.
 2002 SHL leadership course.
 2018 - 2019 Member of the Cochrane Governing Board.

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF ALAMEDA**

CINDY KIEL, J.D., an Executive Associate Vice
Chancellor at UC Davis, MCKENNA
HENDRICKS, a UC Santa Barbara student,
EDGAR DE GRACIA, a UCLA student, and
LELAND VANDERPOEL, an employee at the
Fresno satellite extension of the UCSF Medical
Education Program, FRANCES OLSEN,
Professor of Law at UCLA,

Plaintiffs,

vs.

THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**PETER DOSHI'S DECLARATION IN
SUPPORT OF PLAINTIFFS' MOTION
FOR A PRELIMINARY INJUNCTION**

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID-2206283

Action Filed: August 27, 2020

Trial Date: None Set

1
2 I, Peter Doshi, declare as follows:

- 3 1. I submit this declaration in support of Plaintiffs' Motion for a preliminary injunction. I
4 have personal knowledge of the facts set forth herein and if called to testify, I could
5 competently testify as follows:
- 6 2. I hold a PhD, and I am an Associate Professor (with tenure) in the Pharmaceutical Health
7 Services Research Department at the University of Maryland School of Pharmacy.¹ I
8 teach a required course in the PharmD curriculum, "Medical Evidence," which trains
9 students in skills necessary to critically appraise the scientific literature. I research the
10 drug and vaccine approval process, how the risks and benefits of medical products are
11 communicated, and how to improve the credibility and accuracy of evidence synthesis
12 and biomedical publications. At the University of Maryland, I lead the [RIAT Support](#)
13 [Center](#) which aims to accelerate the correction of the scientific record of clinical trials by
14 making clinical trial publications more accurate and more complete, addressing these
15 problems of publication bias and reporting bias. I have received national recognition for
16 my work on clinical trial data transparency.²
- 17 3. I am also an associate editor of *The BMJ* (formerly, the British Medical Journal), which is
18 roughly equivalent to the *Journal of the American Medical Association* here in the United
19 States.³ (Attached as Exhibit "A" is a copy of my CV.)
20
21
22
23
24

25 ¹ <https://faculty.rx.umaryland.edu/pdoshi/>

26 ² <https://www.nytimes.com/2013/06/30/business/breaking-the-seal-on-drug-research.html>

27 ³ <https://www.bmj.com/about-bmj/editorial-staff/peter-doshi>

- 1 4. I am also a Cochrane review author, part of the team that reviewed the evidence base for
2 neuraminidase inhibitors (anti-influenza drugs like oseltamivir/Tamiflu and
3 zanamivir/Relenza).⁴
- 4 5. I am not affiliated with the defendants, plaintiffs, or lawyers involved in this or any other
5 litigation on this matter and have not received any compensation, either directly or in-
6 kind, for this affidavit. I am submitting this affidavit because the matter relates to my
7 area of study and concerns me.
- 8 6. My credentials related to this specific topic of influenza vaccines are that I have studied
9 influenza policy since around 2004. I have many peer reviewed publications on the topic
10 (see Exhibit A), and my PhD dissertation⁵ is on the topic of CDC and WHO influenza
11 control policies (primarily vaccines). As a testament to my reputation in this field, in
12 2013, I published a peer-reviewed article in *JAMA Internal Medicine* entitled “Influenza
13 Vaccines: Time for a Rethink”. The editor in chief of the journal, a professor of medicine
14 at University of California San Francisco, invited me to write this commentary article,
15 considering me, in her words, “an expert in the field.”
- 16 7. In my opinion, there is an important gap between the science and policy of influenza,
17 with adverse consequences for sound decision making. What I mean by this is that the
18 scientific literature, taken as a whole and critically appraised, as researchers have done in
19 Cochrane and other systematic reviews, demonstrates that the proven benefits of
20 influenza vaccines are modest and information about adverse events has been
21 insufficiently researched, particularly in certain populations such as children. Yet despite
22
23
24

25 ⁴ <http://doi.org/10.1002/14651858.CD008965.pub4>

26 ⁵ <http://dspace.mit.edu/handle/1721.1/69811>

1 this, public health officials and professional societies routinely justify their policies and
2 statement through selective (not systematic and thorough—and ultimately, inaccurate)
3 citations of the evidence base.

- 4 8. Consider Janet Napolitano’s executive order.⁶ In the executive order, the very first
5 assertion of evidence of influenza vaccines’ benefit hyperlinks to a CDC website which
6 prominently states: “Flu vaccines **have been shown** to reduce the risk of flu illness,
7 hospitalization, and death”⁷ (emphasis added). By using the phrase “have been shown,”
8 the CDC presents its claims as an unambiguous assertion of fact. But if one reads the
9 relevant technical document from the same agency, it is clear that CDC is aware that this
10 assertion of fact is unproven. To wit, in its report on influenza vaccines, the CDC’s
11 Advisory Committee on Immunization Practices (ACIP), the body which sets national
12 vaccination recommendations, clearly acknowledges that the studies in the literature that
13 have supported the view that influenza vaccines reduce complications, hospitalizations,
14 and save lives may be biased, which means the reported results may be unreliable. The
15 CDC ACIP document reads: “Influenza vaccination **might reduce** the frequency of
16 secondary complications and risk for influenza-related hospitalization and death among
17 community-dwelling adults aged ≥65 years with and without high-risk medical
18 conditions (160–164). However, these studies have been conducted using medical record
19 databases and did not use reductions in LCI illness as an outcome of interest. **Such**
20 **methods have been challenged** because results might not be adjusted adequately to
21
22
23
24

25 ⁶ <https://ucnet.universityofcalifornia.edu/news/2020/08/2020-21-flu-vaccination-executive-order.pdf>

26 ⁷ CDC (2020) “What are the benefits of flu vaccination?” <https://www.cdc.gov/flu/prevent/vaccine-benefits.htm>

1 control for the possibility that healthier persons might be more likely to be vaccinated
2 than less healthy persons (96,97,165–168)”⁸ (emphasis mine). It should be noted that the
3 phrase “might reduce” was added; a *previous* version had presented the matter in more
4 certain terms: “Influenza vaccination ... reduces the risk for influenza-related
5 hospitalization and death....”⁹ The more circumspect “might reduce” language remains in
6 CDC’s technical documents to this day.¹⁰ Thus in its technical documents, CDC
7 acknowledges that there is no scientific certainty regarding what is arguably the most
8 important questions of influenza vaccine performance: *do influenza vaccines reduce*
9 *serious complications, hospitalizations, and mortality, particularly in the elderly which*
10 *experience most of the serious complications?* Despite this, on its website, the CDC
11 inaccurately presents the evidence as clear cut and definitive, and this CDC webpage was
12 subsequently cited as evidence in support of Janet Napolitano’s executive order. This is
13 an example of the gap between the science and the policy.

- 14 9. The executive order also highlights another type of gap between the evidence and policy
15 on influenza: public health agencies frequently only cite the articles that support their
16 view, and do not cite articles which do not support their view. For example, the CDC
17 ACIP recommendations mentioned above cited a study in the New England Journal of
18 Medicine which reported a large relative reduction in risk of death: 48%.¹¹ Yet
19 researchers have pointed out that these results are completely implausible as influenza is
20
21
22
23

24 ⁸ <https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm>

25 ⁹ <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm>

26 ¹⁰ <https://www.cdc.gov/flu/professionals/acip/immunogenicity.htm>

27 ¹¹ Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the
28 community-dwelling elderly. N Engl J Med 2007;357:1373-81

1 estimated to only cause around 5% of all wintertime deaths, as I explained in an article in
2 The BMJ.¹² Equally concerning is that the CDC does **not** cite or discuss a study with
3 similar results that reported influenza vaccination was associated with a 51% reduced
4 odds of death in patients hospitalized with pneumonia.¹³ The reason CDC does not cite
5 this latter study may be that this study found enormous benefit during the months that
6 influenza was not circulating—an obviously implausible finding. The reserach was done
7 to prove a point. As I explained in The BMJ, “the purpose of the study was to
8 demonstrate that the fantastic benefit they [the study authors’] expected to and did find—
9 and that others have found, such as the two studies that CDC cites—is simply
10 implausible, and likely the product of the ‘healthy-user effect’ (in this case, a propensity
11 for healthier people to be more likely to get vaccinated than less healthy people). Others
12 have gone on to demonstrate this bias to be present in other influenza vaccine studies.^{14 15}
13 Healthy user bias threatens to render the observational studies, on which officials’
14 scientific case rests, not credible.”¹⁶
15
16
17
18

19 ¹² Doshi P. Influenza: marketing vaccine by marketing disease. *BMJ* 2013;346:f3037
20 <https://www.bmj.com/content/346/bmj.f3037>

21 ¹³ Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in
22 patients with pneumonia outside “flu” season: pleiotropic benefits or residual confounding? *Am J*
23 *Respir Crit Care Med* 2008;178:527-33.

24 ¹⁴ Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of
25 influenza vaccine effectiveness in seniors. *Int J Epidemiol* 2006;35:337-44. [Abstract/FREE Full Text](#)
26 [Google Scholar](#)

27 ¹⁵ Jackson LA, Nelson JC, Benson P, Neuzil KM, Reid RJ, Psaty BM, et al. Functional status is a
28 confounder of the association of influenza vaccine and risk of all cause mortality in seniors. *Int J*
Epidemiol 2006;35:345-52. [Abstract/FREE Full Text](#)[Google Scholar](#)

¹⁶ Doshi P. Influenza: marketing vaccine by marketing disease. *BMJ* 2013;346:f3037
<https://www.bmj.com/content/346/bmj.f3037>

10. To assess whether influenza vaccines have any effect in reducing hospitalizations and mortality, it is important to first understand who is hospitalized and dies with, or of, influenza. An infection with influenza virus has, like Covid-19, a vastly different risk profile depending on age. The vast majority of influenza-associated deaths occur in the elderly. Death certificates for the United States show that of the 49,090 recorded influenza deaths in the USA between 1999 and 2018 (using ICD-10 codes J10 and J11), 37,399 of these (or 76% of the 49,090) were in the elderly and 20,596 (or 42% of the 49,090) were in the 85+ years old population.¹⁷ Obviously, if one hopes to reduce hospitalization, ICU, and death rates, one needs to be able to do it in the elderly population. Yet, as I wrote in JAMA Internal Medicine, “In the last 4 decades, just 1 randomized controlled trial has successfully assessed influenza vaccines in the elderly population living in the community, but only 10% of participants were 75 years or older, and the trial was underpowered to detect differences in hospitalization or mortality.”^{18,19} The Cochrane review of influenza vaccines in the elderly identified additional trials that occurred in residential care settings, yet even with the additional data, the Cochrane review concluded “Very few deaths occurred, and no data on hospitalisation were reported.”²⁰ A non-Cochrane systematic review published in The Lancet Infectious

¹⁷ <https://wonder.cdc.gov/controller/saved/D77/D84F318>

¹⁸ Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. *JAMA*. 1994;272(21):1661-16657966893 [PubMed](#)

¹⁹ Doshi P. Influenza Vaccines: Time for a Rethink. *JAMA Intern Med*. 2013;173(11):1014–1016. doi:10.1001/jamainternmed.2013.490

²⁰ Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev*. 2018;2(2):CD004876. Published 2018 Feb 1. <https://doi.org/10.1002/14651858.CD004876.pub4>

1 Diseases came to similar conclusions about the evidence base, concluding: “Evidence for
2 protection in adults aged 65 years or older is lacking.”²¹

3 11. Assessing the efficacy of influenza vaccines is not as straightforward as it might be for
4 drugs. Unlike a drug, there is no single “flu shot” that we are testing in each study.

5 Influenza vaccines are not drugs, they are biologics. Variations in finished product can
6 occur from batch to batch, even of the same manufacturer. While companies may all
7 target the same influenza viruses, they do not all make the same product - they make
8 different products, with different manufacturing approaches, and different excipients.

9 With vaccines, there is no single small molecule active pharmaceutical ingredient that
10 manufacturers can all copy as generic drugs (once the patent has expired) and expect
11 similar efficacy and safety. And to add one more crucial variable of variation, as the
12 public knows, each year manufacturers alter their product, targeting a new virus. This is
13 one reason most people believe there is such marked variation between vaccine
14 performance from year to year—because the product getting tested is not a single, stable
15 product: it is constantly changing.

16 12. One implication of this is that influenza vaccines are put on the market each year without
17 knowing how effective or safe they will end up being. We can only find out after the fact.
18 This helps understand why both the benefits and risks (adverse events) can vary from
19 year to year, product to product, factory to factory.

24 ²¹ Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza
25 vaccines: a systematic review and meta-analysis [published correction appears in Lancet Infect Dis.
26 2012 Sep;12(9):655]. Lancet Infect Dis. 2012;12(1):36-44. [https://doi.org/10.1016/S1473-3099\(11\)70295-X](https://doi.org/10.1016/S1473-3099(11)70295-X)

1 13. The executive order also suffers from another common problem, which may be
2 unintentional, in policies around influenza: it repeatedly refers to influenza as “flu.”
3 Doing so conveys an illogical and unreasonably large expectation of the potential
4 beneficial impact of influenza vaccines. As I write in my 2013 BMJ article: “perhaps the
5 cleverest aspect of the influenza marketing strategy surrounds the claim that “flu” and
6 “influenza” are the same. The distinction seems subtle, and purely semantic. But general
7 lack of awareness of the difference might be the primary reason few people realize that
8 **even the ideal influenza vaccine, matched perfectly to circulating strains of wild**
9 **influenza and capable of stopping all influenza viruses, can only deal with a small**
10 **part of the “flu” problem because most “flu” appears to have nothing to do with**
11 **influenza.** Every year, hundreds of thousands of respiratory specimens are tested across
12 the US. Of those tested, on average 16% are found to be influenza positive. (fig 2).”²²
13 (Emphasis added.)
14

15 14. In any discussion of influenza vaccines, it is important to discuss the risk of side-effects,
16 including unexpected risks. Take the example of two “swine flu” H1N1 vaccines,
17 vaccines for which heightened surveillance was put in place. As governments around the
18 world prepared for a massive vaccination program to protect against a feared “second
19 wave” of H1N1, Anthony Fauci stated: “And apart for some minor issues which you'd
20 expect when you inject something into the arm of an individual, such as a swelling or
21 pain or some discomfort at the site, the track record for serious adverse events is very
22
23
24

25 ²² Doshi P. Influenza: marketing vaccine by marketing disease. *BMJ* 2013;346:f3037
26 <https://www.bmj.com/content/346/bmj.f3037>

good. It's very, very, very rare that you ever see anything that's associated with the vaccine that's a severe event.”²³

15. That year, however, would witness the following, as I wrote about in *JAMA Internal Medicine*: “Australia suspended its universal vaccination program for children younger than 5 years because of a surge in febrile convulsions following vaccination (1 in 110 children).¹⁹ Also in 2009, cases of narcolepsy following vaccination in adolescents were reported in Finland and Sweden. Official inquiries into these events have confirmed influenza vaccine's role in all 3 countries, with the precise biological mechanisms still not understood.²⁰⁻²²”²⁴ As I wrote subsequently, after investigating the case of Pandemrix further, I should note in fairness that “GSK and the European Medicines Agency, which licensed Pandemrix, have not accepted that the association with narcolepsy has been proved to be causal, and research on the topic continues.”¹⁴”²⁵ But the academic and government led studies which judged the relationship between Pandemrix and narcolepsy was likely to be causal have remained in the scientific literature.^{26 27 28}

²³ Fauci A. “How Safe is the Flu Vaccine?” (2009) <https://www.youtube.com/watch?v=TE4cNqcBCEQ>

²⁴ Doshi P. Influenza Vaccines: Time for a Rethink. *JAMA Intern Med.* 2013;173(11):1014–1016. doi:10.1001/jamainternmed.2013.490

²⁵ Doshi P. Pandemrix vaccine: why was the public not told of early warning signs? *BMJ* 2018; 362:k3948

<https://www.bmj.com/content/362/bmj.k3948.full?ijkey=Q078zFNInyGN8CS&keytype=ref>

²⁶ Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. *PLoS One.* 2012;7(3):e33723. doi:10.1371/journal.pone.0033723


²⁷ Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. *PLoS One.* 2012;7(3):e33536. doi:10.1371/journal.pone.0033536

²⁸ Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. *BMJ.* 2013;346:f794. Published 2013 Feb 26. doi:10.1136/bmj.f794

1 16. I recount this information to provide evidence that it is wholly inaccurate to characterize
2 influenza vaccines as risk-free or better-than-nothing, a perception many may be left with
3 from the executive order which does not even discuss potential harms. The fact is that
4 for some people, influenza vaccines were clearly worse than nothing.

5 17. In my view, to support a mandate that requires individuals to receive an influenza
6 vaccine, there should be far more certainty about the evidence base. There should be at
7 least two randomized trials that both demonstrated influenza vaccines reduce
8 hospitalizations, ICU admissions, or mortality. But in reality, despite influenza vaccines
9 being recommended since 1960, there is not even a single randomized trial showing this.
10 The proven benefits should also be large enough that it can be confidently judged that
11 influenza vaccines will bring public health benefits far in excess of any potential harms.
12 The history of influenza vaccines does not support this premise.

13
14 18. I declare under penalty of perjury under the laws of the State of California that the
15 foregoing is true and correct and that this declaration was executed on September 15,
16 2020 in Howard County, Maryland.
17

18
19
20 
Peter Doshi, PhD

Curriculum Vitae of Peter Doshi, PhD

1) Biographical Information

A. Undergraduate Education

Brown University Providence, Rhode Island Bachelor of Arts Anthropology	1999 – 2002
---	-------------

B. Graduate Education

Harvard University Cambridge, Massachusetts Master of Arts Regional Studies—East Asia	2003 – 2006
---	-------------

Massachusetts Institute of Technology Cambridge, Massachusetts Doctor of Philosophy History, Anthropology, and Science, Technology and Society	2006 – 2011
--	-------------

C. Postdoctoral Training

Johns Hopkins University School of Medicine Baltimore, Maryland Postdoctoral fellowship in Comparative Effectiveness Research Divisions of General Pediatrics and General Internal Medicine	2011 – 2013
---	-------------

D. Employment Experience

University of Maryland School of Pharmacy Assistant Professor of Pharmaceutical Health Services Research	2014 – 2019
Associate Professor of Pharmaceutical Health Services Research	2019 – present

BMJ Associate Editor	2013 – present
--------------------------------	----------------

Johns Hopkins University Krieger School of Arts and Sciences Part-time lecturer	November 2012
--	---------------

2) Scholarly Activity

A. Publications in Refereed/Peer Reviewed Journals
(Note: **Name of the faculty member in bold** and the corresponding author underlined. Students, residents, fellows, or post-docs supervised by the faculty member are indicated with an asterisk*)

1. **Doshi P**, Spence O*, Kuzucan A*, Powers JH 3rd. Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017. JAMA Intern Med. 2019;179(5):719–721. doi:10.1001/jamainternmed.2018.7040
2. Desai B*, Hong K*, Powers JH 3rd, **Doshi P**. Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling [published online ahead of print, 2019 Oct 28]. J Gen Intern Med. 2019;10.1007/s11606-019-05460-2. doi:10.1007/s11606-019-05460-2
3. Spence O*, Hong K*, Onwuchekwa Uba R*, **Doshi P**. Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis [published online ahead of print, 2019 Aug 26]. Clin Trials. 2019;1740774519868310. doi:10.1177/1740774519868310
4. **Doshi P**, Sieluk J*, Hung A*. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?. J Am Pharm Assoc (2003). 2019;59(2):195–201. doi:10.1016/j.japh.2018.12.003
5. Jefferson T, **Doshi P**, Boutron I, Golder S, Heneghan C, Hodgkinson A, Jones M, Lefebvre C, Stewart LA. When to include clinical study reports and regulatory documents in systematic reviews. BMJ Evid Based Med. 2018 Dec;23(6):210-217. doi: 10.1136/bmjebm-2018-110963. Epub 2018 Oct 11. PubMed PMID: 30309870.
6. Jørgensen L, **Doshi P**, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 2018 Sep 24;362:k3694. doi: 10.1136/bmj.k3694. PubMed PMID: 30249615.
7. **Doshi P**. Pandemrix vaccine: why was the public not told of early warning signs? BMJ. 2018 Sep 20;k3948. doi: 10.1136/bmj.k3948.
8. Jørgensen L, **Doshi P**, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 2018 Sep 24;k3694. doi: 10.1136/bmj.k3694.
9. Hodgkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, **Doshi P**, et al. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. Systematic Reviews. 2018 Dec [cited 2018 Oct 2];7(1). doi: 10.1186/s13643-018-0766-x
10. Spence O*, Onwuchekwa Uba R*, Shin S*, **Doshi P**. Patient consent to publication and data sharing in industry and NIH-funded clinical trials. Trials 2018

May 3;19(1):269. doi: 10.1186/s13063-018-2651-2.

0 citations (Scopus), 55 social media mentions (PlumX Metrics), 4 readers on Mendeley (PlumX Metrics)

11. **Doshi P**, Hur P*, Jones M, Albarmawi H*, Jefferson T, Morgan DJ, et al. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. JAMA Intern Med 2017;177(10):1452-1459.
4 citations (Scopus), 53 blog and social media mentions (Altmetric), 13 news outlet mentions (Altmetric), 9 readers on Mendeley (PlumX metrics), 7 full text views in EBSCO databases (PlumX Metrics), 342 PDF downloads from journal website
12. **Mayo-Wilson E**, Li T, Fusco N, Bertizzolo L, Canner JK, Cowley T, **Doshi P**, Ehmsen J, Gresham G, Guo N, Haythornthwaite JA, Heyward J, Hong H, Pham D, Payne JL, Rosman L, Stuart EA, Suarez-Cuervo C, Tolbert E, Twose C, Vedula S, Dickersin K. Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. J Clin Epidemiol 2017 Nov;91:95-110.
3 citations (Scopus), 62 blog and social media mentions (PlumX Metrics), 11 readers on Mendeley (PlumX Metrics)
13. **Doshi P**. The unofficial vaccine educators: are CDC funded non-profits sufficiently independent? BMJ 2017 Nov 7;359:j5104.
0 citations (Scopus), 273 social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 1734 full text views on journal website, 205 PDF downloads from journal website
14. Sieluk J*, Palasik B*, dosReis S, **Doshi P**. ADHD medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling. Pharmacoepidemiol Drug Saf 2017 Mar;26(3):274-284.
0 citations (Scopus), 6 social media mentions (Altmetric), 3 readers on Mendeley (Altmetric)
15. **Spelsberg A**, Prugger C, **Doshi P**, Ostrowski K, Witte T, Husgen D, et al. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017 Feb 7;356:j337.
3 citations (Scopus), 263 blog and social media mentions (Altmetric), 7 news outlet mentions (Altmetric), 21 readers on Mendeley (Altmetric), 18,941 full text views on journal website, 1927 PDF downloads from journal website, 9 user-generated Bitly links to article with a total of 200 link clicks (PlumX Metrics)
16. **Doshi P**, Jefferson T. Open data 5 years on: A case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. Trials 2016;17(1).
9 citations (Scopus), 59 blog and social media mentions (Altmetric), 15 readers on Mendeley (PlumX Metrics), 10 full text views in EBSCO databases (PlumX Metrics), 8 user-generated Bitly links to article with a total of 99 link clicks (PlumX Metrics)

17. **Doshi P.** Is this trial misreported? Truth seeking in the burgeoning age of trial transparency. *BMJ* 2016 Oct 24;355:i5543.
2 citations (Scopus), 59 blog and social media mentions (Altmetric), 10 readers on Mendeley (Altmetric), 1761 full text views on journal website, 239 PDF downloads from journal website
18. **Heneghan CJ**, Onakpoya I, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. *Health Technol Assess* 2016 May;20(42):1-242.
10 citations (Scopus), 84 blog and social media mentions (Altmetric), 1 news outlet mention (PlumX Metrics) 1 policy document mention (Altmetric), 46 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics)
19. **Doshi P.** Data too important to share: do those who control the data control the message? *BMJ* 2016 Mar 2;352:i1027.
13 citations (Scopus), 93 blog and social media mentions (Altmetric), 4 news outlet mentions (Altmetric), 20 readers on Mendeley (Altmetric), 9127 full text views on journal website, 1086 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 5 link clicks (PlumX Metrics)
20. **Persaud N, Doshi P.** North American regulatory agencies can and should make clinical trial data publicly available. *CMAJ* 2016 Feb 2;188(2):96-97.
5 citations (Scopus), 21 blog and social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics)
21. Hung A*, Sieluk J*, **Doshi P.** The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks. *JAMA Intern Med* 2016 Jan;176(1):11-12.
1 citation (Scopus), 87 blog and social media mentions (Altmetric), 9 readers on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics), 517 PDF downloads from journal website
22. **Doshi P.** Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing. *BMJ* 2016 Jan 6;352:h6849.
0 citations (Scopus), 19 social media mentions (Altmetric), 3 readers on Mendeley (Altmetric), 733 full text views on journal website, 168 PDF downloads from journal website
23. **Mayo-Wilson E**, Hutfless S, Li T, Gresham G, Fusco N, Ehmsen J, Heyward J, Vedula S, Lock D, Haythornthwaite J, Payne JL, Cowley T, Tolbert E, Rosman L, Twose C, Stuart EA, Hong H, **Doshi P**, Suarez-Cuervo C, Singh S, Dickersin K. Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol for a systematic review. *Syst Rev* 2015;4(1).
2 citations (Scopus), 13 social media mentions (Altmetric), 22 readers on Mendeley (Altmetric)

24. Mayo-Wilson E, **Doshi P**, Dickersin K. Are manufacturers sharing data as promised? *BMJ* 2015 Sep 25;351:h4169.
6 citations (Scopus), 57 blog and social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 974 full text views on journal website, 211 PDF downloads from journal website
25. **Doshi P**. Speeding new antibiotics to market: a fake fix? *BMJ* 2015 Mar 25;350:h1453.
14 citations (Scopus), 150 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 25 readers on Mendeley (Altmetric), 6165 full text views on journal website, 811 PDF downloads from journal website, 2 full text views in EBSCO databases (PlumX Metrics), 6 user-generated Bitly links to article with a total of 286 link clicks (PlumX Metrics)
26. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. *Cochrane Database Syst Rev* 2014;2014(4).
128 citations (Scopus), 398 blog and social media mentions (Altmetric), 37 news outlet mentions (Altmetric), 188 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 5 Wikipedia references (Altmetric), 4 YouTube video mentions (Altmetric), 9 user-generated Bitly links to article with a total of 32 link clicks (PlumX Metrics)
27. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson MJ, et al. Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. *BMJ Open* 2014 Sep 30;4(9):e005253-2014-005253.
8 citations (Scopus), 88 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 23 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 4490 full text views on journal website, 567 PDF downloads from journal website, 9 user-generated Bitly links to article with a total of 18 link clicks (PlumX Metrics)
28. Jefferson T, **Doshi P**. Multisystem failure: the story of anti-influenza drugs. *BMJ* 2014 Apr 10;348:g2263.
31 citations (Scopus), 26 blog and social media mentions (Altmetric), 33 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics) 5952 full text views on journal website, 1344 PDF downloads from journal website, 5 user-generated Bitly links to article with a total of 3 link clicks (PlumX Metrics)
29. Jefferson T, Jones M, **Doshi P**, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ* 2014 Apr 9;348:g2545.
106 citations (Scopus), 776 blog and social media mentions (Altmetric), 32 news outlet mentions (Altmetric), 156 readers on Mendeley (Altmetric), 2 Wikipedia references (PlumX Metrics), 105,987 full text views on journal website, 18,869 PDF downloads from journal website, 1 full text view in EBSCO databases

- (PlumX Metrics), 26 user-generated Bitly links to article with a total of 139 link clicks (PlumX Metrics)
30. **Doshi P**, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: A call for people to publish the findings. *BMJ* 2013;346(7913). 78 citations (Scopus), 336 blog and social media mentions (Altmetric), 47 news outlet mentions (Altmetric), 1 Wikipedia reference (PlumX Metrics), 89 readers on Mendeley (Altmetric), 56,338 full text views on journal website, 5169 PDF downloads from journal website, 19 user-generated Bitly links to article with a total of 134 link clicks (PlumX Metrics)
 31. **Doshi P**. Influenza vaccines: time for a rethink. *JAMA Intern Med* 2013 Jun 10;173(11):1014-1016. 10 citations (Scopus), 95 social media mentions (Altmetric), 1 news outlet mention (PlumX Metrics), 19 readers on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics), 972 PDF downloads from journal website, 4 user-generated Bitly links to article with a total of 2 link clicks (PlumX Metrics)
 32. **Doshi P**, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. *JAMA Intern Med* 2013 Mar 11;173(5):380-382. 19 citations (Scopus), 3 blog mentions (Altmetric), 10 readers on Mendeley (Altmetric), 4 full text views in EBSCO databases, 1079 PDF downloads from journal website, 2 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)
 33. **Doshi P**, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. *BMJ Open* 2013 Feb 26;3(2):10.1136/bmjopen-2012-002496. Print 2013. 38 citations (Scopus), 57 blog and social media mentions (Altmetric), 1 policy document reference (Altmetric), 18 readers on Mendeley (Altmetric), 10,343 full text views on journal website, 1558 PDF downloads from journal website
 34. **Doshi P**, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. *PLoS Med* 2012;9(4):e1001201. 95 citations (Scopus), 117 blog and social media mentions (journal website), 141 readers on Mendeley (Mendeley.com), 1 Wikipedia reference (PlumX Metrics), 62,915 full text views on journal website, 5459 PDF downloads from journal website and PubMed Central, 1 user-generated Bitly link to article with a total of 3 link clicks (PlumX Metrics)
 35. **Jefferson T**, Jones MA, **Doshi P**, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev* 2012 Jan 18;1:CD008965. 89 citations (Scopus), 66 blog and social media mentions (Altmetric), 7 news outlet mentions (Altmetric), 99 readers on Mendeley (Altmetric), 3 Wikipedia references (PlumX Metrics), 1 YouTube video mentions (Altmetric)

36. **Doshi P**, Jones M, Jefferson T. Rethinking credible evidence synthesis. *BMJ* 2012 Jan 17;344:d7898.
39 citations (Scopus), 26 blog and social media mentions (Altmetric), 58 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 11,133 full text views on journal website, 1832 PDF downloads from journal website
37. **Doshi P**. The elusive definition of pandemic influenza. *Bull World Health Organ* 2011 Jul 1;89(7):532-538.
40 citations (Scopus), 41 readers on Mendeley (PlumX Metrics), 515 full text views in EBSCO databases (PlumX Metrics)
38. Jefferson T, **Doshi P**, Thompson M, Heneghan C, Cochrane Acute Respiratory Infections Group. Ensuring safe and effective drugs: who can do what it takes? *BMJ* 2011 Jan 11;342:c7258.
37 citations (Scopus), 12 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 38 readers on Mendeley (Altmetric), 7022 full text views on journal website, 11 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 109 link clicks (PlumX Metrics)
39. Jefferson T, Jones M, **Doshi P**, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. *Cochrane Database Syst Rev* 2010 Feb 17;(2):CD001265. doi(2):CD001265.
60 citations (Scopus), 2 blog and social media mentions (Altmetric), 14 readers on Mendeley (Altmetric)
40. **Doshi P**. Neuraminidase inhibitors--the story behind the Cochrane review. *BMJ* 2009 Dec 8;339:b5164.
58 citations (Scopus), 47 blog and social media mentions (Altmetric), 4 news outlet mentions (Altmetric), 52 readers on Mendeley (Altmetric), 14,332 full text views on journal website, 7 PDF downloads from journal website
41. Jefferson T, Jones M, **Doshi P**, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. *BMJ* 2009 Dec 8;339:b5106.
209 citations (Scopus), 45 blog and social media mentions (Altmetric), 5 news outlet mentions (Altmetric), 2 Wikipedia references (Altmetric), 101 readers on Mendeley (Altmetric), 79,183 full text views on journal website, 13,916 PDF downloads from journal website, 7 full text views in EBSCO databases (PlumX Metrics), 2 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)
42. **Doshi P**. Calibrated response to emerging infections. *BMJ* 2009 Sep 3;339:b3471.
63 citations (Scopus), 2 blog mentions (Altmetric), 1 Wikipedia reference (PlumX Metrics), 8 readers on Mendeley (Altmetric), 9667 full text views on journal website, 30 PDF downloads from journal website
43. **Doshi P**. Trends in recorded influenza mortality: United States, 1900-2004. *Am J*

Public Health 2008 May;98(5):939-945.

48 citations (Scopus), 11 social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 37 readers on Mendeley (Altmetric), 3466 full text views in EBSCO databases (PlumX Metrics)

B. Presentations at Scientific or Professional Meetings

(Note: **Name of the faculty member in bold**. Students, residents, fellows, or post-docs supervised by the faculty member are indicated with an asterisk*)

1. **Doshi P.** The BMJ Investigative Journalism Conference. "Standards for drug approval: too stringent, too lax, or just right?" Berlin, Germany. November 18, 2019
Presentation; International; Podium
2. **Doshi P.** Friends of the National Library of Medicine conference. "Better clinical trials for new product development" Bethesda, MD. June 14, 2017
Invited presentation; National; Podium
3. **Doshi P.** "The gain to be realized by research transparency." 2016 Consumers United for Evidence-based Health Care annual meeting July 29, 2016, Washington DC
Invited presentation; National; Podium
4. **Doshi P**, Sieluk J*, Hung A*. "The Possible Harms of Statins: What do Product Labels and Pharmacy Leaflets Tell Us?" AACP Annual Meeting, Anaheim, CA. July 2016;
Invited presentation; National; Poster
5. **Doshi P.** Johns Hopkins School of Public Health. "The Hopkins mandatory flu vaccination policy, the search for truth, and freedom of speech in an academic institution" Baltimore, MD. June 10, 2016
Invited presentation; Local; Podium
6. **Doshi P.** "Adaptive Licensing & Access to Data" webcast presentation to European Public Health Alliance, Brussels, Belgium. April 18, 2016
Invited presentation; International; Webcast
7. **Doshi P.** "Speeding new antibiotics to market: a fake fix?", National Physicians Alliance annual meeting. Washington, DC.; October 17, 2015
Invited presentation; National; Podium
8. **Doshi P.** "How CUE can engage lay journalists", 2015 Consumers United for Evidence-based Health Care annual meeting, July 24, 2015. Washington, DC
Invited presentation; National; Podium
9. **Doshi P.** "Good and Bad Reanalysis", Society for Clinical Trials. May 19, 2015. Washington, DC
Invited presentation; National; Podium

10. **Doshi P.** "How Open Data Can Reduce Reporting Biases and Help Patients Choose Wisely," Global Health & Innovation Conference. March 29, 2015, New Haven, CT
Invited presentation; National; Podium
11. **Doshi P.** "Who wants my data and what are they going to do with it?", Consumers United for Evidence-based Healthcare (CUE) annual meeting, Washington D.C., July 25, 2014
Invited presentation; Non-reviewed; National; Podium
12. **Doshi P.** "Searching for evidence under the waterline", Health Technology Assessment International (HTAi) annual meeting, Washington, DC, June 18, 2014
Invited presentation; International; Podium
13. **Doshi P.** "'Open' access to clinical trials: rhetoric and fine print", Society for Clinical Trials annual meeting, Philadelphia, May 19, 2014
Invited presentation; National; Podium
14. **Doshi P.** "Thoughts on misleading analyses", Presentation at Institute of Medicine consensus study meeting, February 4, 2014
Invited presentation; National; Podium
15. **Doshi P.** "Restoring Invisible and Abandoned Trials: the RIAT concept", presentation at CBI conference on Clinical Data Disclosure and Transparency, January 30, 2014
Invited presentation; National; Podium
16. **Doshi P.** "Restoring Invisible and Abandoned Trials: the RIAT concept", presentation at "The state of contemporary biomedical literature" conference sponsored by age.na.s, Rome, Italy, December 12, 2013
Invited presentation; International; Podium
17. **Doshi P.** "Restoring Invisible and Abandoned Trials: the RIAT concept", presentation at oPen conference, Naples, Italy, December 13, 2013
Invited presentation; International; Podium
18. **Doshi P.** "Credible evaluation of trials: what kind of data do we need?", Presentation at Institute of Medicine workshop on sharing clinical research data, October 5, 2012
Invited presentation; National; Podium
19. **Doshi P, Bass E.** "Do media understand that systematic reviews are not just another 'new study'?" 18th Annual National Research Services Award (NRSA) Conference; June 23, 2012
Presentation; National; Poster

C. Special Lectures (Invited)

1. "Working with regulatory data – a non-regulatory, non-industry perspective" Presentation to closed FDA-Health Canada meeting, Silver Spring, November 13, 2018; Invited lecture.
2. "Better evidence for better health" Presentation to WHO Uppsala Monitoring Centre 40th Anniversary, Uppsala, Sweden; May 17, 2018; Invited lecture
3. "The RIAT Initiative for Tackling Bias in Biomedical Literature" Presentation to National Library of Medicine ClinicalTrials.gov team, March 5, 2018; Invited lecture.
4. "Interim guidance on how to decide whether to include clinical study reports and other regulatory documents into Cochrane reviews" Presentation to Cochrane Scientific Committee, by web, February 28, 2018; Invited lecture
5. "Ensuring Accuracy in Clinical Trial Publications: Weighing Options" Continuing medical education lecture, Food and Drug Administration. Silver Spring, MD. October 25, 2017; Invited lecture
6. Office of Research Integrity conference "Quest for Research Excellence". Washington, DC. August 9, 2017; Panel Participation
7. "Why we need clinical trial data, and how FDA can help reduce abuse of the medical literature" Food and Drug Administration, Silver Spring, MD. June 6, 2017; Invited lecture
8. "Ensuring accuracy in clinical trial publications: weighing options" online webcast through University of Maryland M-CERSI program. April 20, 2017; Invited lecture
9. "Ensuring accuracy in clinical trial publications: weighing options" Food and Drug Administration, Silver Spring, MD. March 14, 2017; Invited lecture
10. "Finding "Big Data" (OK, big detail) under the waterline" Johns Hopkins University, Baltimore, MD. January 27, 2017; Invited lecture
11. "How We Fooled Ourselves into Thinking the Revolution on Data Transparency Was Won," Johns Hopkins Center for Clinical Trials seminar series January 6, 2016; Invited lecture
12. "The NYAG's contribution to evidence-based medicine," New York State Attorney General's Office. New York, NY; November 9, 2015; Invited lecture
13. "Breaking the Seal on Drug Company Research", presentation at Des Moines University "Leadership series" seminar, Des Moines, Iowa; September 18, 2014; Invited lecture
14. Dean's Convocation panel on "Big Data." University of Maryland School of Law; September 22, 2014; Panel participation

D. Other Publications and Related Activities

1. Publications not peer reviewed

1. Lexchin J, Herder M, **Doshi P**. Canada finally opens up data on new drugs and devices. *BMJ*. 2019;365:l1825. Published 2019 Apr 17. doi:10.1136/bmj.l1825
2. **Doshi P**. EMA scales back transparency initiatives because of workload. *BMJ* 2018;362:k3513. doi: 10.1136/bmj.k3513.
3. **Doshi P**, Shamseer L*, Jones M, Jefferson T. Restoring biomedical literature with RIAT. *BMJ* 2018 Apr 26;361:k1742. doi: 10.1136/bmj.k1742.
0 citations (Scopus), 60 social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 118 PDF downloads from journal website
4. **Doshi P**. EMA recommendation on hydroxyethyl starch solutions obscured controversy. *BMJ* 2018 Mar 20;360:k1287. doi: 10.1136/bmj.k1287.
1 citation (Scopus), 22 blog and social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 161 PDF downloads from journal website
5. **Doshi P**. CDC tightens controls on scientists' communication with news media. *BMJ* 2018 Feb 14;360:k675.
0 citations (Scopus), 5 social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 4 readers on Mendeley (Altmetric), 403 full text views on journal website, 63 PDF downloads from journal website
6. **Doshi P**. FDA to begin releasing clinical study reports in pilot programme. *BMJ* 2018 Jan 23;360:k294.
0 citations (Scopus), 47 blog and social media mentions (Altmetric), 294 full text views on journal website, 61 PDF downloads from journal website
7. **Doshi P**. "Independent" reanalysis of landmark starch solutions trial was published by original authors. *BMJ* 2017 Jul 21;358:j3552.
0 citations (Scopus), 96 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 2 readers on Mendeley (Altmetric), 2536 full text views on journal website, 274 PDF downloads from journal website
8. **Doshi P**. The problem with US website for collecting adverse events after vaccination is resolved. *BMJ* 2017 Sep 8;358:j4164.
0 citations (Scopus), 133 social media mentions (Altmetric), 131 full text views on journal website, 46 PDF downloads from journal website
9. **Doshi P**. US government website for collecting adverse events after vaccination is inaccessible to most users. *BMJ* 2017;357.
0 citations (Scopus), 325 social media mentions and interactions (PlumX Metrics), 2 news outlet mentions (PlumX Metrics), 550 full text views on journal website, 67 PDF downloads from journal website
10. **Doshi P**, Godlee F. The wider role of regulatory scientists. *BMJ* 2017 Apr

27;357:j1991.

4 citations (Scopus), 45 blog and social media mentions (Altmetric), 3 readers on Mendeley (Altmetric), 1224 full text views on journal website, 216 PDF downloads from journal website

11. **Doshi P.** FDA unease about faster drug approval. BMJ 2017;357.
2 citations (Scopus), 124 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 3 readers on Mendeley (Altmetric), 908 full text views on journal website, 169 PDF downloads from journal website
12. **Doshi P.** Medical response to Trump requires truth seeking and respect for patients. BMJ 2017 Feb 7;356:j661.
0 citations (Scopus), 188 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 3 readers on Mendeley (Altmetric), 8710 full text views on journal website, 147 PDF downloads from journal website
13. **Doshi P.** Update: New England journal of medicine publishes correction to 2012 chest trial of hydroxyethyl starch versus colloids. BMJ 2016;352.
3 citations (Scopus), 4 social media mentions (Altmetric), 2 readers on Mendeley (Altmetric), 653 full text views on journal website, 233 PDF downloads from journal website
14. **Zito JM, Doshi P.** For-profit Uses of Real-World Data: What Would Frances Kelsey Do? Med Care 2016 Dec;54(12):1045-1047.
3 citations (Scopus), 1 social media mention (Altmetric), 2 readers on Mendeley (Altmetric)
15. **Doshi P.** FDA drug summaries: a simplification too far? BMJ 2015 Jun 12;350:h3135.
0 citations (Scopus), 14 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 4 readers on Mendeley (Altmetric), 665 full text views on journal website, 181 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 4 link clicks (PlumX Metrics)
16. **Doshi P.** Convicting Zika. BMJ 2016 Apr 7;353:i1847.
4 citations (Scopus), 79 social media mentions (Altmetric), 52 readers on Mendeley (Altmetric), 17,401 full text views on journal website, 1085 PDF downloads from journal website, 4 user-generated Bitly links to article with a total of 39 link clicks (PlumX Metrics)
17. **Doshi P, Jefferson T.** The evidence base for new drugs: New legislation in germany provides another piece of a complex puzzle. BMJ 2015;350.
0 citations (Scopus), 61 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 1 reader on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics), 1118 full text views on journal website, 474 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)
18. **Doshi P, Stahl-Timmins W, Merino JG, Simpkins C.** Visualising childhood

- vaccination schedules across G8 countries. *BMJ* 2015;351.
2 citations (Scopus), 17 social media mentions (Altmetric), 6 readers on Mendeley (Altmetric), 1331 full text views on journal website, 272 PDF downloads from journal website, 1 user-generated Bitly link to article with a total of 1 link click (PlumX Metrics)
19. Jones M, Jefferson T, **Doshi P**, Del Mar C, Heneghan C, Onakpoya I. Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Clin Microbiol Infect* 2015;21(3):217-221.
5 citations (Scopus), 2 social media mentions (PlumX Metrics)
 20. **Doshi P**. No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. *BMJ* 2015 Sep 16;351:h4629.
16 citations (Scopus), 535 blog and social media mentions (Altmetric), 52 news outlet mentions (Altmetric), 46 readers on Mendeley (Altmetric), 21,165 full text views on journal website, 2473 PDF downloads from journal website, 18 user-generated Bitly links to article with a total of 266 link clicks (PlumX Metrics)
 21. **Doshi P**. 21st century cures: is US medicines bill a colossal mistake? *BMJ* 2015 Jul 23;351:h4013.
3 citations (Scopus), 66 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 6 readers on Mendeley (Altmetric), 1563 full text views on journal website, 127 PDF downloads from journal website, 1 user-generated Bitly link to article with a total of 2 link clicks (PlumX Metrics)
 22. **Doshi P**. No vote in US Congress on proposal to create new pathway for approving antibiotics. *BMJ* 2015 Mar 31;350:h1767.
0 citations (Scopus), 3 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 152 full text views on journal website, 60 PDF downloads from journal website
 23. **Doshi P**, Zito J, DosReis S. Digging for data on harms in duloxetine trials: It's time for policy makers to get serious about drug related harms. *BMJ* 2014;348.
2 citations (Scopus), 6 blog and social media mentions (Altmetric), 16 readers on Mendeley (Altmetric), 1092 full text views on journal website, 363 PDF downloads from journal website
 24. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson M, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Sao Paulo Med J* 2014;132(4):256-257.
2 citations (Scopus), 2 readers on Mendeley (PlumX Metrics)
 25. **Doshi P**. US incentive scheme for neglected diseases: a good idea gone wrong? *BMJ* 2014 Jul 21;349:g4665.
4 citations (Scopus), 2 blog and social media mentions (Altmetric), 1 policy document reference (Altmetric), 19 readers on Mendeley (PlumX Metrics), 3158

full text views on journal website, 350 PDF downloads from journal website, 6 user-generated Bitly links to article with a total of 2 link clicks (PlumX Metrics)

26. **Doshi P.** EMA policy on transparency is "strikingly" similar to deal struck with drug company, say experts. *BMJ* 2014 Jun 12;348:g3852.
1 citation (Scopus), 16 blog and social media mentions (Altmetric), 3 readers on Mendeley (PlumX Metrics), 606 full text views on journal website, 98 PDF downloads from journal website, 2 user-generated Bitly links to article with a total of 13 link clicks (PlumX Metrics)
27. Jefferson T, **Doshi P.** Multisystem failure: the story of antinfluenza drugs. *Recent Prog Med* 2014 May;105(5):187-190.
2 citations (Scopus), 11 social media mentions and interactions (PlumX Metrics)
28. **Doshi P.** From promises to policies: is big pharma delivering on transparency? *BMJ* 2014 Feb 26;348:g1615.
6 citations (Scopus), 60 blog and social media mentions (Altmetric), 1 reader on Mendeley (PlumX Metrics), 1510 full text views on journal website, 345 PDF downloads from journal website, 6 user-generated Bitly links to article with a total of 17 link clicks (PlumX Metrics)
29. **Doshi P**, Groves T, Loder E. Clinical trial data: get them while you can. *BMJ: British Medical Journal* 2014 01/11;348(7940):8-8.
4 citations (Scopus), 19 social media mentions (Altmetric), 4 readers on Mendeley (PlumX Metrics), 1270 full text views on journal website, 262 PDF downloads from journal website
30. **Doshi P**, Vedula SS, Li T. Yoda and truth seeking in medicine: Making sense of the curious case of rhBMP-2. *BMJ* 2013;347(7915).
2 citations (Scopus), 12 blog and social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 967 full text views on journal website, 246 PDF downloads from journal website
31. **Doshi P**, Goodman SN, Ioannidis JP. Raw data from clinical trials: within reach? *Trends Pharmacol Sci* 2013 Dec;34(12):645-647.
29 citations (Scopus), 1 social media mention (PlumX Metrics), 34 readers on Mendeley (Mendeley.com)
32. **Doshi P.** Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents. *JAMA Intern Med* 2013 Nov 25;173(21):2009-2011.
7 citations (Scopus), 10 blog and social media mentions (Altmetric), 10 readers on Mendeley (PlumX Metrics), 655 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 89 link clicks (PlumX Metrics)
33. **Doshi P.** Putting GlaxoSmithKline to the test over paroxetine. *BMJ* 2013 Nov 12;347:f6754.
6 citations (Scopus), 67 blog and social media mentions (Altmetric), 23 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics), 3012 full text views

on journal website, 466 PDF downloads from journal website, 1 full text view in EBSCO databases (PlumX Metrics), 2 user-generated Bitly links to article with a total of 11 link clicks (PlumX Metrics)

34. **Doshi P.** Influenza: marketing vaccine by marketing disease. *BMJ* 2013 May 16;346:f3037.
17 citations (Scopus), 952 social media mentions (Altmetric), 9 news outlet mentions (PlumX Metrics), 72 readers on Mendeley (Altmetric), 36,002 full text views on journal website, 4488 PDF downloads from journal website, 29 user-generated Bitly links to article with a total of 1535 link clicks (PlumX Metrics)
35. **Doshi P,** Jefferson T. Drug Data Shouldn't Be Secret. *New York Times* 2012 04/11;161(55738):1.
0 citations (Scopus)
36. **Doshi P, Akabayashi A.** Japanese Childhood Vaccination Policy. *Camb Q Healthc Ethics* 2010 Jul;19(3):283-289.
5 citations (Scopus), 2 social media mentions (Altmetric), 5 readers on Mendeley (Altmetric), 22 full text views on journal website, 51 PDF downloads from journal website
37. Jefferson T, Jones M, **Doshi P, Del Mar C.** Possible harms of oseltamivir--a call for urgent action. *Lancet* 2009 Oct 17;374(9698):1312-1313.
30 citations (Scopus), 26 readers on Mendeley (Mendeley.com)
38. **Doshi P.** Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? *IEEE Technology & Society Magazine* Spring 2006;25(1):10-11.
0 citations (Scopus), 491 full text views on journal website
39. **Doshi P.** Selling 'pandemic flu' through a language of fear. *Christian Science Monitor* 2006 03/21;98(79):9.
0 citations (Scopus)
40. **Doshi P.** Viral Marketing. *Harper's Magazine* 2006 03;312(1870):54.
0 citations (Scopus)
41. **Doshi P.** Are US flu death figures more PR than science? *BMJ* 2005;331(7529):1412.
13 citations (Scopus), 63 blog and social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 11 readers on Mendeley (Altmetric), 1 YouTube video mention (Altmetric), 12,755 full text views on journal website, 1345 PDF downloads from journal website

2. Letters to the editor in refereed journals

1. **Doshi P,** Spence O*, Powers JH. Noninferiority Trials. *N Engl J Med* 2018 Jan 18;378(3):304. 0 citations (Scopus)

2. Jones M, Del Mar C, **Doshi P**. Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients. Clin Infect Dis 2017 Sep 15;65(6):1050. 1 citation (Scopus), 2 readers on Mendeley (PlumX Metrics), 104 PDF downloads from journal website
3. Kuzucan A*, **Doshi P**, Zito JM. Pharmacists can help to end direct-to-consumer advertising. Am J Health Syst Pharm 2017 May 15;74(10):640-642. 0 citations (Scopus), 58 social media mentions and interactions (PlumX Metrics), 1 reader on Mendeley (Altmetric), 81 full text views in EBSCO databases (PlumX Metrics)
4. **Doshi P**, Jefferson T. Neuraminidase Inhibitors and Influenza Infection. JAMA Intern Med 2016 Mar;176(3):415-416. 0 citations (Scopus), 237 PDF downloads from journal website, 22 readers on Mendeley (PlumX metrics)
5. **Doshi P**, Heneghan C, Jefferson T. Oseltamivir for influenza. Lancet 2015 Sep 19;386(9999):1134-1135. 0 citations (Scopus), 1 social media mention (PlumX Metrics)
6. Collignon P, **Doshi P**, Del Mar C, Jefferson T. Safety and efficacy of inactivated influenza vaccines in children. Clin Infect Dis 2015 Feb 1;60(3):489. 1 citation (Scopus), 2 social media mentions (Altmetric), 10 readers on Mendeley (PlumX Metrics), 2 Wikipedia references (PlumX Metrics), 61 PDF downloads from journal website
7. Del Mar C, **Doshi P**, Hama R, Jones M, Jefferson T, Heneghan C, et al. Neuraminidase inhibitors for influenza complications. Lancet 2014;384(9950):1260-1261. 0 citations (Scopus), 1 social media mention (PlumX Metrics), 20 readers on Mendeley (Mendeley.com)
8. **Doshi P**, Jefferson T. Clinical trials: Tamiflu reviewers respond to critics. Nature 2014 May 15;509(7500):288. 1 citation (Scopus), 2 social media mentions (Altmetric), 10 readers on Mendeley (Altmetric), 107 full text views in EBSCO databases (PlumX Metrics), 1 user-generated Bitly link to article with a total of 2 link clicks (PlumX Metrics)
9. **Doshi P**, Jefferson T. Authors' reply to Dunning. BMJ 2014 Apr 30;348:g3018. 0 citations (Scopus), 1 reader on Mendeley (PlumX Metrics), 295 full text views on journal website, 87 PDF downloads from journal website
10. **Doshi P**. The importance of influenza vaccination-reply. JAMA Intern Med 2014 Apr;174(4):645-646. 0 citations (Scopus), 208 PDF downloads from journal website
11. **Doshi P**, Abi-Jaoude E, Lexchin J, Jefferson T, Thomas RE. Influenza vaccination of health care workers. CMAJ 2013;185(2):150. 2 citations (Scopus), 3 readers on Mendeley (Mendeley.com)
12. **Doshi P**. EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood. BMJ 2013;347(7922). 2 citations (Scopus), 5 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 2 readers on Mendeley

(Altmetric), 832 full text views on journal website, 170 PDF downloads from journal website

13. **Doshi P.** The 2009 influenza pandemic. *Lancet Infect Dis* 2013;13(3):193. 1 citation (Scopus), 2 readers on Mendeley (Mendeley.com)
14. Jones M, Hama R, Jefferson T, **Doshi P.** Neuropsychiatric adverse events and oseltamivir for prophylaxis. *Drug Saf* 2012 Dec 1;35(12):1187-8; author reply 1188-90. 8 citations (Scopus), 2 readers on Mendeley (PlumX Metrics), 47 full text views in EBSCO databases, 122 PDF downloads from journal website
15. Heneghan C, Jefferson T, **Doshi P.** Antivirals for treatment of influenza. *Ann Intern Med* 2012 Sep 4;157(5):385-6; author reply 386-7. 0 citations (Scopus)
16. Cochrane Neuraminidase Inhibitors Review Team. Does oseltamivir really reduce complications of influenza? *Clin Infect Dis* 2011 Dec;53(12):1302-3; author reply 1303-4. 0 citations (Scopus), 33 PDF downloads from journal website
17. **Doshi P**, Jefferson T. WHO and pandemic flu. Another question for GSK. *BMJ* 2010 Jun 29;340:c3455. 2 citations (Scopus), 1 social media mention (PlumX Metrics), 4 readers on Mendeley (PlumX Metrics), 1168 full text views on journal website, 4 PDF downloads from journal website
18. Jefferson T, **Doshi P.** WHO and pandemic flu. Time for change, WHO. *BMJ* 2010 Jun 29;340:c3461. 5 citations (Scopus), 1 social media mention (PlumX Metrics), 2 readers on Mendeley (PlumX Metrics), 1343 full text views on journal website, 7 PDF downloads from journal website
19. Collignon P, **Doshi P**, Jefferson T. Ramifications of adverse events in children in Australia. *BMJ* 2010 Jun 9;340:c2994. 7 citations (Scopus), 132 social media mentions (Altmetric), 6 readers on Mendeley (PlumX Metrics), 2885 full text views on journal website, 11 PDF downloads from journal website
20. **Doshi P.** Pandemic influenza: severity must be taken into account. *J Infect Dis* 2010 May 1;201(9):1444-1445. 4 citations (Scopus), 5 readers on Mendeley (PlumX Metrics), 19 full text views in EBSCO databases (PlumX Metrics), 13 PDF downloads from journal website
21. **Doshi P.** Doshi responds. *Am J Public Health* 2008;98(11):1928-1930. 0 citations (Scopus), 5 social media mentions (Altmetric)
22. **Doshi P.** Reason for optimism. *BMJ* 2008;336(7637):172. 0 citations (Scopus), 4 readers on Mendeley (PlumX Metrics), 457 full text views on journal website, 95 PDF downloads from journal website
23. **Doshi P.** Popular and scientific attitudes regarding pandemic influenza. *Emerg Infect Dis* 2008 Sep;14(9):1501-2; author reply 1502. 1 citation (Scopus), 4 readers on Mendeley (PlumX Metrics), 176 full text views in EBSCO database (PlumX Metrics)

24. **Doshi P.** Estimation of death rates from pandemic influenza. *Lancet* 2007 Mar 3;369(9563):739; author reply 739-40. 1 citation (Scopus), 12 readers on Mendeley (Mendeley.com)
25. **Doshi P.** Influenza vaccination: policy versus evidence: Policy is in the lead. *Br Med J* 2006;333(7576):1020-1021. 2 citations (Scopus), 5 readers on Mendeley (PlumX Metrics), 982 full text views on journal website, 298 PDF downloads from journal website

3. Referee for professional or scientific journal

1. AHRQ Effective Health Care Program
2. American Journal of Respiratory and Critical Care Medicine
3. American Journal of Public Health
4. Annals of Internal Medicine
5. BMC Medical Research Methodology
6. BMC Public Health
7. BMJ
8. Canadian Medical Association Journal (CMAJ)
9. CNS Drugs
10. Drug and Therapeutics Bulletin
11. European Journal of Pediatrics
12. European Journal of Public Health
13. Expert Review of Vaccines
14. Health Affairs
15. Health Policy
16. Health Technology Assessment (Italian government)
17. Healthcare Policy
18. Influenza and Other Respiratory Viruses
19. JAMA Internal Medicine
20. Journal of Biomedical Research
21. Journal of Clinical Epidemiology
22. Journal of Medical Ethics
23. New England Journal of Medicine
24. PLOS Medicine
25. PLOS ONE
26. Trials
27. World Medical and Health Policy

4. Editorial positions on professional or scientific journals

Associate Editor
The BMJ (www.bmj.com)

2013 – ongoing

Guest editorial board member <i>Scientific Data</i> (www.nature.com/sdata/)	2017 – 2018
---	--------------------

E. Honors and Awards

New Investigator Award American Association of Colleges of Pharmacy	2015
---	-------------

The Wired Smart List 2013 (UK) http://www.wired.co.uk/magazine/archive/2013/12/features/the-smart-list-2013	2013
--	-------------

Nathan Wolfe/CNN Prize Johns Hopkins Bloomberg School of Public Health	2013
--	-------------

Siegel Teaching Prize Massachusetts Institute of Technology	2011
---	-------------

MIT-Japan Program intern Massachusetts Institute of Technology	2009
--	-------------

Presidential Fellowship Massachusetts Institute of Technology	2006 – 2007
---	--------------------

Noma-Reischauer Prize in Japanese Studies Graduate Student Essay Prize for “The Lost Lessons of SMON [subacute myelo-optico neuropathy]” Kodansha Ltd., Publishers and the Reischauer Institute, Harvard University	2006
--	-------------

Joseph Fletcher Memorial Prize for excellence in an A.M. thesis Harvard University	2006
--	-------------

Summer Foreign Language Assistance Scholarship (FLAS) for Japanese Harvard University	2004
---	-------------

Best Socio-Cultural Anthropologist Brown University	2002
---	-------------

Perry Gatson Scholarship Award for Outstanding Achievement in Anthropology Brown University	2002
---	-------------

3) Service

A. Scientific, Professional and Scholarly Organizations

The BMJ **2013 – indefinite**

The BMJ (formerly the *British Medical Journal*) is an international peer reviewed medical journal. I serve as an associate editor, a paid position, in which capacity I write articles, commission articles, handle manuscripts, and contribute to journal decision making.

International organization; Staff position

Health Canada **2017 – ongoing**

Selected to be on “roster of experts” for Health Canada’s Health Products and Food Branch (HPFB) activated related to the implementation of public release of clinical information

International organization; Volunteer position

European Medicines Agency **Jan - Apr 2013**

Participated in two advisory groups (rules of engagement & good analysis practice) regarding EMA’s draft Policy 0070, Publication of Clinical Trial Data

International organization; Volunteer position

Committee on Publication Ethics **2015 – ongoing**

International organization; Member; 3 years

American College of Cardiology **2013**

Writing committee member on Data Transparency Health Policy Statement

National organization; Volunteer position

AACP **2014 – 2016**

National organization; Member; 2 years

Rho Chi **2017 – ongoing**

Inducted in 2017

National organization; Member; 1 years

Cochrane **2018 – ongoing**

International organization; Member; 5 years

B. Additional professional service

Reagan-Udall Foundation for the FDA **2016 – ongoing**

Unpaid member of IMEDS Steering Committee

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14 Attorneys for the Plaintiffs

15 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**
16 **FOR THE COUNTY OF ALAMEDA**

17 CINDY KIEL, J.D., an Executive Associate
18 Vice Chancellor at UC Davis, MCKENNA
19 HENDRICKS, a UC Santa Barbara student,
20 EDGAR DE GRACIA, a UCLA student, and
21 LELAND VANDERPOEL, an employee at the
22 Fresno satellite extension of the UCSF Medical
23 Education Program, and FRANCES OLSEN,
24 Professor of Law at UCLA,

25 Plaintiffs,

26 vs.

27 THE REGENTS OF THE UNIVERSITY OF
28 CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**THOMAS JEFFERSON'S DECLARATION
IN SUPPORT OF PLAINTIFFS' MOTION
FOR A PRELIMINARY INJUNCTION**

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID-2206283

Action Filed: August 27, 2020

Trial Date: None Set

I, Thomas Jefferson, declare as follows:


//

//

- 1 1. I submit this declaration in support of Plaintiffs’ Motion for a preliminary injunction. I
2 have personal knowledge of the facts set forth herein and if called to testify, I could
3 competently testify as follows:
- 4 2. I hold a MD degree and am a Fellow of Faculty of Public Health on the United Kingdom
5 and a Member of Royal College of General Practitioners. I am a Senior Clinical Tutor at
6 the University of Oxford. My specialty is analyzing evidence-based medicine and bias in
7 drug and vaccines testing.
- 8 3. I am not affiliated with the defendants, plaintiffs, or lawyers involved in this or any other
9 litigation on this matter and have not received any compensation, either directly or in-
10 kind, for this affidavit. I am submitting this affidavit because the matter relates to my
11 area of study and concerns me.
- 12 4. I am the lead author of Cochrane reviews on influenza vaccines, and have published
13 widely on the topic of influenza vaccines, other vaccines, and public health. The process
14 of conducting a systematic review involves a systematic, thorough search and critical
15 assessment of all articles on a given clinical topic. Systematic reviews are a methodology
16 for reducing bias when appraising the scientific literature and help protect against “cherry
17 picking.” Systematic reviews are widely regarded as the most trustworthy sources of
18 information, sitting atop the Evidence-based Medicine Pyramid (Attached as Exhibit “A”
19 is a copy of my resume.)
- 20 5. Dr. Doshi is a close collaborator of the past 10 years, and we have published many
21 articles together. He asked me to read his affidavit and file my own affidavit if I agreed
22 with it. I have read Dr. Doshi’s declaration, and I agree with its contents. I have not read
23 any other affidavits or documents related to this case.

- 1 6. I agree with the point that randomized clinical trials have not demonstrated that
2 administration of influenza vaccine reduce the risk of hospitalization or mortality. As
3 someone who works in the field of evaluating medical evidence and clinical study
4 evidence, completely agree that the few observational (non-randomized) studies showing
5 lowered rates of hospitalization are unreliable and inconsistent with the well controlled
6 clinical trials which have not demonstrated any such reduction.
7
8 7. I would like to make the further broader points based on 25 years' of trial research
9 synthesis: the current influenza vaccines have such low effectiveness that the US CDC
10 has assigned a negative value to their effectiveness, coercion to use them is ideological.
11
12 8. Influenza cannot be ruled out of a differential diagnosis of a presenting respiratory illness
13 on the basis of vaccination, as the vaccines have low effectiveness and there are hundreds
14 of other agents which can be produce an identical set of signs and symptoms.
15
16 9. I declare under penalty of perjury under the laws of the State of California that the
17 foregoing is true and correct and that this declaration was executed on September 15,
18 2020 in Rome, Italy.

19
20
21
22
23
24
25
26
27
28



Thomas Jefferson, MD

CURRICULUM VITAE Thomas Oliver JEFFERSON
(1 August 2020)

Brief biographies appear in the series "Lifeline" on [The Lancet 2003](#); 361:188. (11 January)
and in the Feature [Pioneers of Transparency](#) BMJ 2014;350:g7717

H-Index 58

Two most cited papers:

[Guidelines for authors and peer reviewers of economic submissions to the BMJ](#)

MF Drummond, TO Jefferson. BMJ 313 (7052), 275-283 (1720 citations)

[Vaccines for preventing influenza in healthy adults](#)

V Demicheli, T Jefferson, E Ferroni, A Rivetti, C Di Pietrantonj. Cochrane database of systematic reviews (1558 citations)

Key words: Evidence synthesis, Epidemiology, Health Economics, Regulatory data, Market access

ADDRESS (Home)

Via Adige 28a
 00061 Anguillara Sabazia
 (Roma)
 Italy
 Mobile ++39 32 92025051
 Email jefferson.tom@gmail.com

MEDALS & DECORATIONS

UNPROFOR Medal (1992)
 OFFICER (BROTHER) Order of St John of Jerusalem (1994).
 NATO Medal (Former Yugoslavia Clasp) 1996

RELEVANT ACADEMIC & PROFESSIONAL QUALIFICATIONS

Degree in Medicine and Surgery, Pisa University (1979).
 Diploma of the Royal College of Obstetrician & Gynaecologists UK (DRCOG, 1982).
 Certificate of Vocational Training in General Practice UK (1984).
 Membership of the Royal College of General Practitioners UK (MRCGP 1985).
 Membership of the Chartered Institute of Linguists UK (1985).
 Diploma in Tropical Medicine & Hygiene UK (London School of Hygiene & Tropical Medicine 1987).
 MSc Community Medicine UK (London School of Hygiene & Tropical Medicine 1988).
 Membership of the Faculty of Public Health Medicine UK (MFPHM 1990).
 Accreditation in Public Health Medicine UK (1990).
 Accreditation in General Practice UK (1990).
 Titolo di Scuola di Guerra (1991)
 Certificate in Health Economics, University of Aberdeen UK (1996).
 Fellowship of the Faculty of Public Health Medicine UK (FFPHM 1999).

RECENT and PRESENT ACTIVITIES

Until November 2019 I provided scientific supervision for the Agenas (Agenzia per i Servizi Sanitari Regionali) HTA programme for non-pharmaceuticals. Agenas is an agency of the Italian MoH. Part of my work entailed supervising a group of 10 researchers and taking responsibility for designing, devising and carrying out HTA and Horizon Scanning assessments. I was scientific lead for the European EUNeHTA Joint Action 2 (Workpackage 4 – devices and diagnostics) project (2012-2015, see below). The EUNeHTA Collaboration is a network of European public agencies producing structured HTA information for national use. In 2021 the Collaboration should become a permanent network funded by the

Commission. I was also scientific coordinator for Workpackage 4 which assessed non pharmaceutical interventions, such as in vitro tests. This involved coordinating some 70 researchers from 28 agencies from 23 countries (from Estonia to Bulgaria, to Greece and Sweden). The project started in 2012 and was completed in 2015. I carried out the same role for the previous EUNeHTA project (Joint Action 1 or JA1 with the European Commission). Until November 2019 I was a member of two different workpackages and a reviewer for two projects in these workpackages as part of the EUNeHTA JA3.

I co-developed a methodology for synthesising evidence of effectiveness, efficiency, safety and resource utilisation using regulatory information and data from different sources, both regulatory and open source. This activity was initially funded by NIHR UK until mid-2015, then the Cochrane Methods Innovations Fund (MIF), NIHR again and since 2016 the Cochrane Nordic Centre. The MIF project was a collaboration to draft advice of when and how to include regulatory material in Cochrane reviews. I am developing this work further by streamlining the use of regulatory data and its incorporation into user friendly, timely reviews.

As part of a team in the Nordic Cochrane Centre we carried out a [systematic review of HPV vaccines](#) based on regulatory documents. The evidence set for the review was assembled by us from a variety of sources into an Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies, shortly to be published. At present we are developing the same reviews further with the complete regulatory dataset released by Health Canada after a court case.

Since 2015 I am a Fellow of the Centre for Evidence Based Medicine of the **University of Oxford**, in the UK. I am now Senior Clinical Tutor on the Complex Reviews Module of the MSc in Evidence Based Health course.

I am visiting Professor Visiting Professor Institute of Health & Society at the Faculty of Medicine of Newcastle University (2019-2021).

With the 3 other Cochrane colleagues I am a co-investigator in a John and Laura Arnold Foundation grant for development of a RIAT support centre (2017-2020).

RIAT stands for Restoring Invisible and Abandoned Trials. In short, RIAT is a mechanism that enables researchers to address two long-standing problems in the medical literature: non-publication of trials and misreporting. Our concept was first outlined here: <http://www.bmj.com/content/346/bmj.f2865>

The RIAT Support Center will help accelerate the correction of the scientific record of clinical trials by making it more accurate and more complete.

Finally, with the help of the Cochrane Central Editorial Unit we stabilised of our three long-standing influenza vaccine reviews. These were released in January 2018.

My activity line of regulatory data started with updating of Cochrane review A159 (Neuraminidase Inhibitors for influenza). A159 is currently based exclusively on regulatory information (essentially clinical study reports - CSRs from EMA and comments by FDA and PMDA - about 150K pages in all).

The story is told in:

David Payne. Tamiflu: the battle for secret drug data. BMJ 2012;345:e7303 doi: 10.1136/bmj.e7303 (Published 29 October 2012).
<http://www.bmj.com/content/345/bmj.e7303>

<http://www.nytimes.com/2013/06/30/business/breaking-the-seal-on-drug-research.html?pagewanted=1&r=3&smid=tw-share>

<http://www.newsweek.com/2014/11/21/medical-science-has-data-problem-284066.html>
[The pioneers of transparency](#). BMJ 2015;350:g7717 (Published 02 Jan 2015)

I was a member of EMA's Clinical Trials Advisory Group 2 (CTAG2).

I am on the editorial board of [BMJ Evidence Based Medicine](#) (BMJ EBM).

I am an unpaid collaborator to the project *Beyond Transparency in Pharmaceutical Research and Regulation* led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

I currently teach on the Complex Reviews module of the MSc in Evidence Based Health Care at Oxford University and currently supervising to MSc students. This involves reviews of regulatory data, economic studies, diagnostic studies, qualitative studies and IPI meta-analyses.

I am a member of the WHO Infection Prevention and Control Research and Development Expert Group for COVID-19.

PAST CONSULTANCIES AND OTHER ACTIVITIES

In the past I have carried out research for the **Ministry of Defence UK** (suite of Cochrane reviews on viral and arthropod borne fevers prevention), **NICE** (HTA of zanamivir for influenza), **Roche** (the economics of antivirals neuraminidase inhibitors), **EU** (systematic review of evidence of safety of MMR vaccines and of the economics of pneumococcal vaccines), **WHO** (systematic review of evidence of safety of Hepatitis B vaccines), **Glaxo SmithKline** (systematic review of evidence of safety and effectiveness of DPT vaccines), **Sanofi- Synhtelabo** (Development of Pleconaril), **Istituto Superiore di Sanita'** and **ASSR** (now Agenas), (coordinator of the national clinical guidelines project) (see below), **Netherlands Health Council** (safety of Hepatitis B vaccine update review), **IMS Health**

(Antidiabetic drugs) the **Piemonte Region** of Northern Italy (suite of Cochrane reviews on influenza vaccines), **Agenzia di Sanita' Pubblica Lazio** - Public Health Agency of Lazio Region (guidelines implementation trial project and coordination of a two cluster randomised trials of guidelines implementation, on behalf of the UK's Technology Assessment Programme I updated two reviews on the effects of editorial peer review. I have been involved in a 5 year update and rewrite of his Cochrane review on Neuraminidase Inhibitors exclusively based on regulatory information. (HTA – 10/80/01 Update and amalgamation of two Cochrane Reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children—<http://www.nets.nihr.ac.uk/projects/hta/108001>).

I am a member of the editorial base of the Cochrane Acute Respiratory Infections Group. Reviewer, Cochrane Infectious Diseases, Acute Respiratory Infections, Hepato-biliary, Airways and Colorectal Cancer Groups.

Director, Health Reviews Ltd, my own company.

Member, editorial, board of *Recenti Progressi in Medicina* and *BMC Health Services Research*.

Peer reviewer for BMJ, Lancet, JAMA, JAMA Internal Medicine, CMAJ, New England Journal of Medicine, Vaccine and Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Emerging Technology bulletins.

I am an Academic Editor, PLOS ONE (2013-17) and have been a contributor to Last's Dictionary of Epidemiology (4th edition).

I do anonymous market access consultancy interviews for various pharmaceutical companies.

Between 1996 and 2009 I was the Co-ordinator of the Cochrane Vaccines Field and 1999 and 2012 I was honorary Research Fellow at the UK Cochrane Centre.

In 2011-13, I acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. In 2016-17 I was a member of an independent data monitoring committee for a **Sanofi Pasteur** clinical trial on an influenza vaccine and a member of three advisory boards for **Boehringer Ingelheim** (on bronchodilator drug), Takeda (cardiovascular drug) and Bayer (blood replacement).

As part of my [HTA activity](#) I have interviewed, collaborated and interacted with scores of clinicians in both primary and hospital care both in Italy and the rest of Europe. Over the past thirty years, I have worked in most therapeutic and prevention areas. Also as part of my Italian HTA and scientific activity I have interacted with patient organisations and have considerable knowledge of the regional Italian structure and its workings thanks to my role as consultant to Agenas.

The HTA report output is accessible at: <https://www.agenas.gov.it/aree-tematiche/hta-health-technology-assessment/attivita-hta/report-hta>

The Horizon scanning output is accessible at: <https://www.agenas.gov.it/aree-tematiche/hta-health-technology-assessment/hs-horizon-scanning/report-hs>

Since 2017 I am a member of the Italian MoH National Immunisation Technical Advisory Group (NITAG).

GENERAL PERSONAL & PROFESSIONAL BACKGROUND

I was born on 31 March 1954 in Viareggio (near Pisa), Italy. I was educated in Italy and went to UK in 1980 to do my hospital jobs prior to joining the Army. My professional career has spanned two specialties, General Practice (1980-1985) and Public Health (since 1986). I served in the British Army between 1981 and 1999.

My Army service took place in three continents and two conflicts (South Atlantic and Yugoslavia). I held the rank of Lieutenant Colonel. I am married with five children.

GENERAL PRACTICE CAREER

SHO Medicine, Arbroath Infirmary (1980 - 1981).

SHO Casualty, Croydon (1981).

Post Graduate Medical Officers' Course held Royal Military Academy, Sandhurst and the Royal Army Medical College, London (1981).

SHO O&G, British Military Hospital Hong Kong (1982).

Trainee GP and Regimental Medical Officer in several Gurkha units in Hong Kong and Nepal (1982 - 1984).

GP principal at Royal Military Academy Sandhurst, Armoured Regiment in Germany and Gurkha Battalion in UK and South Atlantic (1984 -1986).

Staff officer (various roles, 1987-1999)

Partner (part-time), North Lane Practice, Aldershot, Hampshire (1999-2001).

PUBLIC HEALTH CAREER

Registrar at the Department of Preventive Medicine at the Royal Army Medical College London (1987-1990).

Honorary Lecturer to the Department of Public Health at King's College Hospital, London (Professors Jim McEwen Norman Noah, 1989 - 1996).

Honorary Senior Lecturer to the Department of Public Health at King's College Hospital, London (1997 - current).

Detachment to the London School of Hygiene and Tropical Medicine on the Diploma in Tropical Medicine and Hygiene Course first and then on Master of Science in Community Medicine (1987- 1988).

Senior Registrar at the RAMC Training Centre near Aldershot (1988 - 1990). Student on the Higher Command and Staff Course at the Italian Army Staff College, Rome (1990 - 1991).

Second in Command of a Medical Battalion in Germany consisting of 250 personnel (1991 - 1992).

Assistant Force Medical Officer, United Nations Protection Force in Yugoslavia (UNPROFOR). I set up all medical facilities for the initial deployment in March 1992 and Director of Public Health for UNPROFOR. I was stationed in Sarajevo (Bosnia- Hercegovina), Belgrade (Serbia) and Zagreb (Croatia) for the duration of six months. Deputy Commander Medical (Preventive Medicine) British Army of the Rhine. I was responsible for all Preventive Medicine services for a population of 120.000 souls (1992-93).

Senior Technical Officer on the Health Services Market Test for British Forces Germany (1993-94). Responsible for developing the Statement of Requirement in preparation for the issuing of the Invitation To Tender and the developing of the purchasing function. Staff Officer, Ministry of Defence, Army Medical Directorate (1994-99). Responsible for health surveillance and health policy formulation for the British Army. My department carried out morbidity surveillance for the British Army and for the NATO SFOR mission in the Former Republic of Yugoslavia (FRY).

In February 1994 I was appointed Visiting Professor in Health Services Research at the University of Pavia, Northern Italy.

In June 1997 I was appointed Edmund Parkes Professor of Preventive Medicine at the Royal Defence Medical College. The chair is recognised by the Faculty of Public Health Medicine of the Royal College of Physicians of the United Kingdom. Additional responsibilities included the strategic management of the Army's 90-strong Environmental Health cadre. This lapsed when I left the Army.

Principal in family medicine, Aldershot, UK, 1999-2001.

British Medical Association HC Roscoe Fellow for the study of the prevention and treatment of the common cold (2000-2002).

Adviser the Lazio Region Public Health Agency (IT) and the Istituto Superiore di Sanità (on the development of evidence-based clinical guidelines) 2001-2005

PRIZES

1982 Army Syntex Award for research into obstetric performance in different ethnic groups (see publication 5).

1984 University of Surrey Research Prize for work on haematological indices of pregnant Gurkha women (see publication 6).

1990 Parkes Memorial Prize for work on the selection and training of Army recruits (see publications 17 e 22).

2009 BMJ prize for best use of BMJ archival material (publication 232)

Past grants:

MOD(UK) - systematic reviews of interventions to prevent influenza in healthy adults

Roche UK Ltd - cost of illness study of the burden of influenza.

BMA Roscoe Fellowship - systematic review of the effects of antivirals for the common cold.

UK HTA programme - systematic review of the effects of zanamavir.

EU - systematic review of safety of MMR vaccines.

EU - systematic review of the economics of pneumococcal vaccines.

WHO - systematic review of evidence of safety of Hepatitis B vaccines.

WHO - systematic review of evidence of safety of aluminium in DTP vaccines.

Glaxo SmithKline Ltd - systematic review of evidence of safety and effectiveness of DPT vaccines.

NHS R&D programme - systematic review of the effects of peer review. An update was commissioned in May 2004.

Regione Piemonte, Italy – systematic reviews of the effects of influenza vaccines in children and elderly and quality studies and their publication on high impact factor journals.

Netherlands Health Council (safety of Hepatitis B vaccine update review)

DH (UK)/NIHR Cochrane review update incentive scheme (several awards)

Lazio Public Health Agency – systematic review of the epidemiology of *S.Pneumoniae*

DH (UK) National coordinating Centre for Methodology

WHO - Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review .

UK NIHR – Developing, updating and rewriting the Cochrane review on Neuraminidase Inhibitors exclusively based on regulatory information.

Cochrane - Methods Innovation Fund (MIF) 2014-17 to develop a methodology for summing up evidence of effectiveness, efficiency and safety using regulatory information and data from different sources, both regulatory and open source.

Arnold Foundation – RIAT centre

RECREATIONAL ACTIVITIES

Weight training, skiing.

MEMBERSHIP OF OTHER ORGANISATIONS (past and present)

Health Economics Study Group (HESG)

International Association of Health Economists (listed in the world directory of Health Economists).

Cochrane Airways Collaborative Review Group

LOCKNET (JAMA/BMJ peer-review network).

World Association of Medical Editors (WAME)

Health Technology Assessment International (international society for HTA)

PUBLICATIONS & REPORTS

1. CAROLI G, JEFFERSON T O. Wedding Party with S.Haifa. Annali Sclavo. 1978; 20: 959-962.
2. CAROLI G, JEFFERSON T O. Finding of E.Coli Phage in Urinary Tract Infections. Annali Sclavo. 1980; 22: 857-860.
3. JEFFERSON T O. Personal View. BMJ. 1982; 284: 1328.
4. JEFFERSON T O, COHEN C. Familial Siringomyelia with Mental Impairment. J R Army Med Corps. 1982; 128: 41-42.
5. JEFFERSON T O, REIDY A J. Incidence of Instrumental Deliveries in Primigravidae of 3 Different Ethnic Groups. J R Army Med Corps. 1983; 129: 46-47.
6. REIDY A J, JEFFERSON T O, KENNEDY P M D. Some Haematological Data on Pregnant Gurkha Women. J R Army Med Corps. 1984; 130: 20-21.

7. JEFFERSON T O. Physical Fitness and Smoking Patterns in a Gurkha Battalion. J R. Army Med Corps. 1986; 132: 168-172.
8. JEFFERSON T O, RASOR P A. Non Simulated Casualty Workload in 2 Field Hospital During Exercise "Bold Gannett". Giornale di Medicina Militare. 1985; 135: 265-268.
9. JEFFERSON T O, TAYLOR V M. Perinatal mortality in infants of two different ethnic groups. Family Practice 1985; 2:175-176.
10. JEFFERSON T O. (Anonymous) Mea culpa. Update. 1985; 31: 932.
11. JEFFERSON T O. Patterns of smoking in 2 infantry battalions. British Army Review. 1986; 82: 84.
12. JEFFERSON T O. A Camera in general practice (Ota's Naevus). Update. 1987; 35: 237.
13. KENNEDY P M D, JEFFERSON T O, REIDY A J. Growth in Gurkha Infants. Family Practice. 1986; 3: 54.
14. JEFFERSON T O. Buon Natale (Letter to the Editor). J Royal Coll Gen Pract. 1986: 291.
15. OLLIER W, FENSTENSTEIN, JEFFERSON T O. HLA Antigens in Nepalese. Proceedings of the 3rd Asian Oceania Histocompatibility Conference, Sapporo 1986.
16. JEFFERSON T O. The Prevention of AIDS: Some Principles for the Inception and Assessment of a Health Education Campaign. Rivista Italiana d'Igiene 1988; 48: 3-11.
17. JEFFERSON T O. An Investigation of Medical Discharges from the British Army 1979-1986. J R Army Med Corps. 1989; 135: 115-123.
18. JEFFERSON T O, BRAND H, LEVRE` E, CAROLI G. The Personal Prevention of Malaria. Rivista Italiana d'Igiene 1989; 430: 443-450.
19. JEFFERSON T O, CAROLI G, MOLINARI G, PEIRONE A P. Public Health and Community Medicine in England. Rivista Italiana d'Igiene 1989; 49: 226-238.
20. BASNET I, HADYAPANIOTOU C, JEFFERSON T O, MILLS A. Abortion Services in Wandsworth (MSc Field Service Attachment). London School of Hygiene & Tropical Medicine, 1988.
21. TAYLOR L E, JEFFERSON T O, CAROLI G. Water Supply Engineering and Public Health in the United Kingdom. Rivista Italiana d'Igiene 1990; 50: 81-93.

22. JEFFERSON T O. An Investigation into Regular Recruit Wastage from the British Army, 1988. J R Army Med Corps 1990; 136: 138-145.
23. TAYLOR L E, JEFFERSON T O, CAROLI G. The Water Supply of London. Rivista Italiana d'Igiene. 1990; 3-4: 169-177.
24. DEMICHELI V, JEFFERSON T O, AMPOLA M, CAROLI G, PEIRONE A P. Il Lay Belief System. Nota 1: Lo Studio del Comportamento Sanitario. Rivista Italiana d'Igiene 1990; 3-4: 134-150.
25. JEFFERSON T O, DEMICHELI V, CAROLI G. Nesso tra Casi di Leucemia Infantile e Centrale Nucleare di Sellafield (U K): un Puzzle Epidemiologico. Rivista Italiana d'Igiene 1990 3-4: 178-191.
26. DEMICHELI V, JEFFERSON T O. Le Conseguenze Economiche della Salmonellosi. Antibioticoterapia per la pratica. 1991; 2: 73-81.
27. JEFFERSON T O. First Aid Training. An Appraisal. The Soldier's Longest Journey. J R Army Med Corps. 1991; 137: 27-30.
28. JEFFERSON T O. Procedures for the collection and bottling of mineral waters - Guidelines for handlers. Rivista Italiana d'Igiene 1990; 5-6: 496-8.
29. BISOGNI L, JEFFERSON T O, DEMICHELI V, LOMOLINO G, PACELLI G. Studio della prevalenza delle infezioni ospedaliere in un ospedale generale di zona. Rivista Italian di Antibioticoterapia per la pratica 1991; 4: 159-63.
30. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Audit nei servizi di Igiene Pubblica: l'opinione dei cittadini sugli interventi per inconvenienti igienici. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 66. Editrice Periodici 1991.
31. DEMICHELI V, LOMOLINO G, JEFFERSON T O. La qualita` delle iniziative di formazione: l'aggiornamento del personale sul problema delle infezioni ospedaliere. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 81. Editrice Periodici 1991.
32. DEMICHELI V, LOMOLINO G, JEFFERSON T O. L'apporto della Economia Sanitaria alla qualita` delle decisioni. La determinazione del costo della sofferenza. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 106. Editrice Periodici 1991.
33. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Affermazioni di consenso e verifica della qualita`. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 107. Editrice Periodici 1991.

34. DEMICHELI V, JEFFERSON T O. Cost-benefit analysis of the introduction of mass vaccination against Hepatitis B in Italy. *Journal of Public Health Medicine* 1992; 4: 367-375. (Paper presented to the third European Health Services Research Meeting - University College London, 13 - 14 December 1991).
35. DEMICHELI V, JEFFERSON T O. Manuale di Programmazione e organizzazione Sanitaria. Quaderni di Epidemiologia 17. La Goliardica Pavese, Pavia 1992.
36. DEMICHELI V, JEFFERSON T O. Criteri di valutazione del nesso causale e loro applicazione alla questione delle relazioni fra le radiazioni ionizzanti e la leucemia infantile. *Tecnica Sanitaria* 1993 (in press).
37. JEFFERSON T O, DEMICHELI V, LOMOLINO G. Problemi di Valutazione epidemiologica nelle piccole catastrofi ambientali. Il caso di Camelford in Cornovaglia. *Tecnica Sanitaria* 1993 (in press).
38. JEFFERSON T O. Public Health Aspects of the war in Yugoslavia. *Public Health* 1993; 107: 75-8.
39. JEFFERSON T O, DEMICHELI V, WRIGHT D A. An economic evaluation of the introduction of vaccination against Hepatitis A in a peace-keeping operation. The case of the United Nations Protection Force in Yugoslavia (UNPROFOR). *International Journal of Technology Assessment in Health Care* 1994; 10:490-97. Poster presented at the Fifth European Health Services Research Conference at Maastricht, (December 1993).
40. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Audit of an environmental service in Italy. *Proceedings of the Summer Conference of the Faculty of Public Health Medicine*, 1992, Eastbourne, Sussex, Inghilterra.
41. JEFFERSON T O, DEMICHELI V. The costs of disease - a look at world literature. Presented at the "Meeting Internazionale sui costi delle malattie e della Salmonellosi", Pavia University (5-6 April 1993) (in press).
42. JEFFERSON T O, DEMICHELI V. Is vaccination against Hepatitis A and B cost-effective? A preliminary look at world literature. Presented at the "Meeting Internazionale sui costi delle malattie e della Salmonellosi", Pavia University (5-6 April 1993) (in press).
43. JEFFERSON T O, DEMICHELI V. Is vaccination against Hepatitis B efficient? A review of world literature. *Health Economics* 1994; 3:25-37. Paper presented at the Fifth European Health Services Research Conference at Maastricht, (December 1993).
44. JEFFERSON T O. Public Health and the war in Yugoslavia. In McKee M (ed): *Health for all in a changing Europe*. HFA 2000 News 1993; 25:4-5.

45. DEMICHELI V, JEFFERSON T O. Cost-benefit analysis of the introduction of mass vaccination against Hepatitis B in Italy (letter to the Editor). *Journal of Public Health Medicine* 1993; 14: 289-290.
46. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V. Purchasers and cost-effectiveness of interventions. Are secondary economic evaluations possible? Abstract presented at the Second Cochrane Colloquium, Hamilton, Ontario, October 1994.
47. JEFFERSON T O, BEHRENS R, DEMICHELI V. Should British soldiers be vaccinated against Hepatitis A? An economic analysis. *Vaccine* 1994; 12:1379-83.
48. JEFFERSON T O, PIERCE B, DEMICHELI V. Economic burden of an outbreak of a communicable disease of unknown aetiology in a military unit. *Journal of Epidemiology and Community Health* 1994; 48:423. (letter to the Editor).
49. AKEHURST R, GRAY A, BUXTON M, CHALMERS I, DONALDSON C, CHURNSIDE R, FENN P, FORBES J, GRIFFIN J, HOWARD S, JEFFERSON T, MC GUIRE A, MUGFORD M, O'BRIEN B, OXMAN A, TOWSE A. Assembling information in reviews of randomised controlled trials for subsequent cost-effectiveness analysis. Oxford: UK Cochrane Centre, Workshop Report, November 1993.
50. JEFFERSON T O, MACMILLAN A H M. Whither diplomatosis? Whither APHOM? *J Royal Army Med Corps* 1994 (letter to the editor).
51. JEFFERSON T O, MUGFORD M, DEMICHELI V. QALY league tables. *Health Economics* 1994; 3:205. (letter to the editor).
52. MUGFORD M, JEFFERSON T O, SOLL R. A Secondary Systematic Review to Assess whether and how results of randomised controlled trials of surfactant treatment for neonatal RDS can be used to inform questions of cost-effectiveness. Abstract presented at the Second Cochrane Colloquium, Hamilton, Ontario, October 1994.
53. MUGFORD M, McGUIRE A, JEFFERSON T O. Results of a survey of health economists on generalising from economic evaluations.
54. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V. An exercise on the feasibility of carrying out secondary economic analyses. Abstract presented at the Second Cochrane Colloquium, Hamilton, Ontario, October 1994.
55. JEFFERSON T O. Environmental problems for workers abroad. In: Berhens R H, Riley W (editors). *Caring for expatriates and workers abroad. Health issues and ethical dilemmas. Proceedings of an international meeting organised by the British Postgraduate Medical Federation the Hospital for Tropical Diseases and the London School of Hygiene and Tropical Medicine.* British Postgraduate Medical Federation, London 1994.

56. JEFFERSON T O, DEMICHELI V. A panel priority rating exercise for the British Forces Germany Health Services Market Test. J Royal Army Med Corps 1995; 141:29-34.
57. DEMICHELI V, CASADIO G P, LANCIOTTI G, NOVACO F, JEFFERSON T O. The Emilia costing study: valutazione dell'impatto economico della salmonellosi umana. Mecosan 1995; 11:8-15.
58. WILLIAMS C, COYLE D, GRAY A, HUTTON J, JEFFERSON T O, KARLSSON G, KESTELOOT K, UYL-DE-GROOT, WAIT S. European School of Oncology advisory report to the Commission of the European Communities for "Europe Against Cancer Programme" - cost-effectiveness in cancer care. European Journal of Cancer 1995; 31:1410-24.
59. JEFFERSON T O. Book Review - A Literature Review of the Cost-Effectiveness of Nuclear Medicine by Jan Carter. King's Fund Centre. London: 1995. BMJ 1995.
60. JEFFERSON T O. Book Review - The Measures of Medicine: Benefits, Harms and Costs by Richard K Riegelman. Blackwell Science. London: 1995. BMJ 1995.
61. JEFFERSON T O. The Army and the Cochrane Collaboration (editorial). J Royal Army Med Corps 1995; 141:57-58.
62. JEFFERSON T O. Book Review - Outcomes into Clinical Practice by T Delamothe (editor). BMJ Publishing Group. London: 1994. J Royal Army Med Corps 1995; 141:57-58.
63. JEFFERSON T O, DEMICHELI V. Studi economici sulle riviste mediche: e' tempo di pensare a linee guida. Mecosan 1995; 13: 8-12.
64. JEFFERSON T O, DEMICHELI V, ENTWISTLE V. Assessing quality of economic submissions to the BMJ. BMJ 1995; 311:393-94 (letter to the editor).
65. JEFFERSON T O, DEMICHELI V. Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice. Health Economics 1995; 4:383-88.
66. SASSI F, DEMICHELI V, JEFFERSON T O. Systematic Review and synthesis of economic studies. Paper presented at the Scientific Basis of Health Services conference. London 2-4 October 1995.
67. JEFFERSON T O, DEMICHELI V, MACMILLAN A H M. Epidemiological needs assessment in the British Army. Poster presented at the Scientific Basis of Health Services conference. London 2-4 October 1995.
68. DEMICHELI V, JEFFERSON T O. Le salmonellosi e lo studio dei costi delle

malattie. In De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; 6-12.

69. JEFFERSON T O, DEMICHELI V. The costs of disease - a look at world literature. In De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; pages 70-74.
70. DEMICHELI V, JEFFERSON T O. Presentazione dello studio sulla valutazione delle conseguenze economiche della salmonellosi umana in Emilia-Romagna. In De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; 90-93.
71. SASSI F, DEMICHELI V, JEFFERSON T O. Pooling cost data from systematic reviews of economic studies. Poster presented at the Third Cochrane Colloquium, Oslo, Norway, 4-8 October 1995.
72. JEFFERSON T O. The quest for trials on the efficacy of human vaccines: results of the handsearch of the Vaccine journal. Poster presented at the Third Cochrane Colloquium, Oslo, Norway, 4-8 October 1995.
73. JEFFERSON T O. Book Review - Chalmers I, Altman DG. Systematic reviews BMJ Publishing Group. London: 1995. J Royal Army Med Corps 1995; 141:179
74. JEFFERSON T O, DEMICHELI V. Economic evaluation of Influenza vaccination and economic modelling. Can results be pooled? Pharmaeconomics 1996; 9 Suppl 3: 67-72.
75. JEFFERSON T O, DEMICHELI V, MACMILLAN A H M. Pilot study of the introduction of the J95 health data collection system. J Royal Army Med Corps 1996; **142**:25-29.
76. JEFFERSON T O, JEFFERSON V M. The quest for trials on the efficacy of human vaccines. Results of the handsearch of "*Vaccine*". Vaccine 1996; 14: 461-64.
77. DRUMMOND M F, JEFFERSON T O for the BMJ Working Party on guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. Buxton M Demicheli V, Donaldson C, Jönsson B, Mugford M, Rennie D, Rovira J, Rutten F, Schulman K, Smith R, Tonks A, Torrance G, Towse A). Guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. BMJ 1996; 313:275-83 (3 August).
78. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V. An exercise on the

feasibility of carrying out secondary economic analyses. *Health Economics* 1996;5:155-165.

79. JEFFERSON T O, DEMICHELI V, MUGFORD M. *Elementary Economic Evaluation in Health Care*. London: BMJ Books 1996.

80. DEMICHELI V, JEFFERSON T O. Economic aspects of vaccination (Editorial). *Vaccine* 1996;

81. JEFFERSON T O. Economic evaluations as an aid to decisions on whether to carry out trials - Commentary. *Lancet* 1996; 348: 141 (20 July).

82. JEFFERSON TO, ROMANO G, DEMICHELI V. La valutazione dell'impatto economico di incidenti tossinfettivi alimentari: problemi metodologici e prospettive italiane. *L'Igiene Moderna* 1996; 105:993-1003.

83. DEMICHELI V, RIVETTI D, JEFFERSON TO. Economic aspects of a small epidemic of Hepatitis A in a religious community in Northern Italy. *Journal of Infection* 1996; 33:87-90

84. JEFFERSON TO (Book Review). *Medical Informatics.....the essentials*. By F T de Dombal. Butterworth Heinemann. Oxford: 1996. *J Royal Med Corps* 1997;143:64.

85. JEFFERSON T O. New and not so new vaccines- Editorial. *BMJ* 1996;313:768 (28 September 1996).

86. JEFFERSON TO, DEMICHELI V, PRATT M, DEEKS J, SASSI F, MACMILLAN A. The effectiveness of vaccines against Hepatitis B in healthcare workers. In Gluud C, Jørgensen T, Morabito A, Pagliaro L, Poynard T, Sutton R (eds). *Cochrane Database of Systematic Reviews*; Issue 4. Update Software 2001.

87. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of Anthrax vaccines. In Garner P, Gelband H, Oliaro P, Salinas R (eds). *Cochrane Database of Systematic Reviews*; Update Software 2001, Issue 4.

88. MILLER SASTJ, JEFFERSON TO. Military Health Surveillance. *J Royal Med Corps* 1997; 143:3 (editorial)

89. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of Plague vaccines. In Garner P, Gelband H, Oliaro P, Salinas R (eds). *Cochrane Database of Systematic Reviews*; Issue 4. Update Software 2001.

90. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of vaccines

against Tick-Borne Encephalitis (TBE). In Garner P, Gelband H, Oliaro P, Salinas R (eds). Cochrane Database of Systematic Reviews; Update Software 2000, issue 4.

91. JEFFERSON TO, DEMICHELI V, PRATT M. Evidence-based vaccinology. The work of the Cochrane Vaccines Field. *Journal of Epidemiology and Community Health* 1998;52:207-208.

92. JEFFERSON TO, SMITH R, DRUMMOND MF, KALE R, YI Y, PRATT M. Evaluating the BMJ guidelines on economic submissions: prospective audit of economic submissions to the *BMJ* and *Lancet*. Paper presented at the Third International Congress on Peer Review in Biomedical Publication, Prague 18-20 September 1997.

93. JEFFERSON TO, DEMICHELI V, HUTTON J. The use of systematic reviews for peer reviewing. Poster presented at the Third International Congress on Peer Review in Biomedical Publication, Prague 18-20 September 1997.

94. JEFFERSON TO, DEMICHELI V. A systematic review of world literature on the economics of influenza. *Information and News on Influenza*. European Scientific Working Group on Influenza. 1997; 7:6.

95. JEFFERSON TO Redundant publication in biomedical sciences. Scientific misconduct or necessity? *Science and Engineering Ethics* 1998; 4:135-40. (See Corrigenda in *Science and Engineering Ethics* 1998; 4:392).

96. RIVETTI D, DEMICHELI V, DEEKS J, JEFFERSON TO, PRATT M. The effectiveness and safety of vaccines against human anthrax: a systematic review. *Vaccine* 1998; 16:880-84.

97. GRAVES PM, DEMICHELI V, JEFFERSON TO, DEEKS JJ, PRATT M. The effects of cholera vaccines. In Garner P, Gelband H, Oliaro P, Salinas R (eds). Cochrane Database of Systematic Reviews; Update Software 2000, Issue 4.

98. JEFFERSON TO. Vaccine trial data systematically assembled, pooled and disseminated by the Cochrane Collaboration. *Vaccine* 1998; 16:1487-95.

99. JEFFERSON TO, DEMICHELI V. No evidence that vaccines cause insulin dependent diabetes mellitus. *Journal of Epidemiology and Community Health* 1998; 52: 674-675.

100. DEMICHELI V, JEFFERSON T O. An exploratory review of the economics of recombinant vaccines against Hepatitis B (HB). In: Ronchi E (Editor) *Biotechnology and Medical innovation: Socio-economic assessment of the technology, the potential and the products*. OECD, Paris 1997 pages 105-123.

101. HUTTON J, JEFFERSON TO. Assessing the potential cost-effectiveness of pneumococcal vaccines: methodological issues and current evidence. Abstract 1998.
102. WRIGHT LA, DEMICHELI V, GILLESPIE WJ, JEFFERSON TO. Morbidity surveillance in the British Army - the first 12 months. *J R Army Med Corps* 1998; 144:11-17.
103. JEFFERSON TO. An introduction to Health Economics. Epidemiology Supercourse on the Web (editor R LaPorte, University of Pittsburgh) 1998. <http://www.pitt.edu/~super1/hec02/>.
104. JEFFERSON TO, DRUMMOND MF, SMITH R, YI Y, PRATT M, KALE R. Evaluating the *BMJ* guidelines on economic submissions - Prospective audit of economic submissions to the *BMJ* and *Lancet*. *JAMA* 1998; 280:275-77.
105. JEFFERSON TO. Vaccines and their adverse effects - real or perceived (editorial). *BMJ* 1998; 317:159-60.
106. JEFFERSON TO. Economic evaluation alongside the UK collaborative ECMO trial (commentary). *BMJ* 1998; 317:915-6.
107. JEFFERSON TO, DEMICHELI V. The socioeconomics of influenza. In Nicholson, Hay and Webster (editors): *Textbook of Influenza*. London: Blackwell 1998 pages 541-47.
108. JEFFERSON TO, DEMICHELI V. Relation between experimental and non-experimental study designs. HB vaccines: a case study. *Journal of Epidemiology and Community Health* 1999; 53:51-54.
109. DEMICHELI V, RIVETTI D, DEEKS JJ, JEFFERSON TO. Vaccines for preventing influenza in healthy adults (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
110. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Neuraminidase inhibitors for influenza. *Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module)*; Oxford: Update Software 2003, Issue 1.
111. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Amantadine & rimantadine for influenza. *Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module)*; Oxford: Update Software 2003, Issue 1.
112. JEFFERSON TO, DEMICHELI V. Methodological quality of economic modelling studies: a case study with hepatitis B vaccines. *Pharmacoeconomics* 1998; 14:251-7.
113. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Cochrane reviews and systematic reviews of economic evaluations: the case of amantadine and rimantadine in

the prevention and treatment of influenza. In: Snacken R, Szucs TD (editors). The socioeconomics of influenza and its control measures. *Pharmacoeconomics* 1999; 16: S85-S98.

114. JEFFERSON TO, DEMICHELI V. J95-EPINATO based planning parameters for medical support to operations other than war (OOTW). *J R Army Med Corps* 1998; 144:72-78.

115. HUTTON J, IGLESIAS C, JEFFERSON TO. Assessing the potential cost-effectiveness of pneumococcal vaccines: methodological issues and current evidence. *Drugs and Aging* 1999 15 Suppl 1:31-36.

116. JEFFERSON TO. What are the costs and benefits of editorials and non-systematic reviews? *BMJ* 1999; 318:135. (Personal View) (9 January).

117. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Prevention and early treatment of influenza in healthy adults. *Vaccine* 2000; 18:957-1030.

118. JEFFERSON TO, MEIER CR, WEGMÜLLER Y. The impact of influenza on adults. Poster presented at the 21st International Congress of Chemotherapy, Birmingham, UK, 4-7 July 1999. *Journal of Antimicrobial Chemotherapy* 1999 4(Suppl): 43. Abstract P10. (Winner of the 21st International Congress of Chemotherapy Young Investigators Award)

119. JEFFERSON TO, WEGMÜLLER Y, BARKER C, WARD P. Influenza in the workplace: effect of Oseltamivir on ability to perform usual activities and attendance at work. Poster presented at the 21st International Congress of Chemotherapy, Birmingham, UK, 4-7 July 1999. *Journal of Antimicrobial Chemotherapy* 1999 4(Suppl): 46. Abstract P23.

120. JEFFERSON TO, RABINOVICH R, TUOMILEHTO J. Vaccines and their real or perceived adverse effects – authors' conclusions are at odds with investigators'. *BMJ* 1999; 318:1487 (letter to the editor).

121. JEFFERSON TO. Should the topics of Cochrane Reviews be Prioritised? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

122. JEFFERSON TO, DEMICHELI V. Should we Review Single Interventions or All Comparators in a Decision-Making Context? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

123. JEFFERSON TO, MILAN S. How are the topics of Cochrane Reviews decided? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

124. JEFFERSON TO. Do vaccines make best use of available resources? (In other words are they cost-effective?). In: Furminger I (editor): 4th European Conference on Vaccinology: the societal value of vaccination. *Vaccine* 1999; 17:S69-73.

125. GODLEE F, JEFFERSON TO (Editors). Peer Review in Health Sciences. London: BMJ Books 1999.
126. JEFFERSON TO. Real or perceived adverse effects of vaccines and the media – a tale of our times (Editorial). Journal of Epidemiology and Community Health 2000; 54:402-3.
127. JEFFERSON TO. Economic and non-economic factors in evaluating prevention versus treatment. Abstract of talk given at the AAAS Annual Meeting and Science Innovation Symposium (Abstract A 51). Washington DC 17-22 February 2000.
128. JEFFERSON TO, DEEKS JJ. The use of systematic reviews for peer reviewing. In: GODLEE F, JEFFERSON TO (Editors). Peer Review in Health Sciences. London: BMJ Books 1999.
129. COLORECTAL CANCER COLLABORATIVE GROUP. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321:531-5.
130. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18:957-1030.
131. JEFFERSON T O, DEMICHELI V, MUGFORD M. Elementary Economic Evaluation in Health Care. Second Edition. London: BMJ Books 2000.
132. HEIJBEL H, JEFFERSON TO. Vaccine Safety – Improving monitoring. Vaccine 2001; 19:2457-60.
132. JEFFERSON TO. Comment: Efficacy and safety of the oral neuraminidase inhibitor Oseltamivir in treating acute influenza. A randomised controlled trial. Evidence-based healthcare 2000; 4:94.
133. MEIER CR, NAPALKOV PN, WEGMUELLER Y, JEFFERSON T, JICK H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. European Journal of Clinical Microbiology and Infectious Diseases 2000;19(11):834-842.
133. JEFFERSON TO, HEIJBEL H. Demyelinating disease and Hepatitis B vaccination - Is there a link? Drug Safety 2001; 24(4):249-54.
134. JEFFERSON TO. Monitoring the safety of vaccines: methodological challenges. Paper presented at the 8th Annual meeting of the European Society of Pharmacovigilance. Verona, Italy 21-23 September 2000. Abstract number 45.

135. JEFFERSON TO, DEMICHELI V. The quality of methods of economic evaluations in healthcare: time for action (editorial). *BMJ* 2002; 324:313-4. (9 February).
136. WAGER E, JEFFERSON TO. Shortcomings of peer review in biomedical journals. *Learned Publishing* 2001; 14:257-63.
137. JEFFERSON TO, DEMICHELI V, VALE L. The quality of systematic reviews of economic evaluations in healthcare and what they are telling us: it is time for action. *JAMA* 2002; 287:2809-2812.
138. BURLS A, CLARK W, STEWART T, PRESTON C, BRYAN S, JEFFERSON T, FRY-SMITH A. Zanamivir for the treatment of influenza in adults. NHS HTA Programme, London: 2002; Vol 6: No 9.
139. JEFFERSON TO, TYRRELL D. Antivirals for the Common Cold (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
140. JEFFERSON TO, ALDERSON P, DAVIDOFF F, WAGER E. Editorial peer review for improving the quality of reports of biomedical studies (Cochrane Methodology Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
141. JEFFERSON TO, TYRRELL D. Vaccines for the Common Cold (Protocol for a Cochrane Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
142. SPIER R, JEFFERSON TO, DEMICHELI V. An editorial policy statement. Submission of economic evaluations of vaccines. *Vaccine* 2002; 20:1693-1695.
143. JEFFERSON TO, ALDERSON P, DAVIDOFF F, WAGER E. Effects of editorial peer review: a systematic review. *JAMA* 2002; 287:2784-2786.
144. JEFFERSON TO, WAGER E, DAVIDOFF F. Measuring the quality of editorial peer review. *JAMA* 2002; 287:2786-2790.
145. WAGER E, GODLEE F, JEFFERSON TO. How to survive peer review. London, BMJ Books 2002.
146. JEFFERSON TO. Advances in the diagnosis and management of influenza. *Current Infectious Diseases Reports* 2002; 4: 206-10.
147. JEFFERSON TO, BIANCO E, DEMICHELI V. Influenza vaccines in adults. *Occupational Medicine* 2002; 52(5):255-58.
148. JEFFERSON TO, DEMICHELI V, VALE L. Methodological quality of economic evaluations of health care interventions – evidence from systematic reviews. In:

Donalson C, Mugford M, Vale L (editors). Evidence-based Health economics: from effectiveness to efficiency in health care. London BMJ Books 2002. Pages 67-88.

149. DEMICHELI V, JEFFERSON TO, VALE L. Effectiveness estimates in economic evaluation. In: Donalson C, Mugford M, Vale L (editors). Evidence-based Health economics: from effectiveness to efficiency in health care. London BMJ Books 2002. Pages 89-98.

150. JEFFERSON TO, BIANCO E. Quanto protetti? Aretre' Roche 2002; 35:24-5.

151. JEFFERSON T, RUDIN M. 1st International Symposium on the Evaluation of Safety of Human Vaccines. Expert Opin Drug Saf 2002; 1(2):195-98.

152. JEFFERSON TO, TRAVERSA G. Hepatitis B vaccination: risk-benefit profile and role of systematic reviews in the assessment of causality of adverse events following immunisation. Journal of Medical Virology 2002; 67:451-53.

153. JEFFERSON TO, DEMICHELI V. Polysaccharide Pneumococcal Vaccines. Editorial . BMJ 2002 (in press).

154. JEFFERSON T, DEMICHELI V, VALE L. Educating authors and reviewers of economic evaluations of health care. JAMA 2002 Aug 28;288(8):959 (Letter to the Editor).

155. JEFFERSON TO, PRICE D, DEMICHELI V. Unintended Events following immunisation with MMR: a systematic review. Pharmacoepidemiology and Drug Safety 2002; 11:S286 (abstract).

156. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. systematic review of the effects of DTP vaccines in children with or without inactivated polio vaccine (IPV). Pharmacoepidemiology and Drug Safety 2002; 11:S285 (abstract).

157. MELE A, JEFFERSON T, FRANCO E, SALMASO S. Change from oral poliovirus vaccine to inactivated poliovirus vaccine. The Lancet 2002; 360:1178 (12 October).

156. BONHOEFFER J, KOHL K, CHEN R, DUCLOS P, HEIJBEL H, HEININGER U, JEFFERSON T, LOUPI E and The Brighton Collaboration. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002; 21:298-302.

157. JEFFERSON TO, SHASHOK K. Journals: how to decide what's worth publishing. Nature 2003; 421:209-10.

158. DEMICHELI V, RIVETTI A, DI PIETRANTONJ C, CLEMENTS CJ, JEFFERSON T. Hepatitis B vaccination and multiple sclerosis - Evidence from a systematic review. Journal of Viral Hepatitis 2003; 5:343-4.

159. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Systematic review of the effects of pertussis vaccines in children. *Vaccine* 2003; 21(17-18):2012-2023.
160. JEFFERSON TO, DEMICHELI V. Economic Analysis on influenza vaccination and treatment. *Annals of Internal Medicine* 2003; 138(7):607 (letter to the Editor).
161. MELE A, JEFFERSON TO. The use of Hepatitis A vaccine in Italy - evidence-based recommendations from an expert panel. *Vaccine* 2003; 21:2223 (editorial).
162. JEFFERSON TO, DEMICHELI V. Observational data on harm are already included in systematic reviews. *BMJ* 2003; 327:750.
163. JEFFERSON TO, PRICE D, DEMICHELI V, BIANCO E. Unintended Events following immunisation with MMR: a systematic review. *Vaccine* 2003; 21(25-26):3954-60.
164. JEFFERSON TO, SHASHOK K, WAGER E. Get Peered! *BMJ* 2003. (Christmas issue).
165. GODLEE F, JEFFERSON TO (Editors). *Peer Review in Health Sciences*. Second edition. London: BMJ Books 2003.
166. MATERIA E, BAGLIO G, CANONACO D, JEFFERSON T, MELE A, MARCHISIO P, DI DOMENICANTONIO R, GUASTICCHI G. Promoting clinical and organizational appropriateness of tonsillectomy in Italy. *European J Public Health* 2003; 13: 86 (Supplement. Abstracts of the 11th Annual EUPHA Meeting Globalisation and health in Europe: harmonising public health practices, Roma 20-22 November 2003.)
167. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Adverse events following immunization with aluminium-containing DTP vaccines - systematic review of the evidence. *Lancet Infect Dis* 2004; 4: 84-90.
168. JEFFERSON T. Informed choice and balance are victims of the MMR-autism saga. *Lancet Infect Dis* 2004; 4: 135-36.
169. JEFFERSON T, PRICE D, DEMICHELI V, BIANCO E. Selective quotation of evidence in vaccines research. *Lancet* 2004; 363: 1738 (letter to the Editor).
170. JEFFERSON TO. The role of editorial peer review in the evaluation of vaccine safety. *Vaccine* 2004; 22: 2073-75.
171. JEFFERSON TO, Demicheli V. The first international symposium on vaccine safety. *Vaccine* 2004; 22: 2042-43.
172. PERRIA C. For the IMPEMEG Study Group (Pierluigi Bartoletti, Paolo Billi, Virgilio Calzini, Maurizio D'Amato, Alfonso Fiorillo, Gabriella Guasticchi, Carmelina Guerriera,

Giuseppe Grasso, Tom Jefferson, Sergio Leotta, Donatella Mandolini, Walter Marrocco, Mazzieri Scheggi, Amina Pasquarella, Carla Perria, Concetta Suraci). **Strategies for the introduction and implementation of a guideline for the treatment of type 2 diabetics by general practitioners (GPs) of the Lazio region of Italy (IMPLEMEG study): Protocol for a cluster randomised controlled trial [ISRCTN80116232]**. BMC Health Services Research 2004, 4:13 (14 Jun 2004)
<http://www.biomedcentral.com/1472-6963/4/13>

173. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Reply to the letter to the Editor Vaccine 2004; 22(21-22):2685.

174. JEFFERSON TO. Bioterrorism and compulsory vaccination. Better vaccines are needed if vaccination is to be made compulsory. (Editorial). BMJ 2004; 329: 524-25. (4 September)

174. JEFFERSON TO. What are we to do about influenza? (Editorial). BMJ 2004; 329: 633-4.

175. SMITH S, DEMICHELI V, JEFFERSON T, HARNDEN A, MATHESON N, DI PIETRANTONJ C. Vaccines for preventing influenza in healthy children (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.

176. RIVETTI D, DEMICHELI V, DI PIETRANTONJ C, JEFFERSON TO, THOMAS R. Vaccines for preventing influenza in the elderly (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.

177. JEFFERSON TO. How to deal with influenza: Author's reply. BMJ 2004;329:1238, doi:10.1136/bmj.329.7476.1238-b

178. BIANCO E, DE MASI S, MELE A, JEFFERSON T. Effectiveness of immune globulina in preventing infectious hepatitis and hepatitis A: a systematic review. Digestive and Liver Disease 2004; 36: 834-42

179. JEFFERSON TO, Demicheli V, Price D. Informed choice, balance and the MMR-autism saga (authors' reply). The Lancet Infectious Diseases 2005; 5(1):3-4..

180. JEFFERSON TO. Glossary of peer review. Journal of Epidemiology and Community Health 2004; 58:272.

181. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A, DI PIETRANTONJ C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005; 365:773-80 (26th of February).

182. JEFFERSON T. L'applicazione della medicina basata sulle prove alla tomoscintigrafia a emissione di positroni (PET). Decidere in Medicina 2005; 2:34-40.

183. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A. Influenza vaccines in healthy children – authors' reply. *The Lancet* 2005; 385:2087.
184. JEFFERSON T. Peer review and publishing: it's time to move the agenda on. *The Lancet* 2005; 366:283-284. DOI:10.1016/S0140-6736(05)66968-1.
185. JEFFERSON T. Microbial challenge studies of volunteers—a challenge worth accepting. *Lancet* 2005 (in press) commentary.
186. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A. Safety of influenza vaccines in children. *Lancet* 2005; 366:803-04.
187. JEFFERSON T, RIVETTI D, RIVETTI A, RUDIN M, DI PIETRANTONJ C, DEMICHELI V. Efficacy and effectiveness of influenza vaccines in the elderly: systematic review. *Lancet* 2005 ; 366:1165 -1174.
188. JEFFERSON T. *Attenti alle bufale*. Roma: Pensiero Scientifico Editore 2005.
189. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. *The Lancet* 2006; 367: 303-13. Published Online January 19 2006; DOI: 10.1016/S0140-6736(06) 67970-1.
190. THOMAS RE, JEFFERSON TO, DEMICHELI V, RIVETTI D. Influenza vaccination for health care workers who work with the elderly: A systematic review. *The Lancet Infectious Diseases* 2006; 6:273-79.
191. JEFFERSON T. Alternative models of quality control for scientific research. *Nature* 2006 (<http://www.nature.com/nature/peerreview/debate/index.html>).
192. JEFFERSON T. *Attenti alle bufale*. Roma, Pensiero Scientifico Editore 2005
193. JEFFERSON T, FERRONI E, CURTALE F, GIORGI ROSSI P, BORGIA P. S. *pneumoniae* in Western Europe: serotype distribution and incidence in children less than 2 years old. *The Lancet Infectious Diseases* 2006; 6:405-10.
194. JEFFERSON T, FRATI D, GRASSO E. *Aviaria: influenza dei polli?* Roma: Pensiero Scientifico Editore 2006
195. JEFFERSON T, RUDIN M, BRODNEY FOLSE S, DAVIDOFF F. Editorial peer review for improving the quality of reports of biomedical studies. *The Cochrane Database of Methodology Reviews* 2006, Issue 1. Art. No.: MR000016.pub2. DOI: 10.1002/14651858.MR000016.pub2.
196. JEFFERSON T. The prevention of seasonal influenza – policy versus evidence. *BMJ* 2006; 333:912-15.

197. JEFFERSON T. Influenza. Clinical Evidence 2006.
196. D RIVETTI, T JEFFERSON, R THOMAS, M RUDIN, A RIVETTI, C DI PIETRANTONJ, V DEMICHELI. Vaccines for preventing influenza in the elderly. Cochrane Database of *Systematic Reviews* 2006, Issue 3. Art. No.: CD004876. DOI: 10.1002/14651858.CD004876.pub2.
197. Jefferson T. Look at all the evidence before stockpiling Amantadine. BMJ 2007; 334:439 (letter to the editor).
198. TO Jefferson, D Rivetti, C Di Pietrantonj, A Rivetti, V Demicheli. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Systematic Reviews* 2007, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub3.
199. TOM JEFFERSON, LUCIA ZARRA, AND LIVIU STOICA. Attenti Alle Bufale ('Beware of Red Herrings'), or, How to Make Evidence-Based Medicine Work for You J. R. Soc. Med. 2006 99: 625-627.
200. TOM JEFFERSON AND LUCIA ZARRA. Bufala spotting, part one: assessing research papers J. R. Soc. Med. 2007 100: 38-39.
201. TOM JEFFERSON AND LUCIA ZARRA. Bufale spotting, part two: assessing systematic reviews J. R. Soc. Med. 2007 100: 180-181.
202. TOM JEFFERSON AND LUCIA ZARRA. Bufale spotting, part three: assessing editorials. J. R. Soc. Med. 2007; 100(6): p. 267
203. CARLA PERRIA, DONATELLA MANDOLINI, CARMELINA GUERRERA, THOMAS JEFFERSON, PAOLO BILLI, VIRGILIO CALZINI, ALFONSO FIORILLO, GIUSEPPE GRASSO, SERGIO LEOTTA, WALTER MARROCCO, CONCETTA SURACI AND AMINA PASQUARELLA. Implementing a guideline for the treatment of type 2 diabetics: results of a Cluster- Randomized Controlled Trial (C-RCT) **[ISRCTN80116232]**. BMC Health Services Research 2007, 7:79 (04 Jun 2007). <http://www.biomedcentral.com/1472-6963/7/79>
204. TOM JEFFERSON AND LUCIA ZARRA. Bufale Spotting, part 5: Assessing a website. J. R. Soc. Med. 2007; 100(8): p. 367 <http://www.jrsm.org/cgi/content/full/100/8/367?ct=ct>
205. TO JEFFERSON, D RIVETTI, C DI PIETRANTONJ. Inactivated influenza vaccines in the elderly—are you sure? (Comment). The Lancet (Published Online Septmber 25, 2007, DOI:10.1016/S0140-6736(07)61389-0).
206. TOM JEFFERSON, RUTH FOXLEE, CHRIS DEL MAR, LIZ DOOLEY, ELIANA FERRONI, BILL HEWAK, ADI PRABHALA, SREE NAIR, AND ALEX RIVETTI.

Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ. 2008; 336(7635): p. 77-80

207. TOM JEFFERSON AND LUCIA ZARRA. Bufale Spotting, part 7: Assessing an advert. J. R. Soc. Med. 2007; 100(11): p. 502

208. T JEFFERSON. Cattive Acque. Il Pensiero Scientifico Editore. 2007

209. TOM JEFFERSON AND LUCIA ZARRA. Bufale Spotting, part 9: assessing an economic evaluation. J R Soc Med. 2008; 101(4): p. 175-176.

210. T JEFFERSON, A RIVETTI, A HARNDEN, C DI PIETRANTONJ, AND V DEMICHELI. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 1 Jan 2008: p. CD004879

211. C CATES, T JEFFERSON, AND B ROWE. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 1 Jan 2008: p. CD000364.
<http://highwire.stanford.edu/cgi/medline/pmid;18425863>

212. TOM JEFFERSON. More cases, doctor? Yes please! Cases J 16 Jul 2008 1(1): p. 38. <http://highwire.stanford.edu/cgi/medline/pmid;18631383>

213. TOM JEFFERSON. Darkness falls. BMJ. 2008; 337(nov12_1): p. a2501

214. FABIO BERNARDINI, MARINA CERBO, TOM JEFFERSON, ALESSANDRA LO SCALZO, MARCO RATTI - Wireless Capsule Endoscopy in the diagnosis of small bowel disease. Age.na.s. HTA Report. Rome, September 2008.
<http://www.ministerosalute.it/dispositivi/paginainternaf.jsp?id=1202&menu=hta>

215. ANTONELLA CAVALLO, MARINA CERBO, DARIO FELLA, TOM JEFFERSON, ANTONIO MIGLIORE, MARIA ROSARIA PERRINI. - Prostheses for primary total hip replacement in Italy. Age.na.s. HTA Report, Rome, September 2008.
<http://www.ministerosalute.it/dispositivi/paginainternaf.jsp?id=1202&menu=hta>

216. ANNA MARIA VINCENZA AMICOSANTE, MARINA CERBO, TOM JEFFERSON, SIMONA PAONE, LAURA VELARDI. Rapid (bed-side) tests for influenza. Age.na.s. HTA Report - Rome, September 2008.

217. T JEFFERSON, C DI PIETRANTONJ, M G DEBALINI, A RIVETTI, AND V DEMICHELI. Inactivated influenza vaccines: Methods, policies, and politics. J Clin Epidemiol 2008; 1-10. <http://highwire.stanford.edu/cgi/medline/pmid;19124222>
doi: 10.1016/j.jclinepi.2008.07.001.

218. T JEFFERSON, C DI PIETRANTONJ, MG DEBALINI, A RIVETTI, V DEMICHELI. Study quality, concordance, take home message, funding and impact. Their relationship in influenza vaccines studies. BMJ 2009 338(feb12_2): p. b354

http://www.bmj.com/cgi/content/abstract/338/feb12_2/b354?ct=ct.

221. T JEFFERSON. Ranking antidepressants. *Lancet* 23 May 2009 373(9677): p. 1759;

219. JEFFERSON T. Influenza. *BMJ Clinical Evidence* 2009.

223 A LO SCALZO, M RATTI, T JEFFERSON, F BERNARDINI, AND M CERBO. Wireless capsule for endoscopy in Italy: adding context-specific data to the review of the evidence from literature. *Int J Technol Assess Health Care* 1 Jul 2009 25(3): p. 297.
<http://highwire.stanford.edu/cgi/medline/pmid;19619348>

224 JEFFERSON T. Pneumococcal vaccines: confronting the confounders. *The Lancet* 2009; [373](#): 2008-09.

225 TOM JEFFERSON. A brief history of shroud waving through the centuries. *BMJ*. 2009; 338(jun30_3): p. b2610
http://www.bmj.com/cgi/content/extract/338/jun30_3/b2610?ct=ct

226. JEFFERSON T, DEL MAR C, DOOLEY L, FERRONI E, AL-ANSARY LA, BAWAZEER GA, VAN DRIEL ML, FOXLEE R, RIVETTI A. [Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review](#). *BMJ*. 2009 Sep 21;339:b3675. doi: 10.1136/bmj.b3675. Review.

227. HERXHEIMER A, CLARKE M, EDWARDS R, JEFFERSON T, LOKE Y. A/H1N1 flu. Time for case-control studies of NSAIDs and oseltamivir. *BMJ*. 2009 Jul 28;339:b3048. doi: 10.1136/bmj.b3048. No abstract available.

228. MIGLIORE A, RATTI M, CERBO M, JEFFERSON T. Health Technology Assessment: managing the introduction and use of medical devices in clinical practice in Italy. *Expert Rev Med Devices*. 2009 May;6(3):251-7. Review. PMID: 19419283 [PubMed - indexed for MEDLINE]

229. T JEFFERSON, M JONES, P DOSHI, AND C DEL MAR. Possible harms of oseltamivir--a call for urgent action. *Lancet* 17 Oct 2009 374(9698): p. 1312.

230. JEFFERSON, T. Guest Editorial: Mistaken identity: seasonal influenza versus influenza-like illness. *Clinical Evidence* 5 October, 2009.

231. TOM JEFFERSON, MARK JONES, PETER DOSHI, AND CHRIS DEL MAR. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. *BMJ*. 2009; 339(dec07_2): p. b5106.
http://www.bmj.com/cgi/content/abstract/339/dec07_2/b5106?ct=ct

232. TOM JEFFERSON AND ELIANA FERRONI. The Spanish influenza pandemic seen through the BMJ's eyes: observations and unanswered questions. *BMJ*. 2009; 339(dec16_3): p. b5313
http://www.bmj.com/cgi/content/extract/339/dec16_3/b5313?ct=ct

233. A MIGLIORE, MR PERRINI, E ROMANINI, D FELLA, A CAVALLO, M CERBO, AND T JEFFERSON. Comparison of the performance of hip implants with data from different arthroplasty registers. *J Bone Joint Surg Br* 1 Dec 2009 91(12): p. 1545.
<http://highwire.stanford.edu/cgi/medline/pmid;19949114>

234. TOM JEFFERSON. Neuraminidase inhibitors produce a small reduction in duration of seasonal influenza in children and reduce transmission in affected households, but effects on serious complications unclear. *Evid. Based Med*. 2010; 15(1): p. 20-21
<http://ebm.bmj.com/cgi/content/extract/15/1/20?ct=ct>

235. FERRONI E, JEFFERSON T (2011). Angelo Celli and research on the prevention of malaria at the turn of the 20th century. *JLL Bulletin: Commentaries on the history of treatment evaluation* (www.jameslindlibrary.org)

236 THOMAS RE, JEFFERSON T, LASSERSON TJ. Influenza vaccination for health care workers who work with the elderly: a Cochrane review. *Health Technology Assessment, H1N1 and pandemic flu A special themed issue of HTA*, 2010;14(55):493-588.

237. MIGLIORE A, CORIO M, PAONE S, CERBO M AND JEFFERSON T. Accommodating intraocular lenses for patients with cataract: A review. *Expert Review of Ophthalmology* 2011 6:4 (431-436).

238. Cochrane Neuraminidase Inhibitors Review Team. Does Oseltamivir Really Reduce Complications of Influenza? *Clinical Infectious Diseases*. 2011 Dec 15;53(12):1302–3.

239. JEFFERSON T. Should journals sell reprints? *BMJ* 2011;343:d6448 doi: 10.1136/bmj.d6448

240. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HENEGHAN CJ, HAMA R, THOMPSON MJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database of Systematic Reviews* 2012, Issue 1. Art. No.: CD008965. DOI: 10.1002/14651858.CD008965.pub3.

241. DOSHI P, JONES MA, JEFFERSON T. Rethinking credible evidence synthesis. *BMJ* 2012; 344:d7898 doi: 10.1136/bmj.d7898

242. Drug Data Shouldn't Be Secret. By PETER DOSHI AND TOM JEFFERSON. The New York Times, April 10, 2012
 URL: <http://www.nytimes.com/2012/04/11/opinion/drug-data-shouldnt-be-secret.html>

Shortened URL: <http://nyti.ms/lvgh9c>

243. DOSHI P, JEFFERSON T, DEL MAR C (2012) The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. *PLoS Med* 9(4): e1001201. doi:10.1371/journal.pmed.1001201

Short URL: <http://bit.ly/HlbwqO> PDF for printing: <http://bit.ly/HFBYTV>

244. JONES M, HAMA R, JEFFERSON T, DOSHI P. Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis *Drug Saf* 2012; 35 (12): 1187-1190.

245. DOSHI P, JEFFERSON T. The first 2 years of the European Medicines Agency's policy on access to documents: Secret no Longer. *Arch Intern Med*. Published online December 19, 2012. doi:

<http://dx.doi.org/10.1001/jamainternmed.2013.3838>

<http://archinte.jamanetwork.com/article.aspx?articleid=1486542>

246. DOSHI P, JEFFERSON T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. *BMJ Open*. 2013 Feb 26;3(2):e002496.

<http://bmjopen.bmj.com/content/3/2/e002496.full> and

<http://dx.doi.org/10.1136/bmjopen-2012-002496>

247. DOSHI P, DICKERSIN K, HEALY D, VEDULA SS, JEFFERSON T. Restoring invisible and abandoned trials: a call for people to publish the findings *BMJ* 2013; 346 doi: <http://dx.doi.org/10.1136/bmj.f2865> (Published 13 June 2013).

248. CHAN A-W, SONG F, VICKERS A, JEFFERSON T, DICKERSIN K, GØTZSCHE PC et al. Increasing value and reducing waste: addressing inaccessible research. *The Lancet*, [Volume 383, Issue 9913](#), Pages 257 - 266, 18 January 2014.

doi:10.1016/S0140-6736(13)62296-5.

<http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2962296-5/fulltext>.

249. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HAMA R, THOMPSON MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database of Systematic Reviews* 2014, Issue 4. Art. No.: CD008965 DOI: 10.1002/14651858.CD008965.pub4

250. HENEGHAN CJ, ONAKPOYA I, THOMPSON M, SPENCER EA, JONES M, JEFFERSON T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ* 2014; 348. DO 10.1136/bmj.g2547. UL <http://www.bmj.com/content/348/bmj.g2547>

251. JEFFERSON T, DOSHI P. Multisystem failure: the story of anti-influenza drugs. *BMJ* 2014;348. DOI 10.1136/bmj.g2263

UL <http://www.bmj.com/content/348/bmj.g2263>

252. JEFFERSON T, DOSHI P. [EMA's double U-turn on its Peeping Tom policy for data release](#). BMJ Blog 2014.
253. JEFFERSON T, DOSHI P, LEMMENS T. EMA's data sharing policy—towards peeping tom based medicine? BMJ Blog 2014.
<http://blogs.bmj.com/bmj/2014/05/22/tom-jefferson-et-al-emas-data-sharing-policy-towards-peeping-tom-based-medicine/>
254. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HAMA R, THOMPSON MJ, ONAKPOYA I, HENEGHAN CJ. Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. BMJ Open 2014;4:e005253-e005253
<http://bmjopen.bmj.com/cgi/content/full/bmjopen-2014-005253?ijkey=AHfmbBvUum2MicR&keytype=ref>
255. Jefferson T. [EMA's release of regulatory data—trust but verify](#)
BMJ Blogs
256. JEFFERSON T. [EMA's Release of Regulatory Data: Possible Fall out for Journals and Research Synthesis](#).
257. TOM JEFFERSON AND PETER DOSHI: Thanksgiving special—menus needed at the EMA's restaurant
258. PETER DOSHI and TOM JEFFERSON. The Evidence Base for New Drugs (editorial). Published: 2 March 2015; BMJ 2015;350:h952.
<http://www.bmj.com/content/350/bmj.h952>
259. TOM JEFFERSON. The EMA revolution gathers pace
<http://blogs.bmj.com/bmj/2015/06/30/tom-jefferson-the-ema-revolution-gathers-pace/>
260. Are we ready for the EMA revolution?
<http://blogs.bmj.com/bmj/2015/06/30/tom-jefferson-are-we-ready-for-the-ema-revolution/>
261. [EMA confidential—the EMA continues consultation on its 0070 policy and concerns appear](#) <http://blogs.bmj.com/bmj/2015/07/09/tom-jefferson-ema-confidential/>
262. KHALED EL EMAM, TOM JEFFERSON, PETER DOSHI
<http://blogs.bmj.com/bmj/2015/08/27/maximizing-the-value-of-clinical-study-reports/>
263. KHALED EL EMAM, TOM JEFFERSON, PETER DOSHI. [The release of regulatory documents under EMA policy 0070: Now you see them, now you don't.](#)

264. DOSHI P, JEFFERSON T. Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. *Trials* (2016) 17:78 DOI 10.1186/s13063-016-1194-7.
<http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1194-7>
265. PETER DOSHI & TOM JEFFERSON. [Access to clinical trial data from the European Medicines Agency](#).
266. JEFFERSON T, DEMICHELI V. Is the timing of recommended childhood vaccines evidence based? *BMJ* 2016; 352 doi: <http://dx.doi.org/10.1136/bmj.i867> (Published 23 February 2016) Cite this as: *BMJ* 2016;352:i867.
<http://www.bmj.com/content/352/bmj.i867>
267. CARL J HENEGHAN, IGHO ONAKPOYA, MARK A JONES, PETER DOSHI, CHRIS B DEL MAR, ROKURO HAMA, MATTHEW J THOMPSON, ELIZABETH A SPENCER, KAMAL R MAHTANI, DAVID NUNAN, JEREMY HOWICK, TOM JEFFERSON. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. *Health Technology Assessment* . 2016 (in press) <http://www.journalslibrary.nihr.ac.uk/hta>
268. JEFFERSON T. Facing the unreliability of clinical trials literature. *Drug and Therapeutics Bulletin of Navarre, Spain*. 2015;23(2).
http://www.navarra.es/home_en/Temas/Portal+de+la+Salud/Profesionales/Documentacion+y+publicaciones/Publicaciones+tematicas/Medicamento/BIT/
269. DAVIS C, LEXCHIN J, JEFFERSON T, GØTZSCHE P, MCKEE M. “Adaptive pathways” to drug authorisation: adapting to industry? *BMJ* 2016;354:i4437 doi: 10.1136/bmj.i4437 (Published 16 August 2016). [Download free here](#)
270. [Tom Jefferson: The EMA’s policy 0070 is live](#) *BMJ blogs*
271. DOSHI P, HUR P, JONES M, ALBARMAWI H, JEFFERSON T, MORGAN DJ, SPEARS PA, POWERS JH. Informed consent to study purpose in randomized controlled trials of antibiotics, 1991-2011. *JAMA Intern Med*. Published online August 21, 2017. doi:10.1001/jamainternmed.2017.3820
272. TOM JEFFERSON. Sticking to principles and anticipating outcomes. *Recenti Prog Med* 2017; 108: 347-49. <https://goo.gl/64jFkp>
- 273 TOM JEFFERSON. [The UK turns to Witty, Vallance, and Van Tam for leadership: revolving doors?](#) *BMJ blogs*.
274. MAHTANI KR, JEFFERSON T, HENEGHAN C. [What makes a systematic review “complex”?](#) *BMJ blogs*.

275. DOSHI P, JEFFERSON T. Disclose Data Publicly, without Restriction. In Davis L, Miller JD, Sharfstein JM, Kesselheim AS. Blueprint for transparency at the US Food and Drug Administration. Winter 2017. Pages 42-45. DOI: 10.1177/1073110517750611.
276. JØRGENSEN L, GØTZSCHE PC, JEFFERSON T. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. *Systematic Reviews* 2018 7:8. <https://doi.org/10.1186/s13643-018-0675-z>.
277. DEMICHELI V, JEFFERSON T, FERRONI E, RIVETTI A, DI PIETRANTONJ C. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Systematic Reviews* 2018, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub6.
278. JEFFERSON T, RIVETTI A, DI PIETRANTONJ C, DEMICHELI V. Vaccines for preventing influenza in healthy children. *Cochrane Database of Systematic Reviews* 2018, Issue 2. Art. No.: CD004879. DOI: 10.1002/14651858.CD004879.pub5.
279. DEMICHELI V, JEFFERSON T, DI PIETRANTONJ C, FERRONI E, THORNING S, THOMAS RE, RIVETTI A. Vaccines for preventing influenza in the elderly. *Cochrane Database of Systematic Reviews* 2018, Issue 2. Art. No.: CD004876. DOI: 10.1002/14651858.CD004876.pub4.
280. JEFFERSON T, RIVETTI A, DEMICHELI V. Why have three long-running Cochrane Reviews on influenza vaccines been stabilised?
<http://community.cochrane.org/news/why-have-three-long-running-cochrane-reviews-influenza-vaccines-been-stabilised>
281. Tom Jefferson and Peter Doshi: RIP PubMed commons
[BMJ Blogs](#)
282. Jefferson T, Jørgensen L. Redefining the “E” in EBM. *BMJ Evidence Based Medicine*. 10.1136/bmjebm-2018-110918.
283. Mahtani K, Jefferson T, Heneghan C, Nunan D, Aaronson J. What is a 'complex systematic review'? Criteria, definition, and examples. 10.1136/bmjebm-2018-110965
<http://dx.doi.org/10.1136/bmjebm-2018-110965>.
284. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. *BMJ Evidence Based Medicine*. Published Online First: 27 July 2018. doi: 10.1136/bmjebm-2018-111012.
285. Jefferson T, Jørgensen L. Human papillomavirus vaccines, complex regional pain syndrome, postural orthostatic tachycardia syndrome, and autonomic dysfunction - a review of the regulatory evidence from the European Medicines Agency. *Indian J Med Ethics*. Published online on October 17, 2016.

286. Hodkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, Doshi P, Heneghan C, Jefferson T, Boutron I, Stewart L. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. *Systematic Reviews* 2018. 7:117. <https://doi.org/10.1186/s13643-018-0766-x>

287. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. *Cochrane Database of Systematic Reviews* 2006 , Issue 2 . Art. No.: CD001169. DOI: 10.1002/14651858.CD001169.pub3.

288. Jørgensen L, Doshi P, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines *BMJ* 2018; 362 doi: <https://doi.org/10.1136/bmj.k3694>

289. Peter Doshi, Tom Jefferson, Mark Jones, John H. Powers III. Baloxavir: Roche's new oseltamivir? <https://www.bmj.com/content/363/bmj.k4531/rr>

290. Tom Jefferson. How Cochrane is doing pharma a good turn. <https://blogs.bmj.com/bmj/2018/11/12/tom-jefferson-cochrane-pharma-good-turn/>

291. Doshi P, Jefferson T, Jones M et al. Call to action: RIAT restoration of a previously unpublished methodology in Gardasil vaccine trials. <https://www.bmj.com/content/346/bmj.f2865/rr-7>
Protocol available at: <https://osf.io/234kw/>. DOI 10.17605/OSF.IO/234KW

292. Tom Jefferson, Florence Bourgeois, Kyungwan Hong, Mark Jones, Haeyoung Lee, Vinay Prasad, O'Mareen Spence, Peter Doshi. Re-analysis of mortality in HPV vaccine trials: systematic review. PROSPERO 2019 CRD42019122348 Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019122348

293. Doshi P, Jefferson T, Jones M et al. Additional trials within scope: a follow-up to our "Call to action: RIAT restoration of a previously unpublished methodology in Gardasil vaccine trials". <https://www.bmj.com/content/346/bmj.f2865/rr-9>

294. Carl Heneghan, Tom Jefferson. Gender-affirming hormone in children and adolescents. <https://blogs.bmj.com/bmjebmspotlight/> (Posted on [25th February 2019](#))

295. Jefferson T (2019). Sponsorship bias in clinical trials – growing menace or dawning realisation? *JLL Bulletin: Commentaries on the history of treatment evaluation*. (<https://www.jameslindlibrary.org/articles/sponsorship-bias-in-clinical-trials-growing-menace-or-dawning-realisation/>)

296. Jefferson T, Formoso G, Venturelli F, Vicentini M, Chiarolla E, Ballini L. Hadrontherapy for cancer. An overview of HTA reports and ongoing studies. *Recenti Prog Med* 2019; 110:566.
297. Doshi et al. Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. *BMJ Evidence-Based Medicine* 2020. <https://doi.org/10.1136/bmjebm-2019-111331>
298. Jørgensen, L., Gøtzsche, P.C. & Jefferson, T. Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports. *Syst Rev* 9, 43 (2020). <https://doi.org/10.1186/s13643-019-0983-y>
299. Jørgensen, L., Gøtzsche, P.C. & Jefferson, T. Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications. *Syst Rev* 9, 42 (2020). <https://doi.org/10.1186/s13643-020-01300-1>.
300. Jefferson T, Demasi M, Doshi P. Statins for primary prevention: what is the regulators role? *Evid. Based Med.* 2020 0: p. [bmjebm-2019-111321](https://doi.org/10.1136/bmjebm-2019-111321)-[bmjebm-2019-111321](https://doi.org/10.1136/bmjebm-2019-111321). <http://ebm.bmj.com/cgi/content/full/bmjebm-2019-111321>.
301. Jefferson T. Covid 19—many questions, no clear answers. <https://blogs.bmj.com/bmj/2020/03/02/tom-jefferson-covid-19-many-questions-no-clear-answers/>
302. Jefferson T. Refining the “E” in EBM. *BMJ Evidence Based Medicine*.

Tom Jefferson: Covid 19—we live in surreal times
<https://blogs.bmj.com/bmj/2020/03/05/tom-jefferson-covid-19-we-live-in-surreal-times/>

Tom Jefferson: Covidair flight 19 from Rome to Oxford and back again.
<https://blogs.bmj.com/bmj/2020/03/10/tom-jefferson-covidair-flight-19-from-rome-to-oxford-and-back-again/>
303. Doshi P, Bourgeois F, Hong K, et al. Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. *BMJ Evidence-Based Medicine* Published Online First: 17 March 2020. doi: 10.1136/bmjebm-2019-111331
<https://doi.org/10.1136/bmjebm-2019-111331>

Tom Jefferson: Covid-19—supermarket wisdom
<https://blogs.bmj.com/bmj/2020/03/20/tom-jefferson-covid-19-supermarket-wisdom/>

COVID-19. Can Historical Antivirals Be of Use?

<https://www.cebm.net/covid-19/covid-19-can-historical-antivirals-be-of-use/>

COVID-19 – The Tipping Point

<https://www.cebm.net/covid-19/covid-19-the-tipping-point/>

COVID-19: What proportion are asymptomatic?

<https://www.cebm.net/covid-19/covid-19-what-proportion-are-asymptomatic/>

Problems in identifying the origins of an outbreak

<https://www.cebm.net/covid-19/problems-in-identifying-the-origins-of-an-outbreak/>

Covid 19 - Modelling the models

<https://www.cebm.net/covid-19/modelling-the-models/>

<https://www.cebm.net/covid-19/sars-cov-2-viral-load-and-the-severity-of-covid-19/>

Are COVID-19 patients in hospital or admitted to hospital?

<https://www.cebm.net/covid-19/are-covid-19-patients-in-hospital-or-admitted-to-hospital/>

303. Jefferson, T. (2020). Sponsorship bias in clinical trials: growing menace or dawning realisation? *Journal of the Royal Society of Medicine*, 113(4), 148–157.

<https://doi.org/10.1177/0141076820914242>

<http://journals.sagepub.com/share/2F3RYZGUQTJTADJT3AJW?target=10.1177/0141076820914242>

COVID-19 – The great plague of Lombardy – a not so distant resonance chamber

<https://www.cebm.net/covid-19/covid-19-the-great-plague-of-lombardy-a-not-so-distant-resonance-chamber/>

Is Lombardy the widow of Hampstead?

<https://www.cebm.net/covid-19/covid-19-is-lombardy-the-widow-of-hampstead/>

What does RCGP surveillance tell us about COVID-19 in the community

<https://www.cebm.net/covid-19/what-does-rcgp-surveillance-tell-us-about-covid-19-in-the-community/>

COVID-19 – Tracking European Mortality

<https://www.cebm.net/covid-19/covid-19-tracking-european-mortality/>

COVID 19 – The Widow of Hampstead Revisited

Effect of Latitude on COVID-19

Six Countries: Three-quarters of the COVID Deaths

COVID-19 Global Charts of Deaths

Covid 19 Epidemic “Waves”

<https://www.cebm.net/covid-19/covid-19-epidemic-waves/>

COVID 19 – Nova et Vetera: Lazarettos of Venice

<https://www.cebm.net/covid-19/covid-19-nova-et-vetera-lazarettos-of-venice/>

COVID-19: Unravelling the Uncertainties

<https://www.cebm.net/covid-19/covid-19-unravelling-the-uncertainties/>

COVID-19: Re-establishing ‘Fever Hospitals’

<https://www.cebm.net/covid-19/covid-19-reestablishing-fever-hospitals/>

COVID 19 - Understanding the Unknown in Acute Respiratory Infections

<https://www.cebm.net/covid-19/covid-19-understanding-the-unknown-in-acute-respiratory-infections/>

COVID-19: Have we forgotten our children in all this?

<https://www.cebm.net/covid-19/covid-19-have-we-forgotten-our-children-in-all-this/>

Let’s bring back Britain’s fever hospitals

<https://www.spectator.co.uk/article/Lets-bring-back-Britains-fever-hospitals>

Don’t place too much faith in models predicting another coronavirus wave

<https://www.telegraph.co.uk/politics/2020/05/16/dont-place-much-faith-models-predicting-another-coronavirus/>

Jefferson, T. Refining the E in EBM. Evid. Based Med. 2020 0: p. bmjebm-2020-111348v1-bmjebm-2020-111348

<http://ebm.bmjournals.com/cgi/content/full/bmjebm-2020-111348v1?ct>

Could mass testing for Covid-19 do more harm than good?

<https://www.spectator.co.uk/article/could-mass-testing-for-covid-19-do-more-harm-than-good->

Rome, 1 August 2020

Thms. & Jfr

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF ALAMEDA**

CINDY KIEL, J.D., an Executive Associate Vice
Chancellor at UC Davis, MCKENNA
HENDRICKS, a UC Santa Barbara student,
EDGAR DE GRACIA, a UCLA student, and
LELAND VANDERPOEL, an employee at the
Fresno satellite extension of the UCSF Medical
Education Program, and FRANCES OLSEN,
Professor of Law at UCLA,

Plaintiffs,

vs.

THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**ANDREW NOYMER DECLARATION IN
SUPPORT OF PLAINTIFFS' MOTION
FOR A PRELIMINARY INJUNCTION**

By Fax

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID- 2206283

Action Filed: August 27, 2020

Trial Date: None Set

I Andrew Noymer declare as follows:

- 1 1. I submit this declaration in support of Plaintiffs’ Motion for a Preliminary Injunction. If
2 called to testify, I could competently testify as follows:
- 3 2. I am an associate professor in the Department of Population Health and Disease
4 Prevention, Program in Public Health, at the University of California, Irvine. My field of
5 academic specialization is population health with a specialization in infectious disease
6 epidemiology. I have published a number of peer-reviewed journal articles on the subject
7 of influenza mortality patterns at the population level. Drawing on my expertise on
8 historical pandemics, I have been a leading interpreter for the public, of the ongoing
9 Covid-19 pandemic, and have been quoted in the *New York Times*, and the *Washington*
10 *Post* and many other media outlets multiple times in 2020. A copy of my curriculum vitae
11 is attached. I provide this declaration voluntarily and without compensation.
- 12 3. I am not against any individual getting the influenza vaccine if it is their choice, but
13 mandating the vaccine is not an appropriate response to the COVID-19 pandemic, for the
14 reasons stated in this declaration.
- 15 4. Just about everyone agrees that vaccines should be tested before they are used. Dr
16 Anthony Fauci: “I would not be satisfied until a vaccine was proven to be safe and
17 effective before it was actually approved for general use”¹. Yet, the influenza vaccine —
18 which is re-formulated each year and often has quite different antigens (composition)
19 from year to year — is not tested for efficacy before it is used. The influenza vaccine is
20 not a single vaccine, but is a different and new vaccine each fall. In my opinion, people
21 should have the right to decline such an untested shot, the efficacy of which is not
22
23
24
25

26 ¹<https://bgr.com/2020/08/31/coronavirus-vaccine-update-phase-3-results-by-november-fauci-interview/> retrieved
27 9/14/2020

1 proven.

- 2 5. The influenza vaccine is not tested each year because it is regarded as generally
3 efficacious, with the assumption that it will be so every year. Yet, in past years before
4 this assumption was made, clinical trials were conducted, and in some years the vaccine
5 was shown to be negatively efficacious. That is to say, not only was there no benefit, but
6 the vaccine group in the randomized controlled trials was actually worse off than the
7 placebo group². This is possible when the vaccine is not only a poor match to the
8 circulating strain of influenza, but, further, it is such a mis-match that it primes the
9 immune system in the “wrong direction”, so to say. The negative efficacy in the 1997-98
10 influenza season, documented in the footnoted reference, is not the only such example.
11 There have been no innovations in influenza vaccine formulation that would exclude a
12 repetition of this embarrassing vaccine failure. Indeed, because influenza vaccines are no
13 longer evaluated by randomized controlled trials, this problem could repeat itself. In my
14 opinion, people should have the right to decline a vaccine which is potentially negatively-
15 efficacious. After all, *primum non nocere* is the maxim of medicine.
16
17 6. There is every reason to believe the 2020-21 northern hemisphere influenza season will
18 be a strange one, but not necessarily a severe one. This makes the above-summarized
19 vaccine mismatch a much more likely scenario this year than years without such unusual
20 circumstances. Due to global circulation of influenza virus, the flu vaccine formulation
21 for the northern hemisphere is based on the prior-winter circulating influenza strains in
22 the southern hemisphere. Because of Covid-19 countermeasures, the southern
23
24
25

26 ²Bridges et al., “Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized
27 controlled trial”, *JAMA*, 2000;284(13):1655-1663. available online at: <https://doi.org/10.1001/jama.284.13.1655>

hemisphere has experienced a highly unusual (and light) flu season³. These same countermeasures (principally: masking, hand hygiene, work from home) will likely make the 2020-21 flu season a mild one in California. While a lenient flu season in the antipodes does not necessarily mean that there will be vaccine strain mismatch, it does raise doubts.

7. The most severe effect of influenza, mortality, occurs absolutely overwhelmingly outside working ages. Moreover, even among the elderly, the widespread adoption of the influenza vaccine in the last decades is not associated with reductions in influenza mortality in population-based studies⁴. Even a perfect influenza vaccine would have a relatively modest impact on mortality in the United States⁵ — and the current vaccines are far from perfect, everyone agrees.

8. There is enormous evidence for cohort, or year of birth, effects in influenza mortality^{6,7}. These effects are generated by the experiences people have in surviving influenza infection in adulthood, which generates robust and long-lived immune memory. Similar influenza viral strains can and do re-circulate years later, when people have aged into elderly status; these people, who survived natural influenza infection, enjoy immunity in old age. Unfortunately, at older ages (approximately 85 and up), influenza vaccines

³<https://www.smh.com.au/politics/federal/aged-care-deaths-fall-during-pandemic-with-influenza-at-record-lows-20200912-p55u2t.html> retrieved 9/14/2020

⁴Simonsen et al., “Impact of influenza vaccination on seasonal mortality in the US elderly population”, *Archives of Internal Medicine*, 2005;165(3):265-272. available online at: <https://doi.org/10.1001/archinte.165.3.265>

⁵Ho & Noymer, “Summertime, and the livin’ is easy: Winter and summer pseudoseasonal life expectancy in the United States”, *Demographic Research* 2017;37(45):1445–1476. available online at: <https://doi.org/10.4054/DemRes.2017.37.45>

⁶Nguyen & Noymer, “Influenza mortality in the United States, 2009 pandemic: Burden, timing and age distribution” *PLoS One* 8(5):e64198 available online at: <https://doi.org/10.1371/journal.pone.0064198>

⁷Acosta et al., “Determinants of influenza mortality trends: Age-period-cohort analysis of influenza mortality in the United States, 1959–2016”, *Demography* 2019;56(5):1723–1746 available online at: <https://doi.org/10.1007/s13524-019-00809-y>

1 themselves are well-understood to be less efficacious. What is more, it is established that
2 natural influenza infection confers a longer-lived immunity than that provided by the
3 annual flu shot. The combination of these factors is that the most effective strategy for an
4 individual may be to experience some influenza infection as a healthy adult, thus
5 generating a better immunity portfolio against influenza for old age. This is a more
6 specific argument than the typical anti-vaccine sentiment that “it's better to survive
7 natural infection” (such as measles); in the case of measles, the vaccine does an excellent
8 job of keeping the virus at bay for a lifetime. The same cannot be said of influenza and
9 the flu shot. In my opinion, it is not the role of employers to dictate which strategy
10 people take (flu shots each and every year, or accumulating stronger immunity through
11 natural flu infection, which can often be mild⁸).

12
13 9. Influenza does not pose an extraordinary peril to the faculty, staff and students of the
14 University of California, and public health measures should be aligned with the
15 magnitude of the risk. For these reasons, I believe that an influenza vaccine
16 encouragement, but not a mandate, is the best approach.

17
18 10. I declare under penalty of perjury under the laws of the State of California that the
19 foregoing is true and correct and that this declaration was executed on September 15,
20 2020 in Irvine, California.

21 ANDREW NOYMER, PhD

22
23 
24

25 ⁸Hayward et al., “Comparative community burden and severity of seasonal and pandemic influenza: Results of the Flu
26 Watch cohort study”, Lancet Respiratory Medicine 2014;2(6):445-454 available online at:
27 [https://doi.org/10.1016/S2213-2600\(14\)70034-7](https://doi.org/10.1016/S2213-2600(14)70034-7)

Curriculum Vitae

Andrew Noymer
University of California
AIRB 2100, 653 E Peltason Drive
Irvine, California 92697-3957

noymer@uci.edu

 0000-0003-2378-9860

<https://webfiles.uci.edu/noymer/web/>

Education

- PhD Sociology, University of California, Berkeley, 2006
(with NICHD & NIA traineeships in Demography)
Studies in the historical demography and epidemiology of influenza and tuberculosis selective mortality
Neil Fligstein (co-chair), Trond Petersen (co-chair), David A. Freedman, George W. Rutherford
- MSc Medical Demography, London School of Hygiene & Tropical Medicine, University of London, 1996
Demographic-epidemiologic models of measles transmission in developing countries: The case of Muyinga sector, Burundi
Felicity Cutts, Nigel Gay (thesis advisors)
- AB Biology, Harvard University, 1995

Employment

- 2012–present Associate Professor, Public Health, University of California, Irvine (UCI)
- 2019–present Associate Professor (by courtesy), Sociology, UCI
- 2014–2015 Director of Graduate Studies, Department of Population Health and Disease Prevention, UCI
- 2012–2013 Associate Professor, Sociology, UCI
- 2008–2012 Assistant Professor, Public Health, UCI
- 2006–2012 Assistant Professor, Sociology, UCI
- 2006–2011 Scientific Staff, International Institute for Applied Systems Analysis (IIASA), Laxenburg, Austria

Journal Articles

- Race and life expectancy in the USA in the Great Depression
Tim A. Bruckner, Ashley M. Ima, Trang T. Nguyen, and Andrew Noymer *Genus* 75(16):22pp. (2019)
- The geometry of mortality change: Convex hulls for demographic analysis.
Audrey F. Lai, Andrew Noymer, and Tsuo Tai *Revue Québécoise/Quetelet Journal* 7(1):27–70 (2019)
- Subacute sclerosing panencephalitis mortality, United States, 1979–2016: Vaccine-induced declines in SSPE deaths.
Lia B. Pallivathucal and Andrew Noymer *Vaccine* 36(35):5222–5225 (2018)
- Models for estimating empirical Gompertz mortality: With an application to evolution of the Gompertzian slope.
Tzu-Han Tai and Andrew Noymer *Population Ecology* 60(1/2):171–184 (2018)

Journal articles, continued

- Summertime, and the livin' is easy: Winter and summer pseudoseasonal life expectancy in the United States.
Tina Ho and Andrew Noymer *Demographic Research* 37(45):1445–1476 (2017)
- 'You've come a long way, baby': The convergence in age patterns of lung cancer mortality by sex, United States, 1959–2013.
Natalie A. Rivadeneira and Andrew Noymer *Biodemography and Social Biology* 63(1):38–53 (2017)
- Did the 1918 influenza cause the twentieth century cardiovascular mortality epidemic in the United States?
Steven Tate, Jamie J. Namkung and Andrew Noymer *PeerJ* 4:e2531 (2016)
- A 'post-honeymoon' measles epidemic in Burundi: Mathematical model-based analysis and implications for vaccination timing.
Katelyn C. Corey and Andrew Noymer *PeerJ* 4:e2476 (2016)
- Clostridium difficile* infection: An emerging cause of death in the twenty-first century.
Viytta N. Abdullatif and Andrew Noymer *Biodemography and Social Biology* 62(2):198–207 (2016)
- Magnitude of Ebola relative to other causes of death in Liberia, Sierra Leone, and Guinea.
Stéphane Helleringer and Andrew Noymer *Lancet Global Health* 3(5):e255–e256 (2015)
- Assessing the direct effects of the Ebola outbreak on life expectancy in Liberia, Sierra Leone and Guinea.
Stéphane Helleringer and Andrew Noymer *PLoS Currents Outbreaks* (2015)
- Divergence without decoupling: Male and female life expectancy usually co-move.
Andrew Noymer and Viola Van *Demographic Research* 31(51):1503–1524 (2014)
- Influenza as a proportion of pneumonia and influenza mortality: United States, 1959–2009.
Andrew Noymer and Ann M. Nguyen *Biodemography and Social Biology* 59(2):178–190 (2013)
- Vitamin D (25OHD) serum seasonality in the United States.
Amy K. Kasahara, Ravinder J. Singh, and Andrew Noymer *PLoS One* 8(6):e65785 (2013)
- Influenza mortality in the United States, 2009 pandemic: Burden, timing and age distribution.
Ann M. Nguyen and Andrew Noymer *PLoS One* 8(5):e64198 (2013)
- Immigrant health around the world: Evidence from the World Values Survey.
Andrew Noymer and Rennie Lee *Journal of Immigrant and Minority Health* 15(3):614–623 (2013)
- Life expectancy during the Great Depression in eleven European countries.
Tim A. Bruckner, Andrew Noymer, and Ralph A. Catalano *Population and Development Review* 39(1):57–74 (2013)
- Hardship of tuberculosis treatment access and adherence among Myanmar migrants at Maesai Hospital, Thailand.
Chunjira Wichai, Amara Soonthorndhada, Sirinapha Jittimane, Andrew Noymer, & Chalumporn Holomyong *Journal of Health Research* 26(4):167–171 (2012)
- Health-related quality of life in older adults: Testing the double jeopardy hypothesis.
Daisy Carreon and Andrew Noymer *Journal of Aging Studies* 25(4):371–379 (2011)
- The 1918 influenza pandemic hastened the decline of tuberculosis in the United States: An age, period, cohort analysis.
Vaccine 29(Suppl. 2):B38–B41 (2011)
- Population decline in post-conquest America: The role of disease.
Population and Development Review 37(1):178–183 (2011)

Journal articles, continued

- Cause of death affects racial classification on death certificates.
Andrew Noymer, Andrew Penner, and Aliya Saperstein *PLoS One* 6(1): e15812. (2011)
- The 1918 influenza pandemic affected sex differentials in mortality: Comment on Sawchuk.
American Journal of Physical Anthropology 143(4):499-500 (2010)
- Testing the influenza-tuberculosis selective mortality hypothesis with Union Army data.
Social Science & Medicine 68(9):1599–1608 (2009)
- The 1918–19 influenza pandemic affected tuberculosis in the United States: Reconsidering Bradshaw, Smith, and Blanchard.
Biodemography and Social Biology 54(2):125–133 (2008)
- Causes of death in nineteenth-century New England: The dominance of infectious disease.
Andrew Noymer and Beth Jarosz *Social History of Medicine* 21(3):573–578 (2008)
- Influenza analysis should include pneumonia. *American Journal of Public Health* 98(11):1927–1928 (2008)
- Les effets à long terme de la grippe espagnole de 1918: Une sélection différentielle selon le sexe.
Michel Garenne and Andrew Noymer *Cahiers de Sociologie et de Démographie Médicales* 48(3):341–354 (2008)
- Contesting the cause and severity of the black death: A review essay.
Population and Development Review 33(3):616–627 (2007)
- The transmission and persistence of ‘urban legends’: Sociological application of age-structured epidemic models.
Journal of Mathematical Sociology 25(3):299–323 (2001)
- Mortality selection and sample selection: A comment on Beckett.
Journal of Health and Social Behavior 42(3):326–327 (2001)
- The 1918 influenza epidemic’s effects on sex differentials in mortality in the United States.
Andrew Noymer and Michel Garenne *Population and Development Review* 26(3):565–581 (2000)
- The Perseus Flasher and satellite glints.
Bradley E. Schaefer, Michael Barber, John J. Brooks, Allen DeForrest, Paul D. Maley, Norman W. McLeod III, Russ McNiel, Andrew J. Noymer, A. K. Presnell, Richard Schwartz, and Scott Whitney
Astrophysical Journal 320(1):398–404 (1987)

Miscellaneous Academic Writing

- Summertime, and the livin’ is easy... and longer *N-IUSSP*, 2018.
Tina Ho and Andrew Noymer <http://www.niussp.org/article/summertime-and-the-livin-is-easy-and-longer/>
- Guest Column: Disease outbreaks & medical sociology *Medical Sociology Newsletter*, 52(4):4 (2016)
- Pandemic influenza: Reducing vulnerability *Options*, Summer 2006, pp. 20–21
Landis MacKellar and Andrew Noymer <http://www.iiasa.ac.at/Options/>

Addressing a Broader Public

- Plans to fight pandemic flu must focus on senior citizens. (Op-Ed) *Chicago Sun-Times*, 5 November 2005
Juliane Baron and Andrew Noymer
- You might be infected — with an urban legend. (Op-Ed) *Los Angeles Times*, 28 December 2003, p. M5
(Sunday opinion section; carried on other newspapers nationwide through LA Times wire service.)

Book Chapters

Epidemics and time: Influenza and tuberculosis during and after the 1918–1919 pandemic (ch. 8, pp. 137–152). D. Ann Herring and Alan C. Swedlund, eds.: *Plagues and epidemics: Infected spaces past and present*. (Wenner-Gren International Symposium Series) Berg (2010)

Long-term effects of the 1918 ‘Spanish’ influenza epidemic on sex differentials of mortality in the USA: Exploratory findings from historical data (ch. 13, pp. 202–217). Andrew Noymer and Michel Garenne. Howard Phillips and David Killingray, eds.: *The Spanish influenza pandemic of 1918–1919: New perspectives*. (Studies in the Social History of Medicine, 12) Routledge (2003)

Encyclopedia entries

Algorithm (pp. 16–17) and Alpha, the significance of a test (p. 18). *Encyclopedia of survey research methods*. Sage Publications (2008)

Algorithm (pp. 9–10). *The Sage encyclopedia of social science research methods*. Sage Publications (2004)

Influenza (pp. 540–542) and Tuberculosis (pp. 946–948). *Encyclopedia of population*. Macmillan Reference (2003)

Book Reviews

Political demography: How population changes are reshaping international security and national politics, ed. by Jack A. Goldstone, Eric P. Kaufmann and Monica Duffy Toft. *Contemporary Sociology* 45(2):177–179 (2016). With Haruka C. Hatori.

Low income, social growth, and good health: A history of twelve countries, by James C. Riley. *Journal of Interdisciplinary History* 39(3):400–402 (2009)

The great influenza: The epic story of the deadliest plague in history, by John M. Barry. *Population and Development Review* 30(3):537–539 (2004)

Island epidemics, by Andrew D. Cliff, Peter Haggett, and Matthew R. Smallman-Raynor. *Journal of Economic History* 62(3):916–918 (2002)

Flu: The story of the great influenza pandemic of 1918 and the search for the virus that caused it, by Gina Kolata. *Population and Development Review* 27(1):187–191 (2001)

Letters

Call to restrict neonicotinoids.
Dave Goulson and 232 signatories *Science* 360(6392):973 (2018)

Did Ebola relatively spare children?
Stéphane Helleringer, Andrew Noymer, Samuel J. Clark, and Tyler McCormick. *Lancet* 386(10,002):1442–1443 (2015)

Ebola Virus Disease in West Africa — The first 9 months.
Stéphane Helleringer, Karen A. Grépin, and Andrew Noymer *New England Journal of Medicine* 372(2):188–189 (2015)

Letters, continued

Questioning the salicylates and influenza pandemic mortality hypothesis in 1918–1919.

Andrew Noymer, Daisy Carreon, and Niall Johnson *Clinical Infectious Diseases* 50(8):1203 (2010)

The March of Dimes [and structural change].

American Journal of Public Health 92(2):158 (2002)

Working Papers *(excludes subsequently-published papers)*

An alternative summary measure of mortality.

CEPED Rapport de recherche n°18. 1998.

Estimates of under-five mortality in Botswana and Namibia: Levels and trends.

IIASA Interim Report IR-98-005

<http://www.iiasa.ac.at/cgi-bin/pubsrch?IR98005>

Awards & Honors

2009: Who's Who in America, 64th edition
Marquis Who's Who

2007: Social Science Assistant Professor Research Award
School of Social Sciences, UC, Irvine

2007: Faculty Career Development Award
Office of the Executive Vice Chancellor and Provost, UC, Irvine

2002: Best Paper in Mathematical Sociology, Mathematical Sociology Section,
American Sociological Association (for urban legend paper in *J. Math. Soc.*)

2002: Best Student Paper in Mathematical Sociology, Mathematical Sociology Section,
American Sociological Association (for urban legend paper in *J. Math. Soc.*)

1996: Selwyn-Clarke Prize, best student in Medical Demography master's program,
London School of Hygiene & Tropical Medicine, University of London

1991: Minor Planet (asteroid) number 4956 named 'Noymer' by the International Astronomical Union
(ref.: *IAU Minor Planet Circular* No. 19341)

Presentations at Meetings, Workshops, Conferences

("PAA" denotes the Annual Meeting of the Population Association of America.)

Human Mortality Database Symposium 2019, Berlin • Using Benford's law to assess life table ensembles: HMD and WHO model life tables

NBER Cohort Studies Meeting 2019, Cambridge • Race and life expectancy in the United States in the Great Depression. With Tim A. Bruckner, Ashley M. Ima, and Trang T. Nguyen.

PAA 2019, Austin • Unraveling the social ecology of polio. With Amarah Mauricio. Session 40. & Measles deaths in the United States, 1890–2016: Age profiles and sex differences help explain pre-vaccine mortality decline. With Stephanie Torrez. Session 197.

Presentations at Meetings, Workshops, Conferences, continued

UC Irvine Mini Conference on Economic History. 2018. • Race and polio mortality in the United States, 1914–69. With Amarah C. Mauricio. [by invitation]

The social impact of epidemics: Workshop marking 100 years of the 1918 Great Flu Epidemic. Oslo, 2018. • Race and mortality: The twentieth-century polio epidemic in the United States. With Amarah C. Mauricio.

XVIII World Economic History Congress, 2018 • Unraveling the social ecology of polio. With Amarah C. Mauricio. Session 030209.

Population, family and health: Global perspectives. Academia Sinica, 2018 • The demographic transition in Taiwan and USA: A convex hull approach. With Ivy K. Miller. Session 1. [by invitation]

Vaccines in the 21st century: Overcoming viruses and misinformation, UC Irvine, 2018 • Reducing mortality through vaccination: Measles in the US and worldwide. [by invitation]

PAA 2018, Denver • Models for estimating empirical Gompertz mortality: With an application to evolution of the Gompertzian slope. With Tzu-han Tai. Poster P3–36.

Health inequalities and urbanization, 17th–20th centuries. Paris School of Economics, 2018 • Unraveling the social ecology of polio. With Amarah C. Mauricio. Session 2. [by invitation]

IUSSP Seminar, “Pandemics: Reflections on the centennial of the 1918 ‘Spanish’ influenza”, 2017, Madrid • A plausible estimate of ‘Spanish’ influenza deaths in Japan, 1918–1920. With Tim Riffe. Session 4. & A tale of two pandemics: Gompertzian patterns of influenza mortality age shifts, United States, 1959–2015. With Alexandra Mardock & Cécile Viboud. Session 7.

PAA 2017, Chicago • Replication and data sharing in demography: Opportunities and challenges for researchers. Session 248. [by invitation]

NBER Cohort Studies Meeting 2017, Los Angeles • The geometry of mortality change: Convex hulls for demographic analysis. With Audrey Lai and Tsuiho Tai. (And IUSSP Seminar, “Mortality: Past, present, and future”, Campinas, Brazil, August 2017.)

PAA 2016, Washington • Deviation from expected? Race and life expectancy in the US during the Great Depression. With Trang Nguyen and Tim-Allen Bruckner. Session 95 (presenter). & ‘You’ve come a long way, baby’: The convergence in age patterns of lung cancer mortality by sex, United States, 1959–2013. With Natalie Rivadeneira. Session 159 (presenter) (and NBER Cohort Studies Meeting, Los Angeles). & Exact Poisson confidence intervals for life expectancy. With Michelle Deville and Tim Riffe. Session 171.

Incidence, Severity, and Impact of Influenza. Institut Pasteur, Paris, 2016 • Exact Poisson confidence intervals for Serfling-type models: An example of influenza and pneumonia excess mortality in the United States, 2009–13. With Rachel C Yip & Ann M Nguyen. Topic 4.

UAPS Seventh African Population Conference, Pretoria, South Africa, 2015 • A preliminary assessment of the impact of Ebola on life expectancy in affected countries. Session 29.

“Who Care\$?” workshop, UC Irvine, 2015 • Ebola Virus Disease outbreak, 2013–15, Guinea, Sierra Leone, Liberia: An update. Day Two, “Plagues and partnerships”. [by invitation]

PAA 2015, San Diego • Origins of the cardiovascular mortality epidemic in the United States, 1920–90. A.N. and Steven Tate. Session 35. & Elasticity of economic development and child mortality, 1950–2011. A.N. and Danzhen You and Haruka Hatori. Session 207 (and UC Global Health Day, 2015, poster).

International Meeting on Emerging Diseases and Surveillance (IMED), 2014, Vienna • Increase in *Clostridium difficile* mortality in the United States, 1999–2011. V. N. Abdullatif and A. Noymer. Poster 23.022.

Presentations at Meetings, Workshops, Conferences, continued

RAPIDD Workshop, “Quantitative studies of major historic epidemic diseases”, Copenhagen, 2014 • Epidemiologic transition theory: Synopsis of and commentary on a social science approach. Session IV. [by invitation]

PAA 2014, Boston • A universal pattern of the evolution of life table entropy and life expectancy. A.N. and Ciarra Coleman. Session 80 & Respiratory viruses’ effect on all-cause mortality: Winter and summer pseudoseasonal life expectancy in the United States. A.N. and Rahema Haseeb. Poster Session 8

PAA 2013, New Orleans • Beyond “best practices”: Waiting times to life expectancy improvements. Sheila Xiao and Andrew Noymer. Session 176. & Male and female life expectancy co-move — even when they diverge. Andrew Noymer and Viola Van. Session 184

IMED, 2013, Vienna • Influenza mortality in the United States, 2009: Burden and timing. Ann M. Nguyen and Andrew Noymer. Poster 22.013 & Assessing the mortality link between respiratory infections and heart disease: A time-series approach. Ann M. Nguyen, Chunyang Li and Andrew Noymer. Poster 22.024

2nd Asian Population Association Conference, 2012, Bangkok • Cancer mortality patterns in Pacific islander populations: A comparative analysis of American Samoa, Guam, Hawai’i, and Saipan. Daisy Carreon and Andrew Noymer. Session 22. & Breastfeeding, age at menarche, and adolescent health: Exploring multi-causal linkages in the Philippines. Marigee Bacolod and Andrew Noymer. Session 80

European Population Conference 2012, Stockholm • Life expectancy during the great depression in eleven European countries. Tim-Allen Bruckner, Andrew Noymer, Ralph Catalano. Session 1.

PAA 2012, San Francisco • Influenza as a proportion of pneumonia and influenza mortality: United States, 1959–2007. Andrew Noymer and Ann M Nguyen. Session 52 & A Similar Pattern of Tuberculosis Mortality Decline in the United States and Thailand, before HIV. Andrew Noymer, Amara Soonthornhdhada and Patama Vapattanawong. Poster Session 7

Third Annual African Network for Influenza Surveillance and Epidemiology (ANISE), Nairobi, 2012 • Influenza and tuberculosis. Session IV. [by invitation]

“Epidemics³”: Third international conference on infectious disease dynamics, Boston, 2011 • Influenza as a proportion of pneumonia and influenza mortality: United States, 1959–2007. (poster) & Influenza and pneumonia mortality do not co-move over time at all ages: An analysis of the United States, 1959–2007. (poster) Andrew Noymer and Ann M Nguyen.

Workshop, “Infectious disease models and data”, Irvine, 2011 • What’s flu got to do with it? The payoff to demography of influenza studies. [by invitation]

“After 1918: History and politics of influenza in the 20th and 21st centuries”, L’École des hautes études en santé publique, Rennes, 2011 • The 1918–19 influenza pandemic affected the decline of tuberculosis. [by invitation]

PAA 2011, Washington & Options for the Control of Influenza VII, Hong Kong, 2010 • Gompertz analysis of pneumonia and influenza death rates by age, United States, 1959–2006. Andrew Noymer and Cécile Viboud. Session 122 & Poster 332.

PAA 2011, Washington • Mortality co-movement at the national level: A quasi-social network analysis. Andrew Noymer, Tanya Jukkala, Christopher S. Marcum. Session 126.

All-UC Group in Economic History & Asia-Pacific Economic and Business History Conference, “The Great Divergence: Perspectives from the Pacific Rim”, Berkeley, 2011 • A comparative analysis of tuberculosis mortality decline in Thailand and the United States. Andrew Noymer, Amara Soonthornhdhada, Patama Vapattanawong. Session 2.

Presentations at Meetings, Workshops, Conferences, continued

IUSSP Seminar on “Lifespan extension and the biology of changing cause-of-death profiles”, Rauischholzhausen, 2011 • Clique analysis of mortality co-movements: A new life expectancy time series analysis. Andrew Noymer, Tanya Jukkala, Christopher S. Marcum. [by invitation]

Workshop, “Death Clustering: Towards new explanations for infant and child mortality in the European past”, Umeå, 2010 • Can seasonality explain clustering of child mortality? A theoretical investigation via simulation. Session 4. [by invitation]

MISMS Meeting, “Historical influenza pandemics: Lessons learned”, Copenhagen, 2010 • The 1918 influenza pandemic hastened the decline of tuberculosis in the US. Session IV. [by invitation]

PAA 2010, Dallas • Author-meets-critics: *Conquest: The destruction of the American Indians* and *El Dorado in the marshes: Gold, slaves and souls between the Andes and the Amazon* by Massimo Livi Bacci. Session 111. [by invitation]

PAA 2009, Detroit • Self-rated health: Is happiness the missing link? Andrew Noymer and Leah Ruppanner. Session 166.

PAA 2009, Detroit & American Public Health Association, 2009 Annual Meeting, Philadelphia • Aging and health for racial minorities: An analysis of the double jeopardy hypothesis using the California Health Interview Survey. Daisy C. Carreon and Andrew Noymer. Poster Sessions 1 & 3268.0.

Flumodcont Project Technical Meeting, “Survey methods for population behavior during seasonal and pandemic influenza”, Istituto Superiore di Sanità, Rome, 2008 • High-stakes collective action, panic behavior, and planning: Insights from sociology for pandemic preparedness. [by invitation]

Keystone Symposium, “Pathogenesis and control of emerging infections and drug resistant organisms”, Bangkok, 2008. • Using routine mortality data to look for pre-pandemic signatures. Abstract 242, poster session 2.

Fourth Joint Japan-North America Mathematical Sociology Conference, Redondo Beach, 2008. • A simulation study of interracial dating dynamics. Andrew Noymer, Cynthia Feliciano, and Belinda Robnett. Session 4.

PAA 2008, New Orleans • Selective mortality in Norway during the 1918 flu pandemic. Session 125. & Early-life influences and the seasonality of mortality: Re-examining the Doblhammer effect. Andrew Noymer and Bert Kestenbaum. Session 158.

UAPS Fifth African Population Conference, Arusha, Tanzania, 2007 • Sibship size and mortality in Africa: Evidence from the DHS. Andrew Noymer and Ndola Prata. Session 92.

Joint IIASA/Peking University workshop on “Pandemic influenza in China: Challenges, responses, needs”, Beijing, 2007 • Plagues past and present: The relevance of historical research to current policy questions. [by invitation]

Wenner-Gren Foundation Conference on “Plagues: Models and metaphors in the human ‘struggle’ with disease”, Tucson, 2007 • Influenza and tuberculosis in 1918: Lessons from an historical plague. [by invitation]

Stanford University/Applied Biosystems Symposium on “Demography and infectious disease: Integrating multiple levels of biological and social organization”, 2007 • Down under, up over: Comparative trends of infectious disease in Australia and the United States in the twentieth century. [by invitation]

Computational & Theoretical Biology Symposium, Rice University, 2006 • Who dies in flu pandemics? Lessons from the 1918 “Spanish” influenza. [by invitation]

Presentations at Meetings, Workshops, Conferences, continued

Conference on “Causal analysis in population studies: Concepts, methods, applications”, Vienna Institute of Demography, 2006 • Causal relations and age, period, cohort analysis: Testability and the case for parsimony. Session 2.

IIASA Workshop on Pandemic Influenza, Laxenburg, Austria, 2006 • Who dies in flu pandemics? Lessons from the 1918 “Spanish” influenza. [by invitation]

IUSSP Seminar on “Longevity: Early-life conditions, social mobility and other factors that influence survival to old age”, Lund/Mölle, 2006 • Testing the influenza-tuberculosis selective mortality hypothesis with Union Army data.

American Thoracic Society, International Conference (ATS 2006), San Diego • Influenza and tuberculosis: Lessons from 1918 for the next flu pandemic. Session D80. [by invitation]

PAA 2006, Los Angeles • Testing the influenza-tuberculosis selective mortality hypothesis in Australia. Session 121. & Testing the influenza-tuberculosis selective mortality hypothesis with Union Army data. Session 135.

Symposium on Avian and Pandemic Influenza, UCSF, 2005 • Theories of differential mortality in the 1918–1919 pandemic. Session II. [by invitation]

American Sociological Association, 2003 Annual Meeting, Atlanta • Age, period, cohort analysis: A plea for theory. Session 497. & The glass ceiling in academia: Findings from a large research university. Trond Petersen and Andrew Noymer. Session 532.

PAA 2002, Atlanta • How many parameters are necessary—or sufficient? A comparison of the Lee-Carter and Brass mortality models. Session 101.

American Sociological Association, 2001 Annual Meeting, Anaheim, California • Competing rumors: A generalized model of information diffusion. Andrew Noymer and Tim Futing Liao. Session 195.

International Health Economics Association, 2001 Conference, York, UK • Disability-adjusted life years and inter-disease comparisons: Stochastic simulations of competing acute and chronic diseases. Session 211.

PAA 2001, Washington • Disability-adjusted life years and inter-disease comparisons: A critical appraisal. Session 13. & The role of externalities and bounded rationality for the evolution of child preferences. Session 71.

Mathematical sociology in Japan and in America: A joint conference, Honolulu, 2000 • The transmission and persistence of ‘urban legends’: Sociological application of age-structured epidemic models.

Second workshop on “Nonlinear demography”, Rostock, Germany, 2000 • Demographic-epidemiologic models of measles transmission in developing countries: Nonlinear demographic tools to determine optimal vaccination policies.

PAA 2000, Los Angeles • The 1918 “Spanish” Influenza’s long-term effects on mortality sex differentials in the USA. Andrew Noymer and Michel Garenne. Session 30 (and American Sociological Association, Methods Section, 2000 Winter Meeting, Los Angeles). & Mortality sex differentials in space and time: Vallin’s paradox in the USA. Session 66 (and REVES 12 meeting, University of Southern California).

PAA 1999, New York • Demographic-epidemiologic models of measles transmission in developing countries. Session 50.

American Sociological Association, Methods Section, 1999 Winter Meeting, Duke University • An alternative summary measure of mortality.

Presentations at Meetings, Workshops, Conferences, continued

The Spanish flu after 80 years: An international conference, Cape Town, 1998 • Long-term effects of the 1918 'Spanish' influenza epidemic on sex differentials of mortality in the USA: Exploratory findings from historical data. Andrew Noymer and Michel Garenne.

Colloquia

Early reflections on COVID-19 mortality

Demography Brownbag, UC Berkeley Demography Department, 25 March 2020. (via zoom)

Race and polio mortality in the United States, 1914–69

UDEM Seminar, Université de Montréal, 13 December 2019

Race and mortality: The twentieth-century polio epidemic in the United States

UC Irvine, Sociology Department, 25 January 2019

"Summertime, and the livin' is easy", or, using seasonal demographic data to answer policy-relevant questions

L'Observatoire sociologique du changement (OSC), Sciences Po, Paris, 7 December 2018.

Marking the 100th anniversary of the 1918 'Spanish' flu pandemic: Selective mortality and the impact on other diseases

Center for Studies in Demography and Ecology, University of Washington, Seattle, 9 November 2018.

Measles mortality in the United States, 1890–2016: Why did deaths decline before the vaccine?

Dondena Seminar, Bocconi University, 17 September 2018.

C-DASA Seminar, UC Irvine, 5 February 2019.

Recent US and Comparative Mortality Patterns

Demography Brownbag, UC Berkeley Demography Department, 14 February 2018.

(Panelist, with Magali Barbieri, Ray Catalano, Josh Goldstein, and Ron Lee.)

The geometry of mortality change: Convex hulls for demographic analysis

Labor/Public Seminar, UCI Economics Department, 4 April 2017.

Max Planck Institute for Demographic Research, Rostock, Germany, 5 September 2017.

Optimal measles vaccination schedules in developing countries: Insights from mathematical modeling

Center for Virus Research, UCI, 14 October 2016.

Rocky Mountain Laboratories, NIAID, Hamilton, Montana, 13 December 2016.

Summertime, and the livin' is easy — respiratory viruses' effect on all-cause mortality: Winter and summer pseudoseasonal life expectancy in the United States

Ohio State University, Institute for Population Research, 8 March 2016.

Health Policy Research Institute, UCI, 28 April 2016.

Département de démographie, Université de Montréal, 30 September 2016.

Tuberculosis and influenza selective mortality in the 1918 pandemic

Hubei (province) Center for Disease Control and Prevention, Wuhan, 15 October 2015.

Cholera in Victorian London: John Snow and the births of epidemiology and germ theory.

Central China Normal University, Wuhan, Hubei Province, 13 October 2015.

National Taiwan University, School of Public Health, Taipei, 2 November 2015.

Colloquia, continued

"I'm going to Disneyland", Or: What levels of vaccination are necessary for measles control and eradication? A mathematical model of measles transmission in developing countries.

Institute for Mathematical Behavioral Sciences, UCI, 12 March 2015.

Public Health Seminar Series, UCI, 4 May 2015.

Ohio State University, Mathematical Biosciences Institute, 7 March 2016.

Centre interuniversitaire québécois de statistiques sociales (CIQSS)/Quebec Inter-University Centre for Social Statistics (QICSS), Montréal, 29 September 2016.

What's flu got to do with it? Changes in the age-structure of influenza mortality during pandemics.

Duke Population Research Institute (DuPRI), 19 September 2013.

Gesundheit und Gesellschaft: The payoff to the social sciences of demographic-epidemiologic studies of disease.

University of Wisconsin, Madison, 26 November 2012.

What's flu got to do with it? The payoff of influenza studies for demography and sociology.

Vienna Institute of Demography, 28 September 2011.

Wirtschaftsuniversität Wien, 5 October 2011.

Population Studies Training Center, Brown University, 3 November 2011.

Centre d'Estudis Demogràfics, Universitat Autònoma de Barcelona, 10 November 2011.

Istituto Superiore di Sanità, Rome, 19 December 2011.

Public Health, UC Irvine, 9 January 2012.

Statistics, UCLA, 10 April 2012.

Demographic approaches to the analysis of influenza time series data

US Centers for Disease Control and Prevention & Thai Ministry of Public Health, Nonthaburi, 20 May 2011.

Pneumonia and influenza death rates: A Gompertz-model approach

Centers for Disease Control and Prevention (OID/NCIRD), Atlanta, 27 October 2010.

The decline of TB mortality: The USA and Southeast Asia in historical-comparative perspective.

College of Public Health, University of Philippines, Manila (UP-M), 21 May 2010.

Do social gatherings predict influenza mortality?

Andrus Gerontology Center, University of Southern California, 7 November 2009.

Institute for Mathematical Behavioral Sciences, UCI, 12 November 2009.

Who dies in flu pandemics? Evidence from 1918.

Stop TB Department, World Health Organization Headquarters, Geneva, 9 September 2009.

The 20th century decline of TB in the USA, with potential comparisons to high- and medium-TB-prevalence countries today.

Institute for Population and Social Research, Mahidol University, Salaya, Thailand, 2 September 2009.

Early life influences: How do survivors fare after mortality crises?

Department of Nutrition, Food Studies, and Public Health, New York University, 9 December 2008.

Office of Population Research, Princeton University, 13 January 2009.

War, race, and disease: Tuberculosis in black and white troops in the Civil War.

Population, Society, Inequality Seminar, University of California, Irvine, 25 November 2008.

Cells-to-Society, Northwestern University, 1 December 2008.

Department of Sociology, New York University, 8 December 2008.

The twentieth century evolution of American mortality.

Economic History Seminar, University of Michigan, Ann Arbor, 6 November 2007.

Population, Society, Inequality Seminar, University of California, Irvine, 29 January 2008.

Colloquia, continued

Cholera in Victorian London: John Snow and the births of epidemiology and germ theory.

Clinical Meeting [Grand Rounds], Ahmadu Bello Univ. Teaching Hospital, Zaria, Nigeria, 25 July 2007.

Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria, 27 July 2007.

Mortality selection: The 1918 influenza pandemic's role in the decline of tuberculosis in the US.

Dep't. of Math. Sciences/Ctr. for Applied Math. and Statistics, NJ Institute of Technology, 28 March 2007.

Institute for Mathematical Behavioral Sciences, UCI, 26 April 2007.

Tuberculosis in the Union Army during the Civil War.

California Center for Population Research, UCLA, 24 January 2007.

Who dies in flu pandemics? Lessons from the 1918 'Spanish' flu.

Stanford University, School of Medicine, 22 November 2005.

UC, Irvine, Sociology Department, 30 November 2005.

Harvard School of Public Health, 5 December 2005.

UW–Seattle, Center for Statistics and the Social Sciences, 7 December 2005.

UW–Seattle, Sociology Department, 8 December 2005.

University of Utah, Huntsman Cancer Institute, 23 May 2006.

Testing the influenza-tuberculosis selective mortality hypothesis with Union Army data.

UC, Berkeley Demography Department, 2 November 2005.

Selective mortality in the 1918 "Spanish" influenza pandemic.

UC, Berkeley Demography Department, 4 May 2005.

The transmission and persistence of 'urban legends': Demographic/epidemic models of rumors.

UC, Berkeley Demography Department, 9 April 2003.

A tale of two diseases: Influenza, tuberculosis, and the 1918 epidemic.

Department of Statistics, UCLA, 5 February 2002.

Center for Health Policy/Center for Primary Care and Outcomes Research, Stanford, 17 July 2002.

Mortality selection and mortality decline: The Case of the 1918 influenza.

California Center for Population Research, UCLA, 13 June 2001.

Sex differentials in mortality and selection effects: The long-term impact of 1918 "Spanish" influenza.

Neyman Seminar, UC, Berkeley Statistics Department, 6 December 2000.

Interrogating disability-adjusted life years: DALYs and inter-disease comparisons.

UC, Berkeley Demography Department, 25 October 2000.

Effets à long terme de l'épidémie de grippe espagnole de 1918 aux Etats Unis

Andrew Noymer and Michel Garenne

INED (Institut national d'études démographiques), Paris, 2 July 1998.

Grants

- 2018 Russel Sage Foundation \$20,000 (sub-award).
(Award 93-18-05) PI: Aliya Saperstein, Stanford
- 2012 Gaspar de Portola program, UCI \$3,000.
For collaboration with Centre d'Estudis Demogràfics, Universitat Autònoma de Barcelona.
- 2011 C-DASA Seed Grant, \$3,000. "Cancer mortality patterns in Pacific islander populations:
A comparative analysis of American Samoa, Guam, Hawai'i, and Saipan"
- 2011 NIH Grant #UL1 TR000153, sub-award, \$4,000.
- 2010 UC Pacific Rim Research Program, Faculty Research/Planning Grant, \$12,000.
- 2009 NIH grant #R25TW008125, sub-award, \$3,000.
- 2005 Institute of Business and Economic Research, UC, Berkeley, Mini-grant for data entry.
- 2004 National Institute of Aging graduate student traineeship (one year).
- 1998 National Institute of Child Health and Human Development graduate student traineeship (four years).
- 1998 Rockefeller Foundation, \$24,300 grant to support historical demography research on the 1918
influenza epidemic (with Michel Garenne). Grant number HS-9810.
- 1997 Grant in support of participation in Young Scientist Summer Program at IIASA, National Science
Foundation, through the American Academy of Arts and Sciences.

Prior Work Experience

- 1997–01 Visitor (short-term), Research Group on Contemporary European Fertility Dynamics
Max-Planck-Institut für demografische Forschung (Max Planck Institute for Demographic Research)
Rostock, Germany
- 1997–99 Visiting Researcher, Centre français sur la population et le développement (CEPED)
Paris, France
- 1997–98 Participant in Young Scientist Summer Program, and Visitor
Population, Development and Environment Project
International Institute for Applied Systems Analysis (IIASA)
Laxenburg, Austria
- 1997 Demographer
Instituto Nacional de Estatística (INE), Ministry of Planning
Luanda, Angola
- 1997 Consultant
Luanda, Angola
work with: USAID; national and international NGOs

Details of work experience before 1997 are available on request.

Teaching

International Short Courses taught:

KOSTAT/APPI Summer Seminar on Population (Korea):

- July 2016 (Third), Workshop 1, “Demographic measurement and theory”, Seoul.
- July 2015 (Second), Workshop 1, “Demographic theory”, Statistical Training Institute, Daejeon.
- August–September 2014 (First), Workshop 2, “Quantitative methods in demography”, Pukyong National University, Busan.

Courses taught at the University of California, Irvine:

Sociology 10A, 10B	Probability and Statistics I, II (undergraduate service)
Sociology 159	Sociology of Health and Illness (undergraduate lecture class)
Sociology 202B	Second-year paper proseminar (graduate service)
Sociology 221B, 221C	Graduate Statistics II, III (graduate service)
Sociology 226A	Formal Demography (graduate service)
Sociology 269	Sociology and Demography of Health (graduate seminar)
Public Health 7, 7A	Introduction to Public Health Statistics I (undergraduate service)
Public Health 7B, 10	Introduction to Public Health Statistics II (undergraduate service)
Public Health 180	Infectious Disease Epidemiology (undergraduate elective)
Public Health 209	Demographic Analysis (graduate elective)
Public Health 213	International Epidemiology (graduate elective)
Public Health 281	Infectious Disease Epidemiology (graduate elective)

PhD Students supervised (date of degree) [* chair]:

Leah Ruppanner (2009). Ryan Acton (2010). Georgiana Bostean (2011). Christopher Marcum (2011). Zoya Gubernskaya (2013). Daisy C. Carreon* (2013). Elizabeth Hemming-Schroeder [Ecology & Evolutionary Biology] (2018). Annie C. Lee [UCLA] (2018). C. Ben Gibson (2018). *advancement committee only*: Courtney Reynolds Murphy (2012), Rupak Datta (2012), Grant Rutledge (2015), Melissa Matlock (2016), Shaun R. Stipp (2018), Sidra Haye (2018).

Professional & Public Service

COVID-19 / SARS-CoV-2: Many campus-, local- and national-level outreach activities, including: campuswide panel on 10 February 2020; CoHs Town Hall on 31 March 2020; several events for elected officials; MSNBC “Meet the Press Daily” on 9 April 2020; etc., etc.

Ebola: Co-convenor (with Stéphane Helleringer), International Union for the Scientific Study of Population (IUSSP) Panel on “the demographic causes and consequences of Ebola and other emerging infectious diseases”.

Public health information: Organizer/presider, public forum at UC Irvine: “Ebola: What you should know”, <https://www.youtube.com/watch?v=2DWcJ6EDSzg> & numerous press interviews in Fall 2014, including national newscast, Columbia Broadcasting System:

<http://www.cbsnews.com/news/ebola-panic-in-us-spreading-much-faster-than-disease/>. Also a panelist at UC Irvine Law School event on “The Constitutional Implications of Ebola: Civil Liberties & Civil Rights In Times of Health Crises” <http://www.law.uci.edu/events/health-policy/implications-of-ebola-2014.html>.

Public service: Member, Metrics Subcommittee, Healthcare Advisory Committee, California Department of Public Health, 2010. *succeeded by:* Metrics Group for California HAI Reporting, 2010–13. *succeeded by:* Metrics Group for HAI Reporting, 2013–14.

President: Society for Biodemography and Social Biology (SBSB); 2015–19.

Board member: Society for Biodemography and Social Biology (SBSB); 2005–15.

Editorial board member: *Contemporary Sociology*, 2007–09; *Biodemography and Social Biology*, 2009–; *Demographic Research*, 2011–15; *PeerJ*, 2015–; *PLoS One*, 2011–15.

NIH (US): Social Sciences and Population Studies A (SSPA) Study Section, October 2014 & May 2015.

European Research Council: Consolidator Grant reviewer, 2018.

Social Sciences and Population Studies A (SSPA) Study Section, October 2014 & May 2015.

Conference organizer: IMBS Workshop on Infectious Disease Models and Data, Irvine, October 2011; IIASA Workshop on Pandemic Influenza, Laxenburg, Austria, 2006.

Session organizer: International Population Conference 2017, Cape Town, Session 180 “The demographic causes and consequences of Ebola and other emerging infectious diseases”. PAA 2015, Session 147 “Mortality trends” & Session 234 “Formal demography of mortality”. PAA 2013, Session 10 “The long-term impact of famines and environmental shocks” & Session 153, “Early life origins of adult health”. PAA 2010, Session 49, “The demographic impact of pandemics”.

Session chair: International Population Conference 2017, Cape Town, Session 180 “The demographic causes and consequences of Ebola and other emerging infectious diseases”. IUSSP Seminar, “Mortality: Past, present, and future”, Campinas, Brazil, August 2017, Day two, Session 3, “Mortality: Data and methodological issues”. PAA 2016, Session 211 “Demography of 21st century epidemics: HIV/AIDS, Ebola, MERS, and other diseases”.

Scientific committee: IUSSP Seminar on “Lifespan Extension and the Biology of Changing Cause-of-Death Profiles”, Rauischholzhausen, Germany, January 2011.

Discussant for: PAA 2019, Session 101, “Family Demography: Methods and Projections”; International Population Conference 2017, Cape Town, Session 180 “The demographic causes and consequences of Ebola and other emerging infectious diseases”; PAA 2017, Session 101, “Global perspectives on health and mortality”; PAA 2014, Session 223, “Measurement and projections of population aging”; PAA 2010, Session 4, “Methodological issues in health and mortality”; PAA 2007, Session 82, “Perspectives on the demographic dividend” & Session 103 “Race/ethnic differences in mortality”; PAA 2003, Session 41, “Health care policy and access to health care”; PAA 2002, Session 119, “Network analysis in social demography”.

Refereed for: *Acta Tropica*; *American Journal of Epidemiology**; *American Journal of Preventive Medicine*; *American Journal of Public Health*; *American Sociological Review*; *Asian Women*; *Biodemography and Social Biology*†; *BMC Research Notes*; Cambridge University Press (book chapter); *BMJ Global Health*; *Canadian Studies in Population**; *Demographic Research*†; *Demography*†; *Emerging Infectious Diseases*†; *Epidemiology**; *Epidemiology and Infection*; *Futures*; *Genus*; *Infection, Genetics and Evolution*; *Influenza and Other Respiratory Viruses*; *Interdisciplinary Communications* (Norwegian Academy of Science and Letters); *International Economics and Economic Policy*; *Journal of Health and Social Behavior*; *Journal of Mathematical Sociology*†; *Journal of the Royal Society Interface*; *Journal of Steroid Biochemistry and Molecular Biology**; *Journal of Theoretical Biology*; *Lung Cancer*; *Mathematical Methods in the Applied Sciences*; *Nature: Scientific Reports*; *PeerJ*; *PLoS Computational Biology*; *PLoS Currents Outbreaks*; *PLoS One*†; *Population and Development Review*†; *Population Research and Policy Review*; *Proceedings of the National Academy of Sciences of the USA*†; *Protein Engineering Design and Selection (PEDS)*; *Science**; *Social Biology*; *Social Forces*; *Social Indicators Research*; *Social Problems*; *Social Psychology Quarterly*; *Social Science History*; *Social Science & Medicine*†; *Sociological Methodology*; *The Sociological Quarterly**; *Theoretical Population Biology*; *Vaccine**; *Vienna Yearbook of Population Research*; *Western Journal of Black Studies*.
* twice; † multiple times

Guest manuscript editor for: *Proceedings of the National Academy of Sciences of the USA*.

Affiliations

UCI Center for Complex Biological Systems
UCI Center for Population, Inequality, and Policy
UCI Center for Virus Research
UCI Demographic and Social Analysis (DASA) program (executive committee member)
UCI Master’s in Public Policy (MPP) program
UCI Institute for Mathematical Behavioral Sciences (IMBS)
UCI Center for Biotechnology and Global Health Policy
UCI Research focus group in Social Dynamics and Complexity
UCI Data Science Initiative, Faculty Advisory Board member

Collaborating Core Faculty, UC Center of Expertise on Migration and Health

Non-resident faculty affiliate, California Center for Population Research (CCPR), UCLA

Member, All-UC Group in Economic History

Foreign Languages

Proficient in French; some knowledge of Portuguese.

Other

Radio host, “Taillights Fade” (indie/alternative music show). KUCI-FM (88.9 MHz), Irvine, California. 2019–present.

References

Available on request.

Updated: 21 April 2020

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14 Attorneys for the Plaintiffs

15 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**
16 **FOR THE COUNTY OF ALAMEDA**

17 CINDY KIEL, J.D., an Executive Associate Vice
18 Chancellor at UC Davis, MCKENNA
19 HENDRICKS, a UC Santa Barbara student,
20 EDGAR DE GRACIA, a UCLA student, and
21 LELAND VANDERPOEL, an employee at the
22 Fresno satellite extension of the UCSF Medical
23 Education Program, and FRANCES OLSEN,
24 Professor of Law at UCLA

25 Plaintiffs,

26 vs.

27 THE REGENTS OF THE UNIVERSITY OF
28 CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**PROFESSOR LASZLO G. BOROS, MD'S
DECLARATION IN SUPPORT OF
PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION**

By Fax

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 130: PM

Reservation ID-2206283

Action Filed: August 27, 2020

Trial Date: None Sent

I Laslo G. Boros, MD declare as follows:

1. I am a medical doctor involved in biomedical research, as well as teaching and currently a Professor of Pediatrics, step 3 in rank of the adjunct series at UCLA, an active investigator of the Institute for Women's and Children's Health at the Lundquist Institute for Biomedical Innovation and the Harbor-UCLA Medical Center's Department of Pediatrics and the former Co-Director of the Stable Isotope Research Laboratory. A copy of my full curriculum vitae is attached to this Declaration as Exhibit "A".
2. I am an academic editor of scientific journals including Scientific Reports - Nature® (ISSN: 2045-2322), published by Springer Nature (1), Molecules – MDPI (ISSN: 1420-3049) Publisher: Multidisciplinary Digital Publishing Institute (2) and Medicine Oncology - (ISSN: 0025-7974) Publisher: Wolters Kluwer (3).
3. My primary focus is studying cancer, inflammatory and immune cell metabolism with the use of specifically designed ¹³C-glucose tracer molecules and mass spectroscopy with particular interest in the activation (4) of the immune system, which can adversely affect human health and lead not only to autoimmune conditions but to diseases like metaplasia and cancers of blood cell forming organs such as the bone marrow (5-7). Part of that interest is reflected in the fact that I have patented a test for immune activation and detection of lymphocytes by antigen challenges (8).
4. Because of my strong interest in inflammation, graft versus host immunology and autoimmunity as an investigator, reviewer and editor, I am very familiar with the published, peer reviewed and currently evaluated literature on what some researchers call virus, viral or vaccine interference, which terminology seems to be common in clinical studies.

- 1 5. The Wolff study cited in the Complaint is one such example of the study of this medical
2 phenomenon, namely, whereby one vaccine (the flu shot) is associated with an increased
3 risk of contracting another virus (the common coronavirus strains). While this is just one
4 observational study in the peer reviewed medical literature (and I would also point out
5 that this observational study also showed a positive or protective association between the
6 seasonal flu vaccine and viruses closer to it molecularly), *it certainly raises a concern*
7 *that providing the flu shot to large populations might actually increase the risk of*
8 *contracting the pandemic coronavirus. Of course, since there are no controlled blinded*
9 *studies (that I am aware of), we do not have an answer to this important question.*
10
11 6. University of California mandated influenza vaccinations as a requirement to avoid a
12 surge of flu cases at health care facilities across the state during the unprecedented public
13 health crisis caused by the coronavirus pandemic.
14
15 7. Yet, based on 170 million episodes of care and 7.6 million deaths in a population turning
16 65 and above, which was associated with a statistically and clinically significant increase
17 in rate of seasonal influenza vaccination in this UK cohort showed no evidence that
18 influenza vaccination reduced hospitalizations or mortality among elderly persons (9).
19
20 8. This analysis (9) used an innovative observational design that reduced the possibility of
21 bias and confounding factors common in other observational studies with estimates
22 precise enough to rule out confounding results from many previous studies (10).
23
24 9. It is therefore suggested that current influenza vaccination strategies prioritizing large
25 cohorts of elderly persons may be less effective than believed at reducing
26 hospitalizations, serious morbidity and mortality in this population, which suggests that

1 supplementary or alternative strategies may be necessary that are mandated by the UC
2 system.

3 10. For younger populations of students, staff and faculty it is crucial to consider potential
4 serious side effects of autoimmunity in response to influenza vaccinations as
5 characterized in detail with identifying cross reacting proteins in the human body (11) at
6 a hearing held by The House Science, Space and Technology Committee with public
7 health officials on efforts to improve flu vaccines and develop a universal flu vaccine.
8 The witnesses in the first panel were Dr. Anthony Fauci, National Institute of Allergy and
9 Infectious Diseases director, and Dr. Daniel Jernigan, director of the Center for Disease
10 Control and Prevention (CDC) Influenza Division.
11

12 11. A study conducted by the Centers for Disease Control had suggested the possibility that
13 women who received A/H1N1pdm2009 (pH1N1) antigen-containing influenza vaccine
14 two years in a row had an increased risk of miscarriage (12), whereby spontaneous
15 abortion (SAB) was associated with influenza vaccination in the preceding 28 days. This
16 information is provided herein as a precautionary measure for repeated H1N1
17 vaccinations because 1) the association did not establish causal relationship between
18 repeated influenza vaccination and SAB and 2) additional research identified limitations
19 regarding cohort, seasons and outcomes in the original study design (13).
20

21 12. The current domestic enterprise for manufacturing influenza vaccines has critical
22 shortcomings (14) as most influenza vaccines are made in chicken eggs, using a 70-year-
23 old process that requires months-long production timelines and use of vaccine viruses
24 adapted for growth in eggs, besides human epithelial cells. This process introduces
25

1 mutations of the influenza vaccine virus that may render the final products less effective
2 and unsuitable for efficient protection against the disease (14).

3 13. However, my research interests are on a molecular level, explaining why or how this
4 observed phenomenon occurs in humans.

5 14. On this level, some researchers talk about pathogenic priming, which is a mechanism of
6 action, suggesting how and why a flu vaccine could cause or contribute to increased
7 COVID-19 infection with severity.

8 15. In that regard, certainly the flu shot with their excipients (and the COVID-19 vaccine if
9 and when it is approved), are cumulative risks in sharply increasing, complicating and
10 exhausting immune responses against single strand RNA viruses, primarily exhausting
11 mitochondrial function and oxidative metabolism in vulnerable tissues (e.g., epithelial
12 and mucosal cells of the respiratory tract and lung function).

13 16. An immune response, regardless of its method of initiation, such as the injection or
14 inhalation of RNA, protein, peptide and/or fatty acid virus particles with chicken egg and
15 adjuvant constituents, if preformed according to specifications, decreases systematic
16 catabolic reaction architectures of the energy producing mitochondrial substrate cycling
17 pathways. Virus hosting and immune cells exhibit new molecule synthesis via anabolic
18 and anaplerotic cycles via reverse carboxylation in mitochondria that hamper the cells'
19 ability to produce metabolic matrix water in order to maintain Krebs-Szent-Györgyi cycle
20 reactions with resulting branching. All the above metabolic adaptive processes result in
21 heavy hydrogen isotope, i.e. deuterium accumulation in all affected host cells, which is a
22 growth requirement of all rapidly proliferating pro- and eukaryote cells that copy either
23
24
25

1 their own nuclear components, such as in cancer (15), or foreign nucleic acid (RNA and
2 DNA), such as in virus hosting cells.

3 17. When mitochondrial complete substrate oxidation is limited during immune activating
4 influenza vaccinations and immune globulin producing cell expansion there are
5 concomitant decreases in mitochondrial citrate, isocitrate and malate recycling processes
6 in target cells that set the stage for deuterium accumulation. This may present increased
7 vulnerability to another virus infection with similar genotypic and morphological
8 characteristics that hide from specific binding and neutralizing properties of antibodies
9 being intensely produced against influenza virus particles, as well as that of the egg and
10 adjuvant constituents of the vaccine.
11

12 18. These processes all contribute to low energy phosphate ATP synthesis with decreasing
13 energy homeostasis in infected individuals with RNA, protein and fat derived virus
14 particles of a vaccine or infection, whichever comes first. Potential interference between
15 similar RNA viruses has recently been described as “a perfect storm” in a prominent
16 scientific journal (16).
17

18 19. This is because “There are important differences in the epidemiology of COVID-19 and
19 seasonal influenza, but symptoms overlap ...”, and,

20 20. The optimal timing of influenza vaccination in healthy individual and patients with
21 confirmed COVID-19 is uncertain ..., and,

22 21. There are no controlled clinical or even experimental studies on the effects of influenza
23 vaccination in either healthy or COVID-19 infected patients, but it may be prudent to
24 delay vaccine administration until after the acute illness has resolved (16).
25

1 22. Nucleic acid building pathways are critical during virus interference, such as the pentose
2 cycle's oxidative and non-oxidative branches as well as sluggish energy-producing
3 reactions in glycolysis that use naturally deuterated glucose and metabolic water of
4 cytoplasmic origin. These pathways support nucleic acid synthesis during antigen
5 presenting (dendritic) cell expansion, immune cell attraction, activation and proliferation,
6 as well as virus hosting (17, 18). The well-described cytokine storm as a result of severe
7 Covid-19 infection may closely be related to deuterium accumulation in long chain
8 saturated fatty acids and phospholipids that make up the envelope and rafts of influenza
9 and corona viruses, which serve as prostaglandin precursors of leukotriene synthesis by
10 acutely infected or healthy cells (19). Although viruses shut down production of
11 prostaglandins to recruit envelope and raft fatty acids and to prevent immune cell
12 attraction by their hosts, once viruses infect new cells, they lose their envelope during
13 disassembly by breaking down long chain (C:22 and above) fatty acids via the
14 prostaglandin, eicosanoid, leukotriene pathways in oxygen deprived cells of a Covid-19
15 infected subject with desaturated hemoglobin, as observed clinically.
16
17 23. It seems inevitable that influenza, COVID-19, and perhaps viruses in general, all thrive
18 when mitochondria reverse to carboxylation that readily limits deuterium depletion via
19 natural fatty acid oxidation in clonally expanding immune or host cells during
20 inflammation and/or a vaccine induced immune response, whereby the eicosanoid
21 precursor arachidonic acid accumulate via chain shortening and desaturation of nuclear
22 membrane-bound long chain fatty acids.
23
24
25
26

- 1 24. In the meantime, lipoxygenase, having an incredibly high deuterium kinetic isotope
2 effect, on the order of 60 or more (20) that converts arachidonic acid to leukotrienes with
3 direct immune cell activating cytokine properties, is shut down in virus hosting and/or
4 vaccine and adjuvant treated cells, alike.
- 5 25. On the other hand, local and generalized low grade systemic inflammation due to
6 influenza vaccinations may elicit both an immune response but also promote virus
7 propagation via arachidonic acid dumping into oxygenated adjacent host tissues and the
8 circulation, where arachidonic acid is a component of the lipid envelope of RNA viruses
9 as well as their rafts for penetrating cellular membranes during virus shedding.
- 10 26. Leukotrienes produced in adjacent cells promote plasma leakage and leukocyte adhesion
11 in postcapillary venules (21), which have been described in COVID-19 (22) and Kaposi's
12 sarcoma (23).
- 13 27. I am not against vaccines, but current (the last six decades) vaccines with many pro-
14 inflammatory ingredients, including heavy metals, polysorbate 80 and other excipients do
15 not promote proper natural immunity. I have attached two abstracts of recent related
16 articles on the role of immunology in health and diseases. (Exhibit "B").
- 17 28. As a medical scientist who has researched immune system function, among others, via
18 metabolic studies for more than 3 decades, and given my understanding of the increasing
19 and complicating immune responses the flu vaccine poses on the human body, mandating
20 the flu vaccine on the entire UC community (and I am a part of that community) during
21 this pandemic that is not caused by the flu, while knowing that 58% of all VAERS (the
22 Vaccine Adverse Reporting System of the CDC) reports filed are reported after the

1 influenza vaccination for which the U.S. treasury has compensated 2.6 billion dollars
2 since 1989 (24), keeping in mind that this only represents 1 out of every 100 vaccine
3 injuries that have actually occurred according to estimates, may likely be a very ill-
4 thought out response to the current Corona health crisis.

5 29. In closing, I want to bring to the court's attention the facts published in a recent working
6 paper by the National Bureau of Economic Research that discusses "Four Stylized Facts
7 About Covid-19" (25). The three authors, among them Andrew Atkeson who is the
8 Stanley M. Zimmerman Professor of Economics and Finance at the Department of
9 Economics at UCLA, cast strong doubt on measures suggested to reducing the spread of
10 Covid-19 and the deaths due to this deadly pandemic. They present the following facts:
11

12 30. First: across all countries and U.S. states that we study, the growth rates of daily deaths
13 from COVID-19 fell from a wide range of initially high levels to levels close to zero
14 within 20-30 days after each region experienced 25 cumulative deaths. (California and
15 the UC system might have passed this stage; therefore I refer to coordinating with local
16 health officials for facts and data.)
17

18 31. Second: after this initial period, growth rates of daily deaths have hovered around zero or
19 below everywhere in the world.


20 32. Third: the cross section standard deviation of growth rates of daily deaths across
21 locations fell very rapidly in the first 10 days of the epidemic and has remained at a
22 relatively low level since then.
23

24 33. Fourth: when interpreted through a range of epidemiological models, these first three
25 facts about the growth rate of COVID deaths imply that both the effective reproduction

1 numbers and transmission rates of COVID-19 fell from widely dispersed initial levels
2 and the effective reproduction number has hovered around one after the first 30 days of
3 the epidemic virtually everywhere in the world.

4 34. I argue that the reaction of the University of California to mandate the flu vaccine for all
5 staff and students, a Pharmaceutical Intervention not without risk, may be an overstated
6 policy based on incomplete assumptions and data as well as a lack of understanding of
7 the possible consequences of such a mandate based on virus interference.
8

9 35. I declare under penalty of perjury under the laws of the State of California that the
10 foregoing is true and correct and that this declaration was executed on September 16,
11 2020 in Szeged, Hungary, European Union.
12

13 
14

15 _____
16 László G. Boros, MD
17
18
19
20
21
22
23
24
25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

EXHIBIT “A”

LB CV from web site

László Géza Boros, MD

☎ HU - EU: +36.20.396.0533; <https://www.laszlogboros.com>

Electronic correspondence: contact@laszlogboros.com; boros.laszlo@yahoo.com



Appointments

<u>Title</u>	<u>Affiliation</u>	<u>Dates of Appointment</u>
Professor	<i>Departments of Pediatrics, Endocrinology & Metabolism, UCLA School of Medicine, Los Angeles, CA, USA</i>	<i>July 2020 – present (step III) July 2017 – June 2020 (step II) July 2014 – June 2017 (step I)</i>
Principal Investigator	<i>UCLA Clinical and Translational Science Institute (CTSI), Los Angeles, CA, USA</i>	<i>July 2011 - present</i>
Investigator	<i>The Lundquist Institute for Biomedical Innovations at the Harbor-UCLA Medical Center, Torrance, CA, USA</i>	<i>January 2006 - present</i>
Chief Scientist	<i>SIDMAP, LLC., Culver city, CA, USA</i>	<i>August 2004 - present</i>
Associate Professor	<i>Departments of Endocrinology & Pediatrics, UCLA School of Medicine, Los Angeles, CA, USA</i>	<i>July 2004 – June 2014</i>
Co-Director	<i>BioMedical Mass Spectroscopy Research Laboratory, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA</i>	<i>December 1998 – Apr 2004</i>
Assistant Professor	<i>Departments of Endocrinology & Pediatrics, UCLA School of Medicine, Los Angeles, CA, USA</i>	<i>September 1998 – June 2004</i>
Research Scientist	<i>Division of General Surgery, The Ohio State University College of Medicine, Columbus, OH, USA</i>	<i>May 1996 – Aug 1998</i>
Medical Student Research Advisor	<i>The Ohio State University College of Medicine, Columbus, OH, USA</i>	<i>January 1995 – Aug 1998</i>
Research Associate 2- B/H, Postdoctoral Researcher	<i>Division of General Surgery, The Ohio State University College of Medicine, Columbus, OH, USA</i>	<i>June 1990 - May 1996</i>
Visiting Scholar	<i>Essen University Medical School Department of Internal Medicine, Essen, Germany</i>	<i>January 1989 – May 1990</i>
Postgraduate Research Fellow	<i>Hungarian Academy of Sciences, Budapest, Hungary</i>	<i>September 1987 – Dec 1989</i>



Education

<u>School & Location</u>	<u>Degrees</u>	<u>Attendance</u>	<u>Field of Study</u>
Miklós Bercsényi High School Törökszentmiklós, Hungary	High School Diploma	1976 – 1980	Biology, Physics
Albert Szent-Györgyi School of Medicine Szeged, Hungary, EU	<u>Doctor of Medicine (M.D.)</u>	1981 – 1987	Medicine

Certifications

Unrestricted License to Practice Medicine in Hungary and the European Union, Hungarian Board of Medical Examiners, [17/1987 O.E. Szeged, Hungary](#)

United States Medical Licensing Examination (USMLE – ID-0-519-920-3) - [Basic Medical Sciences](#) (1995)

Professional Memberships & Awards

Three-year domestic research fellowship award of the Hungarian Academy of Sciences (1987)
 C. Williams Hall Outstanding Publication Award - Academy of Surgical Research of the USA (1997)
 American Society for Leukocyte Biology (ASLB; 1992-1995)
 American Association for Cancer Research (AACR; 1998-2012; Membership No: 70054)
 American Pancreatic Association (APA; 1998-present)
 The American Physiological Society (APS; 1998-2010; Membership No: 31927)
 Richard E. Weitzman Memorial Research Award – University of California, Los Angeles, CA, USA, June 2001
 American Gastroenterological Association (AGA; 2002-2007; Membership No: 902797)
 Excellence in Clinical Research Award – GCRC at Harbor-UCLA Medical Center, September 2004
 Metabolomics Society (2004-present; Membership No: 04942012)
 Géza Hetényi Memorial Membership Award of the Hungarian Gastroenterological Society (2007)
 Public Health Impact Investigator Award of the United States Food and Drug Administration (2011)
 President - USA West Coast Hungarian Scientist Club (2014)
 Science Award the county of Jász-Nagykun-Szolnok – Hungary, European Union (2014)
 Best Publication Award - Metabolomics Society & Springer Nature – San Francisco, CA, USA (2015)
 External Member – Hungarian Academy of Sciences – Medical Sciences (V. - 3839/1/2015/HTMT)
 Regional Member Scientists' Club Szeged – Hungarian Academy of Sciences (2018)
 Twenty Years' [Service Award](#) from the Los Angeles Biomedical Research Institute (LABIOMED) (2019)
 President – Scientific Translators of Ancient Literature - Hungary, European Union (2019-present)

Consulting & Scientific Expert Work

Central Research Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, VIII. Szigony street 43, Hungary - Consultant and Collaborator, Carcinogenesis and Metabolic Profiling 1996 - 2003.

Hermanies, Major, Castelli & Goodman (Cincinnati, OH). Medical Expert Consultant; Parsley vs. Terminix - Pesticide (Isofenphos) Poisoning and Chronic Myeloid Leukemia (case evaluation), 1997 – 2002.

Goodson & Mullins, LTD (Cincinnati, OH). Medical Expert Consultant and Witness; Parsley vs. Terminix (legal arbitration, public) 2002 – 2003. Parsley v. Terminix International Co., No. C-3-97-394, 1998 U.S. Dist. LEXIS 22891 (S.D. Ohio Sept. 15, 1998). Additional reference: Contracting with tortfeasors: Mandatory arbitration clauses and personal injury claims. Elizabeth G. Thornburg, Professor of Law, Southern Methodist University, Dedman School of Law (page 259-260).



<https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=1323&context=lcp>

Biomedicina Research & Development, Inc. (Budapest, Hungary) – Consultant, Tumor Growth Inhibitory Metabolic Effects of Fermented Wheat Germ, 1999 – 2008.

GenPath Pharmaceuticals, Inc. (Cambridge, Massachusetts, USA) – Scientific Advisor and Consultant, 2004 - 2005.

Aveo Pharmaceuticals, Inc. (Cambridge, Massachusetts, USA) – Scientific Advisor and Consultant, 2005 - 2006.

Patrick Swayze's diagnosis with pancreatic cancer medical condition and prognosis coverage (Los Angeles, CA, USA) – Medical Respondent - Access-Hollywood, Entertainment Tonight, E-news! March 6 – 2008

<https://www.accessonline.com/articles/friends-celebrities-offer-support-for-patrick-swayze-62739>

Cornerstone Pharmaceuticals, Inc. (Cranbury, NJ) – Consultant, April 2010 – 2011.

United States Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR) (Jefferson, Arkansas) – Consultant and Advisor, April 2010 – 2019.

Center for Chemical Biology, Stanford University, Stanford Research Institute International (SRI), Ravenswood Avenue, Menlo Park CA 94025 USA – Advisor/Consultant, January 2013 – 2018.

Pacific West Law Group, LLP - Oxygen treatment and deuterium depletion in integrative medicine, Mill Valley CA 94941 USA – Medical Expert Consultant, December 2018 – 2019.

P a t e n t s

Methods and compositions for detecting immune system activation. United States Patent Application number WO2013142303 A1; Application number PCT/US2013/031879; Publication date Sep 26, 2013; Filing date Mar 15, 2013; Priority date Mar 19, 2012

Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof. United States of America Patent Application US20040259816 A1; Application number US 10/824,597; Publication date Dec 23, 2004; Filing date Apr 15, 2004; Priority date Oct 1, 2002


Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof. United States Patent Application number PCT/US2005/011741; Publication date Oct 27, 2005; Filing date Apr 7, 2005; Priority date Apr 15, 2004

Analyzing non-toxic stable labeled glucose isotope formation via mass spectrometry/nuclear magnetic resonance. United States of America Patent Application number US 10/192,744; Publication date Sep 25, 2003; Filing date Jul 9, 2002; Priority date Mar 22, 2002

Using an isotope such as a stable (13C) isotope for labeling a metabolome to examine mechanisms of cellular substrate flow modification in response to various drugs, which can improve the drug discovery and testing processes. United States Patent Application number US 10/192,743; Publication date Sep 25, 2003; Filing date Jul 9, 2002; Priority date Mar 22, 2002



Publication Statistics ([Google Scholar](#))



Editorial work

Scientific Reports (ISSN 2045-2322) [Member of the Editorial Board](#) (2019 - present) – Publisher: Nature

Molecules (ISSN 1420-3049) [Member of the Editorial Board](#) (2019 - present) - Publisher: MDPI

Medicine® (ISSN: 0025-7974) Editor (2016 – present) - Publisher: Wolters Kluwer; (Frequency: Weekly)

Metabolomics (ISSN 1573-3890) Editor & Reviewer (2005 – present)

Pancreas (ISSN 1536-4828) Associate Editor & Reviewer (1999 – present)

Session Chair Assignments

Pharmaceutical & Disease State Applications in Drug Development. Advances in Metabolic Profiling, London, United Kingdom, Nov 1-2, 2005.

Surgical Treatment of Pancreatic Cancer. 41st Meeting of the European Pancreatic Club (APC), Szeged, Hungary, July 3, 2009.

Second Scientific Session, 1st International Symposium on Deuterium Depletion, Budapest, Hungary, May 14, 2010.

Second Scientific Session, 2nd International Symposium on Deuterium Depletion, Budapest, Hungary, May 17-18, 2012. Co-chairman Professor Richard J. Robins, University of Nantes.

Biochemical Aspects and Mechanism of Action of Deuterium Depletion Session, 3rd International Symposium on Deuterium Depletion, Budapest, Hungary, May 08, 2015. Co-chair: Dr. Gabor Somlyai, HYD, LLC.

European Society for Isotope Research (ESIR), Methods & Instrumental Techniques Session, Zadar, Croatia, September 23, 2015. Co-chair: S. Halas, Mass Spectrometry Laboratory, Institute of Physics, Marie Curie-Skłodowska University, Lublin, Poland.

Third Scientific Session, 4th International Symposium on Deuterium Depletion, Budapest, Hungary, October 18, 2019.

Research, Academic & Teaching Committees

MASS SPECTROMETRY ANALYSIS PLANNING COMMITTEE – THE LUNDQUIST INSTITUTE OF BIOMEDICAL INNOVATION AT THE HARBOR-UCLA MEDICAL CENTER, TORRANCE, CA (2000-PRESENT)

UCLA SPECIAL PROGRAM OF RESEARCH EXCELLENCE (SPORE) IN PANCREATIC CANCER - DEVELOPMENTAL RESEARCH PROGRAM COMMITTEE (2002-2008)

UCLA – UCSD (SAN DIEGO) CENTER GRANT FOR PANCREATIC CANCER PRELIMINARY/FEASIBILITY GRANTS COMMITTEE - DEVELOPMENTAL RESEARCH PROGRAM COMMITTEE (2002-2005)

METABOLOMICS (ISSN 1573-3890) (SUPERVISING MEMBER - ELECTION COMMITTEE, 2012)

HIRSHBERG FOUNDATION FOR PANCREATIC CANCER RESEARCH SCIENTIFIC ADVISORY BOARD (2003 – 2016)

HIRSHBERG FOUNDATION FOR PANCREATIC CANCER RESEARCH SEED GRANTS PANEL (REVIEWER, 2003 – 2015)

WEITZMAN RESEARCH AWARD SELECTION COMMITTEE – HARBOR-UCLA RESEARCH AND EDUCATION INSTITUTE FACULTY SOCIETY (2003-20015)

MEMBER - PRESIDENTIAL SUBCOMMITTEE - HUNGARIAN SCIENCE ABROAD - HUNGARIAN ACADEMY OF SCIENCES – SECTION OF MEDICAL SCIENCES (V.) - (2014-2017)

UCLA PEDIATRICS EXECUTIVE DEPARTMENT CHAIR FIVE-YEAR ADMINISTRATIVE REVIEW COMMITTEE – REVIEWER (2015)

ASSOCIATION OF AMERICAN MEDICAL COLLEGES' (AAMC) FACULTY FORWARD ENGAGEMENT PANEL – SELECTED FACULTY SURVEYOR (2016)

AMERICAN COLLEGE FOR ADVANCEMENT IN MEDICINE (ACAM) – EDUCATION COMMITTEE – MEMBER (2016-2019)

¹³CIGNATURE ²HEALTH METABOLIC CLINIC – SANTA MONICA, CA - CHIEF SCIENTIFIC ADVISOR (2016-2019)

Peer Reviewed Publications

1. Pap, A., **Boros, L.G.** Alcohol-induced chronic pancreatitis in rats after temporary occlusion of the biliopancreatic ducts with Ethibloc. *Pancreas* 4: 249-255, 1989.



2. Pap, A., **Boros, L.G.**, Hajnal, F. Essential role of cholecystokinin in pancreatic regeneration after 60% distal resection in rats. *Pancreas* 6: 412-418, 1991.
3. **Boros, L.G.**, Lepow, C., Ruland, F., Flancbaum, L.J., Townsend, M.C. CD-ROM source data uploaded to the operating and storage devices of an IBM 3090 mainframe through a PC terminal. *Computer Methods & Programs Biomedicine* 38: 77-89, 1992.
4. **Boros, L.G.**, Damico, J., Flancbaum, L.J., Townsend, M.C., Beckley, P.D., Jones, S.D. An automated computer method utilizing Procomm Plus and DataEase (4.2) PC - and SAS (6.06) mainframe software for isolated, perfused guinea pig heart studies. *Computer Methods & Programs Biomedicine* 39: 271-284, 1993.
5. Oberyshyn, T.M., Sabourin, C.L., Bijur, G.N., Oberyshyn, A.S., **Boros, L.G.**, Robertson, F.M. Interleukin-1 β gene expression and localization of interleukin-1 β protein during tumor promotion. *Molecular Carcinogenesis* 7: 238-248, 1993.
6. Robertson, F.M., Bijur, G.N., Oberyshyn, A.S., Pellegrini, A., **Boros, L.G.**, Sabourin, C.L., Oberyshyn, T.M. Granulocyte-macrophage colony stimulating factor gene expression and function during tumor promotion. *Carcinogenesis* 15: 1017-1029, 1994.
7. Choban, P.S., McKnight, T., Flancbaum, L.J., Sabourin, C.L., Bijur, G.N., **Boros, L.G.**, Marley, J., Burge, J.C., Robertson, F.M. Characterization of a murine model of acute lung injury (ALI): a prominent role for interleukin-1. *Journal of Investigative Surgery* 9: 95-109, 1994.
8. Robertson, F.M., Pellegrini, A.E., Ross, M.S., Oberyshyn, A.S., **Boros, L.G.**, Bijur, G.N., Sabourin, C.L., Oberyshyn, T.M. Interleukin-1 β gene expression during wound healing. *Wound Repair & Regeneration* 3: 473-84, 1995.
9. Fisher, W.E., **Boros, L.G.**, O'Dorisio, T., O'Dorisio, S., Schirmer, W.J. The influence of diabetes on the growth of pancreatic cancer. *Surgical Forum* 45: 151-152, 1994.
10. Fisher, W.E., **Boros, L.G.**, Tamaddon, K.A., O'Dorisio, S.M., O'Dorisio, T.M., Schirmer, W.J. Somatostatin-receptor status of pancreatic adenocarcinoma predicts response to somatostatin therapy in vitro and in vivo. *Surgical Forum* 16: 138-140, 1995.
11. Fisher, W.E., **Boros, L.G.**, Schirmer, W.J. Reversal of enhanced pancreatic cancer growth in diabetes by insulin. *Surgery* 118: 453-457, 1995.
12. Fisher, W.E., **Boros, L.G.**, Tamaddon, K.A., O'Dorisio, T.M., O'Dorisio, S.M., Schirmer, W.J. GI hormonal changes in diabetes influence pancreatic cancer growth. *Journal of Surgical Research* 58: 754-758, 1995.
13. Fisher, W.E., **Boros, L.G.**, Schirmer, W.J. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. *Journal of Surgical Research* 63: 310-313, 1996.
14. Fisher, W.E., Muscarella, P., **Boros, L.G.**, Schirmer, W.J. Variable effect of streptozotocin-diabetes on the growth of hamster pancreatic cancer (H2T) in the Syrian hamster and nude mouse. *Surgery* 123: 315-320, 1998.
15. Melvin, W.S., **Boros, L.G.**, Muscarella, P., Brandes, J.L., Johnson, J.A., Fisher, W.E., Schirmer, W.J., Ellison, E.C. Dehydroepiandrosterone-sulfate inhibits pancreatic cancer cell proliferation in vitro and in vivo. *Surgery* 121: 392-397, 1996.
16. **Boros, L.G.**, Puigjaner, J., Cascante, M., Lee, P., Brandes, J.L., Bassilian, S., Yusuf, F.I., Williams, R.D., Muscarella, P., Melvin, W.S., Schirmer, W.J. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and cancer cell proliferation. *Cancer Research* 57: 4242-4248, 1997.



17. Fisher, W.E., Doran, T.A., Muscarella, P., **Boros, L.G.**, Ellison, E.C., Schirmer, W.J. Somatostatin receptor subtype 1-5 gene expression in human pancreatic cancer. *Journal of the National Cancer Institute* 90: 322-324, 1998.
18. **Boros, L.G.**, Lee, P., Brandes, J.L., Cascante, M., Muscarella, P., Schirmer, W.J., Melvin, W.S. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? *Medical Hypotheses* 50: 55-59, 1998.
19. **Boros, L.G.**, Brandes, J.L., Yusuf, F.I., Cascante, M., Williams, R.D., Schirmer, W.J. Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin. A possible mechanism of antitumor action. *Medical Hypotheses* 50: 501-506, 1998.
20. **Boros, L.G.**, Brandes, J.L., Lee, P., Cascante, M., Puigjaner, J., Revesz, E., Bray, T.M., Schirmer, W.J., Melvin, W.S. Thiamin supplementation to cancer patients: A double edged sword. *Anticancer Research* 18: 595-602, 1998.
21. **Boros, L.G.**, Williams, R.D. Chronic isofenphos poisoning: case report of agnogenic myeloid metaplasia with a rapid progression into acute myeloid leukemia. *Leukemia Research* 22: 849-851, 1998.
22. Lee P., **Boros, L.G.**, Puigjaner, J., Bassilian, S., Lim, S., Cascante, M. Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-¹³C₂]glucose. *American Journal of Physiology [Endocrinology & Metabolism]* 274: E843-E851, 1998.
23. Muscarella, P., **Boros, L.G.**, Fisher, W.E., Rink, C., Melvin, W.S. Oral dehydroepiandrosterone inhibits the growth of human pancreatic cancer in nude mice. *Journal of Surgical Research* 79: 154-157, 1998.
24. Fisher, W.E., Muscarella, P., **Boros, L.G.**, Schirmer, W.J. Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma. *International Journal of Pancreatology* 24: 169-80, 1998.
25. Rais, B., Comin, B., Puigjaner, J., Brandes, J.L., Creppy, E., Saboureau, D., Ennamany, R., Lee, W-N.P., **Boros, L.G.**, Cascante, M. Oxythimaine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. *FEBS Letters* 456: 113-19, 1999.
26. Cascante, M., Centelles, J.J., Veech, R.L., Lee, W-N.P., **Boros, L.G.**, The role of thiamine (vitamin-B₁) and transketolase in tumor cell proliferation. *Nutrition & Cancer* 36: 150-154, 2000.
27. **Boros, L.G.**, Torday, J.S., Lim, S., Bassilian, S., Cascante, M., Lee, W-N.P. TGF- β_2 promotes glucose carbon incorporation into nucleic acid ribose through the non-oxidative pentose cycle in lung epithelial carcinoma cells. *Cancer Research* 60: 1183-1195, 2000.
28. **Boros, L.G.**, Lim, S., Bassilian, S., Lee, W-N.P. Genistein inhibits non-oxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. *Pancreas* 22: 1-7, 2000.
29. Lee, W-N.P., Bassilian, S., Lim, S., **Boros, L.G.** Loss of regulation of lipogenesis in the Zucker diabetic (ZDF) rat. *American Journal of Physiology [Endocrinology & Metabolism]* 279: E425-E432, 2000.
30. **Boros, L.G.** Population thiamine status and varying cancer rates between Western, Asian and African countries. *Anticancer Research* 20: 2245-8, 2000.
31. **Boros, L.G.**, Lapis, K., Szende, B., Tomoskozi-Farkas, R., Balogh, A., Boren, J., Marin, S., Cascante, M., Hidvegi, M. Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarcinoma cells. *Pancreas* 23: 141-147, 2001.



32. **Boros, L.G.**, Williams, R.D. Isofenphos induced metabolic changes in K562 myeloid blast cells. *Leukemia Research* 25: 883-890, 2001.
33. Comín-Anduix, B., Boren, J., Martinez, S., Moro, C., Centelles, J.J., Trebukhina, R., Petushok, N., Lee, W-N.P., **Boros, L.G.**, Cascante, M. The effect of thiamine supplementation on tumor proliferation: A metabolic control analysis study. *European Journal of Biochemistry* 268: 4177-82, 2001.
34. Boren, J., Cascante, M., Marin, S., Comín-Anduix, B., Centelles, J.J., Lim, S., Bassilian, S., Ahmed, S., Lee W-N.P., **Boros, L.G.** Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow towards nucleic acid and fatty acid synthesis in myeloid tumor cells. *Journal of Biological Chemistry* 276: 37747-37753, 2001.
35. **Boros, L.G.**, Lee, W-N.P., Go, V.L.W. A metabolic hypothesis of cell growth and death in pancreatic cancer. *Pancreas* 24: 26-33, 2002.
36. Bassilian, S., Ahmed, S., Lim, S.K., **Boros, L.G.**, Mao, C.S., Lee, W-N.P. Loss of regulation of lipogenesis in the Zucker diabetic rat. II. Changes in stearate and oleate synthesis. *American Journal of Physiology Endocrinology & Metabolism* 282: E507-13, 2002.
37. **Boros, L.G.**, Cascante, M., Lee, W-N.P. Metabolic Profiling of Cell Growth and Death in Cancer: applications in drug discovery. *Drug Discovery Today* 7: 364-372, 2002.
38. Cascante, M., **Boros, L.G.**, Comin, B., Atauri, P., Centelles, J.J., Lee, W-N.P. Metabolic control analysis in drug discovery and disease. *Nature Biotechnology* 20: 243-249, 2002.
39. **Boros, L.G.**, Lee, W-N.P., Cascante, M. Imatinib and chronic-phase leukemias. *New England Journal of Medicine* 347: 67-68, 2002.
40. **Boros, L.G.**, Torday, J.S., Lee W-N.P., Rehan, V.H. Oxygen-induced metabolic changes and transdifferentiation in immature fetal rat lung fibroblasts. *Molecular Genetics & Metabolism* 77: 230-236, 2002.
41. Comín-Anduix, B., **Boros, L.G.**, Marin, S., Boren, J.A., Callol-Massot, C., Centelles, J.J., Torres, L., Agell, N., Bassilian, S., Cascante, M.S. Fermented wheat germ extract inhibits enzymes of glucose metabolism and induces apoptosis through the activation of poly(ADP-ribose) polymerase in Jurkat T-cell leukemia tumor cultures. *Journal of Biological Chemistry* 277: 46408-464014, 2002.
42. Bulotta, A., Hui, H., Anastasi, E., Bertolotto, C., **Boros, L.G.**, Di Mario, U., Perfetti, R. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. *Journal of Molecular Endocrinology* 29: 347-60, 2002.
43. Guo, T.B., **Boros, L.G.**, Chan, K.C., Hikim, A.P., Hudson, A.P., Swerdloff, R.S., Mitchell, A.P., Salameh, W.A. Spermatogenic expression of RNA-binding motif protein 7, a protein that interacts with splicing factors. *Journal of Andrology* 24: 204-214, 2003.
44. Bulotta, A., Perfetti, R., Hui, H., **Boros, L. G.** Glucagon-like peptide-1 stimulates glucose derived *de novo* fatty acid synthesis and chain elongation during cell differentiation. *Journal of Lipid Research* 44: 1559-1564, 2003.
45. Boren, J., Lee, W.N., Bassilian, S., Centelles, J.J., Lim, S., Ahmed, S., **Boros, L.G.**, Cascante, M. The stable isotope-based dynamic metabolic profile of butyrate induced HT29 cell differentiation. *Journal of Biological Chemistry* 278: 28395-28402, 2003.



46. **Boros, L.G.**, Steinkamp, M.P., Fleming, J.C., Lee, W-N.P., Cascante, M., Neufeld, E.J. Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA): mechanism for the syndrome. *Blood* 102: 3556-3562, 2003.
47. **Boros, L.G.**, Brackett, D.J., Harrigan, G.G. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). *Current Cancer Drug Targets* 3: 445-453, 2003.
48. Marin, S., Chiang, K., Bassilian, S., Lee, W-N.P., **Boros, L.G.**, Fernández-Novell, J.M., Centelles, J.J., Medrano, A., Rodriguez-Gil, J.E., Cascante, M. Metabolic strategy of boar spermatozoa revealed by a metabolomic characterization. *FEBS Letters* 554: 342-346, 2003.
49. Marin, S., Lee, W.N., Bassilian, S., Lim, S., **Boros, L.G.**, Centelles, J.J., Fernandez-Novell, J.M., Guinovart, J.J., Cascante, M. Dynamic profiling of the glucose metabolic network in fasted rat hepatocytes using [1,2-¹³C₂]-glucose. *Biochemical Journal* 381: 287-294, 2004.
50. Williams, R.D., **Boros, L.G.**, Kolanko, C.J., Jackman, S.M., Eggers, T.R. Chromosomal aberrations in human lymphocytes exposed to the anticholinesterase pesticide isofenphos with mechanisms of leukemogenesis. *Leukemia Research* 28: 947-958, 2004.
51. Lee, W.N., Guo, P., Lim, S., Bassilian, S., Lee, S.T., Boren, J., Cascante, M., Go, V.L., **Boros, L.G.** Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. *British Journal of Cancer* 91: 2094-2100, 2004.
52. **Boros, L.G.**, Serkova, N.J., Cascante, M., Lee, W.N. Use of metabolic pathway flux information in targeted cancer drug design. *Drug Discovery Today Therapeutic Strategies* 1: 435-443, 2004.
53. Harrigan, G.G., Brackett, D.J., **Boros, L.G.** Medicinal chemistry, metabolic profiling and drug target discovery: a role for metabolic profiling in reverse pharmacology and chemical genetics. *Mini Reviews in Medicinal Chemistry* 5: 13-20, 2005.
54. Eibl, G., Takata, Y., **Boros, L.G.**, Liu, J., Okada, Y., Reber, H.A., Hines, O.J. Growth Stimulation of COX-2-Negative Pancreatic Cancer by a Selective COX-2 Inhibitor. *Cancer Research* 65: 982-990, 2005.
55. Balog, A., Gyulai, Z., **Boros, L.G.**, Farkas, G., Takacs, T., Lonovics, J., Mandi, Y. Polymorphism of the TNF-alpha, HSP70-2, and CD14 genes increases susceptibility to severe acute pancreatitis. *Pancreas* 30:e46-e50, 2005.
56. Vizan, P., **Boros, L.G.**, Figueras, A., Capella, G., Mangués, R., Bassilian, S., Lim, S., Lee, W-N.P., Cascante, M. K-ras codon-specific mutations produce distinctive metabolic phenotypes in human fibroblasts. *Cancer Res.* 65: 5512-5, 2005.
57. **Boros, L.G.**, Nichelatti, M., Shoenfeld, Y. Fermented Wheat Germ Extract (Avenar) in the Treatment of Cancer and Autoimmune Diseases. *Ann N Y Acad Sci.* 1051: 529-542, 2005. DOI: 10.1196/annals.1361.097
58. **Boros, L.G.**, Nichelatti, M., Shoenfeld, Y. Fermentiertes Weizenkeimextrakt (Avenar) bei der Behandlung von Krebs- und Autoimmunerkrankungen. *Ann N Y Acad Sci (GER).* 1051: 529-542, 2005.
59. Serkova, N., **Boros, L.G.** Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. *Am J Pharmacogenomics* 5: 293-302, 2005.
60. **Boros, L.G.**, Lerner, M.R., Morgan, D.L., Taylor, S.L., Smith, B.J., Postier, R.G., Brackett, D.J. [1,2-¹³C₂]-D-glucose profiles of the serum, liver, pancreas and DMBA-induced pancreatic tumors of rats. *Pancreas* 31: 337-43, 2005.



61. Maguire, G., Lee, W.-N.P., Manheim, D., **Boros, L.G.** SIDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways. *Expert Opin Drug Discov* 1: 351-359, 2006.
62. Rehan, V.K., Wang, Y., Sugano, S., Santos, J., Patel, S., Sakurai, R., **Boros, L.G.**, Lee, W.P., Torday, J.S. In utero nicotine exposure alters fetal rat lung alveolar type II cell proliferation, differentiation, and metabolism. *Am J Physiol Lung Cell Mol Physiol*. 292: 323-333, 2007.
63. Centelles, J.J., Ramos-Montoya, A., Lim, S., Bassilian, S., **Boros, L.G.**, Marín, S., Cascante, M., Lee, W.-N.P. Metabolic profile and quantification of deoxyribose synthesis pathways in HepG2 cells. *Metabolomics* 3: 105-111, 2007.
64. Huang, J., Gabrielsen, J.S., Cooksey, R.C., Luo, B., **Boros, L.G.**, Jones, D.L., Jouihan, H.A., Soesanto, Y., Knecht, L., Hazel, M.W., Kushner, J.P., McClain, D.A. Increased glucose disposal and AMP-dependent kinase signaling in a mouse model of hemochromatosis. *Journal of Biological Chemistry* 282: 37501-37507, 2007.
65. **Boros, L.G.**, Boros, T.F. Use of metabolic pathway flux information in anticancer drug design. *Ernst Schering Found Symp Proc*. 4:189-203, 2007.
66. Harrigan, G.G., Maguire, G., **Boros, L.G.** Metabolomics in Alcohol Research and Drug Development. *Alcohol Res Health* 31(1): 26-35, 2008.
67. Vazquez, A., Beg, Q.K., de Menezes, M.A., Ernst, J., Bar-Joseph, Z., Barabasi, A.L., **Boros, L.G.**, Oltvai, Z.N. Impact of the solvent capacity constraint on E. coli metabolism. *BMC Syst Biol*. 2: 7, 2008.
68. **Boros, L.G.**, Deng, Q., Pandol, S.J., Tsukamoto, H., Go, V.-L.W., Lee, W.-N.P. Ethanol Diversely Alters Palmitate, Stearate, and Oleate Metabolism in the Liver and Pancreas of Rats Using the Deuterium Oxide Single Tracer. *Pancreas* 38:e47-e52, 2009.
69. Kominsky, D.J., Klawitter, J., Brown, J.L., **Boros, L.G.**, Melo, J.V., Eckhardt, S.G., Serkova, N.J. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. *Clinical Cancer Research* 15: 3442-50, 2009.
70. Hui, H., Huang, D., McArthur, D., Nissen, N., **Boros, L.G.**, Heaney, A.P. Direct spectrophotometric determination of serum fructose in pancreatic cancer patients. *Pancreas* 38:706-12, 2009.
71. Beger, R.D., Hansen, D.K., Schnackenberg, L.K., Cross, B.M., Fatollahi, J.J., Lagunero, F.T., Sarnyai, Z., **Boros, L.G.** Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-C(6)]-d-glucose tracer in mice. *Metabolomics*. 5(3):336-345, 2009.
72. Espinoza, D.O., **Boros, L.G.**, Crunkhorn, S., Gami, H., Patti, M.E. Dual modulation of both lipid oxidation and synthesis by peroxisome proliferator-activated receptor-gamma coactivator-1alpha and -1beta in cultured myotubes. *FASEB J*. 24(4): 1003-1014, 2010.
73. Liu, H., Huang, D., McArthur, D.L., **Boros, L.G.**, Nissen, N., Heaney, A.P. Fructose Induces Transketolase Flux to Promote Pancreatic Cancer Growth. *Cancer Research* 70(15): 6368-6376, 2010.
74. Huang, D., Dhawan, T., Young, S., Yong, W.H., Boros, L.G., Heaney, A.P. Fructose impairs glucose-induced hepatic triglyceride synthesis. *Lipids Health Dis*. 10(1):20, 2011. - designated as 'Highly accessed'
75. Gu, W., Lloyd, D.J., Chinookswong, N., Komorowski, R., Sivits, G., Graham, M., Winters, K.A., Yan, H., **Boros, L.G.**, Lindberg, R.A., Veniant, M.M. Pharmacological targeting of glucagon and GLP-1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice. *J Pharmacol Exp Ther* 338: 70-81, 2011.



76. Sonko, B.J., Schmitt, T.C., Guo, L., Shi, Q., **Boros, L.G.**, Leakey, J.E., Beger, R.D.. Assessment of usnic acid toxicity in rat primary hepatocytes using ¹³C isotopomer distribution analysis of lactate, glutamate and glucose. *Food Chem Toxicol* 49(11): 2968-2974, 2011.
77. Bhalla K., Hwang B.J., Dewi R.E., Ou L., Twaddel W., Fang H.B., Vafai S.B., Vazquez F., Puigserver P., **Boros, L.G.**, Girnun G.D.. PGC1 α promotes tumor growth by inducing gene expression programs supporting lipogenesis. *Cancer Res* 71(21): 6888-6898, 2011.
78. **Boros L.G.**, Huang, D., Heaney, A.P. Fructose Drives Glucose via Direct Oxidation and Promotes Palmitate/Oleate Co-Release from Hepg2 Cells: Relevance with the Randle Cycle. *Metabolomics: Open Access* 2: 107, 2012. doi: 10.4172/2153-0769.1000107
79. Huang, J., Simcox, J., Mitchell, T.J., Jones, D., Cox, J., Luo, B., Cooksey, R.C., **Boros, L.G.**, McClain, D.A.. Iron regulates glucose homeostasis in liver and muscle via AMP-activated protein kinase in mice. *FASEB J* 27: 2845-2854, 2013. doi: 10.1096/fj.12-216929
80. Singh, A., Happel, C., Manna, S.K., Acquah-Mensah, G., Carratero, J., Kumar, S., Nasipuri, P., Krausz, W.K., Wakabayashi, N., Dewi, L., **Boros, L.G.**, Gonzalez, F.J., Gabrielson, E., Wong, K.K., Girnun, G., Biswal, S. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. *Journal of Clinical Investigation* 123(7): 2921–2934, 2013. doi: 10.1172/JCI66353
81. Yang, Y., Lane, A.N., Ricketts, C.J., Sourbier, C., Wei, M.-H., Shuch, B., Pike, L., Wu, M., Rouault, T.A., **Boros, L.G.**, Fan, T.W.-M., Linehan, W.M. Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma. *PLoS ONE* 8(8): e72179, 2013. doi: 10.1371/journal.pone.0072179
82. Tedeschi P.M., Markert E.K., Gounder M., Lin H., Dvorzhinski D., Dolfi S.C., Chan L.L., Qiu J., DiPaola R.S., Hirshfield K.M., **Boros L.G.**, Bertino J.R., Oltvai Z.N., Vazquez A. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. *Cell Death and Disease* 4: e877, 2013. doi: 10.1038/cddis.2013.393
83. Jenkins, Y., Sun, T.-Q., Markovtsov, V., Li, W., Nguyen, H., Foretz, M., Li, Y., Pan, A., Uy, G., Gross, L., Baltgalvis, K., Yung, S.L., Gururaja, T., Kinoshita, T., Owyang, A., Smith, I.J., McCaughey, M., White, K., Godinez, G., Alcantara, R., Choy, C., Ren, H., Basile, R., Sweeny, D.J., Xu, X., Issakani, S.D., Carroll, D.C., Goff, D.A., Shaw, S.J., Singh, R., **Boros, L.G.**, Laplante, M.-A., Marcotte, B., Kohen, R., Viollet, B., Marette, A., Payan, D.G., Kinsella, T.M., Hitoshi, Y. AMPK Activation through Mitochondrial Regulation Results in Increased Substrate Oxidation and Improved Metabolic Parameters in Models of Diabetes. *PLoS ONE* 8(12): e81870, 2013. doi:10.1371/journal.pone.0081870
84. Lamonte, G., Tang, X., Chen, J.L., Wu, J., Ding, C.K., Keenan, M.M., Sangokoya, C., Kung, H.N., Ilkayeva, O., Boros, L.G., Newgard, C.B., Chi, J.T. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. *Cancer and Metabolism* 1(1): 23, 2013. doi: 10.1186/2049-3002-1-23 (Highly Accessed)
85. Cantoria, M.J., **Boros, L.G.**, Meuillet, M.J. Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells. *Metabolomics* 10: 91-104, 2014. doi: 10.1007/s11306-013-0555-4 - Best Publication Award - Metabolomics Society & Springer – San Francisco, CA, USA, July 02, 2015
86. Laderoute, K.R., Calaoagan, J.M., Chao, W.-r., Dinh, D., Denko, N., Duellman, S., Kalra, J., Liu, X., Papandreou, I., Sambucetti, L., **Boros, L.G.** 5'-AMP-Activated Protein Kinase (AMPK) Supports the Growth of Aggressive Experimental



- Human Breast Cancer Tumors. *Journal of Biological Chemistry* 289: 22850-64, 2014. PMID: 24993821 doi: 10.1074/jbc.M114.576371.
87. Reitman, Z.J., Duncan, C.G., Poteet, E., Winters, A., Yan, L.J., Gooden, D.M., Spasojevic, I., **Boros, L.G.**, Yang, S.H., Yan, H. Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and D-2-hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia. *Journal of Biological Chemistry* 289: 23318-28, 2014. PMID: 24986863 doi: 10.1074/jbc.M114.575183.
88. Varma, V., **Boros, L.G.**, Nolen, G.T., Chang, C-W., Wabitsch, M., Beger, R.D., Kaput, J. Metabolic fate of fructose in human adipocytes: A targeted ¹³C tracer fate association study. *Metabolomics* 11(3): 529-544, 2015. doi: 10.1007/s11306-014-0716-0
89. Glick, G.D., Rossignol, R., Lyssiotis, C.A., Wahl, D., Lesch, C., Sanchez, B., Liu, X., Hao, L.Y., Taylor, C., Hurd, A., Ferrara, J.L., Tkachev, V., Byersdorfer, C., **Boros, L.G.**, Opipari, A.W. Targeting increased anaplerotic metabolism of pathogenic T cells to treat immune disease. *Journal of Pharmacology & Experimental Therapeutics* 351: 298-307, 2014. PMID: 25125579 doi: 10.1124/jpet.114.218099.
90. Buescher, J.M., Antoniewicz, M.R., **Boros, L.G.**, Brugess, S., Brunengraber, H., Clish, C.B., DeBerardinis, R.J., Feron, O., Frezza, C., Ghesquiere, B., Gottlieb, E., Hiller, K., Jones, R.G., Kamphorst, J.J., Kibbey, R.G., Kimmelman, A.C., Locasale, J.W., Lunt, S.Y., Maddocks, O., Malloy, C., Metallo, C.M., Meuillet, E.J., Munger, J., Nöh, K., Rabinowitz, J.D., Ralser, M., Sauer, U., Stephanopoulos, G., St-Pierre, J., Tennant, D.A., Wittmann, C., Vander Heiden, M.G., Vazquez, A., Voudsen, K., Young, J.D., Zamboni, N., Fendt, S-M.. A roadmap for interpreting ¹³C metabolite labeling patterns from cells. *Current Opinion in Biotechnology* 34C: 189-201, 2015. doi: 10.1016/j.copbio.2015.02.003
91. **Boros, L.G.**, Somlyai, G. Compartmentalized NADPH Synthesis, Intramolecular Deuterium Disequilibrium and Water Pools of Mammalian Cells. *Molecular Cell* 55: 253–263, 2014. [http://www.cell.com/molecular-cell/comments/S1097-2765\(14\)00402-X](http://www.cell.com/molecular-cell/comments/S1097-2765(14)00402-X)
92. Varma, V., **Boros, L.G.**, Nolen, G. T., Chang, C-W., Wabitsch, M., Beger, R.D., Kaput, J. Fructose alters intermediary metabolism of glucose in human adipocytes and diverts glucose to serine oxidation in the one-carbon cycle energy producing pathway. *Metabolites* 5(2): 364-385, 2015. doi: 10.3390/metabo5020364
93. Montal, E. D., Dewi, R., Bhalla, K., Ou, L., Hwang, B.J., Ropell, A. E., Gordon, C., Liu, W-J., DeBerardinis, R. J., Sudderth, J., Twaddell, W., **Boros, L. G.**, Shroyer, K. R., Duraisamy, S., Drapkin, R., Powers, R. S., Rohde, J. M., Boxer, M. B., Wong, K-K., Girnun, G. D. PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. *Molecular Cell* 60(Nov 19): 1-13. doi: 10.1016/j.molcel.2015.09.025
94. **Boros, L.G.**, D'Agostino, D.P., Katz, H.E., Roth, J.P., Meuillet, E.J., Somlyai, G. Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle. *Medical Hypotheses* 87: 69-74, 2016. doi: 10.1016/j.mehy.2015.11.016
95. **Boros, L.G.**, Somlyai, G., Collins, T.Q., Patel, H., Beger, R.D. Serine Oxidation via Glycine Cleavage (SOGC) Continues its Emergence as a Hallmark of Defective Mitochondria. *Cell Metabolism* 23: 635–648, 2016. <https://goo.gl/vTHaCO>
96. **Boros, L.G.**, Collins, T.Q., Somlyai, G. What to eat or what not to eat - that is still the question. *Neuro-Oncology* 19(4): 595-596, 2017. doi: 10.1093/neuonc/now284



97. Somlyai, G., Collins, T.Q., Meuillet, E.J., Hitendra, P., D'Agostino, D.P., **Boros, L.G.** Structural homologies between Phenformin, Lipitor and Gleevec aim the same metabolic oncotarget in leukemia and melanoma. *Oncotarget* 8: 50187-50192, 2017. doi: 10.18632/oncotarget.16238
98. Edderkaoui, M., Chheda, C., Soufi, B., Zayou, F., Hu, R., Ramanujan, V.K., Pan, X., **Boros, L.G.**, Tajbakhsh, J., Madhav, A., Bhowmick, N., Wang, Q., Lewis, M., Tuli, R., Habtezion, A., Murali, R., Pandol, S.J. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. *Gastroenterology* 155: 1985–1998, 2018. doi: 10.1053/j.gastro.2018.08.028
99. Joyner, M.J., **Boros, L.G.**, Fink G. Biological Reductionism versus Redundancy in a Degenerate World. *Perspectives in Biology and Medicine* 61(4): 517-526, 2018. doi: 10.1353/pbm.2018.00612018
100. **Boros, L.G.**, Collins, T.Q., Boros, E.A., Lantos, F., Somlyai, G. Deuterium and metabolic water matter – what this means biochemically and clinically. *Science Advances* 4(8): eaat7314, 2018. DOI: 10.1126/sciadv.aat7314 - <https://advances.sciencemag.org/content/4/8/eaat7314/tab-e-letters>

Book Contributions

1. **Boros, L.G.**, Singer, M.V. Animal models of chronic pancreatitis. A critical review of experimental studies. *In: Pancreatitis. New data and geographical distribution.* Eds. H. Sarles, CD Johnson, JF Saunier. Chapter 7, pages: 67-82. *Arnette Blackwell, Paris, France 1991.*
2. Robertson, F.M., Bijur, G.N., Oberyszyn, A.S., Nill, M.R., **Boros, L.G.**, Spencer, W.J., Sabourin, C.L., Oberyszyn, T.M. Interleukin-1 α in murine multistage carcinogenesis. *In: Skin Cancer: Mechanisms and Human Relevance.* Eds. Hasan Mukhtar. Chapter 20, pages: 255-272. *CRC Press, Boca Raton, Ann Arbor, London, Tokyo 1995.*
3. Singer, M.V., **Boros, L.G.**, Mayr, C. Experimentelle Modelle der chronischen Pankreatitis. *In: Erkrankungen des exokrinen Pankreas.* Eds. Mössner, J., Adler, G., Fölsch, U.R., Singer, M.V., eds.. Jena, Stuttgart: Gustav Fischer, 1995: 303-312.
4. Cascante, M., Comin, B., Raïs, B., Boren, J., Centelles, J.J., Puigjaner, J., Lee, W-N.P., **Boros, L.G.** Application of metabolic control analysis to the design of a new strategy for cancer therapy. *In: Technological and Medical Implications of Metabolic Control Analysis.* Eds. Cornish-Bowden, A. and Cardenas, M.L. Kluwer Academic Publishers, The Netherlands, 1999: 173-180.
5. **Boros, L.G.**, Cascante, M., Lee, W-N.P. Stable Isotope-Based Dynamic Metabolic Profiling in Disease and Health. *In: Metabolite Profiling: Its Role in Biomarker Discovery and Gene Function Analysis.* Eds. Harrigan, G.G. and Goodacre, R.; Kluwer Academic Publishers, United States of America, 2003 pp. 141-169.
6. **Boros, L.G.**, Lee, W-N.P. Metabolic Network Characteristics in Cell Growth and Death in Cancer. *In: Nutritional Oncology, Second Edition,* Eds. Heber, Blackburn, Go, & Milner; Elsevier, United States of America, 2006 pp. 57-68.
7. **Boros, L.G.**, Lee, W-N.P. Targeted Drug Design and Metabolic Pathway Flux. *In: Metabolome Analyses: Strategies for Systems Biology.* Eds. Vaidyanathan, S., Harrigan, G.G. and Goodacre, R.; Springer, Boston, United States of America, 2005 pp. 323-337.
8. Cascante, M., **Boros, L.G.**, Boren J.A. Modeling of Regulation of Glycolysis and Overall Energy Metabolism Under a Systems Biology Approach. *In: Handbook of Neurochemistry & Molecular Neurobiology 3rd, Brain Energetics, Integration of Molecular and Cellular Processes;* Eds. Gibson & Dienel; Part 8, 2006 pp. 861-875.



9. Sarnyai, Z., **Boros, L.G.** Modeling Networks of Glycolysis, Overall Energy Metabolism and Drug Metabolism under a Systems Biology Approach. In: Annual Reports in Medicinal Chemistry, Chapter 20, Volume 43, 2008 pp. 329–349.
10. Cantoria, M.J., Patel, H., **Boros, L.G.**, Meuillet, E.J. Metformin and Pancreatic Cancer Metabolism. Pancreatic Cancer - Insights into Molecular Mechanisms and Novel Approaches to Early Detection and Treatment (In). Dr. Kelly McCall (Ed.), ISBN: 978-953-51-1375-1, InTech, DOI: 10.5772/57432. Available from: <http://www.intechopen.com/books/pancreatic-cancer-insights-into-molecular-mechanisms-and-novel-approaches-to-early-detection-and-treatment/metformin-and-pancreatic-cancer-metabolism>
11. **Boros L.G.**, Beger R.D., Meuillet E.J., Colca J.R., Szalma S., Thompson P.A., Dux L, Farkas Gy. Jr., Somlyai G. Targeted ¹³C-labeled tracer fate associations for drug efficacy testing in cancer. In: Tumor Cell Metabolism – Pathways, Regulation & Biology, Eds. Shoshan, M. (Karolinska Institute, Stockholm, Sweden) & Mazurek, S.L. (Justus-Liebig-University, Giessen, Germany), Chapter 15 pages 349-372, 2014. ISBN 978-3-7091-1823-8 ISBN 978-3-7091-1824-5 (eBook) DOI 10.1007/978-3-7091-1824-5 Publisher Springer Vienna; Copyright Holder: Springer-Verlag Wien

Abstracts

1. **Boros, L.G.**, Pap, A, Berger, Z. Chronic pancreatitis-like lesions provoked by duct occlusion with Ethibloc in rats can be maintained by alcohol administration. Presented at the European Pancreatic Club, Manchester, England, September, 1985.
2. **Boros, L.G.**, Pap, A. Recovery of the pancreatic enzyme content in Ethibloc induced obstructive pancreatitis can be inhibited by alcohol administration. Presented at the European Pancreatic Club, Nijmegen, The Netherlands, September, 1986.
3. **Boros, L.G.**, Hajnal, F., Pap, A., Takats, T., Nagy, I. Pancreatic insufficiency and atrophy provoked by intraductal oleic acid can be progressed by alcohol and regenerated by cholecystokinin octapeptide (CCK 8). Presented at the European Pancreatic Club, Marseille, France, September, 1987.
4. **Boros, L.G.**, Berger, Z., Pap, A., Takats, T., Nagy, I. CCK-8 accelerates, the CCK antagonist CR-1409 inhibits pancreatic regeneration after resection in rat. Presented at the European Pancreatic Club, Budapest, Hungary, August, 1988.
5. **Boros, L.G.**, Pap, A., Takats, T., Nagy, I. Alcohol inhibits the regeneration after pancreatic resection in rats. Presented at the European Pancreatic Club, Budapest, Hungary, August, 1988.
6. **Boros, L.G.**, Oberyszyn, T.M., Sabourin, C.L., Bijur, G.N., Oberyszyn, A.E., Robertson, F.M. Cytokines regulating neutrophil migration during cutaneous inflammation. Presented at the Association of Leukocyte Biology, Charlestown, NC, USA, December, 1992.
7. **Boros, L.G.**, Muscarella P., Brandes, J.L., Johnson J.A., Schirmer, W.J., Ellison, E.C., Melvin, W.S. The effect of BZA-5B, a farnesyl protein transferase inhibitor, on the growth of human pancreatic cancer. Presented at the American Gastroenterological Society, Washington, DC, USA, May, 1996.
8. Muscarella P., **Boros, L.G.**, Brandes, J.L., Johnson J.A., Melvin, W.S., Schirmer, W.J., Ellison, E.C. Dehydroepiandrosterone-sulfate inhibits pancreatic cancer cell proliferation in vitro and in vivo. Presented at the American Gastroenterological Society, Washington, DC, USA, May, 1996.
9. **Boros, L.G.**, Muscarella P., Brandes, J.L., Johnson J.A., Melvin, W.S., Schirmer, W.J., Ellison, E.C. Orally administered dehydroepiandrosterone inhibits the growth of subcutaneously injected pancreatic cancer cells in nude mice. Presented at the American Gastroenterological Society, San Francisco, CA, USA, May, 1997.



10. **Boros, L.G.**, Puigjaner, J., Rais, B., Comin, B., Lee, P., Melvin, W.S., Schirmer, W.J., Cascante, M. Oxythiamine and dehydroepiandrosterone inhibit the non-oxidative synthesis of ribose and cancer cell proliferation. Presented at the American Gastroenterological Society, San Francisco, CA, USA, May, 1997.
11. Rais, B., Comin, B., **Boros, L.G.**, Lee, P., Melvin, W.S., Schirmer, W.J., Cascante, M. Inhibition of Ehrlich's ascites tumor cell proliferation by pentose cycle inhibitors is associated with an arrest in the G0-G1 cell cycle phases. Presented at the The First Annual Meeting on Experimental Therapeutics of Human Cancer, Frederick, Maryland, USA, June, 1998.
12. Guenther, D.A., Huang, E., Ikramuddin S., **Boros, L.G.**, Melvin, W.S. Natural killer cell activity is not different following laparoscopy compared to open surgery. Presented at the Society of American Gastrointestinal and Endoscopic Surgeons, San Antonio, Texas, USA, March, 1999.
13. Cascante, M., Comin, B., Boren, J., Moro, C., Martinez, S., Centelles, J.J., Lee W-N.P., and **Boros, L.G.** Plenary lecture: Inhibition of tumor ribose-phosphate synthesis: A new strategy to control tumor proliferation. Presented at the ComBio99. Australian Society for Biochemistry and Molecular Biology, Sidney, Australia, September, 1999.
14. Cascante, M., Comin, B., Rais, B., Centelles, J.J., Puigjaner, J., Lee, W-N.P., **Boros, L.G.** Application of metabolic control analysis to the design of a new strategy for cancer therapy. Presented at the MCA 99 NATO Advanced Research Workshop on Technological and Medical Implications of Metabolic Control Analysis, Visegrad, Hungary, July, 1999.
15. **Boros, L.G.**, Comin, B., Boren, J., Martinez, S., Moro, C., Centelles, J.J., Lee, W.N.P., and M. Cascante. Over-expression of transketolase: a mechanism by which thiamine supplementation promotes cancer growth. Presented at the American Association for Cancer Research, San Francisco, CA, USA, April, 2000.
16. **Boros, L.G.**, Torday, J.S., Lim, S., Bassilian, S., Cascante, M., and Lee, W.N.P. TGF- β increases nucleic acid ribose synthesis through the non-oxidative pentose cycle in lung carcinoma cells. Presented at the American Association for Cancer Research, San Francisco, CA, USA, April, 2000.
17. Lee, W-N.P., Bassilian, S., Lim, S., **Boros, L.G.** 2-Deoxyglucose inhibits both the oxidative and non-oxidative branches of the pentose cycle. Presented at the Federation of American Societies for Experimental Biology, San Diego, CA, USA, April, 2000.
18. Steinkamp, M.P., Fleming, J.C., **Boros, L.G.**, Neufeld, E.J. Thiamine depletion in thiamine-responsive megaloblastic anemia (TRMA) mutant fibroblasts leads to a reduction in non-oxidative ribose synthesis. Presented at the American Society for Biochemistry and Molecular Biology and The American Society for Pharmacology and Experimental Therapeutics (ASBMB/ASPE), 2000.
19. Comin, B., Boren, J., Moro, S., Martinez, S., Lee, W-N.P., **Boros, L.G.**, Centelles, J.J., Cascante, M. New antitumoral drugs based on ribose-phosphate synthesis tested by metabolic control analysis. Presented at the 18th International Congress of Biochemistry and Molecular Biology, Birmingham, UK, July, 2000.
20. Boren, J., Comin, B., Centelles, J.J., Moro, S., Martinez, S., Le, W-N.P., **Boros, L.G.**, Cascante, M. Modeling metabolic networks for the search of new targets in cancer therapy. Presented at the Biochemical Systems Theory (SYMBIOSYS), Puerto de la Cruz, Tenerife, Canary Islands, Spain, September, 2000.
21. **Boros, L.G.**, Lee, W-N.P., Hidvegi, M., Go, V.L.W. Metabolic effects of fermented wheat germ extract with anti-tumor properties in cultured MIA pancreatic adenocarcinoma cells. Presented at the Combined Meeting of the International Association of Pancreatology and the American Pancreatic Association, Chicago, Illinois, USA, November, 2000.



22. **Boros, L.G.**, Lee, W-N.P., Go, V.L.W. Metabolic targets of tumor growth inhibitory signals in MIA pancreatic adenocarcinoma cells: a metabolic hypothesis of cellular signaling pathways. Presented at the Combined Meeting of the International Association of Pancreatology and the American Pancreatic Association, Chicago, Illinois, November, 2000.
23. Lee, W-N.P., Mao, C.S, Bassilian, S., **Boros, L.G.** Plasma fatty acid production and the role of de novo lipogenesis in energy transport. Presented at the American Federation for Medical Research Western Regional Meeting Metabolism III Session, Carmel, CA, February, 2001.
24. **Boros, L.G.**, Lee, W-N.P., Williams, R.D. Isofenphos organophosphate pesticide induces metabolic changes of the invasive phenotype in K562 myeloid blast cells. Presented at the American Federation for Medical Research Western Regional Meeting Metabolism III Session, Carmel, CA, February, 2001.
25. **Boros, L.G.**, Boren, A.J., Marin, S., Cascante, M., Lim, S., Bassilian, S., Ahmed, S., Lee, W-N.P. STI571 decreases glucose derived nucleic acid synthesis but increases direct glucose oxidation in K562 myeloid blast cells. Presented at the American Association for Cancer Research, New Orleans, LA, USA, March, 2001.
26. Lee, W-N.P., Lim, S., Bassilian, S., Ahmed S., Mao, C.S., **Boros, L.G.** Glucose metabolic changes in HepG2 cells induced by the phosphorylase inhibitor CP-329,626. Presented at the Federation of American Societies for Experimental Biology, Orlando, Florida, USA, March 31-April 4, 2001.
27. Lee, W-N.P., Martinez, S., Lim, S., Bassilian, S., Ahmed, S., Boren, J., Mao, C., **Boros, L.G.**, Cascante, M. Diverse metabolic changes of glucosamine induced insulin resistance in HepG2 cells. Presented at the International Conference of Pediatric Endocrinology Montreal 2001, Montreal, Canada, Sept, 2001.
28. Rehan, V., Feng, S., Rehan, Y.H., Lee, W-N.P., Torday, J.S., **Boros, L.G.** Evidence for metabolic phenotype changes during trans-differentiation of pulmonary lipofibroblasts to myofibroblasts in response to hyperoxia. Presented at the Pediatric Academic Societies Annual Meeting, Baltimore, MD, April-May, 2001.
29. Lee, W-N.P., Martinez, S., Lim, S., Bassilian, S., Ahmed, S., Boren, J., Mao, C., **Boros, L.G.**, Cascante, M. Diverse Metabolic Changes of Glucosamine Induced Insulin Resistance in HEPG2 Cells. Presented at the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology (LWPES/ESPE) 6th Joint Meeting, Montreal, Canada, July, 2001.
30. **Boros, L.G.**, Syed, A.S., Bassilian S., Lim, S., Lee, W-N.P. Lack of proliferative and metabolic response in MIA pancreatic adenocarcinoma cell cultures to STI571 (Gleevec). Presented at the American Pancreatic Association, Chicago, Illinois, November, 2001.
31. Bulotta, A., Perfetti, R., Hui, H., **Boros, L.G.** Differentiation of cultured ARIP carcinoma cells is mediated via glucose intermediary metabolic changes in response to Glucagon-like peptide 1 (GLP-1) treatment. Presented at the American Pancreatic Association, Chicago, Illinois, November, 2001.
32. **Boros, L.G.**, Go, V.L., Lee, W-N.P. Metabolic Profiling of Cell Growth and Death in Cancer. Presented at the Cambridge Healthtech Institute's Premier Conference on Metabolic Profiling: Pathways to Discovery (keynote address), Sheraton Chapel Hill Hotel, Chapel Hill, North Carolina, December 4, 2001.
33. **Boros, L.G.**, Bassilian S., Lim, S., Lee, W-N.P. STI571 (Gleevec) inhibits de novo palmitate but does not affect nucleic acid synthesis in MIA pancreatic adenocarcinoma cells. Presented at the American Federation for Medical Research Western Regional Meeting Metabolism III Session, Carmel, CA, February, 2001.



34. Tucker, C., **Boros, L.G.**, Patel, S.M., Santos, J., Reddy, S.G., Lee, W-N.P., Torday, J.S., Rehan, V.K.. Dihydroxycholecalciferol (Vitamin D₃) affects lipid metabolism differentially in pulmonary alveolar type II cells and fibroblasts. Presented to the Pediatric Academic Societies' Annual Meeting, Baltimore, MD, May, 2002.
35. Cascante, M., Comin, B., Raïs, B., Centelles, J.J., Puigjaner, J., Lee, W-N.P., **Boros, L.G.** Metabolic control theory and stable isotope based metabolic profiling. Presented at the EMBIO Meeting, Barcelona, Spain, June, 2002.
36. Cascante, M., Comin, B., Atauri, P., Ramos, A., Vizán, P., **Boros, L.G.**, Centelles, J.J., Mazurek, S., Eigenbrodt, E., Frederiks, W.M., Lee, W-N.P., Boren, J. Modeling metabolic networks in drug discovery and disease. Presented at the European Science Foundation (ESF) Meeting, Granada, June, 2002.
37. **Boros, L.G.**, Go, V.L.W., Lee, W-N.P. Stable isotope-based metabolic profiling in pancreatic cancer: applications in biomarker discovery and gene function analysis. Presented at the American Pancreatic Association, Chicago, Illinois, November, 2002.
38. **Boros, L.G.**, Deng, Q., Pandol, S.J., Tsukamoto, H., Go, V.L.W., Lee, W-N.P. Ethanol induced tissue specific lipotoxicity in the liver and pancreas. Presented at the American Pancreatic Association, Chicago, Illinois, November, 2002.
39. **Boros, L.G.**, Harrigan, G.G. Stable isotope-based metabolic profiling: applications in biomarker discovery & gene function testing. Presented at the Cambridge Healthtech Institute's Second Conference on Metabolic Profiling, Sheraton Chapel Hill Hotel, Chapel Hill, North Carolina, December 4, 2002.
40. Tucker, C., **Boros, L.G.**, Santos, J., Bassilian, S., Torday, J.S., Lee, W-N. P., Rehan, V. Differential proliferative and metabolic effects of vitamin D₃ on near-term fetal rat lung fibroblasts and type II cells. Presented at the American Federation for Medical Research Western Regional Meeting Neonatology Session, Carmel, CA, February, 2003.
41. Ramos-Montoya, A. **Boros, L.G.**, Bassilian, S., Lim, S., Lee, W-N.P., Cascante, M. Pentose and purine synthetic pathway inhibitors do not have synergistic effect on colon carcinoma cell growth. Presented at the American Federation for Medical Research Western Regional Meeting Metabolism III Session, Carmel, CA, February, 2003.
42. Bulotta, A., Perfetti, R., Hui, H., **Boros, L.G.** Glucagon-like peptide-1 regulates insulin release via glucose derived de novo fatty acid synthesis and chain elongation in pancreatic carcinoma cells. Presented at the American Diabetes Association Meeting Metabolism III Session, Chicago, IL, March, 2003.
43. Tucker, C., **Boros, L.G.**, Santos, J., Torday, J.S., Rehan, V. Differential proliferative and metabolic effects of vitamin-D₃ on near-term fetal rat lung fibroblasts and type II cells. Presented at the Pediatric Academic Societies' Annual Meeting in Seattle, Cardiopulmonary Development Session, Washington, May 3-6, 2003.
44. Lee, W-N.P., **Boros, L.G.**, Mao, C.S. Tracer approaches to determining glyconeogenesis. Presented at the American Society for Parenteral and Enteral Nutrition Meeting, Nutrition Week, San Antonio, TX, January, 2003.
45. **Boros, L.G.** Metabolic profiling using stable isotope tracer technology GC/MS. Presented at the 20th Annual Conference on Metabolic Profiling: Biomarker Discovery, Drug Efficacy and Fundamental Biochemistry, Asilomar, CA, October 15-18, 2004.
46. **Boros, L.G.**, Lerner, M., Morgan, D., Taylor, S., Postier, R., Brackett, D. Different positional accumulation of [1,2-¹³C₂]glucose into RNA ribose of DMBA-induced pancreatic tumors, pancreas and liver. Presented at the American Pancreatic Association, Chicago, Illinois, November 4-5, 2004.
47. Guo, P., Bassilian, S., Lim, S., Lee, W.-N.P., **Boros, L.G.** Doxorubicin induces Mia PaCa-2 cell apoptosis by increasing GSK-3 β expression, β -catenin degradation and by limiting DNA/RNA ribose synthesis in the pentose cycle. Presented at the American Pancreatic Association, Chicago, Illinois, November 4-5, 2004.



48. Miljus, J., Melo, J.V., **Boros, L.G.**, Anderson, N., Talpaz, M., Leibfritz, D., Eckhardt, S.G., Serkova, N. Metabolic profile of imatinib resistance in chronic myeloid leukemia cells. Presented at the 46th American Society of Hematology Meeting in San Diego, CA, December 4-7, 2004.
49. **Boros, L.G.** CASE STUDY: Single metabolic mechanism of Gleevec resistance regardless of the genetic makeup of leukemia cells. Presented at the 5th Annual Metabolic Profiling: Pathways in Discovery Meeting, Lake Buena Vista, FL, December 13-14, 2004.
50. **Boros, L.G.**, Lee, W-N.P. Predicting clinical resistance to Gleevec treatment by in vitro applied stable isotope-based dynamic metabolic profiling (SIDMAP). Presented at the 2005 FDA Science Forum, Washington, DC, April 27-28, 2005.
51. Sahai, I., M. Montefusco, C.M., Fleming, J.C., **Boros, L.G.**, Tartaglini, E., Chick, G., Neufeld, E.J. Role of Defective High-Affinity Thiamine Transporter slc19a2 in Marrow from a Mouse Model of Thiamine-Responsive Anemia Syndrome: Evidence for Defective Deoxyribose and Heme Synthesis. Presented at the 47th American Society of Hematology, San Diego, CA, December 3-6, 2005. [link](#)
52. Sugano, S., **Boros, L.G.**, Wang, Y., Santos, J., Lee, W-P., Torday, J.S., Rehan, V.K. Maternal nicotine exposure: lung alveolar type II cell proliferation, differentiation and metabolic profile. Presented at the Western Society for Pediatric Research (WSPR), Carmel, CA, February 3, 2006. (WINNER OF THE WSPR LOWELL GLASGOW STUDENT RESEARCH AWARD).
53. Erkkila, K., Liu, P.Y., Lee, P.W-N., **Boros, L.G.**, Ferrini, M., Sinha Hikim, A.P., Wang, C., Lue, Y.H., Swerdloff, R.S.. XXY mice exhibit altered palmitate and stearate metabolism in the brain. Presented at the Annual Meeting of the Endocrine Society (ENDO), Boston, MA, June 24-27, 2006.
54. **Boros, L.G.**, Kochegarov, A., Szigeti, I., Lee, S.T., Jancso, G., Jákl, G., Somlyai, G. Deuterium depleted water alters glucose-derived fatty acid and cholesterol synthesis of tumor cells. Presented at the Annual International Meeting of the Metabolomics Society, Boston, MA, June 25-29, 2006.
55. Beger, R.D., Hansen, D.K., Schnackenberg, L.K., Fatollahi, J.J., **Boros, L.G.** Decreased glycogen and RNA ribose synthesis and turnover from [U-¹³C₆]-D-glucose is an early metabolic marker of valproic acid toxicity on the liver in mice. 3rd Annual Meeting of the Metabolomics Society, Manchester, UK, June 11-14, 2007.
56. **Boros, L.G.**, Szigeti, I. Szabo, G. Sarnyai, Z. Delayed uptake of [U-¹³C₆]-D-glucose and abnormal ¹³C isotopomer production after acute and chronic antipsychotic treatment in mice. Presented at the Annual International Meeting of the Metabolomics Society, Manchester, UK, June 11-14, 2007.
57. Vizan, P., **Boros, L.G.**, Peiris, M., Figueras, A., Capella, G., Mangués, R., Lee, W-N.P., Selivanov., Cascante, M. K-ras codon-specific mutations produce distinctive metabolic phenotypes in mice fibroblasts. Presented at the Annual International Meeting of the Metabolomics Society, Manchester, UK, June 11-14, 2007.
58. Harris, D.M., Li, L., Fatollahi, J.J., Lagunero, F.T., Cross, B.M., Go, V.L.W., **Boros, L.G.** Luteolin inhibits proliferation and de novo fatty acid synthesis in pancreatic cancer cells. Presented at the American Association for Cancer Research, San Diego, CA, USA, April, 2008.
59. Sonko, B.J., Guo, L., Schmitt, T., Leakey, J., **Boros, L.G.**, Beger, R. In Vitro Usnic Acid Concentration/Time Dependency Toxicity Evaluation. Models and Mechanisms of Hepatotoxicity, Society of Toxicology, Salt Lake City, Utah, USA, March 7-11, 2009.



60. Sonko, B.J., Schmitt, T.M., **Boros, L.G.**, Sakar, S., Syed, A., Beger, R. Effect of Chronic MPTP Administration on Glycolysis and TCA cycle Pathways in Mouse Model of Parkinson's Disease. Twenty-sixth International Neurotoxicological Conference, Portland, Oregon, USA, June 5-10, 2010.
61. Varma, V., Nolen, G.T., **Boros L.G.**, Kaput, J. Fructose Metabolism and Its Influence on Glucose Metabolism in Human Adipocytes. 70th - Integrated Physiology Session, American Diabetes Association, Orlando, Florida, June 25-29, 2010.
62. Bolin, D., Ahmad, M., Banner, B., **Boros, L.G.**, Cai, J., Gillespie, P., Goodnow, P., Gubler, M.L., Hamilton, M.M., Hayden, S., Huang, K.S., Liu, X., Lou J.P., Mark D., McDermott L., Perrotta A., Qian Y., Ren Y., Rondinone C., Rowan K., Spence C., Tilley J., Sergi J., Thakkar K., Yi L., Yun W., Xiang Q., Zhang X., Conde-Knape C., Olivier A.R. A Novel Approach for the Treatment of Type 2 Diabetes (T2D): Characterization of a Potent, Orally Active, Small Molecule Glycogen Synthase Activator. 70th Scientific Sessions – Insulin Action and Metabolism, American Diabetes Association, Orlando, Florida, June 25-29, 2010.
63. Varma, V., Nolen, G.T., **Boros, L.G.**, Kaput, J. Fructose Alters Glucose Metabolism of Human Adipocytes. 1st Annual Foods Program Science and Research Conference, Food and Drug Administration, White Oak Campus, Silver Spring, Maryland, June 21-22, 2011.
64. Varma, V., Nolen, G.T., **Boros, L.G.**, Kaput, J. Fructose is a Potent Lipogenic Macronutrient in Human Adipocytes. Joint meeting on Diabetes and Obesity – 'Pathogenesis of Diabetes: Emerging Insights into Molecular Mechanisms' (J8) AND 'Genetic & Molecular Basis of Obesity and Body Weight Regulation' (J7) at Santa Fe, NM, January 29-February 3, 2012.
65. Cantoria, M.J., **Boros, L.G.**, Meuillet, M.J.. Metformin Inhibits the TCA Cycle and Fatty Acid Synthesis in MIAPaCa-2 Pancreatic Cancer Cells. International Association of Pancreatology and the American Pancreatic Association Joint Meeting, Miami, FL, October 31, November 02, 2012 (PII-60)
66. Yang, Y., Lane, A., Ricketts, C., Wei, M.H., Pike, L., Wu, M., Rouault, T.A., **Boros, L.G.**, Fan, T., Linehan, M. (C063) Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma (HLRCC). Presented at the 9th American Associations for Cancer Research and Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research, Preclinical Models, Maui, Hawaii, February 21-25, 2013.
67. **Boros, L.G.**, Serkova, N.J., Laderoute, K.R., Linehan, W.M., Meuillet, M.J.. Stable ¹³C Isotope Enriched Metabolome (Isotopolome) Wide Associations (IWAS) Improve System Wide Association Studies (SWAS) for Phenotype and Drug Research. World Biotechnology Congress, Medical Biotechnology, Boston, MA, June 3-6, 2013.
68. **Boros, L.G.**, Lee, W-N.P. Cross-labeled ¹³C-stearate fate detection in the [1,2-¹³C₂]-d-glucose derived isotopolome improves system wide associations when compared with external; [U-¹³C₁₈]-stearate incubation in rosiglitazone treated HEPG₂ Cells. 9th Annual Conference of the Metabolomics Society, SECC, Glasgow, Scotland, July 1-4, 2013.
69. Cantoria, M.J., **Boros, L.G.**, Patel, H., Han, H., Ignatenko, N. Meuillet, M.J. Metformin-induced metabolic changes are k-ras-dependent in animal models of pancreatic cancer. Presented at the American Association for Cancer Research, San Diego, CA, April 8, 2014.
70. **Boros, L.G.**, Meuillet, M.J., Somlyai, I., Jancsó, G., Jákl, G., Krempels, K., Puskás, L.G., Nagy, I.L., Molnár, M., Laderoute, K.L., Thompson, P.A., Somlyai, G. Fumarate hydratase and deuterium depletion control oncogenesis via NADPH-dependent reductive synthesis: mitochondrial matrix water, DNA deuteration and epigenetic events. Presented at the American Association for Cancer Research, San Diego, CA, April 8, 2014.



71. Weston, R., Rodier, J., Coffey, S., Glickenhau, A., **Boros, L.G.**, MacDonald, M.E., Carroll, J.B. Investigating Hepatic Dysfunction In The Httq111/+ Mouse With A Perturbagen-based Primary Hepatocyte System. *J Neurol Neurosurg Psychiatry* 85: A19-A20, 2014. doi:10.1136/jnnp-2014-309032.58
72. **Boros, L.G.** Targeted ^{13}C Tracer Fate Association Studies for Clinical Isobolomics. Presented at SciX 2014, the Federation of Analytical Chemistry and Spectroscopy Societies (FACSS), Reno, Lake Tahoe, NV, USA, September 30, 2014.
73. Vijayalakshmi, V., **Boros, L.G.**, Nolen, G.T., Beger, R.D., Kaput, J. Fructose diverts glucose to glycerol and serine oxidation in the one-carbon cycle energy producing pathway of human adipocytes. Diabetes and Metabolic Dysfunction, Mitochondria, Metabolism and Heart Failure, Keystone Symposium at the Santa Fe Community Convention Center, Santa Fe, NM, USA, January 27 – February 1, 2015.
74. **Boros, L.G.** Biochemical interpretations of $^2\text{H}/^1\text{H}$ ratio contrast magnetic resonance spectroscopy: tissue phenotyping by mitochondrial matrix (metabolic $^1\text{H}_2\text{O}$) and cytoplasmic ($^2\text{H}^1\text{HO}$) water ratios in cells. 3rd International Congress on Deuterium Depletion, Budapest, Hungary, EU, May 07, 2015 – 13th Presentation (23 minutes) LASZLO G. BOROS - <http://www.deuteriumdepletion.com/2015program.php>
75. **Boros, L.G.**, Katz, H.E., Roth, J.P., Somlyai, G. Gluconeogenesis and the pentose cycle impact deuterium depleted water efficacy in anticancer therapeutics. 3rd International Congress on Deuterium Depletion, Budapest, Hungary, EU, May 08, 2015 – 4th Presentation (52 minutes) LASZLO G. BOROS - <http://www.deuteriumdepletion.com/2015program.php>
76. Blanco, F.F., Zarei, M., Brody, J.R., **Boros, L.G.**, Winter, J.M. The RNA binding protein, HuR, regulates pancreatic cancer cell metabolism. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1191. doi:10.1158/1538-7445.AM2015-1191 - <http://goo.gl/L0UszO>
77. **Boros, L.G.**, Somlyai, G. Deuterium and Hydrogen Ratios Determine Proton Spin-Lattice T1-Weighted Magnetic Resonance Images: Clinical Applications in Cancer. European Society for Isotope Research, ESIR Isotope Workshop XIII September 20 – 24, pp: 92-93, 2015, Zadar, Croatia. Eds: Krajcar Bronić, I., Horvatinčić, N., Obelić, B., Publisher: Ruđer Bošković Institute, Zagreb, Croatia, 2015; ISBN 978-953-7941-08-6 - <http://esir2015.irb.hr/Programme/Deuterium-and-hydrogen-ratios-determine-proton-spin-lattice-T1-weighted-Magnetic-Resonance-Images-Clinical-applications-in-cancer>
78. **Boros, L.G.**, Patel, H., Somlyai, G. The oncoisotopic effect of deuterium and carbon-dependent oncoisotope depletion in processed carbohydrates by ketogenic mitochondrial substrate oxidation. 1st Annual Conference on Nutritional Ketosis and Metabolic Therapeutics, Tampa Bay, Florida, January 28-30, 2016
79. Zarei, M., Blanco, FF., **Boros, L.G.**, Yeo, C.J., Brody, J.R., Winter, J.M. Post-transcriptional regulation of IDH1 by the RNA-binding protein HuR is important for pancreatic cancer cell survival under nutrient deprivation. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr B41. - <http://goo.gl/ZUo51p>
80. **Boros, L.G.**, Nutritional ketosis improves nanomechanics for ATP synthase and TCA cycle turnover via aspartate mediated proton transfer in mitochondria. 2nd Annual Conference on Nutritional Ketosis and Metabolic Therapeutics, Tampa Bay, Florida, February 1-4, 2017.
81. Somlyai, G., Molnár, M., Somlyai, I., Fórizs, I., Czuppon, G., **Boros, L.G.** Hydrogen/deuterium ratio is a key regulator of energy production and cell proliferation – submolecular dimensions of drug development. 3rd International Conference on Clinical Sciences Drug Discovery, Reston, Virginia, USA, November 9-11, 2017.



82. Yee, J.K., Lu, Q., Lim, S., Han, G., Desai, M., **Boros, L.G.**, Ma, L. Flavonoids in the treatment of non-alcoholic fatty liver disease: a tracer-based cell culture study. Pediatrics Endocrine Society (PES) Annual Meeting, Fort Worth, Texas, USA, April 24-27, 2020.

Invited Presentations, Keynotes & Teaching

1. Distribution of stable ^{13}C labels in structural macromolecules of pancreatic adenocarcinoma cells from [1,2- $^{13}\text{C}_2$]glucose: The application of mass spectrometry to cancer cell metabolism. Central Research Institute of Experimental Medicine of the Hungarian Academy of Sciences and the Hungarian Gastroenterological Society Research Section Seminars, Invited Speaker, Budapest, Hungary, June, 1997
2. Ribose synthesis in tumor cells: A new target for anti-tumor therapy. Faculty and Student Research Conference, Department of Human Nutrition, The Ohio State University, Columbus, OH, USA, October, 1997
3. Thiamine and the tumor proliferation process; ribose synthesis through transketolase. Abbott-Ross Laboratories Research Seminar, Invited Speaker, Columbus, OH, USA, May 1997
4. Inhibition of tumor proliferation through the synthesis of RNA ribose. Pathology 850(b): Seminars in Pathology - Continuing Medical Education Program, The Ohio State University, Columbus, OH, USA, April, 1997
5. Inhibition of tumor cell proliferation through the synthesis of nucleic acid ribose: a new approach to tumor therapy. University of Barcelona department of Biochemistry Research Seminar, Barcelona, Catalonia, Spain, November, 1998
6. Gas Chromatography/Mass Spectrometry Chemical Analysis, Summer Student Advisor. Harbor-UCLA Research and Education Institute, Torrance, CA, USA, June-July, 1999.
7. Carbon ^{13}C mass isotope studies in cancer cell glucose metabolism: a practical application in tumor cell metabolic response to transforming growth factor-beta ($\text{TGF-}\beta_2$) treatment. Schebo-Tech presentation, Giessen, Germany, August, 1999
8. The role of thiamine (vitamin B_1) in the proliferation of tumor cells: clinical consequences. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, January 6, 1999
9. Transforming growth factor-beta ($\text{TGF-}\beta_2$) induces non-oxidative glucose metabolic changes in tumor cells: an explanation for hypoxia resistance in tumors. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, September 22, 1999
10. Thiamine-responsive megaloblastic anemia and the role of vitamin B_1 in nucleic acid synthesis. Nutrition Research Seminars UCLA School of Medicine, Department of Nutrition, Los Angeles, CA, USA, January 31, 2000
11. Impaired non-oxidative nucleic acid ribose synthesis in thiamine responsive megaloblastic anemia. Endocrine Clinical Conference, UCLA School of Medicine, Department of Endocrinology. Torrance, CA, USA, March 15, 2000
12. Characterization of tumor cell metabolism with stable glucose isotopes and GC/MS in response to growth modifying agents. Sala de Graus, Facultat de Biologia. University of Barcelona, Barcelona, Spain, May 19, 2000
13. Metabolic phenotypic changes in pancreatic adenocarcinoma cells after fermented wheat germ extract (Avenar) treatment. UCLA School of Medicine, Center for Human Nutrition research seminars, Los Angeles, CA, USA, July 21, 2000



14. Methods of determining the metabolic phenotype of mammalian cells. UCLA School of Medicine, Harbor-UCLA Medical Center Basic Science Seminar, Torrance, CA, USA, December 12, 2000
15. Metabolic adaptation to promoters and inhibitors of human cell transformation. University of California Irvine, Division of Endocrinology, Diabetes and Metabolism, Faculty Science Seminar, Irvine, CA, USA, January 24, 2001
16. Metabolic markers of the lipofibroblast-myofibroblast trans-differentiation process in premature rat lung. UCLA School of Medicine, Center for Human Nutrition seminar presentation, Los Angeles, CA, USA, January 26, 2001
17. Metabolic characteristics of lipofibroblast-myofibroblast trans-differentiation in premature rat lung. UCLA School of Medicine, Department of Pediatrics research seminar, Los Angeles, CA, USA, February 15, 2001
18. Metabolic pathology of lipofibroblast-myofibroblast trans-differentiation. Harbor-UCLA Medical Center, Department of Pathology Grand Rounds, Torrance, CA, USA, February 16, 2001
19. Treatment of chronic myeloid leukemia with Bcr-Abl tyrosine kinase inhibitor Gleevec: the metabolic consequences. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, July 11, 2001
20. Basics of mass spectrometry and proteomics analyses. Introduction to Biomedical Research and Experimental Techniques. Fellow/Faculty Continued Education Program, University of California Research and Education Institute, Torrance, CA, USA, August 29, 2001
21. Metabolic Adaptation of Mammalian Cells to Growth Modifying Signals. Weitzman memorial research award acceptance lecture 2001, Faculty Society of Harbor-UCLA, Torrance, CA, USA, September 13, 2001
22. Stable isotope labeling of proliferation-related macromolecules using [1,2-¹³C₂]glucose: the effect of growth modifying signals. Cedar Sinai Medical Center Research Conference, Los Angeles, CA, September 14, 2001
23. STI571 (Gleevec) and leukemia cell proliferation. Leukemia Research Group and Task Force Meeting, UCLA School of Medicine, Department of Internal Medicine Division of Hematology, Los Angeles, CA, October 1, 2001
24. Metabolic adaptive changes in chronic myeloid leukemia cells in response to STI571 (Gleevec) treatment. Endocrine/Metabolism Research Seminar Series, Cedar Sinai Medical Center, Los Angeles, CA, USA, October 5, 2001
25. Pancreatic and leukemia tumor growth-control through metabolic pathway-linked signal transduction pathways: the lesson learned with STI571. UCLA School of Medicine, Center for Human Nutrition Research Seminar, Los Angeles, CA, USA, October 19, 2001
26. ThermoQest Finnegan LCQ Classic, Duo, Deca and triple quadrupole (TSQ) basic instrument operations. Atmospheric pressure ionization (API) and ion trap theory. Harbor-UCLA Research and Education Institute, laboratory course, Torrance, CA, USA, December 11-12, 2002
27. Opposite metabolic adaptive changes in tumor genesis and tumor growth control in leukemia tumor cells. Sala de Gaus, Facultat de Biologia. University of Barcelona, Barcelona, Spain, USA, December 18, 2001
28. Metabolic effects of ethanol injury in the liver and pancreas: tissue specific differences in fatty acid synthesis. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, January 9, 2002
29. Tissue specific lipotoxicity in the liver and pancreas after ethanol administration in rats. UCLA School of Medicine, Center for Human Nutrition Research Seminar, Los Angeles, CA, USA, January 25, 2002



30. Tumor cell metabolism and novel treatment modalities: Bcr-Abl tyrosine kinase inhibitor Gleevec. Endocrine and Metabolism Clinical Research Conference, City of Hope National Medical Center, Duarte, CA, USA, February 6, 2002
31. Molecules with memory: the stable isotope labeled metabolome in biomedical research. GC/MS research presentation, Visiting Professor Grand Rounds Part II, Torrance, CA, USA, March 5, 2002
32. Tracing pathways in dynamic metabolic profiling and their utilization in the drug discovery process. GC/MS research presentation, Visiting Professor Grand Rounds Part IV, Torrance, CA, USA, March 5, 2002
33. Metabolic profiles of tumor cells in response to novel anti-proliferative treatment modalities. Waters Metabolomics Technology Forum, Waters Corporation, Milford, MA, USA, March 26 & 27, 2002
34. Metabolic profiling of metabolic diseases with unknown mechanisms: how to make silent genes to talk. Harvard School of Medicine, Department of Hematology Research Seminar, Boston, MA, USA, March 27, 2002
35. Glucagon like peptide-1 (GLP-1) induced metabolic adaptation of pancreatic epithelial cells to differentiation and insulin release. Endocrine/Metabolism Research Seminar Series, Cedar Sinai Medical Center, Los Angeles, CA, USA, May 17, 2002
36. Glucagon like peptide-1 (GLP-1) induces differentiation and insulin release of pancreatic epithelial cells: Potential use for the treatment of type 2 diabetes mellitus. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, June 12, 2002
37. Ethanol-induced tissue specific lipotoxicity in the liver and pancreas: a new application of the stable isotope-based metabolic profiling technology. Research Seminar, University of Southern California (USC), Los Angeles, CA, USA, July 8, 2002
38. Stable isotope-based dynamic metabolic profiling for industrial drug target screening, drug efficacy testing and new drug development. Research Seminar, Pharmacia, Saint Louis, MO, USA, August 12, 2002
39. Utilization of ^{13}C labeled stable glucose isotopomers in the industrial drug testing process. Research Seminar, Sigma-Aldrich-Isotech, Miamisburg, OH, USA, August 13, 2002
40. Use of asparagine as a substitute for glutamine in cell cultures: effects on glucose metabolism. University of California School of Medicine Harbor-UCLA Research and Education Institute Summer Fellow Education Program Presentation, Torrance, CA, USA, August 14, 2002
41. Introduction to mass spectrometry for biomedical research and experimental techniques. Fellow/Faculty Continued Education Program, University of California School of Medicine Harbor-UCLA Research and Education Institute, Torrance, CA, USA, September 5, 2002
42. Metabolic profiling with stable isotopes and GC/MS. The Harbor-UCLA Symposium and Workshop On Metabolic Profiling and Metabolic Control Analysis, University of California School of Medicine Harbor-UCLA Research and Education Institute, Torrance, CA, USA, September 21, 2002
43. Differential effects of vitamin D_3 on premature lung cells. The Harbor-UCLA Symposium and Workshop On Metabolic Profiling and Metabolic Control Analysis, University of California School of Medicine Harbor-UCLA Research and Education Institute, Torrance, CA, USA, September 22, 2002
44. Application of metabolic profiling in cancer drug discovery: Gleevec. The Harbor-UCLA Symposium and Workshop On Metabolic Profiling and Metabolic Control Analysis, University of California School of Medicine Harbor-UCLA Research and Education Institute, Torrance, CA, September 23, 2002



45. Diagnostic applications of stable isotope tracers and their prognostic value in drug sensitivity testing of human tumor cells. Oncotech, Tustin, CA, USA, December 10, 2002
46. Adrenal cortical carcinoma: mass spectral analysis of plasma steroid profile (case presentation). Harbor-UCLA Medical Center, Department of Endocrinology Grand Rounds, Torrance, CA, USA, January 03, 2003
47. Stable isotopes in metabolic profiling of pancreatic tumor cell physiology: tracer designs, applications and data analysis/presentation methods. Pancreatic SPORE grant meeting research seminar, UCLA School of Medicine, Department of Surgery, Los Angeles, CA, January 9, 2003
48. Drug target discovery and drug testing through metabolic profiling. 5th Annual Biomedical Investment & Strategic Partnering Opportunities Conference by the Southern California Biomedical Council (SCBC) Poster Presentation Session, Los Angeles, CA, USA, March 11, 2003
49. Drug target discovery and drug testing through metabolic profiling. 5th Annual Biomedical Investment & Strategic Partnering Opportunities Conference by the Southern California Biomedical Council (SCBC) Poster Presentation Session, Los Angeles, CA, USA, March 11, 2003
50. Improving Drug Target Discovery And Drug Effectiveness For The Industry Through Metabolic Profiling. 5th Annual Biomedical Investment & Strategic Partnering Opportunities Conference by the Southern California Biomedical Council (SCBC), Los Angeles, CA, USA, March 13, 2003
51. Vitamin-D₃ for the treatment of lung fibrosis. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, April 23, 2003
52. Early diagnosis of pancreatic cancer using serum metabolome GC/MS analysis and [1,2-¹³C₂]glucose as the tracer. Cambridge Isotope Laboratories, Andover, MA, July 2, 2003
53. Stable Isotope-Based Metabolic Profiling (SIDMAP) of human cancer. Utah Venture Associate presentation, Harbor-UCLA Medical Center, Torrance, CA, August 15, 2003
54. Glucagon-like peptide-1 stimulates glucose derived *de novo* fatty acid synthesis and insulin production during beta cell differentiation. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, September 17, 2003
55. Metabolic pathways regulating cell cycle and apoptosis. UCLA School of Medicine, Harbor-UCLA Medical Center Basic Science Seminar, Torrance, CA, USA, October 7, 2003
56. Biomarkers of tumor cell proliferation and apoptosis revealed by metabolomics. International Society for Analytical and Molecular Morphology, Santa Fe, NM, October 14, 2003
57. Glucagon-like peptide-1 regulates *de novo* fatty acid synthesis and insulin release of beta cells. Endocrine & Metabolism Clinical Research Conference, City of Hope National Medical Center, Duarte, CA, USA, October 29, 2003
58. Rottlerin in the treatment of pancreatic cancer. Department of Veterans Affairs - Greater Los Angeles Hospital, Los Angeles, CA, January 14, 2004
59. Unique metabolic characteristics of IBC cells aiding diagnosis and treatment. Inflammatory Breast Cancer Research Foundation - Activist Meeting, Washington DC, MD, April 30, 2004.



60. Metabolic Profiles Associated with Aggressive Inflammatory Breast Cancer Cell Growth: exploring new avenues of diagnosis and treatment. Inflammatory Breast Cancer Research Foundation - Board Meeting, Washington DC, MD, April 30, 2004
61. Organ Specific Metabolic Abnormalities in Thiamine Responsive Megaloblastic Anemia and Diabetes in Children. Harbor-UCLA Medical Center, Department of Pediatrics Grand Rounds, Torrance, CA, USA, July 29, 2004
62. Unlocking Thiamine Responsive Megaloblastic Anemia: an unknown disease entity of the past. General Clinical Research Center Excellence in Clinical Research Award for 2003; award acceptance lecture, Torrance, CA, USA, September 21, 2004
63. Time of Flight Mass Spectrometry: from science to clinic. UCLA School of Medicine, Harbor-UCLA Medical Center Basic Science Seminar, Torrance, CA, USA, October 5, 2004
64. Clinical Trials in a Test Tube: Understanding the Powers of Stable Isotope-based Dynamic Metabolic Profiling (SIDMAP) in Drug Discovery. Eight Annual Functional Genomics Meeting, Cambridge Healthtech Institute, Boston, MA, November 9, 2004
65. Understanding Glivec-induced metabolic network changes as markers of response in cancer. Oncology Research Management Board, Novartis Pharmaceuticals, Basel, Switzerland, March 22, 2005
66. Targeted drugs and the tracer labeled metabolome of tumor cells: how to predict resistance and develop intervention strategies. University of Utah, Department of Biochemistry Research Seminar, Salt Lake City, UT, April 18, 2005
67. Understanding drug resistance and failure using stable isotope-based dynamic metabolic profiling (SIDMAP). 62nd Annual Meeting of the Korean Society for Biochemistry & Molecular Biology, Cellular Metabolism and Metabolomics Seminar Lecture, Seoul, Korea, May 19, 2005
68. Predicting clinical resistance to targeted therapies using stable isotope-based dynamic metabolic profiling (SIDMAP). Korean Institute of Science and Technology Research Seminar, Seoul, Korea, May 19, 2005
69. Applications of stable isotope-based dynamic metabolic profiling (SIDMAP) in drug resistance. Pohang University of Sciences and Technology Department of Chemistry Research Seminar, Pohang, Korea, May 20, 2005
70. Classic laws of physics and mass spectrometry: time of flight, quadrupole, ion trap instruments and their principles of operation. AP Physics student class, Carson High School, Carson, California, June 10, 2005
71. Stable Isotope Based Metabolic Profiling (SIDMAP) and its Applications. First Scientific Meeting of the Metabolomics Society, Tsuruoka City, Japan, June 23, 2005
72. Tracer substrate-based metabolomics: data handling, biomarkers and patient stratification. Metabolomics Standards Workshop, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, August 1-2, 2005
73. Why targeted drug therapies are doomed to fail: uncovering the mechanism of action using stable isotope-based dynamic metabolic profiling. Connective Tissue Research Institute, University City Science Center, Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, PA, October 18, 2005
74. Evolving metabolic tracer technologies and targeted drug resistance in cancer. Third International Conference on Tumor Cell Metabolism, Plenary Lecture, Louisville, KY, October 20, 2005



75. Predicting Clinical Resistance to Gleevec Treatment by *in vitro* Applied Stable Isotope-based Dynamic Metabolic Profiling. Advances in Metabolic Profiling, Pharmaceutical and Disease State Applications, London, UK, November 1, 2005
76. Metabolic effects of anti-psychotic treatments and the development of type 2 diabetes. Department of Pharmacology, University of Cambridge, United Kingdom, November 3, 2005
77. Ethanol-induced organ-specific lipotoxicity in the plasma, liver and pancreas: an *in vivo* tracer substrate-based metabolomics study. Center for Regulatory and Environmental Analytical Metabolomics (CREAM) at the University of Louisville, 1st CREAM Symposium, Louisville, KY, November 5 & 6, 2005
78. Identifying Patients Who are at Risk for Developing Resistance to Targeted Therapies. IBC Life Sciences Metabolic Profiling Using Metabolomics and Metabonomics Technology to Accelerate Drug Discovery and Development, Research Triangle Park, NC, November 14-15, 2005
79. Developing Metabolic Biomarkers by Measuring Isotopomer Ratios of Specific Metabolites: Metabolic Profiling and Analytical Methods, Orlando, Florida, December 7-8, 2005
80. Tumor cell metabolism. Basic Science Seminar, UCLA School of Medicine Department of Surgery, General Surgery Basic Science Seminar, Los Angeles, CA, December 21, 2005
81. Flexibility of the metabolic network and targeted drug failures. UCLA School of Medicine, Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center Basic Science Seminar, Torrance, CA, USA, April 18, 2006
82. Fermented Wheat Germ (Avenar) Effect and Mechanism of Action as Determined by Stable Isotope-based Dynamic Metabolic Phenotyping. International Society for the Study of Xenobiotics (ISSX), Cheju Island, Korea, May 27, 2006
83. Tracer substrate-based metabolomics to unlock metabolic phenotypes. Buck Institute for Age Research, Novato, CA, July 21, 2006.
84. Metabolic targeted therapies during and after failed small molecule kinase inhibitors in cancer. Conference on Small Molecule Science, San Diego, CA, July 25, 2006
85. Tracer Substrate-based Metabolomics and the 2005 Nobel Prize award in Physiology & Medicine. Innovation in Life Science, Healthcare Research & Product Development, Bryn Mawr College, Philadelphia, USA, October 16-19, 2006
86. Clinical Genomics in Gastroenterology. Asian Pacific Digestive Disease Week, Lahug Cebu City, Philippines, November 20, 2006
87. Mass Isotopomer Markers of Drug Efficacy and Toxicity in Plasma and Urine. Global Technology Community's (GTCbio) 2nd Modern Drug Discovery and Development Summit, Philadelphia, PA, December 4-6, 2006
88. Clinical metabolic biomarkers of drug safety and efficacy using ¹³C-labeled substrates. Division of Endocrinology & Metabolism Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, September 6, 2006. AMA PRA Category 1 Credits™. Institute for medical quality and the California Medical Association's continued medical association (CME) accreditation standards (IMQ/CMA)
89. [1,2-¹³C₂]-D-glucose tolerance test in obesity. Keynote Lecture & Honorary Membership Recipient Presentation at the 49th International Meeting of the Hungarian Gastroenterological Association, Pancreatology Plenary Section, Tihany, Hungary, June 3, 2007



90. Stable ^{13}C isotope tracer substrate studies in drug target development, efficacy and safety testing. Research Seminar, Department of Pathophysiology and the Hungarian Academy of Sciences Szeged Regional Arm, Szeged, Hungary, June 9, 2007
91. Abnormal ^{13}C isotopomer production after acute and chronic antipsychotic treatment in mice. The Eight International Conference on Systems on Systems Biology; Systems Biology in Medicine, Long Beach, California, USA, October 5, 2007
92. Determination of New Biomarkers for Liver Toxicity in the form of Stable Isotope Labeled Metabolites. InnovationWell InterAction Meeting Session, Systems-based Biology & Toxicology, Bryn Mawr College, Philadelphia, PA, USA October 17, 2007
93. Use of metabolic pathway flux information in cancer drug design. Oncogenes meet metabolism – from deregulated genes to a broader understanding of tumor physiology, Berlin, Germany, November 14-16, 2007
94. Functional analysis of pancreatic cancer genes, signaling pathways and drugs using metabolomics. Fourth Hirshberg Symposium for Pancreatic Cancer Research, Los Angeles, California, USA, February 4, 2008
95. Metabolic pathway flux information and systems biology approaches in CNS disorders. 10th International Neuroscience Winter Conference, Sölden, Austria, April 5-10, 2008
96. Discovering markers of metabolic side effects from responses to drugs by altered synthesis and turnover of fatty acids and cholesterol. IBC's 13th Annual World Congress on Drug Discovery & Development of Innovative Therapeutics (DDT), World Trade Center, Boston, MA, August 4-7, 2008
97. Individual variations of metabolism, diabetes and obesity markers, ^{13}C substrate based dynamic metabolic profiling (SIDMAP) and SiD-ELISA. United States Food and Drug Administration (FDA) National Center for Toxicological Research Science and Collaboration Seminar, Jefferson, Arkansas, August 27, 2008
98. Non-invasive methods of studying cancer cell metabolism, drug action and drug response. American College for the Advancement in Medicine (ACAM) – Integrative approaches in Oncology, Las Vegas, Nevada, October 19, 2008. The American College for Advancement in Medicine designates this educational activity for 1.00 AMA PRA Category 1 Credit TM. Physicians can claim credit commensurate with the extent of their participation in the lecture.
99. Luteolin inhibits *in vitro* pancreatic cancer cell proliferation: a comparative tracer isotope study with a targeted fatty acid synthesis inhibitor compound (C75). UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, December 19, 2008
100. Stable (^{13}C) Isotope-labeled Metabolite Fragments' Isotopomer Regression Analysis (SIMFIRA) Studies in Cancer. Cancer Metabolism Workshop, Bethesda North Conference Center, Rockville, Maryland, July 9-10, 2009
101. Metabolic Flux and Nutritional Phenotypes. Nutritional Phenotype Database (dbNP) Workshop of the US Food and Drug Administration, Jefferson, Arkansas, January 21, 2010
102. Stable isotope tracer metabolite markers of failing kidney function. Department of Pathology Faculty Research Seminar, University of California at San Francisco, San Francisco, California, March 11, 2010
103. Intermediary metabolism and macromolecule synthesis in response to deuterium depletion in pancreatic, breast and lung cancer cell lines. 1st International Symposium on Deuterium Depletion, Budapest, Hungary, May 13-14, 2010



104. Tracer substrate-based metabolomics in renal cancer for target identification, reverse genomics and biomarker identification. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health – M. Linehan's Laboratory, Bethesda, Maryland, July 12, 2010
105. Tracer substrate-based metabolomics: a technological overview. Stanford Research Institute (SRI) International Biosciences Division Friday Seminars, Menlo Park, CA, July 30, 2010
106. Fructose alters glucose metabolism in adipocytes: FDA initiatives for stable isotope plasma markers of obesity, diabetes and cancer. UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, October 12, 2010
107. Diverse substrate utilization by tumor cells: clinical implications. Pulmonary Clinical Conference, Greater Los Angeles Veterans Administration, Los Angeles, CA, December 21, 2010
108. Bioinformatics of Glucose-tracer Based Metabolomics. Seventh Hirshberg Symposium for Pancreatic Cancer Research, Los Angeles, California, USA, February 18, 2011
109. Metabolomics for Population and Drug Research: Peer Reviewed Methods and Program Initiatives. UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, April 12, 2011
110. Metabolomic Studies of Cancer Using ^{13}C Tracer Substrates and Model Fitting. Cancer Research UK, Cambridge, United Kingdom, June 2, 2011
111. Cornering tumor cells in hypoxia: ^{13}C substrate guided tour of the metabolic network. Genentech Research Seminars, San Francisco, CA, USA, July 07, 2011
112. Research at academic institutions and pharmaceutical companies: from ideas to drugs. UCLA School of Medicine, Los Angeles Biomedical Research Institute - Career Pathways in Biological Sciences Student Fellowship Program, Torrance, CA, USA, August 02, 2011
113. Metabolomics and Drug Development in the Post-Genomic Era. Department of Pharmaceutical & Biomedical Sciences, College of Pharmacy at the University of Georgia, Athens, GA, February 29, 2012
114. Business and Science Perspectives for Stable Isotope Tracer-based Metabolomics in 2012. Institute for Veterinary Physiology and Biochemistry, Justus-Liebig-University, Giessen, Germany, July 02, 2012
115. Impact of growth signaling and the kinase inhibitor Glivec on tumor cell metabolism. Department of Nutritional Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ, August 29, 2012
116. Metformin, cholesterol, K-ras: Contextual synthetic inhibition of fatty acid synthase. Science Fridays, Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center, Torrance, CA, USA, November 02, 2012
117. ^{13}C Substrate-based Metabolomics and Drug Development in the Post-Genomic Era. Discovery Biology, Rigel Pharmaceuticals, Inc., South San Francisco, CA, November 16, 2012
118. Targeted Tracer Fate Associations (TTFAS) in the ^{13}C -labeled Metabolome. Preston Robert Tisch Brain Tumor Center at the Duke University Medical Center, Durham, NC, June 19, 2013 (Certified by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME credit (AMA PRA Category 1 Credit)TM)
119. Targeted ^{13}C Tracer Fate Association Studies (TTFAS): Isotopolomics powered by SiDMAP. Johns Hopkins School of Medicine, Baltimore, MD, June 20, 2013.



120. Isocitrate dehydrogenase-1 (IDH-1) mutation and D-2-hydroxyglutarate deregulate mitochondrial function. Endocrine Clinical Research Conference, Harbor-UCLA Medical Center, Torrance, CA, USA, August 07, 2013.
121. Serine oxidation and glycine cleavage SOGC-isobolome as the signature of malignancy and targeted drug resistance. United States Food & Drug Administration (FDA) National Center for Toxicological Research, Center Wide Biomarker Study Concept Seminar, Jefferson, Arkansas, November 15, 2013.
<http://harborpeds.org/news/dr-laszlo-boros-cancer-sog-pathway>
122. Failing molecular drug targets: how to overcome them using targeted metabolic tracer fate associations. Discovery Biology, Rigel Pharmaceuticals, Inc., South San Francisco, CA, November 18, 2013.
123. Deuterium depletion and mitochondrial NADPH production: the link for epigenetic control of oncogenesis. Science Fridays, Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center, Torrance, CA, USA, December 13, 2013. <http://youtu.be/GkYAjabGxJs> - doi: 10.12918/SCIENCEFRDEC132014LGB
124. Mitochondrial fumarate hydratase deficient metabolic network of tumor cells. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 20, 2014. (Hungarian) https://youtu.be/-rMQd0n_TR8
125. Metabolic control analysis (MCA) using targeted ¹³C tracer substrate fate associations. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 18, 2014 (English) <http://youtu.be/Pms6k9AQ3bQ>
126. Deuterium depletion controls oncogenesis via NADPH-dependent reductive synthesis via the pentose cycle. Celebrate Half a Century of Medical Innovations at LA BioMed, Torrance, CA, USA, April 24, 2014.
127. Targeted Deuterium Fate Association Study in Medicine Using Deuterobolomics (TDFAS). Patent Committee Business Development & Technology Management Faculty Presentation, Los Angeles BioMedical Research Institute at the Harbor-UCLA Medical Center [LAB0106], Torrance, CA, USA, November 14, 2014.
128. Partial deuteration of hydrogen bonded systems and their role in cancer development. Science Fridays, Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center, Torrance, CA, USA, November 21, 2014
129. Molecular Biology, Functional Biochemistry and Deuterobolomics in Scriptures. Department for the Study of Religions, Faculty of Arts, University of Szeged, Szeged, Hungary, European Union, December 4, 2014.
<http://youtu.be/a7PdYx0hHU4> - DOI: 10.13140/2.1.4907.5525
130. Stable isotope methods to trace metabolic channels. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 10, 2014 (English)
131. Metabolic and cytoplasmic water in hydrogen bonding networks of biomolecules. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 10, 2014 (English)
132. Metabolic and cytoplasmic water in hydrogen bonding networks of DNA. UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, April 28, 2015
133. Anti-cancer properties of metformin via mitochondrial deuterium depletion. Endocrine Clinical Research Conference, UCLA School of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA, July 29, 2015



134. Submolecular regulation of cell transformation by deuterium. UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, November 25, 2015
135. Mitochondrial deuterium depletion as the central mechanism of anti-cancer drug action. UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, December 02, 2015
136. How carbohydrates become oncometabolites when intracellular deuterium depletion fails. UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, December 08, 2015
137. Stable isotope-based dynamic metabolic phenotyping. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 08, 2016
138. Oncogenes, oncometabolites, oncoisotopes and cell transformation. Combined Biochemistry Seminar Lecture, Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, March 08, 2016
139. Deuterobolomics: Course Proposal for the Honor Collegium at UCLA UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, March 15, 2016
140. Nanoindentations of fast moving enzymes and their lubrication with deuterium depleted water in mitochondria: applications for hyperbaric oxygen and nutritional ketosis. Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, Hyperbaric Biomedical Research Laboratory, University of South Florida, Tampa, FL, USA, April 29, 2016
141. Nanoindentations of fast moving enzymes and their lubrication with deuterium depleted water: oncological applications for ATP synthase in the matrix of mitochondria. UCLA Center for Excellence in Pancreatic Diseases Research Seminar, Greater Los Angeles Veterans Administration, Los Angeles, California, May 04, 2016
142. Biological Nanomechanics: ATP Synthesis and Deuterium Depletion. UCLA School of Medicine, Los Angeles Biomedical Research Institute Basic Science Seminar, Torrance, CA, USA, August 23, 2016 - <https://youtu.be/6P8gqB4zLGQ>
143. Metabolomics and Biomarkers for the Prevention of Cancer and other Degenerative Diseases. American College for the Advancement in Medicine (ACAM) – Preventive approaches in Oncology, Tucson, Arizona, September 16, 2016. Educational activity for 1.00 AMA PRA Category 1 Credit™.
144. Ketogenic Diet and Deuterium Depleted Water for the Prevention and Treatment of Cancer and Neurodegenerative Conditions. American College for the Advancement in Medicine (ACAM) – Preventive approaches in Oncology, Tucson, Arizona, September 16, 2016. Educational activity for 1.00 AMA PRA Category 1 Credit™.
145. Nanomechanics of ATP Synthesis and Deuterium Depletion. Biochemistry, Biophysics, Molecular and Cell Biology PhD Elective Course in 2016/2017 first semester - Department of Biochemistry, Albert Szent-Györgyi Medical University, Szeged, Hungary, EU, October 12, 2016
146. The Effect of Deuterium Depletion on Cancer Cell Metabolism: Therapeutic Perspectives. 2nd International Conference for Cancer Metabolism and Therapy (CMT2017), First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China, October 15, 2017
147. In Memoriam: The Scientific Contributions of Dr. Wai-Nang Paul Lee. 3rd International Conference for Cancer Metabolism and Therapy (CMT2018), Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China, October 13, 2018



148. Deuterium Depleted Metabolic Water and Mitochondrial Health. China Academy Of Science & Technology Development, Shenzhen, China, March 23, 2019
149. Deutenomics, the inherent autonomic discrimination of deuterium by Nature: medical implications. Hirshberg Foundation Seed Grant Awardees Presentations, University of California Los Angeles School of Medicine UCLA Faculty Center Sequoia Room, September 20, 2019
150. Mitochondrial depletion (deuterium depletion) restrains prokaryote proliferation and virus hosting cellular events thus alleviates the use of biologics. New Frontiers of Biology, Biological Drugs - Precision Medicine and -omic Sciences: The Role of Biologists, Place Parco dei Principi, Rome, Italy, European Union, April 18, 2020
151. Metabolic profiling and deutenomics of mitochondrial diseases. Institute for Women's and Children's Health at The Lundquist Institute and the Harbor-UCLA Medical Center, Torrance, CA, USA, June 01, 2020

Peer Review Panels

African Journal of Biotechnology (ISSN 1684-5315) (2014); Analytical Biochemistry (ISSN 0003-2697) (2003); Anti-Cancer Drugs (ISSN: 0959-4973) (2016); Biochemical Pharmacology (ISSN: 0006-2952) (2005); Biochimica et Biophysica Acta - Molecular Basis of Disease (ISSN: 0925-4439) (2015); Biomarkers in Medicine (ISSN 1752-0363) (2007); BMC Cancer (ISSN 1471-2407) (2017); BMC Systems Biology (ISSN 1752-0509) (2014); British Journal of Cancer (ISSN 0007-0920) (2008); Cancer & Metabolism (ISSN 2049-3002) (2013); Cancer Cell International (ISSN 1475-2867) (2011); Cancer Epidemiology, Biomarkers & Prevention (ISSN 1538-7755) (2017); Cancer Investigation (ISSN 1532-4192) (2010); Cancer Letters (ISSN 1872-7980) (2007); Cancer Metabolomics (ISSN 2299-1085) (2012); Cancer Research (ISSN 1538-7445) (2011); Cancers (ISSN 2072-6694) (2014); Carcinogenesis (ISSN 1460-2180) (2009); Cell Biology & Toxicology (ISSN 1573-6822) (2007); Cell Chemical Biology (ISSN: 1074-5521) (2016); Cells (ISSN 2073-4409) (2019); Cellular Oncology (ISSN 2211-3428) (2011); Chemistry and Biodiversity (ISSN: 1612-1880) (2016); Digestive Diseases & Sciences (ISSN: 1573-2568) (2003); Drug Design, Development and Therapy (ISSN 1178-8881) (2013); Dutch Cancer Society (Nederlandse Kankerbestrijding) (2003); European Journal of Pharmacology (ISSN 0014-2999) (2006); Evidence-Based Complementary and Alternative Medicine (ISSN 1741-4288) (2013); Federation of European Biochemical Societies (FEBS) Letters (ISSN 0014-5793) (2005); Free Radical Biology & Medicine (ISSN 0891-5849) (2009); French Recherche Médicale - Research pioneers programme CHEMISTRY FOR MEDICINE (2018); Frontiers in Endocrinology (ISSN 1664-2392) (2019); Genes & Nutrition (ISSN: 1555-8932) (2019); Harbor-UCLA Research and Education Institute (REI), Grants & Contracts (2001 - 2004); Hormone & Metabolic Research (ISSN 0018-5043) (2000); International Journal of Cancer (ISSN 1097-0215) (2007); International Journal of Molecular Sciences (ISSN 1422-0067) (2019); Israel Science Foundation (2016); Journal of Industrial and Engineering Chemistry (ISSN: 1226-086X) (2017); Journal of Theoretical Biology (ISSN: 0022-5193) (2018); Journal of Translational Medicine (ISSN: 1479-5876) (2015); Lipids in Health and Disease (ISSN: 1476-511X) (2015); Lung Cancer (ISSN 0169-5002) (2010); Metabolic Engineering (ISSN 1096-7176) (2012); Metabolites (ISSN 2218-1989) (2013); Metabolomics (ISSN 1573-3890) (2004); Molecular Cancer Research (ISSN: 1541-7786 (Print)) (2019); Molecular Cancer Therapeutics (ISSN: 1535-7163 (Print)) (2019); Molecular Medicine Reports (ISSN 1791-2997) (2017); Molecules (ISSN 1420-3049) (2013); Natural Sciences & Engineering Research Council of Canada (2000); Nature Protocols (ISSN 1754-2189) (2007); NMR in Biomedicine (ISSN 1099-1492 (Online)) (2018); Nutrients (ISSN 2072-6643) (2019); Nutrition & Cancer (ISSN 1532-7914) (2004); Oncogene (ISSN 0950-9232) (2004); Oncotarget (ISSN · 1949-2553) (2018); Pancreatology (ISSN: 1424-3903) (2016); Pharmacology & Therapeutics (ISSN 0163-7258) (2012); Phytomedicine (ISSN: 0944-7113) (2017); Public Library of Science (PLOS) Computational Biology (ISSN 1553-7374) (2018); Scientific Reports – Nature Publishing Group (ISSN: 2045-2322) (2018); The European Foundation for Alcohol Research (ERAB) (2017); The Journal of Pediatrics (ISSN 0022-3476) (2006); University of Alabama at Birmingham Clinical Nutrition Research Center (2004)



Funding History & Current Support

ACTIVE

1. STABLE ISOTOPE PROFILES OF SERUM, SALIVA, URINE AND CELL PELLETS IN HEALTH AND DISEASE

Epigenix Foundation, El Segundo, CA, USA

P.I. – L. G. Boros

01/15/2017 - 12/15/2020

Continued Medical Education (CME) and College Course Development

\$60,000 25%

This grant is to cover CignatureHealth teaching functions and clinical stable deuterium and oxygen isotope sample collection in various body fluids. MRI and ^{13}C tracer guided metabolomics are also covered under this amendable project towards additional clinical deuterobolomics research efforts including tENOX2 profiling.

2. HEPATOTOXICITY FLUX STUDY FOR REGORAFENIB

United States Food and Drug Administration, Jefferson, Arkansas, USA

P.I. – L. G. Boros

09/15/2016 – 09/01/2021

^{13}C and ^2H markers of Stivarga's Liver Toxicity

\$25,410 40%

This project will determine precise mitochondrial toxicity markers in the liver with a translational edge regarding regorafenib

3. DEUTEROBOLOMICS AND KETOBOLOMICS

Epigenix Foundation, El Segundo, CA, USA

P.I. – L. G. Boros

05/15/2016 - 05/15/2017

Continued Medical Education (CME) and College Course Development

\$75,000 30%

This grant is to develop biochemistry courses that train physicians and honors students for interpreting deuterium and hydrogen biochemistry in response to ketogenic dietary modifications which deplete deuterium with applications in biology and medicine. The topic is for continued medical education (CME) credits and also considered for the UCLA Honors College.

4. HUNTINGTON SOCIETY OF CANADA - New Pathways Research Grant

Western Washington University, Bellingham, WA, USA

WWU (P.I. – J. Carroll); UCLA SubK (Co-P.I. – L. Boros)

01/01/2016 - 12/31/2016

Peripheral silencing of Htt^{Q111} in Huntington's disease

\$18,000 15%

This grant is to establish whether peripheral silencing of Htt^{Q111} is associated with rescue of central metabolic dysregulation in Huntington's disease using U- ^{13}C -glucose to determine striatal ^{13}C -lactate -, glutamate and – palmitate ^{13}C labeling.

5. RO1CA169919 US NIH/NCI

University of Maryland and UCLA Liver Cancer Research Project

JHSM (P.I. – G. Girnun); UCLA SubK (Co-P.I. – L. Boros)

09/01/2012 - 08/31/2017

Metabolic control of hepatocellular carcinoma by PGC1-alpha

\$337,000 5%

Stable isotope tracer substrate technology is used to reveal peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC1alpha) in liver carcinogenesis and its Systems' Biology and how it affecting the metabolic network.



PENDING

6. **CA150640P1** – United States Department of Defense (P.I. – Boros) 03/31/2016 - 10/30/2019
Contextual Metabolic Background for Pancreatic Cancer Treatment \$325,000 20%

This project reveals ^{13}C plasma and tissue markers of deuterium depleting Metformin actions in the context of fatty acid and cholesterol intake in animals and patients. (This project has passed proposal screening and is invited for full submission by Sept 29, 2015 to the DoD)

COMPLETED

1. **MRDF 53656** (P.I. - Boros) 01/01/1995-12/31/1995
The Ohio State University Department of Surgery \$4,996
Tumor ribose synthesis pathways.

This project allowed preliminary/feasibility investigations in the field of tumor specific nucleic acid ribose synthesis pathways from glucose as the precursor and source for nucleic acid backbone sugar synthesis.

2. **PO1 CA42710-12** (P.I. - Heber) 01/01/1998-12/31/1998
US NIH Clinical Nutrition Research Unit/UCLA (CNRU) \$15,000
Lipid and RNA ribose synthesis in tumor cells and the mechanism of soy protein action on pentose cycle activity using ^{13}C labeled glucose or acetoacetate.

This project provided preliminary/feasibility funding for studying specific inhibitors of pentose cycle enzymes in order to inhibit *in vitro* pancreatic tumor cell growth and transformation.

3. **Fulbright** (P.I. - Cascante) 01/07/1999-31/06/2000
Commission for Cultural, Educational and Scientific Exchange of Spain \$12,780
Travel grant for scientific exchange and visits between the US and Spain.
4. **Harbor-UCLA Inaugural Collegium** (P.I. - Boros) 2001
Harbor-UCLA Research and Education Institute \$12,000 N/A
Equipment purchase award for an atmospheric pressure chemical ionization (APCI) probe for the LCQ Deca ion trap mass spectroscopy instrument.
5. **MO1 RR00425-34** (P.I. - Anderson) 12/01/1977 - 09/30/2003
US DHHS/NIH/NCRR (Mass Spectroscopist - Boros)
General Clinical Research Center

This project provided continued support for an inpatient General Clinic Research Center (GCRC) unit, outpatient GCRC facilities, a Perinatal Clinical Research Center (PCRC) at Martin Luther King Drew Medical Center, and a Satellite GCRC at Cedars-Sinai Medical Center.

6. **MA 1760/2-1 & 1760/2-2; German Research Communications (Deutsche Forschungsgemeinschaft (DFG))** (P.I. – Mazurek) 02/01/2001 - 01/31/2003
Habilitation and scientific exchange studies for Dr. Sybille Mazurek \$20,000.00 N/A
7. **Henry L. Guenther Core Metabolic Profiling Laboratory (P.I. – Lee)** 08/01/2003
Harbor-UCLA Research & Education Institute (Co-P.I. – Boros) \$380,000.00



This project provides funds for a one-time purchase of a time of flight (TOF) mass spectrometer (Applied Biosystems - Voyager), a Liquid Chromatograph Finnegan Deca Ion Trap mass spectrometer (LCQ-Deca) and their support peripherals.

- | | |
|---|-------------------------|
| 8. Inflammatory Breast Cancer Research Foundation (P.I. - Boros) | 03/01/2003 - 02/28/2004 |
| Metabolic profile of inflammatory breast cancer cells. | \$20,000 |
| N/A | |

This project provides funding to clarify inflammatory breast cancer metabolic characteristics and to develop new treatment strategies based on metabolic pathway inhibitors in this rapidly growing undifferentiated cancer on a renewable seed grant basis.

- | | |
|--|-------------------------|
| 9. RO1 HL66182-01A1 SUBK (P.I. - Neufeld) | 10/01/2001 - 09/30/2006 |
| US DHHS/NIH/NCI (P.I.-Boros; Operating Institution Project Director) | \$20,050 14% |
| Pathophysiology of Thiamine-Responsive Anemia Syndrome | |

This project describes the biochemical defect involved in the thiamine responsive megaloblastic anemia syndrome using stable isotope based metabolic profiling *in vitro* and *in vivo*.

- | | |
|--|-------------------------|
| 10. PO1 CA42710-16 SUBK (P.I. Heber) | 05/01/1992 - 04/30/2007 |
| UCLA Subcontract (Mass Spectroscopist - Boros) | \$19,637 5% |
| Clinical Nutrition Research Unit: Stable Isotope Core. | |

The major goal of this project is to develop chemo preventative approach to cancer through nutrition modification. To operate and co-direct the GC/MS core for CNRU approved projects.

- | | |
|--|------------------------|
| 11. 6-FY2002-181 (P.I.-Torday) | 06/01/2003 - 5/31/2007 |
| March of Dimes (Boros-Co. I.) | \$68,182 10% |
| The Role of Myofibroblasts in the Pathophysiology of Bronchopulmonary Dysplasia. | |

The aim of this project is to determine the mechanism of lipo-fibroblast transdifferentiation in newborns using combined genetic and metabolic profiling approaches.

- | | |
|---|-------------------------|
| 12. RO1 HL66182-01A1 SUBK (P.I. – Eibl) | 03/01/2004 - 31/12/2008 |
| US NIH/NCI (Co-P.I. – Boros) | \$225,000 10% |
| The Role of COX-2 and PPAR- γ in Pancreatic Cancer | |

The proposed studies explicate the effect of COX-2 and PPAR gamma inhibitors in pancreatic cancer anti-proliferative treatment and metabolic phenotype.

- | | |
|--|-------------------------|
| 13. REI Project #: 200279-00-00 (Los Angeles Biomedical Research Institute) | 07/01/2004 - 06/30/2010 |
| Hirshberg Foundation for Pancreatic Cancer Research (P.I. - Boros) | \$25,000 14% |
| Biochemistry of Pancreatic Cancer using Stable Isotope-based Metabolic Profiling | |

This project describes the biochemical defect involved in the development and progression of pancreatic cancer using stable isotope based metabolic profiling *in vitro* and *in vivo*.

- | | |
|---|-------------------------|
| 14. RO1CA140492 US NIH/NCI | |
| Johns Hopkins School of Medicine and UCLA Nrf2 Lung Cancer Research Project | |
| JHSM (P.I. – S. Biswal); UCLA SubK (Co-P.I. – L. Boros) | 04/01/2010 - 03/31/2015 |
| Regulation of Tumorigenesis and Therapeutic Resistance by Nrf2 in Lung Cancer | \$325,000 5% |



Stable isotope tracer substrate technology is used to reveal therapeutic resistance in lung cancer using several Nrf2 gene constructs and their effect on the metabolic network.

15. UCLA 20038-01 (Interim) - NIH NCI Chemical Biology Consortium
Stanford Research Institute (SRI) and UCLA Applicant Organizations

SRI (P.I. – Sambucetti); UCLA-Metabolomics Core (P.I. – Boros)	05/01/2011 - 06/31/2012
Project Consortium for new Cancer Drug Development	\$108,877 25%

This project determines the effect of AMP-Kinase growth signaling in cancer cell energy metabolism *in vitro* and *in vivo*.

16. 1 P01 AT003960-01A1

US NIH/NCI (P.I. – Go); Metabolomics Core (Co-P.I.s – Lee-Boros)	10/01/2007 - 09/30/2012
UCLA Center for Excellence in Pancreatic Diseases	\$125,000 5%

Stable isotope tracer substrate technology is used to reveal natural phytochemical and nutritional products and their preventive/therapeutic applications in pancreatic diseases, including inflammation and cancer.

17. HUNTINGTON SOCIETY OF CANADA - New Pathways Research Grant

Western Washington University, Bellingham, WA, USA	
WWU (P.I. – J. Carroll); UCLA SubK (Co-P.I. – L. Boros)	07/01/2013 - 06/31/2014
Mapping hepatic dysfunction in Huntington's disease	\$135863
5%	

This grant is to quantify metabolic flux from ^{13}C -labeled glucose and palmitate in primary hepatocytes from Htt^{+/+} and Htt^{Q111/+} mice fed medium- and high-fat diets. Additional transcriptomic data sets from parallel cultures of purified hepatocytes are generated to refine existing genome-scale models of hepatic metabolism, in hopes of identifying key signaling nodes that could serve as targets for future therapeutic development.

18. HUNTINGTON SOCIETY OF CANADA - New Pathways Research Grant

Western Washington University, Bellingham, WA, USA	
WWU (P.I. – J. Carroll); UCLA SubK (Co-P.I. – L. Boros)	07/01/2015 - 06/30/2016
Mapping hepatic dysfunction in Huntington's disease	\$93,000
15%	

This grant is to quantify metabolic flux from ^{13}C -labeled glucose, glutamine and palmitate tracers in primary hepatocytes isolated from Huntington's mice fed a normal diet across an allelic series of 6 different allele lengths using Huntington's gene constructs.

19. Pilot 1506944155 - The University of Arizona Cancer Center

National Cancer Institute-designated Comprehensive Cancer Center	
The UACC — Orange Grove Campus, Tucson, AZ, USA	
UACC (P.I. – H. Patel, MD); Harbor-UCLA Consortium (Co-P.I. – L. Boros)	07/01/2015 - 06/31/2016
Pilot project to study metabolic profile in patients with pancreatic adenocarcinoma	\$140,000 15%

This grant is to determine targeted tracer fate association patterns (TTFAS) by metabolic products of $[\text{U-}^{13}\text{C}_6]\text{-D-glucose}$ in control subjects and in patients with pancreatic cancer. The study is designed to establish functional ^{13}C -based plasma markers of mitochondrial deuterium depletion and oxygen saturation to enhance anti-cancer drug efficacy based on individual metabolic profiles.



L a n g u a g e s & C o m m u n i c a t i o n s S k i l l s

Fluent and literate in English and Hungarian, basic language skills in German, advanced computer skills, Microsoft-office, Word Perfect, Corel graphics, Mass Spectra analyses/processing using Excel macros and Visual Basic

C o u r s e s , C o m p l i a n c e a n d C e r t i f i c a t i o n s

Advanced Tools for Proteomics and Pharmaceutical Analysis – Dionex Corporation 2001 Spring Seminar Series for Laboratory Professionals, *Woodland Hills, CA, May 17th, 2001*

Data and Safety Monitoring Policy and Procedures for the General Clinical Research Centers (GCRCs) of the United States – Harbor-UCLA Medical Center, *Torrance, CA, March 28th, 2001*

LCQ Operations – ThermoQest Finnegan LCQ Classic, Duo, Deca and triple quadrupole (TSQ) basic instrument operations, including atmospheric pressure ionization (API) and ion trap theory, tuning, calibration, data collection, maintenance, qualitative and quantitative data analysis/processing using Xcalibur - *Riviera Beach, Florida, February 26- March 2, 2001*

Responsible Conduct of Research Curriculum – Harbor-UCLA Research and Education Institute General Clinical Research Center, *Torrance, CA, February 28th, 2001*

Protecting Study Volunteers in Research – Educational/Training Course Certification – Harbor-UCLA Research and Education Institute – *Torrance, CA, Sep 29th, 2000*

Laboratory Animal Care and Handling Course, guided by the Institutional Laboratory Animal Care and Use Committee (ILACUC) of the University of California at Los Angeles, *Torrance, CA, October, 1998*

Basic Life Support cognitive and skills evaluation certificate for healthcare providers, curriculum of the American Heart Association – Ohio Valley, Columbus State C.C. Training Center, *Columbus, OH, June 12th, 1998*

Laboratory Animal Care and Handling Course, guided by the Institutional Laboratory Animal Care and Use Committee (ILACUC) of the Ohio State University, *Columbus, Ohio, July, 1990*

The Impact of Colorful Fruits and Vegetables on Health, UCLA Center for Human Nutrition, *Los Angeles, CA, September 5, 2001*

Matrix assisted laser desorption time of flight mass spectrometry (MALDI-TOF) sample preparations, operations, data analysis. UCLA Department of Chemistry, *Los Angeles, CA, March 18, 2001*

Human Proteome Organization (HUPA) & Amersham Proteomics Tour 2002. University of California Faculty Center, *Los Angeles, CA, September 19, 2002*

Finnigan Technology Forum: Gel analysis by mass spectrometry, Protein quantitation and analysis of phosphoproteins. Thermo Finnigan Western Region, *La Jolla, CA, November 21, 2002*

Linear ion trap technology, high throughput quantitative analysis by liquid chromatography/mass spectrometry (LC/MS/MS), advanced structural characterization, and metabolite and impurity identification. Applied Biosystems Applications seminar, *Buena Park, CA, November 22, 2002*

Southern California Biomedical Council Presentation Preparation Course for Venture and Investment Opportunities. KPMG International, *Los Angeles, CA, February 6, 2003*



Preparative Screening Course for Academic Institutions, the Southern California Biomedical Council and Kaiser Permanente Management Ground (KPMG) International, *Los, Angeles, CA, February 13, 2003*

Protected Health Information (PHI) Health Insurance Portability & Accountability Act Certificate of the Harbor-UCLA Research and Education Institute, *Torrance, CA, May30, 2003*

Voyager-DE™ STR BioSpectrometry™ Workstation (Applied Biosystems MALDI-TOF) Training Course, *Foster City, California, July 13-16, 2004*

Research Services Training: Current Laboratory Animal Handling and Use. Los Angeles Biomedical Research Institute, *Torrance, CA, June 06, 2005*

Title 8, Section 5193 California Code of Regulations Bloodborne Pathogen and Disease Training Course. Los Angeles Biomedical Research Institute, *Torrance, CA, June 13, 2005*

Infectious Agents and Diagnostics Specimens Transportation Saf-T-Pack Training (Tested As Per 49CFR 172.700 / IATA 1.5). Los Angeles Biomedical Research Institute, *Torrance, California, July 14, 2005*

Integrated Medical Research Information System - iMedRIS Data Corporation on-site Training Course at the Los Angeles Biomedical Research Institute, *Torrance, California, July 15, 2005*

Sexual Harassment Prevention Training Course – State of California Code Training Course at the Los Angeles Biomedical Research Institute, *Torrance, California, December 16, 2005*

Mandated Section Test Los Angeles County Department of Health Services Harbor-UCLA Medical Center Re-orientation: Infection Control, Environment of Care, Family Violence, Cultural Diversity, HIPAA & Age Appropriate Care Considerations. Result: Pass; *Torrance, California, July 10, 2006*

Department of Health & Human Services – USA; Los Angeles County DHS Compliance Training Program, *June 22, 2007*

Mandatory Online Sexual Harassment Prevention Course for University of California (UC) Faculty. Sexual Harassment Prevention Training - required by California law (AB1825), *October 11, 2007*

Mandatory Compliance Briefing: University of California Ethical Values and Conduct. *April 05, 2010*

Mandatory Online Sexual Harassment Prevention Course for University of California (UC) Faculty Title VII of the Civil Rights Act of 1964 - Title IX of the Education Amendments of 1972, *April 05, 2010*

Basics of Drug Safety and Pharmacovigilance. Pharmacovigilance audit compliance course of global drug safety and pharmacovigilance regulations. FDA and EMA drug safety regulations. Park Avenue Presentations, Inc., webinar: *Wednesday, December 8, 2010*

California Medical Waste Management Act Inspection Mandatory Course. N-14 Board Room, LABiomed at the Harbor-UCLA Medical Center, Gil Armangué, CHMM, Safety Director, *November 30, 2010*

General Training - Corporate Integrity Agreement (CIA). Office of the Inspector General (OIG), USA Department of Health and Human Services per Novartis Pharmaceuticals. *January 23, 2011*



Interactions with Health Care Providers (HCPs): Payments, Meals and the Provision of Other Items - Corporate Integrity Agreement (CIA). Office of the Inspector General (OIG), USA Department of Health and Human Services per Novartis Pharmaceuticals. January 23, 2011

Federal Compliance and Process/Approval Mechanisms - Corporate Integrity Agreement (CIA). Office of the Inspector General (OIG), USA Department of Health and Human Services per Novartis Pharmaceuticals. January 23, 2011

The Health Insurance Portability and Accountability Act (HIPAA) LABiomed Online Educational Training Course - Protection of Research Subjects, February 09, 2011

Good Clinical Practices Properly Informed Investigator/Faculty Certificate – General Clinical Research Center at the Harbor-UCLA Medical Center, Torrance, CA, February 12, 2011

Association for the Accreditation of Human Research Protection Programs, Inc., From the Investigator's Point of View – LABioMed – UCLA Certification Update and Course, RB-2, Torrance, CA, October 27, 2011

Investigator Manual - accreditation updates for responsibilities of investigators and staff when conducting human research. LABioMed – UCLA Certification Update Course, RB-3, Torrance, CA, December 02, 2011

Human Research Protection Program Accreditation - Protocol and Consent Form Template (Unit 2, 2012). Research Building (RB)-2, Torrance, CA, March 19, 2012

Sexual Harassment Prevention Training Course (supervisory employees) – Unlawful Harassment and Non-Retaliation Policy Review, two-year mandatory re-certification – State of California Code Training Course at the Los Angeles Biomedical Research Institute, Torrance, California, April 20, 2012

Financial Conflict of Interest (FCOI) Training, Office of Research Administration Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, December 07, 2012

Financial Conflict of Interest (FCOI), National Institutes of Health Office of Extramural Research, Bethesda, Maryland, USA, December 11, 2012 - <http://grants.nih.gov/grants/policy/coi/tutorial2011/fcoi.htm>

Office of Continuing Medical Education, Duke School of Medicine, Conflict of Interest Disclosure For Presenters, May 29, 2013.

Workplace Safety, Hazardous Substances & Materials. Hazard Communication & GHS – What Employees Need to Know". Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, November 22, 2013

Workplace Safety, Hazardous Substances & Materials. Hazard Communication & GHS – What Supervisors Need to Know". Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, November 22, 2013.

Human Biomedical Research Basic Scientists - Collaborative Institutional Training Initiative at the University of Miami, Florida, USA – Pass - REFERENCE ID – 13515591, July 18, 2014. (Expire July 17, 2017)

Human Biomedical Research Staff - Collaborative Institutional Training Initiative at the University of Miami, Florida, USA – Pass - REFERENCE ID – 13515590, July 18, 2014. (Expire July 17, 2017)

Human Biomedical Research Investigators – FDA Regulated Research - Collaborative Institutional Training Initiative at the University of Miami, Florida, USA – Pass - REFERENCE ID – 13515593, July 18, 2014.



University of California Los Angeles (UCLA) Employee Safety Handbook material re-certified
ehs.ucla.edu/SafetyHandbook.pdf, July 27, 2017

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) - University of California, Los Angeles (UCLA)
(ID: 762) - PEDIATRICS-ENDOCRINOLOGY - UCLA HIPAA (ID:13861) June 29, 2015

Supervisor Anti-Harassment (CA) - 300: Intersections: LawRoom Inspired Employer Solutions course of the Los
Angeles Biomedical Research Institute, Torrance, California, February 10, 2016

Accident Investigations - BUSINESS & LEGAL RESOURCES – The importance of accident investigation, how to talk to
witnesses, what questions to ask when evaluating an accident scene, how to determine causal factors, and how to
identify corrective actions – Pass: August 30, 2016

Americans with Disabilities Act – What Supervisors Need to Know - BUSINESS & LEGAL RESOURCES – To handle job
interviews and post-offer discussions properly, deal appropriately with leaves of absence and reinstatement, and
avoid discrimination based on disability – Pass: August 30, 2016

Basic First Aid for Medical Emergencies - BUSINESS & LEGAL RESOURCES – to recognize the benefits of obtaining
first-aid and CPR certification; identify proper procedures for a variety of medical emergencies; assist in
administering first aid when a co-worker is injured; and do no further harm – Pass: August 30, 2016

Fire prevention and extinguishers in California - BUSINESS & LEGAL RESOURCES – To understand the requirements
enforced by the California Occupational Safety and Health Administration for both fire prevention and portable fire
extinguishers – Pass: August 30, 2016

Hazard Communication and GHS - What Supervisors Need to Know - BUSINESS & LEGAL RESOURCES – To recognize
the revised chemical labels and safety data sheets, or SDSs, and train employees to read and interpret GHS-
compliant labels and SDSs – Pass: August 30, 2016

Laboratory Recordkeeping for Supervisors - BUSINESS & LEGAL RESOURCES – To cover all the basic laboratory safety
records you have to maintain concerning the use of hazardous chemicals in the lab – Pass: August 30, 2016

Laboratory Safety- the Supervisor's Role - BUSINESS & LEGAL RESOURCES – To gain a better understanding of your
role as a supervisor in implementing and maintaining chemical hygiene and safety in the laboratory – Pass: August
30, 2016

Violence in Workplace- How to Prevent and Defuse for Supervisors - BUSINESS & LEGAL RESOURCES – To identify
the causes of workplace violence, spot the signs of potential violence, follow required security
procedures, respond effectively to violent acts, and recognize and respond to terrorist threats – Pass: August 30,
2016

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) – Los Angeles Biomedical Research Institute
(LABIOMED) (ID: 2094) - PEDIATRICS – EXPORT COMPLIANCE (ID:16800) - Oct 06, 2016

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) – Los Angeles Biomedical Research Institute
(LABIOMED) (ID: 2094) - PEDIATRICS – CONFLICT OF INTEREST COURSE – Introduction (Cal-Basic) (ID: 15177) -
Financial Conflicts of Interest: Overview, Investigator Responsibilities, and Cal Rules (Cal-Basic) (ID: 15070) -
Institutional Responsibilities as They Affect Investigators (Cal-Basic) (ID: 15072) - Oct 06, 2016

COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) – Los Angeles Biomedical Research Institute
(LABIOMED) (ID: 2094) - PEDIATRICS – STAGE-1 ANIMAL RESEARCH POST-APPROVAL MONITORING – June 19, 2018



COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM) – Los Angeles Biomedical Research Institute (LABIOMED) (ID: 2094) - PEDIATRICS – ANIMAL WELFARE REFRESHER – June 26, 2018

SUPERVISORS [CALIFORNIA] - HARASSMENT PREVENTION FOR SUPERVISORS (AB1825 COMPLIANT) May 30, 2019

SCIENTIFIC REPORTS - NATURE - EDITORIAL BOARD MEMBER COURSE - [CERTIFICATE OF COMPLETION](#) - July 01, 2019

BIOMEDICAL RESEARCH – BASIC/REFRESHER – STAGE 2 (Curriculum/Course Learner Group) - (CITI PROGRAM) – EXPIRATION DATE: 24 SEP 2022 – RECORD ID: 33153483

HUMAN RESEARCH - BIOMEDICAL RESEARCHERS & STAFF (ID 38617) - COMPLETION DATE 10-FEB-2020, EXPIRATION DATE 09-FEB-2023, RECORD ID 33953071 - [HTTPS://WWW.CITIPROGRAM.ORG/VERIFY/?W61BEE093-26D8-4B72-9022-354E77238881-33953071](https://www.citiprogram.org/verify/?W61BEE093-26D8-4B72-9022-354E77238881-33953071)

Personal

Date and Place of Birth: June 12, 1962, Szolnok, Hungary

Marital status: Single (divorced)

Child: 1 Daughter (born March 26, 1988, Germany)

Native of Hungary and citizen of the European Union

Lawfully Admitted Permanent Resident of the United States of America: Professional holding an advanced degree and of exceptional ability" [#203 (b) a(A) of the Immigration and Nationality Act; category E26]" – May 04, 1993 – January 19, 2011

Citizen of the United States of America: January 19, 2011



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

EXHIBIT “B”

ABSTRACTS

1. Khatami M. Cancer; an induced disease of twentieth century! Induction of tolerance, increased entropy and 'Dark Energy': loss of biorhythms (Anabolism v. Catabolism). Clin Transl Med. 2018;7(1):20. Published 2018 Jul 2. doi:10.1186/s40169-018-0193-6

[Metric--5% top rated]

Maintenance of health involves a synchronized network of catabolic and anabolic signals among organs/tissues/cells that requires differential bioenergetics from mitochondria and glycolysis (biological laws or biorhythms). We defined biological circadian rhythms as Yin (tumoricidal) and Yang (tumorigenic) arms of acute inflammation (effective immunity) involving immune and non-immune systems. Role of pathogens in altering immunity and inducing diseases and cancer has been documented for over a century. However, in 1955s decision makers in cancer/medical establishment allowed public (current baby boomers) to consume million doses of virus-contaminated polio vaccines. The risk of cancer incidence and mortality sharply rose from 5% (rate of hereditary/genetic or innate disease) in 1900s, to its current scary status of 33% or 50% among women and men, respectively. Despite better hygiene, modern detection technologies and discovery of antibiotics, baby boomers and subsequent 2-3 generations are sicker than previous generations at same age. American health status ranks last among other developed nations while America invests highest amount of resources for healthcare. In this perspective we present evidence that cancer is an induced disease of twentieth century, facilitated by a great deception of cancer/medical establishment for huge corporate profits. Unlike popularized opinions that cancer is 100, 200 or 1000 diseases, we demonstrate that cancer is only one disease; the severe disturbances in biorhythms (differential bioenergetics) or loss of balance in Yin and Yang of effective immunity. Cancer projects that are promoted and funded by decision makers are reductionist approaches, wrong and unethical and resulted in loss of millions of precious lives and financial toxicity to society. Public vaccination with pathogen-specific vaccines (e.g., flu, hepatitis, HPV, meningitis, measles) weakens, not promotes, immunity. Results of irresponsible projects on cancer sciences or vaccines are increased population of drug-dependent sick society. Outcome failure rates of claimed 'targeted' drugs, 'precision' or 'personalized' medicine are 90% (± 5) for solid tumors. We demonstrate that aging, frequent exposures to environmental hazards, infections and pathogen-specific vaccines and ingredients are 'antigen overload' for immune system, skewing the Yin and Yang response profiles and leading to induction of 'mild', 'moderate' or 'severe' immune disorders. Induction of decoy or pattern recognition receptors (e.g., PRRs), such as IRAK-M or IL-1dRs ('designer' molecules) and associated genomic instability and over-expression of growth promoting factors (e.g., pyruvate kinases, mTOR and PI3Ks, histamine, PGE2, VEGF) could lead to immune tolerance, facilitating cancer cells to hijack anabolic machinery of immunity (Yang) for their increased growth requirements. Expression of constituent embryonic factors would negatively regulate differentiation of tumor cells through epithelial-mesenchymal-transition and create "dual negative feedback loop" that influence tissue metabolism under hypoxic conditions. It is further hypothesized that induction of tolerance creates 'dark energy' and increased entropy and temperature in cancer microenvironment allowing disorderly cancer proliferation and mitosis along with increased glucose metabolism via Crabtree and Pasteur Effects, under mitophagy and ribophagy, conditions that are toxic to host survival. Effective translational medicine into treatment requires systematic and logical studies of complex interactions of tumor cells with host environment that dictate clinical outcomes. Promoting effective immunity (biological circadian rhythms) are fundamental steps in correcting host differential bioenergetics and controlling

13

**PROFESSOR LASZLO G. BOROS, MD'S DECLARATION IN SUPPORT OF
PLAINTIFFS' MOTION FOR A PRELIMINARY INJUNCTION
CASE NO. HG 20072843**

cancer growth, preventing or delaying onset of diseases and maintaining public health. The author urges independent professionals and policy makers to take a closer look at cancer dilemma and stop the 'scientific/medical ponzi schemes' of a powerful group that control a drug-dependent sick society before all hopes for promoting public health evaporate.

2. Khatami M. Is cancer a severe delayed hypersensitivity reaction and histamine a blueprint?. Clin Transl Med. 2016;5(1):35. doi:10.1186/s40169-016-0108-3 Abstract

Longevity and accumulation of multiple context-dependent signaling pathways of long-standing inflammation (antigen-load or oxidative stress) are the results of decreased/altered regulation of immunity and loss of control switch mechanisms that we defined as Yin and Yang of acute inflammation or immune surveillance. Chronic inflammation is initiated by immune disruptors-induced progressive changes in physiology and function of susceptible host tissues that lead to increased immune suppression and multistep disease processes including carcinogenesis. The interrelated multiple hypotheses that are presented for the first time in this article are extension of author's earlier series of 'accidental' discoveries on the role of inflammation in developmental stages of immune dysfunction toward tumorigenesis and angiogenesis. Detailed analyses of data on chronic diseases suggest that nearly all age-associated illnesses, generally categorized as 'mild' (e.g., increased allergies), 'moderate' (e.g., hypertension, colitis, gastritis, pancreatitis, emphysema) or 'severe' (e.g., accelerated neurodegenerative and autoimmune diseases or site-specific cancers and metastasis) are variations of hypersensitivity responses of tissues that are manifested as different diseases in immune-responsive or immune-privileged tissues. Continuous release/presence of low level histamine (subclinical) in circulation could contribute to sustained oxidative stress and induction of 'mild' or 'moderate' or 'severe' (immune tsunami) immune disorders in susceptible tissues. Site-specific cancers are proposed to be 'severe' (irreversible) forms of cumulative delayed hypersensitivity responses that would induce immunological chaos in favor of tissue growth in target tissues. Shared or special features of growth from fetus development into adulthood and aging processes and carcinogenesis are briefly compared with regard to energy requirements of highly complex function of Yin and Yang. Features of Yang (growth-promoting) arm of acute inflammation during fetus and cancer growth will be compared for consuming low energy from glycolysis (Warburg effect). Growth of fetus and cancer cells under hypoxic conditions and impaired mitochondrial energy requirements of tissues including metabolism of essential branched amino acids (e.g., val, leu, isoleu) will be compared for proposing a working model for future systematic research on cancer biology, prevention and therapy. Presentation of a working model provides insightful clues into bioenergetics that are required for fetus growth (absence of external threat and lack of high energy-demands of Yin events and parasite-like survival in host), normal growth in adulthood (balance in Yin and Yang processes) or disease processes and carcinogenesis (loss of balance in Yin-Yang). Future studies require focusing on dynamics and promotion of natural/inherent balance between Yin (tumoricidal) and Yang (tumorigenic) of effective immunity that develop after birth. Lawless growth of cancerous cells and loss of cell contact inhibition could partially be due to impaired mitochondria (mitophagy) that influence metabolism of branched chain amino acids for biosynthesis of structural proteins. The author invites interested scientists with diverse expertise to provide comments, confirm, dispute and question and/or expand and collaborate on many components of the proposed working model with the goal to better understand cancer biology for future designs of cost-effective research and clinical trials and prevention of cancer. Initial events during oxidative stress-induced damages to DNA/RNA repair mechanisms and inappropriate expression of inflammatory mediators are potentially correctable, preventable or druggable, if future studies were to focus on systematic understanding of early altered immune response dynamics toward multistep chronic diseases and carcinogenesis.

Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor

tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med. 2018;7(1):11. Published 2018 Mar 1. doi:10.1186/s40169-018-0185-6

References:

- 1) <https://www.nature.com/srep/about/editorial-board#biologicalphysics> (BIOLOGICAL PHYSICS)
- 2) <https://www.mdpi.com/journal/molecules/editors>
- 3) <https://journals.lww.com/md-journal/Pages/Open-Access-Editorial-Board.aspx>
- 4) G D Glick, et al. Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol Exp Ther. 2014; 351(2):298-307. doi: 10.1124/jpet.114.218099
- 5) L G Boros, R D Williams. Chronic isofenphos poisoning: case report of agnogenic myeloid metaplasia with a rapid progression into acute myeloid leukemia. Leuk Res. 1998; 22(9):849-51. doi: 10.1016/s0145-2126(98)00052-6
- 6) L G Boros, R D Williams. Isofenphos induced metabolic changes in K562 myeloid blast cells. Leuk Res. 2001; 25(10):883-90. doi: 10.1016/s0145-2126(01)00043-1
- 7) R D Williams, et al. Chromosomal aberrations in human lymphocytes exposed to the anticholinesterase pesticide isofenphos with mechanisms of leukemogenesis. Leuk Res. 2004; 28(9):947-58. doi: 10.1016/j.leukres.2003.12.014
- 8) G D Glick, A W Oipari, L G Boros. Methods and compositions for detecting immune system activation. United States Patent Application number PCT/US2013/031879; Publication date Sep 26, 2013; Filing date Mar 15, 2013; Priority date Mar 19, 2012, September 2013 Patent: WO2013142303 A1
- 9) M L Anderson, et al. The Effect of Influenza Vaccination for the Elderly on Hospitalization and Mortality. An Observational Study With a Regression Discontinuity Design. Original Research in Ann Intern Med. 2020; 173(4):322-323. <https://doi.org/10.7326/M19-3075>

- 10) A Donzelli. Effect of Influenza Vaccination for the Elderly on Hospitalization and Mortality. Ann Intern Med. 2020; 173(4):322. doi: 10.7326/L20-0828. <https://doi.org/10.7326/L20-0828>
- 11) https://youtu.be/a7el_zNfq4A - full recording: <https://www.c-span.org/video/?466609-1/flu-vaccine-science-innovation>
- 12) J G Donahue, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. Vaccine. 2017; 35(40):5314-5322. doi: 10.1016/j.vaccine.2017.06.069
- 13) J G Donahue, et al. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15. Vaccine. 2019; 37(4):6673-6681. <https://doi.org/10.1016/j.vaccine.2019.09.035>
- 14) D J Trump, The White House. Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health. September 19, 2019. <https://www.whitehouse.gov/presidential-actions/executive-order-modernizing-influenza-vaccines-united-states-promote-national-security-public-health/>
- 15) G Somlyai, et al. Naturally occurring deuterium is essential for the normal growth rate of cells. FEBS Lett. 1993; 317(1-2):1-4. doi: 10.1016/0014-5793(93)81479-j
- 16) E A Belongial, M T Osterholm. COVID-19 and flu, a perfect storm. Science. 2020; 368(6496):1163.(EDITORIAL) DOI: 10.1126/science.abd2220
- 17) L G Boros, et al. Deuterium and metabolic water matter – what this means biochemically and clinically. Science Advances. 2018; 4(8):eaat7314. <https://advances.sciencemag.org/content/4/8/eaat7314/tab-e-letters>

- 1 18) L G Boros, et al. Submolecular regulation of cell transformation by deuterium depleting water
2 exchange reactions in the tricarboxylic acid substrate cycle. Med Hypotheses. 2016; 87:69-74.
3 <https://doi.org/10.1016/j.mehy.2015.11.016>
- 4 19) M Lorzate, H-G Kräusslich. Role of Lipids in Virus Replication. Cold Spring Harb Perspect
5 Biol. 2011 Oct; 3(10): a004820. doi: 10.1101/cshperspect.a004820
- 6 20) D V Chistyakov, et al. Deuterated Arachidonic Acids Library for Regulation of Inflammation
7 and Controlled Synthesis of Eicosanoids: An In Vitro Study. Molecules. 2018; 23(12):3331. doi:
8 10.3390/molecules23123331
- 9 21) S E Dahlén, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary
10 venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U
11 S A. 1981;78(6): 3887-91. doi: 10.1073/pnas.78.6.3887
- 12 22) C D Funk, A Ardakani. A Novel Strategy to Mitigate the Hyperinflammatory Response to
13 COVID-19 by Targeting Leukotrienes. Front Pharmacol. 2020;
14 <https://doi.org/10.3389/fphar.2020.01214>
- 15 23) J A Chandrasekharan, N S-Walia. Arachidonic Acid Derived Lipid Mediators Influence Kaposi's
16 Sarcoma-Associated Herpesvirus Infection and Pathogenesis. Front Microbiol. 2019;
17 <https://doi.org/10.3389/fmicb.2019.00358>
- 18
19
20
21
22
23
24
25

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF ALAMEDA**

CINDY KIEL, J.D., an Executive Associate Vice
Chancellor at UC Davis, MCKENNA
HENDRICKS, a UC Santa Barbara student,
EDGAR DE GRACIA, a UCLA student, and
LELAND VANDERPOEL, an employee at the
Fresno satellite extension of the UCSF Medical
Education Program, and FRANCES OLSEN,
Professor of Law at UCLA,

Plaintiffs,

vs.

THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**PLAINTIFF FRANCES OLSON'S
DECLARATION IN SUPPORT OF
PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION**

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID- 2206283

Action Filed: August 27, 2020

Trial Date: None Set

I Frances Olsen declare as follows:

1. I submit this declaration in support of Plaintiffs’ Motion for a Preliminary Injunction. If called to testify, I could competently testify as follows:
2. On the recommendation of my doctor, I have often taken a seasonal flu shot. I stopped taking them after studying the various effects that Thimerosal has on some individuals, and when flu vaccine without Thimerosal became available, I began taking flu shots periodically, including last year.
3. When UCLA began working remotely and faculty were urged to create Fiat Lux undergraduate seminars (1 credit graded pass/no-pass) for the Spring Quarter, especially if they addressed the SARS-CoV-2 virus or COVID-19, I agreed to do so. In connection with preparing this seminar I read a great deal, including a number of articles from the major medical journals.
4. The more I learned, the more accurately I could evaluate my own strengths and vulnerabilities. Overall, my health is excellent. I have never had influenza, and certainly not as an adult; but my immune system has long been relatively ineffective against other respiratory illnesses, especially those caused by common coronaviruses. I seem to contract the common cold readily and it often lingers on tenaciously.
5. When I learned of the Pentagon study that found a strong correlation between flu uptake and vulnerability to the SARS coronavirus—among a group of military personnel, those who had taken the annual flu vaccine were 36% more likely to contract SARS-CoV-1 than those who had not taken the flu vaccine—I regretted having had a flu shot last season. This regret grew as I found more studies showing a similar correlation between flu shot uptake and vulnerability to several non-influenza respiratory viruses, including coronaviruses.

- 1 6. The combination of my historic vulnerability to common coronaviruses, my recent
2 influenza vaccination, and being in CDC's next-to-the-highest risk category by age led
3 me to avoid all exposure to SARS-CoV-2 as far as possible. For months, I have not been
4 inside any occupied building (except my own home, where I live alone) and when
5 exercising outdoors I have maintained at least 20 feet distance from all others. I
6 appreciate that I am in a privileged position to be able to thus bring my exposure to any
7 airborne virus to a very low level indeed.
- 8 7. Prior to the end of July, I had already determined that I would not take a flu shot this
9 year, after looking into the matter in some detail and taking into consideration what is
10 best for my own health and the continuity of education for the students in my UCLA
11 classes, what is best for our community, and minimizing the burden on our hospitals and
12 the health system overall.
- 13 8. My own situation provides merely one example why the decision should be the choice of
14 the individual. Such decisions about one's health are far better made on an individual
15 basis than imposed on a one-size-fits-all fiat from above.
- 16 9. The flu mandate as written would not allow individualized decisions to be made by people
17 in the UC community with the unbiased advice the doctors who serve us. It would not be
18 enough that our doctors most familiar with our particular medical history and risks
19 determined that a flu shot would be more likely to do harm than good to the individual and
20 to the broader community; the UC doctors can only advise an exemption for narrow
21 circumstances of immediate danger to the individual herself.
- 22
23
24
25
26

1 10. I declare under penalty of perjury under the laws of the State of California that the
2 foregoing is true and correct and that this declaration was executed on September 15,
3 2020 in Los Angeles, California.
4

5 
6

7 _____
8 Frances Olsen
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF ALAMEDA**

CINDY KIEL, J.D., an Executive Associate Vice
Chancellor at UC Davis, MCKENNA
HENDRICKS, a UC Santa Barbara student,
EDGAR DE GRACIA, a UCLA student, and
LELAND VANDERPOEL, an employee at the
Fresno satellite extension of the UCSF Medical
Education Program, and FRANCES OLSEN,
Professor of Law at UCLA,

Plaintiffs,

vs.

THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**PLAINTIFF EDGAR DE GRACIA'S
DECLARATION IN SUPPORT OF
PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION**

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID- 2206283

Action Filed: August 27, 2020

Trial Date: None Set

I Edgar de Gracia declare as follows:

1

**PLAINTIFF EDGAR DE GRACIA'S DECLARATION IN SUPPORT OF PLAINTIFFS'
MOTION FOR A PRELIMINARY INJUNCTION**

1. I submit this declaration in support of Plaintiffs' Motion for a preliminary injunction. I have personal knowledge of the facts set forth herein and if called to testify, I could competently testify as follows:
2. I am a student at UCLA. I am 37 years old. I am 6ft tall and weigh in at 165. I work out with weights and intervals about 4-5 times a week and cycle 1-2 days a week for about 45 minutes. I train jiu-jitsu about once a week and also try to play tennis once every 2 weeks.
3. I eat about 2150 calories per day while consuming 195g of carbs, 70g of fat, and 185g of protein. I don't smoke, I rarely drink alcohol, I stay away from pharma prescribed pills, and I try to eat as healthy and lean as I possibly can to maintain a low body fat percentage of about 7-9% and keep muscle mass high. I take my vitamins, I drink lemon water every morning to jump-start my day and get in my vitamin C and I try to get sun and vitamin D at least 45 min a day.
4. I have traveled the world many times over and have been to many countries and one thing I can say is that I am very proud of my immune system and that fact that I don't ever get a cold or have had the flu in about 7 years.
5. I have never had a flu shot and I know my body well enough to say that I do not want to change anything I am already doing to maintain a healthy lifestyle and I don't want any of those chemicals in my body ruining or getting in the way of what my body has already been doing for almost 38 years.

- 1 6. I am fully compliant with the UC vaccine mandate because I had all the shots required of
2 me when I attended public school. However, I feel I should have a right to reject taking a
3 vaccine which is a medical procedure and is not directly related to the pandemic.
4 7. I declare under penalty of perjury under the laws of the State of California that the
5 foregoing is true and correct and that this declaration was executed on September 14,
6 2020 in Los Angeles, California.
7

8 
9
10 Edgar de Gracia

Richard Jaffe, Esq.
State Bar No. 289362
770 L Street, Suite 950
Sacramento, California 95814
Tel: 916-492-6038
Fax: 713-626-9420
Email: rickjaffeesquire@gmail.com

Robert F. Kennedy Jr., Esq.
(Subject to *pro hac vice* admission)
Children's Health Defense
1227 North Peachtree Parkway
Peachtree, Georgia 30269
Tel: 917-743-3868

Attorneys for the Plaintiffs

**SUPERIOR COURT OF THE STATE OF CALIFORNIA
FOR THE COUNTY OF ALAMEDA**

CINDY KIEL, J.D., an Executive Associate Vice
Chancellor at UC Davis, MCKENNA
HENDRICKS, a UC Santa Barbara student,
EDGAR DE GRACIA, a UCLA student, and
LELAND VANDERPOEL, an employee at the
Fresno satellite extension of the UCSF Medical
Education Program, and FRANCES OLSEN,
Professor of Law at UCLA,

Plaintiffs,

vs.

THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**PLAINTIFF MCKENNA HENDRICKS'
DECLARATION IN SUPPORT OF
PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION**

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID- 2206283

Action Filed: August 27, 2020

Trial Date: None Set

I, McKenna Hendricks, declare as follows:


1. I submit this declaration in support of Plaintiffs' Motion for a Preliminary Injunction.

2. I have personal knowledge of the facts set forth below, and if called to testify, I could competently testify as follows:
3. I am a twenty-year-old student at UCSB and am in good health. I exercise four to five days a week and eat healthy on a consistent basis. I also drink plenty of water, avoid any drugs and alcohol, and try to spend plenty of time outside and move around frequently.
4. Growing up, I would get sick every time my mom took me to get a flu shot. Therefore, I have not received the flu shot in many years. I gave the vaccine another chance in October of 2019 and once again fell ill shortly after. Every experience I have had with the flu shot has been negative and I do not wish to subject myself to another. Every year I had not received a flu shot, I did not contract any sickness (flu or other).
5. I am confident in my body's ability to protect myself against infectious diseases and prefer to rely on my own strong immune system, rather than subjecting myself to chemicals and artificial immunity. I do not wish to risk immunosuppression and sensitize my body to a possible pathogen, but instead work to build long-term, active immunity.
6. I am also wary of the efficiency of the flu vaccine, as experts can only predict what the strain will be each flu season. This does not guarantee the vaccine would work. I do not believe a mandatory flu shot would protect anyone from the current pandemic at hand that is unrelated to the flu.
7. Not only is there little proof that flu vaccines are effective, but they contain many harmful chemicals, including but not limited to formaldehyde, ammonium sulfate, phenol, monosodium glutamate, and ethyl mercury.
8. Chancellor Henry T. Yang recently announced that all courses for the upcoming fall quarter will be offered through remote instruction, except for a small number of laboratory courses

1 and performing arts courses. As of now, the flu vaccine is still required by November 1 of
2 this year, with no change in the policy regarding classes being all online.

3 9. I have been fully compliant with the UC vaccine mandate, as I was required to get them over
4 the years for public school as well. I feel as though my right to control what I put in body is
5 being encroached, as my health is my responsibility.

6 10. I declare under penalty of perjury under the laws of the State of California that the foregoing
7 is true and correct and that this declaration was executed on September 10, 2020 in Santa
8 Barbara, California.
9

10
11 
12 _____
13 McKenna Hendricks
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice*
10 admission) Children's Health
11 Defense 1227 North Peachtree
12 Parkway Peachtree, Georgia 30269
13 Tel: 917-743-3868

14 Attorneys for the Plaintiffs

15 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**
16 **FOR THE COUNTY OF ALAMEDA**

17 CINDY KIEL, J.D., an Executive Associate
18 Vice Chancellor at UC Davis, MCKENNA
19 HENDRICKS, a UC Santa Barbara student,
20 EDGAR DE GRACIA, a UCLA student, and
21 LELAND VANDER POEL, an employee at the
22 Fresno satellite extension of the UCSF Medical
23 Education Program, and FRANCES OLSEN,
24 Professor of Law at UCLA,

25 Plaintiffs,

26 vs.

27 THE REGENTS OF THE UNIVERSITY OF
28 CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**PLAINTIFF LELAND VANDER
POEL'S DECLARATION IN SUPPORT
OF PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION**

BY FAX

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID- 2206283

Action Filed: August 27, 2020


Trial Date: None Set

I, Leland Vander Poel, declare as follows:

1. I submit this declaration in support of Plaintiffs' Motion for a Preliminary Injunction.

2. I have personal knowledge of the facts set forth below, and if called to testify, I could competently testify as follows:
3. I am a sixty-two-year-old employee at UCSF Fresno Medical Education Program and am in good health. I exercise four to five days a week. I am a twenty-five year plus lacto-ovo vegetarian. I am a non-smoker and non-drinker. I eat mainly organic and non-GMO fresh fruits and vegetables.
4. I have enjoyed good health throughout my life. I am rarely sick. I proactively manage my stress with wellness techniques such as meditation and nutrition. On occasions when I do feel like I'm coming down with something, I take proactive measures to get rest and recuperate rapidly. Usually without aid of over the counter remedies.
5. I am confident in my body's ability to protect myself against infectious diseases and prefer to rely on my own strong immune system, rather than subjecting myself to chemicals and artificial immunity. I do not wish to risk immunosuppression and sensitize my body to a possible pathogen, but instead work to build long-term, active immunity.
6. I am also wary of the efficacy and safety of the flu vaccine, as experts can only predict what the strain will be each flu season. This does not guarantee the vaccine would work. I do not believe a mandatory flu shot would protect anyone from the current pandemic at hand that is unrelated to the flu.
7. Not only is there little proof that flu vaccines are effective, but they contain many harmful chemicals, including but not limited to formaldehyde, ammonium sulfate, phenol, monosodium glutamate, and ethyl mercury.
8. I have enjoyed a thirteen year plus career at UCSF Fresno and hope to continue to do so.

1 9. I declare under penalty of perjury under the laws of the State of California that the foregoing
2 is true and correct and that this declaration was executed on September 14, 2020 in Fresno,
3 California.

4
5
6 

7 Leland Vander Poel
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27